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Abstract 
Drug toxicities represent a major problem in drug discovery and development; therefore 
there is a push to develop new technologies to detect these early on. In this thesis I 
investigated the utility of zebrafish embryos and larvae in evaluating the biological activity of 
novel compounds and developed new methods for assaying the potential toxic effects of 
drugs in vivo. An electrocardiogram (ECG) recording set-up for zebrafish embryos and larvae 
was developed to assay drug-induced cardiotoxicity. The set-up was validated by testing 
drugs known to induce cardiotoxicity in humans in zebrafish larvae. The results obtained 
were in agreement with those documented in humans demonstrating the utility of the 
zebrafish larva in detecting drug-induced cardiotoxicity. The zebrafish embryo was also 
found to be a useful model for probing the biological activity of novel and marketed 
compounds providing an insight into the relationship between chemical properties and 
biological effects. Additionally, the assessment of the anti-inflammatory activity of a set of 
reference drugs revealed that the zebrafish larva also presents a promising model for 
therapeutic drug screens. Overall, the results described in this thesis show that the zebrafish 
presents an effective, reliable and rapid model for assessing the biological activity of drugs in 
vivo. 
 
 
 
 
Acknowledgements 
I would firstly like thank my supervisor Professor Ferenc Müller for his continued support, 
enthusiasm, advice, encouragement and guidance during my PhD. Secondly; I would like to 
thank my co-supervisor Professor Attila Sik for his continued support and for his help 
particularly with the zebrafish electrocardiogram (ECG) work. I would also like to thank my 
supervisor at KIT (Karlsruhe Institute of Technology, Germany) Dr. Urban Liebel for his 
advice, guidance and encouragement during my time in Germany. 
 
I would like to thank all past and present colleagues at the University of Birmingham, 
especially Harmeet Gill, Rhiannon Hurst, Sahar Avazzadeh, Irene Miguel, Jennifer Roberts 
and Nan Li for creating such a great working environment. I would like to thank all my 
colleagues at KIT, especially Yu Liang, Ravindra Peravali and Jochen Gehrig. I would also like 
to thank all my former colleagues at Biotecont Ltd., especially Eva Doro for introducing me 
to zebrafish ECGs. I would like to thank our collaborators at AcureOmics AB, especially 
Professor Torbjörn Lundstedt and Associate Professor Katrin Lundstedt-Enkel for all their 
help and support and for introducing me to multivariate analysis. I would also like to thank 
our collaborators at the School of Chemistry Dr. John S. Fossey, Antonio Feula and Mariwan 
M. Salih for creating such a fruitful collaboration. I would like to thank Marie Curie Actions 
for funding my PhD and everyone from the ‘Biology of Liver and Pancreatic Development 
and Disease’ (BOLD) Initial Training Network for all the great discussions and meetings. 
Finally, I would like to thank both my parents, as without their continued support I would 
not be where I am now. I would also like to thank my brother for his invaluable support and 
help and for taking an interest in my research. 
List of abbreviations 
ECG  electrocardiogram 
NSAID  non-steroidal anti-inflammatory drug 
COX  cyclooxygenase 
CYP  cytochrome P450 
ADR  adverse drug reaction 
dpf  days post fertilisation 
hpf  hours post fertilisation 
GI  gastrointestinal 
DMSO  dimethyl sulphoxide 
GC-MS  gas chromatography-mass spectrometry 
LC-MS  liquid chromatography-mass spectrometry 
GFP  green fluorescent protein 
SAR  structure activity relationship 
QSAR  quantitative structure activity relationship 
ADME  absorption, distribution, metabolism and excretion 
ABC  adenosine triphosphate binding-cassette 
ATP  adenosine triphosphate 
DNA  deoxyribonucleic acid 
RNA  ribonucleic acid 
MDR1  multi-drug resistance protein 1 
DMT1  divalent metal transporter 
OP  organophosphate 
TILLING targeted induced local lesions in genome 
NAPQI  n-acetyl-p-benzoquinone-imine 
ROS  reactive oxygen species 
UTP  uridine triphosphate 
UDP  uridine diphosphate 
REACH  registration, evaluation, authorisation and restriction of chemicals 
OECD  organisation for economic co-operation and development 
ICH  international conference on harmonisation 
ZFET  zebrafish embryo toxicity test 
LC50  lethal concentration 50 
EC50   effective concentration 50 
NOEC  no observed effect concentration 
LOEC  lowest observed effect concentration 
PCA  principal component analysis 
PLS  partial least squares 
OPLS  orthogonal partial least squares 
OPLS-DA orthogonal partial least squares discriminant analysis 
PTU  phenylthiourea 
MS222  ehtyl-3-aminobenzoate methane sulphonic acid 
PFA  paraformaldehyde 
PBS  phosphate buffered saline 
PBST  phosphate buffered saline tween 
Cx40  connexin-40 
TdP  torsades de pointes 
C-LTCC  l-type voltage dependent calcium channel 
AV  atrioventricular 
hERG  human ether-à-go-go-related gene 
zERG  zebrafish ether-à-go-go-related gene 
bpm  beats per minute 
ms  milliseconds 
nm  nanometres 
mV  millivolts 
Hz  hertz 
cAMP  cyclic adenosine monophosphate 
BDM  2,3-butanedione-monoxime 
PAS  per-arnt-sim 
fH  heart rate 
PVC  premature ventricular contractions 
DILI  drug-induced liver injury 
IVH  intraventricular hemorrhage 
VBH  ventricular brain hemorrhage 
BDA  cis-2-butene-1,4-dial 
MW  molecular weight 
logP  partition coefficient 
clogP  computed logP 
logD  distribution constant 
V  molecular volume 
S  molecular surface area 
O  ovality 
ELUMO energy of lowest unoccupied molecular orbital 
EHOMO energy of highest occupied molecular orbital 
H  hardness 
DM  dipole moment 
NPSA  non-polar surface area 
PSA  polar surface area 
HBA  number of hydrogen bond acceptors 
HBD  number of hydrogen bond donors 
HB  sum of hydrogen bond acceptors and donors 
pKa  acid dissociation constant 
ICM  intermediate cell mass 
zMPO  zebrafish myeloperoxidase 
NK  natural killer 
NADPH nicotinamide dinucleotide monophosphate 
Duox  dual oxidase 
ChIn  chemically induced inflammation assay 
ORO  oil red o 
nAChR  nicotinic acetylcholine receptor 
TR  toxic ratio 
TI  teratogenic index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of Contents 
 
Chapter One: GENERAL INTRODUCTION .................................................................................... 1 
1.1 Drug development ............................................................................................................ 1 
1.1.1 Adverse drug reactions (ADRs)................................................................................... 5 
1.2 The zebrafish embryo as a model for drug screening ...................................................... 6 
1.2.1 Zebrafish background ................................................................................................. 6 
1.2.2 Zebrafish embryo development and anatomy .......................................................... 6 
1.2.3 The zebrafish embryo as a drug screening tool ......................................................... 8 
1.2.3.1 Advantages and disadvantages of the zebrafish embryo model for drug 
screening…………………………………………………………………………….………………………...8 
1.2.3.2 Advantages and disadvantages of the zebrafish embryo model for drug 
screening compared to other fish models.……………………………………………………11 
1.2.3.3 Advantages of the zebrafish embryo in vivo model over in vitro models for use 
in drug screening………………………………………………………………………………………....12 
1.2.3.4 The zebrafish embryo as a complementary model to existing in vitro 
models…………………………………………………………………………………….……………………14 
1.2.4 Zebrafish embryo drug screens ................................................................................ 15 
1.3 Solubility and penetration of compounds into zebrafish embryos ................................ 17 
1.4 Zebrafish embryo drug metabolism ............................................................................... 20 
1.5 Toxicity ............................................................................................................................ 25 
1.5.1 Selective toxicity ....................................................................................................... 28 
1.5.2 Species specific differences in toxicity ..................................................................... 29 
1.5.3 The zebrafish embryo as a toxicological model ....................................................... 30 
1.6 Multivariate analysis ....................................................................................................... 32 
1.6.1 Principal component analysis ................................................................................... 32 
1.6.2 Partial least squares ................................................................................................. 33 
1.7 Aims of thesis .................................................................................................................. 37 
Chapter Two: MATERIAL AND METHODS ................................................................................. 38 
2.1 Materials ......................................................................................................................... 38 
2.1.1 Chemicals ................................................................................................................. 38 
2.1.1.1 28 Reference drugs…………………………….………………………………………………..………39 
2.1.1.2 Six validation drugs…………………………………………….………………………………..………40 
2.1.1.3 Azetidines…………….…………………………………………….………………………………..………40 
2.1.1.4 Ƴ-lactams……………..…………………………………………….………………………………..………41 
2.1.2 Enzymes .................................................................................................................... 42 
2.1.3 Equipment ................................................................................................................ 42 
2.1.4 Zebrafish lines .......................................................................................................... 43 
2.1.5 Solutions ................................................................................................................... 44 
2.2 Stainings .......................................................................................................................... 46 
2.2.1 Fixation ..................................................................................................................... 46 
2.2.2 Sudan black staining ................................................................................................. 46 
2.3 Statistical analysis ........................................................................................................... 46 
2.3.1 Students T-Test......................................................................................................... 46 
2.3.2 ANOVA ...................................................................................................................... 47 
2.3.3 Multivariate analysis ................................................................................................ 47 
2.4 Fish husbandry and embryological techniques .............................................................. 47 
2.4.1 Adult zebrafish maintenance ................................................................................... 47 
2.4.2 Zebrafish breeding and embryo collection .............................................................. 48 
2.4.3 Raising of zebrafish embryos ................................................................................... 48 
2.4.4 Dechorionation ......................................................................................................... 49 
Chapter Three: DEVELOPMENT OF A ZEBRAFISH EMBRYO AND LARVAL 
ELECTROCARDIOGRAPHY TOOL FOR THE DETECTION OF CARDIOTOXICITY ........................... 50 
3.1 Introduction and Overview ............................................................................................. 51 
3.1.1 The zebrafish embryo as a model for evaluating cardiotoxicity .............................. 51 
3.1.2 Zebrafish heart development ................................................................................... 52 
3.1.3 Electrophysiology of the zebrafish heart ................................................................. 53 
3.1.3.1 Generation of electrical activity in the heart…..……………………….…………..………49 
3.1.3.2 Ventricular myocyte action potential cycle……..…………………………………..……… 50 
     3.1.3.3 Adult zebrafish electrocardiogram……………………………………………………………….59 
3.1.4 Zebrafish as a model for QT prolongation ............................................................... 62 
3.1.5 Zebrafish as a model for drug-induced QT prolongation ......................................... 65 
3.1.6 Zebrafish as a model for arrhythmia and related cardiac disorders ........................ 69 
3.2 Aims................................................................................................................................. 70 
3.3 Methods .......................................................................................................................... 72 
3.3.1 Preparation of electrocardiogram apparatus .......................................................... 72 
3.3.2 ECG recording method ............................................................................................. 73 
3.3.3 ECG temperature experiments ................................................................................ 75 
3.3.4 Invasive ECG recordings ........................................................................................... 76 
3.3.5 ECG drug treatments ................................................................................................ 76 
3.3.6 Agarose-embedded ECG recordings ........................................................................ 78 
3.3.7 ECG data analysis ..................................................................................................... 78 
3.4 Results ............................................................................................................................. 81 
3.4.1 Stability and reproducibility of zebrafish embryo and larval ECG signals ............... 81 
3.4.2 Investigation into methods to exclude motion artefact from zebrafish embryo and 
larval ECG recordings ........................................................................................................ 85 
3.4.3 Investigation into methods to immobilize zebrafish embryos and larvae during ECG 
recordings .......................................................................................................................... 89 
3.4.4 Identification and characterisation of variables of zebrafish embryo and larval ECG 
recordings .......................................................................................................................... 93 
3.4.5 Zebrafish larval ECG recording set-up as a tool for detecting drug-induced 
cardiotoxicity ..................................................................................................................... 98 
3.5 Discussion...................................................................................................................... 107 
3.5.1 Optimisation of a zebrafish embryo and larval ECG recording set-up .................. 107 
3.5.2 Comparison of our ECG recording set-up to other zebrafish ECG recording set-ups
 ......................................................................................................................................... 111 
3.5.3 A larval zebrafish model for QT prolongation ........................................................ 112 
3.5.4 A larval zebrafish model for atrioventricular block and arrhythmia...................... 114 
3.5.5 The zebrafish larva as a preclinical model for cardiotoxicity ................................. 116 
3.5.6 Current limitations of the zebrafish embryo and larval ECG recording set-up and 
future perspectives ......................................................................................................... 117 
3.6 Conclusion ..................................................................................................................... 119 
Chapter Four: CHARACTERISATION OF THE BIOLOGICAL ACTIVITY OF NOVEL AZETIDINE AND 
Ƴ-LACTAM COMPOUNDS USING THE ZEBRAFISH EMBRYO ................................................... 120 
4.1 Introduction and Overview ........................................................................................... 121 
4.1.1 Zebrafish as a model for testing of novel small molecules .................................... 121 
4.1.2 The zebrafish larva as a model for hepatotoxicity ................................................. 122 
4.1.3 Zebrafish liver development .................................................................................. 124 
4.1.4 Zebrafish liver structure ......................................................................................... 125 
4.2 Aims............................................................................................................................... 126 
4.3 Methods ........................................................................................................................ 131 
4.3.1 Toxicity and morphology testing of novel Ƴ-lactams ............................................. 131 
4.3.2 Fluorescence imaging of vasculature/red blood cells in Ƴ-lactam-treated embryos
 ......................................................................................................................................... 134 
4.3.3 Toxicity and morphology testing of novel azetidines ............................................ 135 
4.3.4 Fluorescence imaging of vasculature/red blood cells in azetidine-treated embryos
 ......................................................................................................................................... 136 
4.3.5 Oil Red O staining ................................................................................................... 136 
4.3.6 Acridine orange staining ........................................................................................ 137 
4.3.7 Sudan black staining ............................................................................................... 137 
4.3.8 Brightfield liver image analysis............................................................................... 137 
4.3.9 Motility assays ........................................................................................................ 138 
4.4 Results ........................................................................................................................... 140 
4.4.1 Ƴ-Lactam dose-range finding study ........................................................................ 140 
4.4.2 Evaluation of the morphological effects induced by Ƴ-lactams ............................ 142 
4.4.3 Specific characterisation of Ƴ-lactams 3a, 3f and 3h ............................................. 148 
4.4.3.1 Specific characterisation of Ƴ-lactam 3a………...…………………………………...…....149 
4.4.3.2 Specific characterisation of Ƴ-lactam 3f and 3h……………………………….…..…….154 
4.4.4 Morphology analysis of azetidine-treated zebrafish embryos .............................. 160 
4.4.5 Neurobehavioural effects of azetidines ................................................................. 167 
4.4.6 Specific characterization of azetidine 2a ............................................................... 169 
4.5 Discussion...................................................................................................................... 175 
4.5.1 Toxicity and morphological effects of Ƴ-lactams on zebrafish embryos ............... 175 
4.5.2 Possible mechanisms for hemorrhage formation with Ƴ-lactam 3a ..................... 175 
4.5.3 Liver toxicity with Ƴ-lactams 3f and 3h .................................................................. 177 
4.5.4 Toxicity and morphological effects of azetidines on zebrafish embryos ............... 180 
4.5.5 Azetidine locomotor effects and similarities to nicotine ....................................... 181 
4.5.6 Similarities between azetidine and nicotine phenotypes ...................................... 182 
4.5.7 Similarities between azetidine 2a and nicotine phenotypes ................................. 182 
4.5.8 Similarities in responses between Ƴ-lactams and azetidines ................................ 185 
4.5.9 Limitations of current study and future work ........................................................ 187 
4.6 Conclusions ................................................................................................................... 188 
Chapter Five: DEVELOPMENT OF A DRUG TOXICITY PREDICTION TOOL USING THE ZEBRAFISH 
EMBRYO .................................................................................................................................. 190 
5.1 Introduction and Overview ........................................................................................... 191 
5.1.1 Zebrafish embryo as a model for toxicological studies .......................................... 191 
5.1.2 Using biological data to create predictive models ................................................. 192 
5.1.3 Problems encountered with predictive models and how these can be overcome
 ......................................................................................................................................... 193 
5.2 Aims............................................................................................................................... 196 
5.3 Methods ........................................................................................................................ 197 
5.3.1 Toxicity and morphology assessment of 28 reference drugs in zebrafish embryos
 ......................................................................................................................................... 199 
5.4 Results ........................................................................................................................... 201 
5.4.1 Zebrafish embryo mortality induced by 28 reference drugs ................................. 201 
5.4.2 Morphological effects of 28 reference drugs on zebrafish embryos during 
development ................................................................................................................... 206 
5.4.3 Development of a QSAR model based on zebrafish embryo toxicity endpoints and 
morphological features ................................................................................................... 214 
5.4.4 Effect of dechorionation on the morphological responses of the 28 reference drugs
 ......................................................................................................................................... 221 
5.4.5 Comparison of the toxicity of the 28 reference drug set between zebrafish 
embryos and rodents ...................................................................................................... 224 
5.5 Discussion...................................................................................................................... 226 
5.5.1 Relationship between toxicity and physiochemical descriptors ............................ 226 
5.5.2 Novelty of QSAR model based on zebrafish embryo developmental toxicity ....... 229 
5.5.3 Influence of the zebrafish embryo chorion on drug penetration .......................... 231 
5.5.4 Comparability of zebrafish embryo toxicity data to rodent toxicity data ............. 232 
5.5.5 Limitations of study and future perspectives ........................................................ 234 
5.6 Conclusion ..................................................................................................................... 235 
Chapter Six: CHARACTERISATION OF THE ANTI-INFLAMMATORY RESPONSES OF A 28 
REFERENCE DRUG SET IN ZEBRAFISH LARVAE ....................................................................... 237 
6.1 Introduction and Overview ........................................................................................... 238 
6.1.1 Zebrafish immune system ...................................................................................... 238 
6.1.2 Zebrafish innate immune system ........................................................................... 238 
6.1.3 Zebrafish adaptive immune system ....................................................................... 239 
6.1.4 Zebrafish as a model for studying inflammation ................................................... 239 
6.1.5 Chemically induced inflammation (ChIn) assay ..................................................... 241 
6.1.6 Role of hydrogen peroxide in inflammation .......................................................... 242 
6.1.7 In vivo visualisation of leukocytes and hydrogen peroxide levels following acute 
inflammation in zebrafish larvae..................................................................................... 243 
6.2 Aims............................................................................................................................... 244 
6.3 Methods ........................................................................................................................ 244 
6.3.1 Sudan black staining ............................................................................................... 245 
6.3.2 SYTOX® blue staining .............................................................................................. 246 
6.3.3 Chemically induced inflammation (ChIn) assay ..................................................... 247 
6.3.4 HyPer zebrafish assay (In vivo quantification of hydrogen peroxide levels) ......... 250 
6.4 Results ........................................................................................................................... 253 
6.4.1 Tail-fin wounding .................................................................................................... 253 
6.4.2 Automated chemically induced inflammation assay (ChIn) .................................. 257 
6.4.3 SYTOX® blue staining .............................................................................................. 261 
6.4.4 Evaluation of the anti-oxidant properties of a selection of the 28 reference drugs
 ......................................................................................................................................... 267 
6.5 Discussion...................................................................................................................... 268 
6.5.1 Anti-inflammatory responses of 28 reference drugs ............................................. 268 
6.5.2 Current limitations and future perspectives of the zebrafish anti-inflammatory 
screen .............................................................................................................................. 273 
6.5.3 Anti-oxidant properties of selected reference drugs ............................................. 276 
6.5.4 Current limitations and future perspectives of the zebrafish HyPer screen ......... 278 
6.6 Conclusion ..................................................................................................................... 278 
Chapter Seven: GENERAL DISCUSSION AND PERSPECTIVES .................................................. 280 
7.1 Overview ....................................................................................................................... 280 
7.2 The implementation of the zebrafish embryo as a pre-clinical model in drug 
development ....................................................................................................................... 280 
7.3 Using the zebrafish embryo as a model to detect cardiotoxicity ................................. 283 
7.4 The zebrafish larva as a model for therapeutic drug screening ................................... 285 
7.5 The zebrafish embryo as a screening tool to assess the biological activity of novel 
compounds ......................................................................................................................... 287 
7.6 Overall conclusion ......................................................................................................... 288 
Chapter Eight: APPENDIX ........................................................................................................ 290 
Chapter Nine: REFERENCES .................................................................................................... 291 
Chapter Ten: PUBLICATIONS .................................................................................................. 321 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of figures 
 
Figure 1.1 – Beneficial and undesired properties of drug candidates. ....................................... 2 
Figure 1.2 – Overview of the drug development process ........................................................... 4 
Figure 1.3 – Anatomy of the 2 day old zebrafish embryo .......................................................... 8 
Figure 1.4 – Summary of phase 1 and phase 2 reactions that occur in humans.. ................... 22 
Figure 1.5 – Basis of principal component analysis (PCA) ........................................................ 33 
Figure 1.6 - Transformation of data with multiple X and Y variables into a two dimensional 
representation using partial least squares (PLS). ..................................................................... 34 
Figure 1.7 – Transformation of data with multiple X and Y variables into a two dimensional 
representation using orthogonal partial least squares (OPLS)................................................. 35 
Figure 1.8 – Comparison of PLS-DA and OPLS-DA models…………………………………………………… 36 
Figure 3.1 – Summary of zebrafish heart development. .......................................................... 53 
Figure 3.2 – Ventricular myocyte action potential. .................................................................. 55 
Figure 3.3 – Atrial myocyte action potential. ........................................................................... 58 
Figure 3.4 – Components of a human ECG recording. ............................................................. 60 
Figure 3.5 – Structure of the zebrafish zERG channel. ............................................................. 64 
Figure 3.6 – Structural model of the hERG channel pore component ...................................... 65 
Figure 3.7 – Schematic of hERG channel gating....................................................................... 66 
Figure 3.8 – Screenshot of an ECG recording from a 3 dpf zebrafish (digital filter 15)............ 75 
Figure 3.9 – Screenshot of the ECG settings window in LabChart Pro7. .................................. 79 
Figure 3.10 – Screenshot of single waveforms (green) and an averaged waveform (black) 
generated from an analysed ECG recording segment .............................................................. 79 
Figure 3.11 – Screenshot of the ‘tableview’ showing ECG parameters generated from the 
average waveform .................................................................................................................... 80 
Figure 3.12 – ECG set-up. ......................................................................................................... 82 
Figure 3.13 – ECG signal filtering and processing.. .................................................................. 83 
Figure 3.14 – ECG signal reproducibility.. ................................................................................. 84 
Figure 3.15 – Effect of cromakalim drug treatment on ECG interval durations. ..................... 87 
Figure 3.16 - Exclusion of motion artefact through the use of electro-mechanical uncouplers
 .................................................................................................................................................. 88 
Figure 3.17 – Exclusion of motion artefact by performing an invasive ECG recording ............ 89 
Figure 3.18 – Agarose embedding as a form of immobilization….. ......................................... 91 
Figure 3.19 – Forms of immobilization.. ................................................................................... 92 
Figure 3.20 – Optimisation of recording temperature ............................................................. 94 
Figure 3.21 – Optimisation of recording stage......................................................................... 96 
Figure 3.22 – Optimisation of electrode position on zebrafish heart....................................... 97 
Figure 3.23 – Effect of electrode distance from the zebrafish heart on ECG signal morphology
 .................................................................................................................................................. 98 
Figure 3.24 – QTc prolongation in zebrafish larvae after treatment with terfenadine. ........ 100 
Figure 3.25 – QTc prolongation in zebrafish larvae after treatment with haloperidol and 
pimozide.................................................................................................................................. 101 
Figure 3.26 – QTc interval changes in zebrafish larvae after exposure to drugs not known to 
prolong the QT interval in vivo ............................................................................................... 103 
Figure 3.27 – Arrhythmia development in zebrafish larvae after exposure to terfenadine.. 105 
Figure 3.28 – AV block in zebrafish larvae after exposure to the QT prolonging drug 
pimozide…………………………………………………………………………………………………………………………… 106 
Figure 3.29 – AV block in zebrafish larvae treated with verapamil ....................................... 107 
Figure 3.30 – Comparison of ECG signal between human adults, adult zebrafish and zebrafish 
embryos .................................................................................................................................. 108 
Figure 4.1 – Overview of zebrafish liver development ........................................................... 125 
Figure 4.2 – Scheme of azetidine and Ƴ-Lactam synthesis ..................................................... 127 
Figure 4.3 – Example of a log-concentration mortality plot for Ƴ-lactam 3a ........................ 132 
Figure 4.4 – Screenshot from KomiPL software showing tracking of individual zebrafish larvae 
by the software (highlighted in white) ................................................................................... 139 
Figure 4.5 – Heat map showing the mean cumulative percentage mortality of zebrafish 
embryos treated with Ƴ-lactams at different concentrations over time ................................ 141 
Figure 4.6 – Selection of phenotypes observed following treatment of zebrafish embryos with 
Ƴ-lactam compounds .............................................................................................................. 143 
Figure 4.7 -- A two-component PCA model of zebrafish embryo biological responses 
(observations) against morphological features, toxicity endpoints and physiochemical 
descriptors (variables) following treatment with Ƴ-lactams over a 120 hour exposure period
 ................................................................................................................................................ 146 
Figure 4.8 – LogP values plotted against log(1/EC50) values for tested Ƴ-lactams ............... 147 
Figure 4.9 – Ventricular brain hemorrhage (VBH) formation in zebrafish larvae after 
treatment with Ƴ-lactam 3a ................................................................................................... 150 
Figure 4.10 – Red blood cell localization and blood vessel architecture of 100 µM 3a-treated 
zebrafish embryos visualised using Tg(gata-1:DsRed);Tg(fli-1:EGFP) .................................... 152 
Figure 4.11 – Acridine orange staining of dead cells in zebrafish larvae presenting with 
ventricular brain hemorrhage ................................................................................................ 154 
Figure 4.12 – Liver necrosis and steatosis in zebrafish larvae treated with 10 µM Ƴ-lactam 3f
 ................................................................................................................................................ 156 
Figure 4.13 – Liver necrosis and steatohepatitis in zebrafish larvae treated with Ƴ-lactam 3h 
at 2000 µM ............................................................................................................................. 157 
Figure 4.14 – Partial liver necrosis and steatohepatitis in zebrafish larvae treated with Ƴ-
lactam 3h at 1000 µM ............................................................................................................ 158 
Figure 4.15 – Increase in circulating leukocytes in and around the liver and increase in liver 
size after treatment of zebrafish larvae with Ƴ-lactam 3h…………………………………………………159 
Figure 4.16 – Heat map showing morphological effects observed in zebrafish larvae after 
exposure to the six selected azetidines……………………………..……………………………………………….161 
Figure 4.17 – Heat map showing the mean mortality rate of zebrafish embryos after 
treatment with the six selected azetidines over time ............................................................. 164 
Figure 4.18 – A combined biplot two-component PCA model of zebrafish embryo biological 
responses (observations) against morphology features and physiochemical descriptors 
(variables) following treatment with a selection of azetidines over a 120 hour exposure 
period.. .................................................................................................................................... 166 
Figure 4.19 – Effects of six selected azetidines on 6 dpf zebrafish larval locomotor activity 169 
Figure 4.20 – Morphological effects observed after treatment of zebrafish embryos with 
azetidine 2a………………………………………………………………………………………………………………………170 
Figure 4.21 – Specific characterization of azetidine 2a vasculature effects using the Tg(fli-
1:EGFP) transgenic zebrafish line ........................................................................................... 171 
Figure 4.22 – Specific characterization of azetidine 2a blood circulation effects using the 
Tg(fli-1:EGFP)(gata-1:DsRed) transgenic zebrafish line ......................................................... 173 
Figure 4.23 – Ventricular brain hemorrhage (VBH) phenotype observed with azetidine 2a . 174 
Figure 4.24 – Depiction of hemorrhage localization in the brain ventricles of 3 dpf zebrafish 
larvae ...................................................................................................................................... 176 
Figure 5.1 – Chemical structures of the 28 reference drugs .................................................. 198 
Figure 5.2 – A two-component PCA model of zebrafish embryo mortality (observations) 
against concentrations and exposure times (variables) following treatment with 28 reference 
drugs over a 120 hour exposure period. ................................................................................. 204 
Figure 5.3 – LogP values plotted against log(1/EC50) values for the 28 reference drugs ..... 209 
Figure 5.4 – A three-component PCA model of zebrafish embryo responses (observations) 
against variables (toxicity endpoints and morphological features) following treatment with 
28 reference drugs over a 120 hour exposure period ............................................................. 213 
Figure 5.5 – Three-component hierarchical OPLS model of physiochemical descriptors and 
biological endpoints (variables) against biological responses (observations) ....................... 216 
Figure 5.6 – VIP plot showing the most important physiochemical properties contributing to 
zebrafish embryo mortality after exposure to the 28 reference drugs .................................. 217 
Figure 5.7 – Chemical structures of six validation drugs ........................................................ 218 
Figure 5.8 – Predictivity of the hierarchical OPLS regression model ...................................... 221 
Figure 5.9 – A two-component OPLS-DA model of biological responses (observations) against 
morphological features and mortality (variables) following drug treatment of zebrafish 
embryos with or without chorion ........................................................................................... 223 
Figure 5.10 – Correlation between zebrafish logLC50 and rodent logLD50 values for 28 
reference drugs and six validation drugs. ............................................................................... 225 
Figure 6.1 – Depiction of the area used for counting the number of leukocytes after cutting 
the tail fins of 3 dpf zebrafish larvae ...................................................................................... 245 
Figure 6.2 – Fluorescence analysis of leukocyte localization within neuromasts using the 
Tg(cldnB:GFP)(lyz:DsRed2)nz50 transgenic zebrafish line ..................................................... 249 
Figure 6.3 – Plot of inflammatory response over time for 1% DMSO control zebrafish larvae 
at 3 dpf. ................................................................................................................................... 249 
Figure 6.4 – Outline of image analysis process for hydrogen peroxide ratiometric analysis. 252 
Figure 6.5 – Anti-inflammatory responses of 28 reference drugs at 10 µM after tail-fin 
wounding of zebrafish larvae ................................................................................................. 254 
Figure 6.6 – Anti-inflammatory responses of 28 reference drugs at 100 µM after tail-fin 
wounding of zebrafish larvae ................................................................................................. 256 
Figure 6.7 – Anti-inflammatory responses of the 28 reference drugs at 10 µM using the 
zebrafish ChIn assay ............................................................................................................... 258 
Figure 6.8 - Anti-inflammatory responses of the 28 reference drugs after treatment at 100 
µM evaluated using the zebrafish ChIn assay ........................................................................ 260 
Figure 6.9 – Anti-inflammatory activity and extent of copper chelation of a selection of the 28 
reference drugs evaluated using the zebrafish ChIn assay at 50 µM ..................................... 264 
Figure 6.10 – Change in HyPer ratio after treatment of 3 dpf zebrafish larvae with a selection 
of the 28 reference drugs following initial acute inflammation by cutting of tail-fins .......... 268 
Figure 6.11 – Arachidonic acid pathway ................................................................................ 272 
Figure 6.12 – Free radical generation and anti-oxidant defence mechanisms ...................... 277 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of tables 
 
Table 1.1 – Different types of ADRs ............................................................................................ 5 
Table 2.1 – Chemicals used for experiments ............................................................................ 38 
Table 2.2 – List of 28 reference compounds used .................................................................... 39 
Table 2.3 – List of six validation drugs used. ............................................................................ 40 
Table 2.4 – List of selected azetidines used .............................................................................. 41 
Table 2.5 – List of Ƴ-lactams used ............................................................................................ 41 
Table 2.6 – Equipment and software used ............................................................................... 42 
Table 2.7 – Zebrafish transgenic lines used.............................................................................. 44 
Table 3.1 – ECG parameters measured and their meanings .................................................... 80 
Table 4.1 – Chemical structures of tested azetidines ............................................................. 128 
Table 4.2 – Chemical structures and diastereoisomer ratios for tested Ƴ-lactams................ 129 
Table 4.3 – Morphology features scored and their associated abbreviations ....................... 133 
Table 4.4 – Calculated toxicological endpoints for tested Ƴ-lactams..................................... 142 
Table 4.5 – EC50 and teratogenic index values for the nine tested Ƴ-lactams ...................... 144 
Table 4.6 – Toxic ratio (TR) values for toxicity observed with Ƴ-lactams ............................... 148 
Table 4.7 – Comparison of the effects observed after nicotine and azetidine 2a treatment of 
zebrafish embryos. .................................................................................................................. 184 
Table 5.1 – Chemical descriptors with explanation of terms ................................................. 195 
Table 5.2 – 28 reference drug set. .......................................................................................... 197 
Table 5.3 – Toxicological endpoints (LC50, NOEC and LOEC) calculated for each of the 28 
reference drugs during phase 1 after 120 hours of exposure ................................................ 205 
Table 5.4 – Concentration ranges of 28 reference drugs used in study 2 .............................. 207 
Table 5.5 – Toxicological endpoints (EC50, NOEC2 and LOEC2) and teratogenic index values 
calculated for each of the 28 reference drugs from study 2 .................................................. 208 
Table 5.6 – Toxic ratio (TR) values for toxicity observed with 28 reference drugs................. 210 
Table 5.7 – Specific phenotypes associated with drug classes from 28 reference drug set ... 211 
Table 5.8 – Calculated toxicological endpoints for validation drug set and concentration 
ranges used for phase 2 study ................................................................................................ 219 
Table 5.9 – Teratogenic index values, logTR (toxic ratio) values and physiochemical 
descriptors (logP and pKa) for validation drug set ................................................................. 219 
Table 6.1 – SYTOX® blue staining results for 28 reference drugs at 10 µM ........................... 262 
Table 6.2 – Overview of the responses of the 28 reference drugs in the zebrafish tail-fin 
wounding assay, ChIn assay and SYTOX® blue staining. ........................................................ 266 
Table 6.3 – Comparison between documented anti-inflammatory effects of 28 reference 
drugs reported in humans/rodents to those observed in zebrafish larvae ............................ 274 
Supplementary Table 8.1 – Modelling parameters used to create log concentration mortality 
plots for selection of Ƴ-lactams .............................................................................................. 290 
Supplementary Table 8.2 – Modelling parameters used to create log concentration response 
plots for selection of Ƴ-lactams .............................................................................................. 290 
 
1 
 
Chapter One: GENERAL INTRODUCTION 
1.1 Drug development 
Traditionally, the discovery of new drugs came about through chance, such as in the case of 
penicillin. However, advances in science and increased understanding of compound 
chemistry led to the systematic screening and isolation of novel compounds from plants and 
microbes (Patel and Gordon, 1996). The extraction of such compounds was found to be time 
consuming, hence with the introduction of combinatorial chemistry there was suddenly a 
huge rise in the creation of synthetic drugs. Almost all drugs marketed today are synthetic 
drugs. Synthetic drugs are created based on Lipinski’s rule of five where a compound is 
considered to be drug-like if it has <10 hydrogen bond acceptors, <5 hydrogen bond donors, 
a molecular weight <500 g/mol and a logP value <5 (Andrews et al., 2000). Compounds that 
do not meet these criteria are less orally bioavailable, are more likely to bind to plasma 
proteins and cause non-specific effects including toxicity (Andrews et al., 2000).  
 
Current drug screening approaches are based on in vitro methods where large libraries 
consisting of natural and synthetic compounds are screened against specific cellular or 
molecular targets (Mayr and Bojanic, 2009). These approaches are cheap and extremely 
rapid but are biased towards a specific target and are not representative of the in vivo 
scenario. For example, a drug may be able to bind to its target to induce therapeutic effects 
but may also lead to unwanted side effects due to metabolism into a reactive intermediate 
in the body (Figure 1.1). This is seen with the non-steroidal anti-inflammatory drug (NSAID) 
diclofenac. The therapeutic properties of diclofenac are attributed to its inhibition of the 
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cyclooxygenase (COX) 2 enzyme, which attenuates the inflammatory response (Bort et al., 
1999). However, liver toxicity has been reported in some patients as an unwanted side effect 
of diclofenac treatment (Bort et al., 1999). Liver toxicity is a result of the metabolism of 
diclofenac by cytochrome P450 (CYP) enzymes into a 5-hydroxydiclofenac metabolite which 
impairs the function of mitochondria (Bort et al., 1999).  
 
Figure 1.1 – Beneficial and undesired properties of drug candidates. 
Drugs are designed to have an effect on a specific target in order to induce a therapeutic 
effect. However, parent drugs themselves or metabolites can bind to secondary targets either 
leading to a beneficial therapeutic effect, a neutral effect or a negative toxic effect. 
 
The drug candidates that are identified from initial in vitro screening approaches are 
optimised for potency and selectivity by making changes to their chemical structures based 
on structure activity relationships (SARs). These optimised compounds then undergo in vitro 
toxicity tests where cytotoxicity is recorded at several concentrations (Li, 2001). Those drugs 
presenting with little or no toxicity at therapeutic concentrations (high therapeutic index) 
are then taken forward so that absorption, distribution, metabolism and excretion (ADME) 
studies can be performed (Li, 2001). These studies involve using Caco-2 cell lines and 
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hepatocyte co-cultures expressing various CYP enzymes to enable intestinal permeability 
and metabolic stability of these compounds to be determined (Li, 2001). Following on from 
this in vitro cellular or functional activity assays are performed. Those drugs showing good 
cellular or functional activity are then selected for testing in vivo. A drug candidate which 
shows high efficacy (specific binding to target), low toxicity (few or no side effects) and very 
good bioavailability (excellent absorption into the bloodstream) is then selected for testing 
in humans in phase 1-3 clinical trials. In human clinical trials, the dose of the lead compound 
and the formulation is optimised. In addition to this, human pharmacokinetic/pharmacodynamic 
assessments are performed as well as further evaluations on the safety of the compound. If 
the lead compound displays serious toxic side effects, the drug development process will be 
halted and the whole process has to be initiated from scratch. However, if the compound is 
successful in human clinical trials and presents a significant benefit over existing drugs for 
the therapeutic indication it is being targeted for it can be prepared for marketing. Once 
marketing authorisation is received the lead compound can be marketed as a drug. Post-
marketing surveillance of the drug is performed for at least a year to further evaluate the 
safety of the drug and to collect data on possible side effects. If the side effects reported are 
severe and life-threatening the drug can be taken off the market. The whole drug 
development process is outlined in Figure 1.2. 
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Figure 1.2 – Overview of the drug development process. To bring one drug on the market it can take up to 15 years and cost between 
500 million and 1 billion US dollars. 
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1.1.1 Adverse drug reactions (ADRs) 
Following the release of a new compound, post-marketing surveillance is carried out to 
identify any adverse drug reactions (ADRs) that could develop which may have not been 
picked up in pre-clinical studies or in human clinical trials (Edwards and Aronson, 2000). 
ADRs represent a major problem with a relative incidence rate of 1 in 10,000 individuals, 
accounting for around 100,000 deaths per year (Edwards and Aronson, 2000). ADRs can be 
broadly classified into five different categories (shown below in Table 1.1).  
 
Table 1.1 – Different types of ADRs.  
Source: Table adapted from Edwards and Aronson (2007) 
Type of ADR Description Incidence 
A (Predictable) Dose-dependent, predictable 
from primary, secondary and 
safety pharmacology 
Main cause of ADRs (around 
75%), high morbidity, low 
mortality (e.g. hemorrhage 
with anti-coagulants) 
B (Idiosyncratic) No dose-dependency, not 
predictable, idiosyncratic 
response 
Responsible for only 25% 
ADRs, but the majority of 
these are life-threatening  
(e.g. acute porphyria) 
C (Chronic effects) Long term adaptive changes, 
can be anticipated 
Occurs commonly with some 
drug classes (e.g. 
benzodiazepines) 
D (Delayed effects) Effects that occur later on, 
e.g. teratogenicity and 
carcinogenicity 
Low number of cases 
E (End of treatment effects) Rebound effects following 
discontinuation of therapy 
Occurs commonly with some 
drug classes (e.g. 
benzodiazepines) 
 
ADRs are mainly manifested in the form of cardiotoxicity and hepatotoxicity and present a 
real problem to pharmaceutical industries and health authorities. Particularly, idiosyncratic 
toxicity which is not predictable and occurs rarely is difficult to detect early on during the 
drug development process. For example, in 1993 the nucleoside analogue fialuridine went 
6 
 
into human clinical trials after prior animal tests in mice, rats, dogs and primates showed no 
adverse effects (Xu et al., 2014). However, once clinical trials were initiated trial subjects 
developed liver toxicity (Xu et al., 2014). Out of the 15 trial subjects tested, two needed liver 
transplants and five died (Xu et al., 2014). This demonstrates the importance of being able to 
detect and exclude compounds with the potential to cause idiosyncratic responses early on 
in the drug development process, as failure to do so can have fatal consequences.  
 
1.2 The zebrafish embryo as a model for drug screening 
1.2.1 Zebrafish background 
The zebrafish (Danio rerio) is a freshwater fish (cyprinoid teleost) originating from south Asia 
(Briggs, 2002). An adult zebrafish can grow up to 6 cm in length and can live for two to three 
years (Briggs, 2002). The adult zebrafish reaches sexual maturity within 3-5 months of age 
and one mating pair is able to produce around 100 eggs (Briggs, 2002). Zebrafish can be 
maintained in artificial aquaria and have become a popular model organism for scientific 
experimentation around the world. 
 
1.2.2 Zebrafish embryo development and anatomy 
Zebrafish development can be split up into several stages. The first stage of zebrafish 
development is the zygote stage (1-cell stage) which occurs from 0 to 0.75 hours post 
fertilisation (hpf) followed by the cleavage stage (0.75-2.25 hpf) where the cell starts to 
divide (Kimmel et al., 1995). Following on from this is the blastula stage (2.25-5.25 hpf) 
where epiboly (cell movement) begins (Kimmel et al., 1995). During the gastrula stage (5.25-
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10.33 hpf) epiboly continues and the tail bud is formed. This is followed by the segmentation 
stage (10.33-24 hpf) where the somites and pronephros form. The pharyngula period (24-48 
hpf) marks initiation of the heartbeat and the beginning of pigment development in the 
zebrafish embryo (Kimmel et al., 1995). The hatching period (48-72 hpf) which is 
characterised by the formation of pectoral fins and fin blades is followed by the larval period 
(72 hpf-29 dpf) where continued growth of the zebrafish and the completion of organ 
development occurs (Kimmel et al., 1995). From 48/72 hpf until 120 hpf zebrafish are 
regarded as post-hatched embryos (Strähle et al., 2012). The juvenile period lasts from 30 
until 89 dpf and is characterised by the formation of adult fins and pigments (Kimmel et al., 
1995). From 90 dpf onwards the zebrafish is regarded as an adult. 
 
Zebrafish embryos do not require an outside nutrient source whilst they are developing as 
the yolk sac contains lipids necessary for growth of the embryo (Langheinrich, 2003). Only 
after five days when most of the yolk sac has been consumed is there a requirement for an 
external food source (Langheinrich, 2003). Adult zebrafish like other fish species can obtain 
oxygen through their gills, however zebrafish at embryonic stages obtain oxygen by 
transdermal diffusion, as oxygen supply is not dependent on cardiovascular function (Jacob 
et al., 2002)(Rombough, 2002). In terms of general anatomy zebrafish embryos show 
differences to humans in that they do not have a prostate gland, long bones, limbs or lungs 
and in place of a stomach have an intestinal bulb (Lieschke and Currie, 2007). Despite these 
anatomical differences zebrafish do possess many organs such as a liver and pancreas which 
are very similar to their human counterparts and have a conserved function in both species. 
The main features of a 2 dpf zebrafish embryo are outlined in Figure 1.3. 
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Figure 1.3 – Anatomy of the 2 day old zebrafish embryo. 
 
1.2.3 The zebrafish embryo as a drug screening tool 
As previously described, in vivo models are essential in order to evaluate drug candidates for 
efficacy, metabolism and toxicity during the drug development process. Using in vivo 
models, such as rodents requires large amounts of compound and long treatment regimes. 
Zebrafish embryos on the other hand have several advantages which make them suitable for 
drug screening (see section 1.2.3.1 for further details). The zebrafish embryo is particularly 
useful for the identification of new drug targets, modelling specific diseases and determining 
the toxicity mechanisms of novel compounds (Zon and Peterson, 2005)(Hill et al., 2005). 
 
1.2.3.1 Advantages and disadvantages of the zebrafish embryo as a model for 
drug screening 
Zebrafish embryos have many advantages over other animal models in regards to their use 
for scientific research and also specifically for drug screening. General features of zebrafish 
embryos that make them advantageous to use for scientific research include: 1) low 
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maintenance costs, 2) small size, 3) optical transparency, 4) external fertilization, 5) fast 
development, 6) survival without external feeding up to 5 days post fertilization (dpf) and 7) 
similarities in toxic responses to humans and other mammals (Langheinrich, 2003). 
Additionally, the use of zebrafish embryos contributes to the 3Rs (reduction, refinement and 
replacement) of animals in research, as zebrafish embryos are not protected and do not 
require a licence until after 5 dpf.  
 
For drug screening purposes rodents are widely used as the in vivo model of choice due to 
their close ancestral relation to humans, as many developmental and physiological processes 
are conserved between the two species. Additionally, the same drug administration routes 
as those planned for human use can be employed when using rodents. Despite rodents 
being a mainstay for drug screening and particularly toxicological testing, compared to 
zebrafish, rodent development is slow and occurs in utero (Wheeler and Brändli, 2009). 
Additionally, maintenance costs are more expensive when using rodents, rodent studies 
have more stringent regulatory restrictions surrounding their use and large amounts of 
compound are required for dosing regimens (Hill et al., 2005).  
 
Early development in all vertebrate species is highly conserved with similarities evident in 
the genes, receptors and molecular pathways utilized (Hill et al., 2005). Therefore, using 
simple vertebrates such as zebrafish may be representative of what happens in more 
complex animals, such as humans despite the evolutionary distance (Hill et al., 2005). 
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Features which make zebrafish embryos particularly suited for drug screening include: 1) the 
ability to absorb chemicals (especially low molecular weight compounds) transdermally, 2) 
the ability to survive in very small volumes of liquid as low as 50 µL in 96 well or 384 well 
plates, 3) the possibility to test large numbers at one time, 4) the possibility to perform 
automated drug screens and 5) the possibility to fluorescently label tissues or organs of 
interest (Goldsmith, 2004). Additionally, after 3 dpf (4-5 dpf) zebrafish can ingest compounds 
orally, as they have a fully functional gastrointestinal (GI) tract which can aid diffusion of 
drugs that cannot be absorbed by transdermal diffusion (Goldsmith, 2004)(Belanger et al., 
2010). Dimethyl sulphoxide (DMSO) is often used as a solvent to solubilise compounds that 
are not readily soluble in water. Zebrafish embryos are DMSO tolerant up to 1.5%, which 
means that they can also be used to test poorly water soluble compounds.  
 
Zebrafish also show high similarity to humans in terms of pharmacology, physiology and 
genetics (Crawford et al., 2011), as well as presenting with similar toxic and teratogenic 
effects to humans after drug exposure (Parng et al., 2002). The zebrafish genome has two 
more chromosome pairs than humans and has many duplicated genes (Hill et al., 2005). 
However, many of these duplicated genes have a new function and may be expressed in 
different tissues compared to their ancestors (Hill et al., 2005). This has its benefit as 
knockdown of a specific gene in zebrafish embryos may not be embryo lethal compared to 
the mammalian counterpart (Hill et al., 2005). Additionally, the high fecundity of zebrafish 
also has its advantages when establishing a new transgenic line, as it is much quicker and 
cheaper than establishing one in rodents (Murphey et al., 2006).  
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The disadvantages of using zebrafish embryos for scientific research include their 
evolutionary distance to humans, meaning that some processes cannot be modelled in 
zebrafish (e.g. lung development) due to differences in anatomy. Additionally, the same drug 
administration routes intended for human use cannot be employed in zebrafish embryos, 
which therefore make rodents a more suitable model for this purpose. Studies on the ADME 
properties of a compound are more difficult to perform when using zebrafish embryos, as 
studies addressing this have only begun to be developed (Diekmann and Hill, 2013). 
Furthermore, drug metabolism pathways have not been as extensively characterised in 
zebrafish compared to rodents and other mammals.  
 
1.2.3.2 Advantages and disadvantages of the zebrafish embryo as a model for 
drug screening compared to other fish models 
The closest fish model to zebrafish is the medaka (Oryzia latipes), which compared to 
zebrafish can generally only survive in the laboratory for 1 year and it produces very few 
embryos which are difficult to remove, clean and collect (Hill et al., 2005). Apart from 
medaka, the carp (Cyprinus carpio) is particularly useful for toxicological studies and the 
puffer fish for genetic studies, as it lacks junk deoxyribonucleic acid (DNA) (Hill et al., 2005). 
However, the zebrafish is still the preferred option over these aforementioned fish species 
for scientific research, as it has been extensively studied, so far greater resources and 
published literature are available compared to other fish species. For example, information 
is readily available on the physiology, genetics and biochemistry of zebrafish at all stages of 
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development (Hill et al., 2005). Additionally, the technology and techniques available for 
zebrafish are far more than for any other fish species (Kari et al., 2007). 
 
1.2.3.3 Advantages of the zebrafish embryo in vivo model over in vitro models 
for use in drug screening 
In comparison to cell culture models, the zebrafish embryo in vivo model enables the 
interaction between different cells and tissues to be investigated in a complex multicellular 
organism with the opportunity to study cell-cell and cell-matrix interactions, as well as the 
uptake, metabolism and excretion of a compound (Scholz et al., 2008). Despite the 
popularity of in vitro approaches and particularly the growing interest in toxicogenomics 
which enables gene expression changes upon exposure to a compound to be monitored at 
high throughput with miniscule compound consumption; these in vitro approaches do have 
their drawbacks (Pettit et al., 2010). For example, in vitro approaches do not replicate what 
happens in the whole organism as cell or organ cultures are used (Pettit et al., 2010). 
Additionally, large datasets are generated which take time to process and the results that 
are obtained are often further complicated by normal variations in gene expression (Pettit et 
al., 2010). Additionally, cell culture serum required for maintaining cell cultures can pose a 
barrier to drug penetration, as serum proteins can interact and bind to drugs preventing 
them from reaching their targets or being activated (Wheeler and Brändli, 2009).  
 
Induced pluripotent stem (iPS) cells are also becoming increasingly popular in scientific 
research. These cells are derived directly from humans and have the capability to 
differentiate into various cell types including endodermal, mesodermal and ectodermal cells 
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(Yamanaka, 2009). These cells offer advantages over in vivo and other in vitro methods in 
that they are directly derived from the patient and therefore contain the same genetic 
information (Yamanaka, 2009). This is particularly useful for performing drugs screens in 
diseased cells, especially diseases where the genotype can influence the severity of the 
disease (e.g. long QT syndrome) (Yamanaka, 2009). Due to iPS cells being a relatively new 
technology there are some obstacles that still need to be overcome, such as the possibility of 
the cells forming teratomas (germ cell tumours) and there being no way to confirm whether 
nuclear programming has been completed (Yamanaka, 2009). Additionally, as mentioned 
above using iPS cells does not replicate the in vivo scenario, highlighting the same limitation 
of other in vitro methods.   
 
Zebrafish offer the advantage in conjunction with rodent models that initial ADME 
assessments can be performed. In vitro ADME assessments can also be performed but they 
only allow certain parts of the ADME response to be modelled at one time (Wheeler and 
Brändli, 2009). For example, Caco-2 cells can only be used to determine intestinal stability, 
whereas hepatocyte co-cultures can only be used to determine metabolism, so the whole 
ADME response cannot be modelled all at once (Li, 2001). In addition to ADME, zebrafish 
embryos can also be used to determine toxicity of compounds in vivo, which takes into 
account several factors including ADME. Therefore, more screens are shifting from cell-
based to whole animal in vivo screens, particularly zebrafish screens due to the above 
mentioned advantages (Choi and Tontonoz, 2013).  
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1.2.3.4 The zebrafish embryos as a complementary model to existing in vitro 
models 
In drug development, the goal would be to introduce the zebrafish embryo test as a 
complementary method to existing in vitro and in vivo tests already in place. Specifically, the 
zebrafish embryo model could be utilised as a pre-screen after selection of candidate drugs 
from the initial in vitro screening approaches. This would therefore help to exclude any toxic 
compounds before they are tested in rodents. 
 
A cell cycle inhibitor screen was performed by Murphey and colleagues using three different 
methods to compare in vitro and in vivo drug screening approaches (Murphey et al., 2006). 
The screening methods employed included: 1) a mammalian cell line method, 2) a zebrafish 
cell line method and 3) a zebrafish embryo screening method (Murphey et al., 2006). When 
using the zebrafish embryo screening method 14 novel compounds were found, which were 
previously not identified using the mammalian cell line approach (Murphey et al., 2006). Six 
of them were found to have an effect in the mammalian cell line, suggesting that their 
effects were conserved among vertebrates (Murphey et al., 2006). Three compounds were 
found to be inactivated by serum in cell line culture and therefore not effective in the 
mammalian or zebrafish cell lines and three compounds were found to only be active in 
zebrafish embryos (Murphey et al., 2006). Interestingly, one compound was found to be 
effective only in the zebrafish cell line and zebrafish embryos, suggesting the effect of this 
compound was species specific (Murphey et al., 2006). The lessons learnt from this study are 
that the way forward in drug development would not be to replace the existing in vitro 
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screening methods with the zebrafish embryo test, but to actually combine them together as 
complementary methods, as no one single test can address all the questions being asked. 
 
1.2.4 Zebrafish embryo drug screens 
As mentioned previously, the many advantages of zebrafish embryos make them particularly 
attractive as models for drug screening applications. The first chemical screen utilising 
zebrafish embryos was carried out by Peterson and colleagues where compound-treated 
zebrafish embryos were visually assessed during development to identify any abnormal 
morphological features that developed after compound exposure (Peterson et al., 2000). 
Some of the phenotypes that were observed after compound exposure included 
hyperpigmentation and abnormal ear development (Peterson et al., 2000). Since then, many 
compound screens have been performed, specifically looking at vasculature (Tran et al., 
2007), dorsoventral patterning (Bowman and Zon, 2010), pigmentation (Peal et al., 2010) 
and erythropoiesis (Wheeler and Brändli, 2009).  
 
When searching for compounds that could have a therapeutic effect, targeted screening is 
generally employed where compounds that inhibit or suppress a particular phenotype are 
screened for (Hong and Brewster, 2006). To create an abnormal phenotype of interest (e.g. 
skin cancer) a particular compound could be administered or a genetic technique (e.g. zinc-
finger nucleases/morpholino knockdown/TILLING [targeted induced local lesions in 
genomes]) could be employed to knockdown a specific gene that leads to the mutant 
phenotype. Recovery of the normal state or reduced severity of the phenotype would then 
be used as an endpoint for such assays.  
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A zebrafish embryo screen performed by Peterson and colleagues involved using a targeted 
gene knockdown approach where a zebrafish gridlock mutant was generated (Peterson et 
al., 2004). In this mutant aortic blood flow was affected (a similar condition occurs in 
humans) meaning that the trunk and tail regions of the fish did not receive any blood 
(Peterson et al., 2004). After screening a library of compounds to find suppressors of this 
mutation, two novel compounds were identified that could rescue this phenotype, 
presenting potential therapies for humans suffering from this condition (Peterson et al., 
2004).  
 
Additionally, in a zebrafish embryo screen performed by Jung and colleagues the compound 
PPA was used to induce a hyperpigmentation phenotype in zebrafish embryos (Jung et al., 
2005). Initial biochemical studies revealed that PPA affected the ATPase synthase pathway 
(Jung et al., 2005). Therefore, a zebrafish embryo screen was performed to identify inhibitors 
of this pathway (Jung et al., 2005). Novel inhibitors were identified from this screen which 
could attenuate this phenotype, representing potential therapies for sufferers of 
hyperpigmentation disorders (Ni-Komatsu and Orlow, 2007).  
 
The advent of high throughput screening techniques has meant that drug screens can now 
be automated at every stage of the process by using embryo sorting robots, liquid handling 
robots and automated imaging/analysis tools.  
 
The first high throughput screen utilising zebrafish embryos was an organ-specific screen 
developed by Burns and colleagues where the myocardium was labelled with the green 
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fluorescent protein (GFP) (Burns et al., 2005). Using automated video monitoring and 
custom-written video analysis scripts, the heartbeats of the zebrafish embryos in each well 
could be automatically determined (Burns et al., 2005). Hence, small molecules could then 
be screened in 96 well plates to see how they modulated the heart rate (Burns et al., 2005). 
 
With the latest technological developments and the growing understanding of the zebrafish 
embryo the number of high throughput screens has increased (Gerlai, 2010)(Pardo-Martin et 
al., 2010)(George et al., 2011)(Ishaq et al., 2013)(Veneman et al., 2013)(Lin et al., 2013). This 
number will keep on increasing and in the future many screens may only require minimal 
manual input.  
 
1.3 Solubility and penetration of compounds into zebrafish embryos 
To determine whether a compound will diffuse readily into a zebrafish embryo and 
distribute to its target, the logP (logarithm of the partition ratio between octanol and water) 
can be calculated based on the chemical structure of the compound or by empirical 
measurement (Taylor et al., 2010). 
 
At early developmental stages the chorion can be a barrier to diffusion of large molecules, as 
the chorion has pores of a certain size and so very large and bulky molecules may not be 
able to penetrate into the zebrafish embryo (Milan et al., 2003). These compounds tend to 
have logP values <1 and are most commonly either weak acids or bases (Milan et al., 2003). 
However, the problem of penetration can be overcome by: 1) injecting compounds directly 
into the zebrafish embryos immediately after fertilization, 2) by injecting the compounds 
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directly into the blood circulation of zebrafish embryos at later stages of development or 3) 
by dechorionating the zebrafish embryos either manually or with an enzyme before 
performing drug treatments (Milan et al., 2003). Generally, for drug screening zebrafish 
embryos in their chorions are used, as microinjection and dechorionation techniques are 
more time consuming and therefore not feasible when screening thousands of compounds. 
Additionally, for poorly water soluble highly hydrophobic compounds DMSO can be used as 
a solubilisation aid (Milan et al., 2003).  
 
In studies carried out by Milan and colleagues and Sachidanandan and colleagues 
compounds with logP values >1 were found to be absorbed readily in zebrafish embryos 
(Milan et al., 2003)(Sachidanandan et al., 2008). Additionally, bioanalysis studies have 
confirmed that compounds with logP values >1 have better uptake into zebrafish embryos, 
as they are more lipophilic in nature (Alderton et al., 2010).  
 
In humans even after a compound has entered the circulation, the compound may bind to 
plasma proteins affecting the amount of free compound still available (Wood, 1986). 
Generally, compounds that are weak bases will bind α1-glycoprotein and compounds that 
are weak acids will bind albumin (Wood, 1986). Furthermore, in zebrafish there may be the 
possibility that some compounds bind to yolk sac proteins, therefore limiting the amount of 
free drug available. Additionally, pKa is also an important factor that needs to be taken into 
consideration regarding drug penetration, as the pH can influence the amount of free drug 
available. In the gastrointestinal tract the pH gradients can have a strong impact on the 
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uptake of compounds and therefore lead to differences in uptake between 
humans/mammals and zebrafish. 
 
The only method to determine accurately the amount of free drug is to carry out bioanalysis 
of samples and measure the parent drug and metabolite levels both inside and outside the 
zebrafish (Alderton et al., 2010). Such approaches are currently being explored and 
implemented into zebrafish screens, as they enable pharmacokinetic aspects to be 
investigated (Alderton et al., 2010) (Diekmann and Hill, 2013). 
 
Pharmacokinetics differ greatly between zebrafish embryos and mammals due to the 
different exposure routes employed. Zebrafish embryos undergo constant water-borne drug 
exposure and receive drugs mainly by dermal diffusion, whereas mammals are exposed to 
drug as a single dose either orally, dermally or via inhalation, thereby relying on intestinal 
absorption or intravascular delivery. In zebrafish embryos the liver is by-passed and the drug 
directly enters the systemic circulation. As in mammals drugs are most commonly 
administered orally there is potential for extensive drug metabolism to occur in the liver 
(first-pass metabolism) before it reaches the systemic circulation (Julkunen et al., 1985). This 
is because after oral administration the drug needs to pass through the digestive tract into 
the hepatic portal system where the drug is then transported to the liver (Julkunen et al., 
1985). With certain drug types first pass effects can lead to either increased risk of toxicity or 
reduced risk of toxicity.  
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An additional effect that can also occur is enterohepatic circulation where the drug passes 
through the liver into the intestine, is absorbed by enterocytes and then travels back to the 
liver again (Roberts et al., 2002). This can occur with certain types of drugs and can lead to 
an increase in the drug half-life which can be potentially dangerous (Roberts et al., 2002).   
 
The differences in exposure routes make it difficult to extrapolate drug effects from 
zebrafish embryos to mammals. To determine whether the different exposure routes lead to 
differences in internal drug concentrations it would be particularly useful to determine 
pharmacokinetic parameters. These include the area under the curve (AUC) which reflects 
the exposure of the body to the drug, the Cmax which represents the peak plasma 
concentration and the elimination rate constant ke which represents the time taken for the 
drug to be cleared from the body. Determining such parameters in zebrafish embryos could 
aid extrapolation. 
 
1.4 Zebrafish embryo drug metabolism 
Drug metabolism involves two phases, namely phase 1 and phase 2 reactions (Figure 1.4). In 
phase 1 reactions, compounds are either inactivated/activated by CYP enzymes (haem-
containing mono-oxygenases) or by non-CYP enzymes, e.g. alcohol/aldehyde 
dehydrogenases, peroxidases, xanthine oxidase, mono/diamine oxidases, aromatases and 
flavin mono-oxygenases (Roberts, 2005). In phase 2 reactions, these intermediary 
metabolites are then conjugated to glutathione (glutathione S-transferase) or glucuronic 
acid (uridine diphosphate [UDP] glucuronosyl transferases), acetylated (N-acetyl 
transferases), sulphated (sulphotransferases) or methylated (methyltransferases) so that 
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they can then be excreted more easily (Roberts, 2005). Occasionally, a phase 3 reaction may 
also occur where phase 2 metabolites are further metabolised (e.g. conversion of 
glutathione conjugates to acetyl cysteine conjugates) (Goldstone et al., 2010).  
 
Additionally, in humans polymorphic variants of CYP enzymes (e.g. CYP2D6) and also phase 2 
enzymes (e.g. N-acetyl transferases) exist, meaning that in some individuals drug 
metabolism may be faster and in others it may be slower. It is therefore important to take 
this into consideration when creating new drugs in order to prevent toxicity and the 
development of ADRs (Dorne et al., 2003). 
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Figure 1.4 – Summary of phase 1 and phase 2 reactions that occur in humans. Compounds undergoing phase 1 and phase 2 metabolism 
can form metabolites that are unreactive which can be safely excreted from the body or they can form toxic metabolites, such as reactive 
oxygen intermediates or free radicals which can cause cell or tissue damage. 
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Zebrafish embryos and larvae have been shown to be able to perform both phase 1 and 
phase 2 reactions (Alderton et al., 2010). Non-CYP phase 1 enzymes, such as monoamine 
oxidase and alcohol/aldehyde dehydrogenase have also been identified in zebrafish embryos 
(Alderton et al., 2010). 
 
Compared to rodents, zebrafish metabolism has not been as extensively characterised. 
There is more data for phase 1 reactions compared to phase 2 reactions. It has been found 
that in total zebrafish have 94 CYP enzymes (Goldstone et al., 2010). CYP families 5 to 51 
have mainly endogenous functions (steroidogenic and hydroxylase enzymes), however these 
CYPs share the most sequence similarity to humans and account for a third of the total CYPs 
found in zebrafish (Goldstone et al., 2010). CYP families 1 to 3 are much more complex; 
however these include the main enzymes involved in drug metabolism (Goldstone et al., 
2010). There are fewer orthologues of human CYPs in the zebrafish CYP families 1 to 3 and 
particularly CYP family 2 has many more genes compared to humans, as well as a few 
clusters unique to zebrafish (e.g. CYP2J1) (Goldstone et al., 2010)(Alderton et al., 2010). 
Additionally, it has been found that expression of CYP genes in the zebrafish embryo is highly 
dependent on developmental stage with different CYP genes beginning expression at 
different developmental time points (Goldstone et al., 2010). CYP1A1 has been most 
extensively studied in zebrafish and it has been found to be induced in both embryonic and 
adult stages (Spitsbergen and Kent, 2003). The similarity in CYP enzymes between zebrafish 
and humans means that the zebrafish represents a good model to study CYP-mediated drug 
metabolism. For example, the classic metabolic conversion of phenacetin to paracetamol by 
CYP1A2 in humans is also replicated in zebrafish embryos (Alderton et al., 2010). 
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Additionally, classical drug-drug interactions such as those seen between cimetidine and 
terfenadine also occur in zebrafish with cimetidine potentiating the effects of terfenadine by 
inhibiting CYP3A4 (Milan et al., 2003). CYP3A4 accepts a variety of substrates and is 
responsible for the metabolism of around 50% of marketed drugs (Dorne et al., 2003). 
 
In terms of phase 2 reactions, the zebrafish is able to carry out sulphation via cytosolic 
sulphotransferase and has also been found to carry out glucuronidation and glutathione 
conjugation (Goldsmith, 2004)(Alderton et al., 2010). However, phase 2 metabolism does 
show some differences to humans, as fish have lower glucuronosyl activity (Alderton et al., 
2010). For example, cisapride metabolism in zebrafish yields a main metabolite that is found 
only in minor quantities in dogs and there is no evidence of zebrafish producing glucuronide 
metabolites commonly seen in humans following cisapride exposure (Alderton et al., 2010). 
Therefore, these species specific differences need to be taken into account when 
extrapolating results to humans. 
 
Additionally, in the zebrafish genome 41 ATP-binding cassette (ABC) transporters have been 
identified (Dean and Annilo, 2005)(Scholz et al., 2008). ABC transporters are important for 
getting drugs out of the cell (drug efflux) but require adenosine triphosphate (ATP) for 
transport, as the energy generated from the hydrolysis of ATP is required to drive the 
transport process (Brinkmann and Eichelbaum, 2001). Examples of ABC transporters include 
multi-drug resistance protein 1 (MDR1) which has been extensively studied as its over-
expression can hinder drugs getting into a cell to exert an effect (Brinkmann and Eichelbaum, 
2001)(Bresolin et al., 2005). Influx transporters, such as the divalent metal transporter 1 
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(DMT-1), which transports iron into the cell does not require energy and has also been found 
to be expressed in zebrafish embryos (Donovan et al., 2002). Therefore, it is also possible to 
study drug entry and exit in the zebrafish embryo. 
 
1.5 Toxicity 
The main reason for drug failures during the drug development process is toxicity. Toxicity 
can be restricted to specific organs or can affect the whole body. Every compound has the 
potential to be toxic, but it is the dose that defines whether a compound is toxic or not. 
Toxicity can be caused by parent compounds themselves or chemically reactive 
intermediates which are formed following metabolism (Gillette et al., 1974). The toxicity of 
compounds can be divided into eight general groups based on their modes of action (MOA). 
These eight groups include group 1 (non-polar narcosis), group 2 (polar narcosis), group 3 
(uncoupling of oxidative phosphorylation), group 4 (inhibition of the acetylcholinesterase 
enzyme), group 5 (reactive toxicity), group 6 (glutathione depletion), group 7 (estrogenic 
activity) and group 8 (drug-induced auto-immunity) (Verhaar et al., 1996)(Nendza and 
Wenzel, 2006).  
 
Group 1 compounds are non-reactive and have no specific target causing baseline toxicity, 
which is non-specific toxicity caused by compounds partitioning into biological membranes 
interfering with membrane structure and function (Nendza and Wenzel, 2006)(Su et al., 
2014). Baseline toxicity can be predicted from logP (also known as logKow), which is the 
octanol-water partition coefficient (Su et al., 2014). A compound with a high logP value is 
more likely to partition into a biological membrane to cause unspecific effects and 
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depression of biological activity (narcosis) (Su et al., 2014). An example of a compound that 
belongs to this group is 1,4-dichlorobenzene (Su et al., 2014).  
 
Group 2 compounds (polar narcotics) like group 1 compounds are not reactive but are 
slightly more toxic due to hydrogen bond donor acidity (Su et al., 2014)(Ramos et al., 1998). 
Phenol is an example of a group 2 compound (Nendza and Wenzel, 2006).  
 
Group 3 compounds include compounds which have specific effects on oxidative 
phosphorylation (process by which ATP is generated) (Nendza and Wenzel, 2006). For 
example, oligomycin inhibits the ATP synthase enzyme and stops protons flowing through 
the Fo sub-unit (Terada, 1990).  
 
Group 4 compounds specifically target the acetylcholinesterase enzyme, which has an 
important function at neuromuscular junctions by terminating synaptic transmissions. The 
organophosphate (OP) insecticide malathion is a compound that specifically inhibits the 
acetylcholinesterase enzyme preventing hydrolysis of acetylcholine (Krstić et al., 2008).  
 
Group 5 compounds cause toxicity due to their highly reactive nature.  Acrolein is a group 5 
compound which is a highly reactive electrophile that binds to and depletes cellular 
nucleophiles such as glutathione (Kehrer and Biswal, 2000). Acrolein also readily reacts with 
nucleophilic sites in DNA and with cysteine, lysine and histidine residues of proteins via 
sulphydryl alkylation (Gillette et al., 1974). Acrolein can also initiate lipid peroxidation, which 
is a secondary process where lipid radicals are formed that can damage cell membranes 
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(Kehrer and Biswal, 2000). Nitrobenzaldehyde is another compound that falls into this group 
(Ramos et al., 1998).  
 
Group 6 compounds cause glutathione depletion. Glutathione, as mentioned previously 
conjugates reactive intermediates. Glutathione is therefore an important cellular protector 
and when its levels are reduced, toxic insult can occur (Gillette et al., 1974). Paracetamol 
metabolism leads to the formation of a reactive intermediate N-acetyl-p-benzoquinone 
imine (NAPQI) (Gillette et al., 1974). At therapeutic paracetamol doses, this reactive 
intermediate is removed from the body by conjugation with glutathione (Gillette et al., 
1974). Glutathione is a scavenger of free radicals (Gillette et al., 1974). Free radicals include 
superoxide, nitric oxide, trichloromethyl, thiyl and hydroxyl radicals (Halliwell and Chirico, 
1993). These free radicals will act in a chain reaction by removing/adding an electron to 
biological molecules converting them in the process to radicals as well (Halliwell and Chirico, 
1993). Additionally, hydrogen peroxide can also cause direct cellular damage at high levels 
(Halliwell and Chirico, 1993). To control levels of these reactive species (free radicals and 
hydrogen peroxide), the cell has several anti-oxidant defence mechanisms which include the 
enzymes superoxide dismutase (converts superoxide radical to hydrogen peroxide) and 
catalase/glutathione peroxidase (converts hydrogen peroxide to water) (Halliwell and 
Chirico, 1993). When levels of these enzymes are low or the generation of reactive oxygen 
species (ROS) is high, the result will be cellular damage particularly to mitochondria, as free 
radicals can perturb mitochondrial respiration (Halliwell and Chirico, 1993).  
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Group 7 compounds are those that affect the estrogen receptor. These compounds are able 
to mimic natural estrogens, thereby disrupting the endocrine functions of the estrogen 
receptor leading to malformations of the reproductive tract, as well as reduced fertility 
(Gould et al., 1998). Bisphenol A is an example of a group 7 compound, as it binds to the α 
sub-unit of the estrogen receptor resulting in altered estrogenic activity that can lead to 
sexual dysfunction in humans (Gould et al., 1998). 
 
Compounds from group 8 cause toxicity by binding to proteins in the body and forming a 
new entity, a hapten (Olsen, 2004). This hapten is recognised as foreign by the immune 
system eliciting an auto-immune response, such as in the case of minocycline-induced auto-
immunity (Olsen, 2004).  
 
1.5.1 Selective toxicity 
Metabolism of compounds mainly occurs in the liver. However, some compounds are 
metabolised only in certain regions of the body where a specific enzyme or target is present. 
This can in some instances lead to increased toxicity, such as in the case of allylamine, which 
is converted by amine oxidase to acrolein and hydrogen peroxide in the heart (Nelson and 
Boor, 1982).  
 
Many compounds that have toxic effects are often metabolised to reactive intermediates, 
such as in the case of paracetamol, benzo[a]pyrene and benzene (Thakker et al., 
1977)(Bolton et al., 2000). However, compounds can also cause toxicity due to them being 
structurally similar to key endogenous compounds. This is seen with polyporic acid from the 
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mushroom Hapalopilus rutilans that specifically inhibits dihydroorotate dehydrogenase, the 
enzyme responsible for the production of uridine triphosphate (UTP) (Kraft et al., 1998). 
Inhibition of UTP synthesis leads to severe clinical effects in humans, as UTP is an important 
source of energy and an activator of substrates for metabolic reactions (Kraft et al., 1998).  
 
1.5.2 Species specific differences in toxicity 
The toxicity of compounds as mentioned previously can differ between species. This is 
because of differences in toxicokinetics. For example chocolate is particularly toxic to dogs 
and cats, as it contains the methylxanthine theobromine which can lead to symptoms such 
as vomiting and tachycardia (Dvorakova and Zapletal, 2001). This is due to the slow rates of 
CYP metabolism in these two animals compared to humans (Dvorakova and Zapletal, 2001).  
 
For phase 2 reactions the differences between species is most pronounced. For example, the 
glucuronidation rate in birds is comparable to humans; however in fish and cats glucuronosyl 
transferase activity is lower (around 10-fold less) (Hayes, 2001). These differences in 
metabolism are therefore important to consider when evaluating the effects of compounds 
in animals and extrapolating their effects to humans.  
 
Differences in exposure routes between zebrafish embryos and mammals also contribute to 
species specific differences. This is because the different exposure routes could lead to 
differences in internal drug concentrations. It has been shown that if in vitro LC50 values are 
compared to plasma concentrations at the LC50 (LC50plasma), a much better correlation can 
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be obtained (Ekwall et al., 1998) (Sjöström et al., 2008). Therefore, it may better to 
determine internal drug concentrations before making comparisons. 
 
1.5.3 The zebrafish embryo as a toxicological model 
As mentioned previously, the zebrafish embryo has several advantages over other animal 
models which makes it particularly suited to drug screening applications, especially for 
toxicological investigations. The optical transparency of the zebrafish embryo means that 
simple visual assessments for toxicity can be performed using a light microscope without the 
need for expensive or complicated equipment. There is also a high similarity in the toxic 
responses after chemical exposure (e.g. cadmium and methyl mercury chloride) between 
zebrafish and mammals, particularly on a gene expression level (Yang et al., 2007). This 
therefore highlights the suitability of the zebrafish embryo as a model for toxicity testing. 
 
There is a high demand to use ethically acceptable alternative testing methods to assess the 
toxic risk of new chemicals (e.g. pharmaceuticals, waste products and industrial solvents) 
within the European union (EU) to comply with the ‘Registration, Evaluation and 
Authorisation of Chemicals’ (REACH) initiative which aims to reduce testing on vertebrates 
(Scholz et al., 2013). 
 
The zebrafish embryo acute toxicity test (ZFET) has recently been implemented into the 
‘Organisation for Economic Co-operation and Development’ (OECD) test-guidelines and is 
now available as OECD test guideline 236 (Busquet et al., 2014).  A validation study of this 
new guideline was performed where 20 chemicals were tested in zebrafish embryos at five 
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different concentrations in three independent runs and in at least three different 
laboratories (Busquet et al., 2014). The zebrafish embryos were exposed to the chemicals for 
96 hours with 20 zebrafish embryos tested per concentration/control (Busquet et al., 2014). 
Acute lethality was used as an endpoint with four indicators used to confirm lethality, 
namely non-detachment of the tail bud from the yolk sac, lack of heartbeat, lack of somite 
formation and coagulation of the embryo (Busquet et al., 2014). The results obtained 
showed good reproducibility within and between laboratories (Busquet et al., 2014). 
However, for more toxic chemicals and those chemicals tested close to their solubility limit 
the reproducibility was lower (Busquet et al., 2014). Additionally, in a study performed by 
Berlanger and colleagues the ZFET test was found to have a high predictive power for 
predicting the acute toxicity of fish to new chemicals (Belanger et al., 2013).  
 
Toxicity can be quantified and compared between species by determining toxicity endpoints. 
These include LC50 (concentration of compound which is lethal to 50% of the tested 
population), EC50 (concentration of compound which has an effect in 50% of the tested 
population), NOEC (no observed effect concentration) and LOEC (lowest observed effect 
concentration). In a study performed on 60 water-soluble compounds by Ali and colleagues 
the zebrafish embryo logLC50 values that were calculated were found to show high similarity 
to rodent logLD50 values (Ali et al., 2011). These findings are quite unexpected considering 
the differences in exposure routes between zebrafish and rodents. Additionally, the study by 
Ali and colleagues also showed that compound class significantly influenced toxicity where 
for example alcohols were found to be less toxic in zebrafish compared to rodents (Ali et al., 
2011).  
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1.6 Multivariate analysis 
Multivariate analysis is a useful technique when interpreting and analysing large datasets 
with many variables, such as toxicity data where there are multiple toxicity endpoints. 
 
1.6.1 Principal component analysis 
Principal component analysis (PCA) is a method used to identify patterns in large datasets 
with multiple variables. PCA reduces the dimensionality of the data (i.e. the number of 
variables); creating a new coordinate system where principal component 1 points in the 
direction of the data where there is the highest spread (variance), as shown in Figure 1.5. 
Principal component 2 is plotted orthogonal to principal component 1 and shows the second 
highest spread in the data. More components can then be added to show further variance 
within the data.  
 
Once a PCA analysis has been performed two plots are created, the first one is the scores 
plot and the second one is the loading plot. The scores plot shows the observations 
(samples) and the loading plot the variables. The scores are representative of the distance of 
the observations from the origin with scores located in the centre of a scores plot having no 
influence on the model. Scores that are close to one another show high similarities 
compared to those that are far apart. Variables that are close together on the loading plot 
co-vary and show dependency on one another. The score and loading plots are interpreted 
by superimposing them. This way it is possible to identify relationships/patterns between 
observations and variables. The closer a score is to a variable the higher a value it has for 
that variable. When using bimodal plots, the scores and loadings are automatically 
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superimposed on one plot. For all multivariate analysis models including PCA models the R2X 
and Q2 values determine the dispersion and stability of the data. A model with an R2X value 
>0.7 and a Q2 value >0.4 is deemed to be of good quality. 
 
Figure 1.5 – Basis of principal component analysis (PCA). PCA creates a new coordinate 
system where the principal components pass through the data where there is the highest 
variance. Key: blue triangles = observations (obtained data), red circles = variables 
 
1.6.2 Partial least squares 
Partial least squares (PLS) is a method for regression analysis and thus can be used to model 
the relationship between variables X and Y, as well as predict new values for Y. This makes 
PLS particularly useful for quantitative structure activity relationship (QSAR) modelling, as for 
example the X variables (physiochemical descriptors of compounds) can be used to predict 
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the Y variables (biological effects of compounds). The aim of PLS is to reduce the 
dimensionality of the data and maximise the covariance between the X-scores designated T 
and the Y-scores designated U, as shown in Figure 1.6. The first PLS component is 
represented by two lines. The first line is within the X-space and in the direction w1 (X-
weight forms the matrix w1). The second line is within the Y-space and in the direction c1 (Y-
weight forms the matrix c1). The second PLS component is also represented by two lines and 
similarly to the first component one line is in the direction w2 and the other in the direction 
c2. Additional components are added to improve the model as much as possible.  
 
Figure 1.6 - Transformation of data with multiple X and Y variables into a two dimensional 
representation using partial least squares (PLS). PLS enables co-variance between X and Y to 
be investigated when there are multiple X and multiple Y variables. Key: X-scores = T, Y-scores 
= U, X-weights = w, Y-weights = c, blue triangles = observations, red circles = variables 
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Orthogonal partial least squares (PLS) is an extension of PLS where an orthogonal signal 
correction is applied to remove variation that has no direct relation to the responses 
observed (Sadeghi-Bazargani et al., 2010).  
 
In a standard PLS the Y vector can be anywhere relative to X. In OPLS modelling however the 
Y vector is placed in alignment with the first component in the X matrix, as shown in Figure 
1.7. This separates the correlated and uncorrelated variables. The X and Y loadings are 
represented by p and q, respectively on an OPLS loading plot.  
 
Figure 1.7 – Transformation of data with multiple X and Y variables into a two dimensional 
representation using orthogonal partial least squares (OPLS). OPLS enables correlated 
variables to be distinguished from correlated variables aiding interpretation of the models 
created. Key: X-scores = T, Y-scores = U, X and Y loadings = pq, blue triangles = responses, 
purple circles = biological endpoints, red circles = biological variables 
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Hierarchical OPLS models are an alternative to conventional OPLS models where the 
principal components derived from an initial PCA analysis are used as the Y values.  
 
Another variation of OPLS is OPLS-Discriminant Analysis (DA). In OPLS-DA the distinctions 
between two different groups can be easily made. This is because OPLS-DA is able to 
separate the variation which is predictive from that which is not (Bylesjö et al., 2006). 
Discriminant analysis can also be combined with PLS (Figure 1.8A), but OPLS-DA models are 
preferred as they enable much clearer visualisation of differences (Figure 1.8B). 
 
Figure 1.8 – Comparison of PLS-DA and OPLS-DA models. A) PLS-DA scores and loading 
plots, B) OPLS-DA scores and loading plots. OPLS-DA enables clear differences between 
different groups of observations to be observed. Key: X-scores = T, Y-scores = U, X and Y 
loadings = pq, blue triangles = responses, purple circles = biological endpoints, red circles = 
biological variables 
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1.7 Aims of thesis 
In recent years, the pressure on pharmaceutical companies has increased to produce new 
drugs, which are safe, effective and commercially valuable. However, the drug development 
process takes a long time and costs a lot of money, thus it is of upmost importance to 
eliminate drug candidates with the potential to produce toxicity in humans early on in the 
drug development process. Specifically, organ-specific toxicities which are difficult to detect 
as they are rare and occur sporadically present a particular problem. Cardiotoxicity presents 
one of the highest causes of drug failure in drug development. Currently, there is no gold 
standard model to detect this. Therefore, in this thesis I aimed to develop a cardiotoxicity 
screening tool using the zebrafish embryo as a model organism. The aim was to develop a 
screening tool which could also be up-scaled and thus had the capability to be used routinely 
in pre-clinical testing routines in the future. Another aim of this thesis was to evaluate the 
zebrafish embryo as a model for assaying biological activity of novel compounds, as well as 
to develop an innovative predictive tool that could be used to predict the toxicity of novel 
compounds. The final aim of this thesis was to evaluate the zebrafish embryo as a model for 
therapeutic drug screening using a high throughput anti-inflammatory screening tool.  
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Chapter Two: MATERIAL AND METHODS 
2.1 Materials 
2.1.1 Chemicals 
Only chemicals purchased outside of the laboratory are listed (Table 2.1). Standard 
chemicals used in the laboratory, such as solvents (e.g. ethanol) are not listed.  
 
Table 2.1 – Chemicals used for experiments. 
Chemical Source 
Gentamycin sulphate (BP918-1) Fisher Scientific, Loughborough, UK 
Paraformaldehyde reagent grade (P6148-
1KG)  
Sigma-Aldrich, Poole, UK & Munich, Germany 
Oil red O (O0625-25G) Sigma-Aldrich, Poole, UK 
N-Phenylthiourea (P7629-25G) Sigma-Aldrich, Poole, UK 
Dimethyl sulfoxide (D8418-100ML) Sigma-Aldrich, Poole, UK & Munich, Germany 
Dulbecco’s phosphate buffered saline 
(PBS) (D5662-1L) 
Sigma-Aldrich, Munich, Germany & Poole, UK 
Tween 20 (P1379-250ML) Sigma-Aldrich, Poole, UK & Munich, Germany 
Ethyl-3-aminobenzoate methane sulfonate 
(MS222/MESAB) (E10521-10G)  
Sigma-Aldrich, Poole, UK 
Hydrogen peroxide solution (216763) Sigma-Aldrich, Munich, Germany 
Potassium acetate (98%) (W292001-10KG) Sigma-Aldrich, Munich, Germany 
Sudan black B staining reagent (380B-1KT) Life technologies, Darmstadt, Germany 
Verapamil hydrochloride (0654) Tocris Bioscience, Bristol, UK 
Cromakalim (1377) Tocris Bioscience, Bristol, UK 
Penicillin G sodium salt (P3032) Sigma-Aldrich, Poole, UK 
Haloperidol (H1512-5G) Sigma-Aldrich, Poole, UK 
Pimozide (P1793-500MG) Sigma-Aldrich, Poole, UK 
(-)-Blebbistatin (B0560-1MG) Sigma-Aldrich, Poole, UK 
(+)-Tubocurarine chloride pentahydrate 
(P3750-250MG)  
Sigma-Aldrich, Poole, UK 
2,3-Butanedione monoxime (B0753) Sigma-Aldrich, Poole, UK 
Trypan blue solution 0.4% (T8154)    Sigma-Aldrich, Poole, UK 
Low melting point agarose (35-20100) PEQLAB Biotechnologie, Erlangen, Germany 
TWEEN® 20 (P5927) Sigma-Aldrich, Munich, Germany 
Potassium hydroxide (03564 Fluka) Sigma-Aldrich, Munich, Germany 
Methylene blue solution (03978) Sigma-Aldrich, Munich, Germany & Poole, UK 
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Unscented paraffin wax (327204) Sigma-Aldrich, Poole, UK 
Propylene Glycol (134368)                           Sigma Aldrich, Poole, UK 
Sodium acetate (S7899-100ML)                   Sigma Aldrich, Poole, UK      
Acridine Orange (A6014-10G)                       Sigma Aldrich, Poole, UK      
SYTOX® blue nucleic acid stain (S11348) Sigma-Aldrich, Munich, Germany 
Copper II sulphate pentahydrate 
(1027871000)                     
Merck Millipore, Darmstadt, Germany 
 
2.1.1.1 28 Reference compounds 
The 28 marketed reference drugs used in this thesis are listed in Table 2.2. 
 
Table 2.2 – List of 28 reference compounds used. 
Compound name Supplier Order code CAS no. LogP pKa 
Amantadine hydrochloride Sigma-Aldrich A1260-5G 768-94-5 2.5 10.7 
Amiloride hydrochloride  Axxora Llc 
LKT-A5133-
M500 2609-46-3 -0.3 8.7 
Bendroflumethiazide 
Fluka Sigma-
Aldrich B5775-1G 73-48-3 1.9 8.5 
Captopril Calbiochem® 211875-1GM 62571-86-2 0.3 4.0 
Carbamazepine Sigma-Aldrich C4024-1G 298-46-4 2.5 16.0 
Chlorprothixene 
hydrochloride Sigma-Aldrich C1671-1G 6469-93-8  5.2 9.8 
Chlorzoxazone Sigma-Aldrich C4397-25G 95-25-0 1.6 9.4 
Erythromycin Sigma-Aldrich E5389-1G 114-07-8 3.1 8.9 
Fenofibrate Sigma-Aldrich F6020-5G 49562-28-9 5.3 -4.9 
Flupenthixol 
dihydrochloride 
Tocris 
Bioscience 4057 2413-38-9 4.5 15.6 
Folic acid Sigma-Aldrich F8798-5G 59-30-3 -2.5 3.4 
Glipizide Sigma-Aldrich G117-500MG 29094-61-9 1.9 5.9 
Hydrochlorothiazide Sigma-Aldrich H2910-5G 58-93-5 -0.1 7.9 
3,4-Dihydroxy-L-
phenylalanine Sigma-Aldrich D9628-5G 59-92-7 -2.4 2.3 
L-thyroxine Sigma-Aldrich 
T2376-
500MG 51-48-9 4.0 0.3 
Meclizine dihydrochloride Molekula 89967039 1104-22-9 5.8 8.1 
Metoclopramide 
hydrochloride Sigma-Aldrich M0763-10G 7232-21-5 2.6 9.3 
Prednisone Sigma-Aldrich P6254-1G 53-03-2 1.5 12.6 
Sulindac Sigma-Aldrich S4429-5G 38194-50-2 3.4 4.7 
Terfenadine Sigma-Aldrich T9652-5G 50679-08-8 7.1 13.2 
Tetracycline Sigma-Aldrich T3258-5G 60-54-8 -1.3 3.3 
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2-Mercapto-1-
methylimidazole Sigma-Aldrich 301507-5G 60-56-0 -0.3 10.4 
Enalapril maleate salt Sigma Aldrich 
E6888-
250MG 76095-16-4 0.1 3.0 
3,3′,5-Triiodo-L-thyronine 
Sigma Aldrich 
T2877-
250MG 6893-02-3 2.9 0.3 
Malathion  Sigma Aldrich 
36143-
100MG 121-75-5  2.4 -6.8 
D-penicillamine Sigma Aldrich P4875-1G 52-67-5  -1.8 1.8 
Metformin  hydrochloride 
Tocris 
Bioscience 2864 1115-70-4 -0.5 12.4 
Tioguanine  Sigma Aldrich 
A4882-
500MG 154-42-7 -0.1 10.5 
 
2.1.1.2 Six Validation drugs 
The six validation drugs used to validate the quantitative structure activity (QSAR) model are 
listed in Table 2.3. 
 
Table 2.3 – List of six validation drugs used. 
Compound name Supplier Order code CAS no. LogP pKa 
Diclofenac sodium  
Calbiochem-
Novabiochem GmbH 287840-1GM 15307-79-6 4.51 4.15 
(+-)-Ibuprofen  
Calbiochem-
Novabiochem GmbH 401003-1GM 15687-27-1 3.97 4.91 
Hydroxycarbamide Sigma-Aldrich H8627-1G 127-07-1 -1.80 10.14 
Riboflavin Sigma-Aldrich R4500-5G 83-88-5 -1.46 10.20 
Doxorubicin Sigma-Aldrich 44853-1MG 25316-40-9 1.27 9.53 
Glutamic acid Sigma-Aldrich G1251-100G  56-86-0 -3.69 2.23 
 
2.1.1.3 Azetidines 
The selection of azetidines probed for biological activity in this thesis is listed in Table 2.4.  
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Table 2.4 – List of selected azetidines used. Compounds kindly provided by Antonio Feula 
(UoB) 
Compound name  Full compound name 
Molecular weight 
(g/mol) LogP 
2a 
1-(((cis)-1-Benzyl-4-phenylazetidin-2-
yl)methyl)piperidine 321.23 3.6 
2b 
N-(((cis)-1-Benzyl-4-phenylazetidin-2-
yl)methyl)propan-2-amine 295.22 2.9 
2c 
1-((cis)-1-Benzyl-4-phenylazetidin-2-yl)-N-
(pyridin-2-ylmethyl)methanamine 344.21 -1.6 
2d 
N-Benzyl-1-((cis)-1-benzyl-4-(furan-3-
yl)azetidin-2-yl)methanamine 333.20 2.6 
2e 
N-Benzyl-1-((cis)-1-benzyl-4-(2-
bromophenyl)azetidin-2-yl)methanamine 421.13 5.3 
2f 
2-((((cis)-1-Benzyl-4-(pyridin-3-yl)azetidin-
2yl)methyl)amino)ethanol 320.17 0.66 
 
 
2.1.1.4 Ƴ-lactams 
The selection of Ƴ-lactams probed for biological activity in this thesis is shown in Table 2.5. 
 
Table 2.5 – List of Ƴ-lactams used. Compounds kindly provided by Mariwan H. Salih (UoB) 
Compound name Full compound name Molecular weight (g/mol) LogP 
3a 
N-benzyl-3-hydroxy-3-methyl-5-
phenylpyrrolidin-2-one 281.14 2.81 
3b 
N-benzyl-5-(3,4-dimethoxyphenyl)-3-
hydroxy-3-methylpyrrolidin-2-one 341.40 2.48 
3c 
N-benzyl-3-hydroxy-3-methyl-5-
(naphthalen-1-yl)pyrrolidin-2-one 331.41 4.53 
3d 
N-(4-chlorobenzyl)-3-hydroxy-3-
methyl-5-phenylpyrrolidin-2-one 315.79 3.52 
3e 
 N-(4-methoxybenzyl)-3-hydroxy-3-
methyl-5-phenylpyrrolidin-2-one 311.37 2.73 
3f 
N-benzyl-5-(furan-3-yl)-3-hydroxy-3-
methylpyrrolidin-2-one 271.31 1.98 
3g 
N-benzyl-3-hydroxy-3-methyl-5-
(thiophen-2-yl) pyrrolidin-2-one 287.38 2.45 
3h 
N-benzyl-5-(2-bromophenyl)-3-
hydroxy-3-methylpyrrolidin-2-one 326.35 1.05 
3i 
N-benzyl-3-hydroxy-3-methyl-5-(4-
nitrophenyl) pyrrolidin-2-one 360.25 3.67 
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2.1.2 Enzymes 
Streptomyces griseus type XIV pronase (protease Streptomyces griseus type XIV pronase (Sigma-Aldrich, Poole, UK & Munich, Germany). 
 
2.1.3 Equipment  
Items used regularly in the lab such as plastic Pasteur pipettes, Petri dishes and water baths 
are not included on the list but everything else that was used is (Table 2.6). 
 
Table 2.6 – Equipment and software used. 
Equipment Source 
Disposable scalpel (No 10) Sigma-Aldrich, Munich, Germany 
Digital microscope camera DFC300 FX Nikon, Kingston, UK 
Fluorescence stereo microscope (MZ10F)  Leica, Bensheim, Germany 
Camera software for fluorescence microscope 
(Irfanview) 
www.irfanview.net  
Incubator for fish embryos Heraeus, Hanau, Germany 
Scan˄R high content screening station Olympus Biosystems, Munich, Germany 
Image J (version 4.2) http://rsbweb.nih.gov/ij/  
Stereomicroscope (SMZ800) with camera 
(DMX1200) 
Nikon, Kingston, UK 
Camera software for stereomicroscope (ACT-1 
version 2.7) 
Nikon, Kingston, UK 
Zoom stereomicroscope (SMZ1500) with epi-
fluorescence illuminator and camera (DS-Qi1Mc) 
Nikon, Kingston, UK 
Camera software for zoom stereomicroscope 
(NIS elements) 
Nikon, Kingston, UK 
Stereomicroscope (SMZ645) with 2X lens Nikon, Kingston, UK 
Mechanical micromanipulators (MM3) Nashirige, London, UK 
Inchworm step motors  Lumen Dynamics Group  
MicroFil (P85)  World Precision Instruments (WPI) UK, 
Hitchin, England 
Borosilicate glass micropipettes (P84) World Precision Instruments (WPI) UK, 
Hitchin, England 
Differential amplifier NPI electronics GmbH, Tamm, Germany 
PowerLab 4/35 data acquisition unit ADI Instruments, Oxford, UK 
LabChart 7 Pro (version 7.3) ADI Instruments, Oxford, UK 
Puller (PN-31) Nashirige, London, UK 
Black 384 well plate (781900) Greiner Bio-One GmbH, Frickenhausen, 
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Germany  
Multipette® plus (4981 000.019) Eppendorf Vertrieb Deutschland GmbH, 
Wesseling-Berzdorf, Germany 
LabView Vision National Instruments, Munich, 
Germany 
MATLAB 7.11 R2010b  MathWorks, Ismaning, Germany 
PELCO® clear wall glass bottom dishes (35 X 10 
mm) 
PLANO GmbH, Wetzlar, Germany 
High capacity lab table (68-500) Scientifica, Uckfield, UK 
Faraday cage Scientifica, Uckfield, UK 
Temperature controller (Cryocon 24C) Cryogenic control systems Inc., 
California, USA 
Disposable mini-Petri dishes (S08185) Fisher Scientific UK Ltd, Loughborough, 
UK 
96 well microtiter plate (655180) Greiner Bio-One GmbH, Frickenhausen, 
Germany  
Multi-channel Pipette (613-5252) VWR International GmbH, Darmstadt, 
Germany 
SIMCA (Windows 7 64-bit) Umetrics AB, Umeå, Sweden 
FLIPR Tetra locomotion measurement system Custom-made by Richter Gedeon Nyrt., 
Budapest, Hungary 
KomiPL software Custom-made by Pictron Ltd, Budapest, 
Hungary 
Nunc* polystyrene 4 well rectangular dishes 
(267061) 
Thermo Fisher Scientific, Langensbold, 
Germany 
 
2.1.4 Zebrafish lines 
Wild-type zebrafish embryos used for experiments were from the AB* strain with one 
mating pair found to produce around 1000 fertilized zebrafish embryos. Various transgenic 
lines were also used, as summarised in Table 2.7. 
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Table 2.7 – Zebrafish transgenic lines used. 
Zebrafish transgenic lines Provided by Reference 
Tg(fli-1:EGFP) Professor Roy Bicknell, 
University of Birmingham 
(Lawson and Weinstein, 
2002) 
Tg(fli-1:EGFP)(gata-1:DsRed) Professor Roy Bicknell, 
University of Birmingham 
(Bill et al, 2008) 
Tg(cldnB:GFP)(lyz:DsRed2)nz50 Dr. Clemens Grabher, KIT (d'Alençon et al, 2010) 
Tg(cpa5:GFP)(lyz:DsRed2)nz50 Dr. Clemens Grabher, KIT (Forrester et al, 2012) 
Tg(lyz.HyPer) Dr. Clemens Grabher, KIT (Henry et al, 2013) 
 
2.1.5 Solutions 
Solutions were made as follows: 
-E3 embryo medium stock solution (containing 5 mM sodium chloride, 0.33 mM calcium 
chloride, 0.33 mM magnesium sulphate and 0.17 mM potassium chloride) was diluted 1 in 
60 with deionised water to give a final working dilution which was then stored at 28°C until 
needed. Gentamycin (0.5 mL) was also added to 1 litre of the final working dilution to 
prevent bacterial growth. 
-Pronase stock solution at 10 mg/mL was prepared by dissolving Streptomyces griseus Type 
XIV powder (Sigma-Aldrich) in E3 medium. Once the stock solution was made it was stored 
at -20°C. When required, the stock solution was thawed and kept at 37°C. The final working 
solution of pronase used was 1 mg/mL which was prepared by dissolving the stock solution 
in E3 embryo medium.  
-Paraformaldehyde (PFA) which was required for fixation was prepared by dissolving 8 g of 
PFA powder in 200 mL of phosphate buffered saline (PBS) solution (2.67 mM potassium 
chloride, 137.93 mM sodium chloride, 8.06 mM sodium phosphate dibasic heptahydrate and 
1.47 mM monopotassium phosphate) to produce a 4% working solution. The 4% working 
solution was kept in a water bath for 3-4 hours until completely dissolved. Once dissolved 
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completely the solution was aliquoted into 15 mL falcon tubes and stored at -20°C. When 
required for use, the aliquots were thawed at room temperature.  
-Phenylthiourea (PTU) stock solution (10 mM), was prepared by dissolving 150 mg of PTU 
powder in 100 mL of E3 embryo medium, heating to 60°C and then stirring until the powder 
was completely dissolved. The stock solution was then stored at 4°C until ready to use. To 
make the final working dilution of PTU, a 1 in 50 dilution was performed in E3 embryo 
medium and the solution was stored at 28°C.  
-Ethyl-3-aminobenzoate methane sulphonic acid salt (MS222) stock solution (0.4%) was 
prepared by dissolving 200 mg of powder in 49 mL of distilled water. To this 1 mL of Tris at 
pH 9 was added to bring the pH of the solution to 7-7.5. The solution was then vortexed 
several times and covered in kitchen foil to protect it from light. The solution was stored at 
4°C until ready for use. Final working dilutions were made by diluting in E3 embryo medium. 
-Drug solutions: Metformin, thiamazole, captopril, amantadine, chlorprothixene, 
flupenthixol and metoclopramide drug stock solutions were prepared using E3 embryo 
medium. Copper sulphate stock solution was prepared with distilled water. Fenofibrate 
stock solution was prepared using acetone with no dilution exceeding 0.01% acetone. All 
other drug stock solutions were prepared using DMSO with no dilution exceeding 0.1% 
DMSO. Stock solutions were kept at -20°C until required for use. Working dilutions were 
prepared fresh on the day of the experiment using E3 embryo medium.  
 
 
 
 
46 
 
2.2 Stainings 
2.2.1 Fixation 
Fixation was performed by transferring zebrafish embryos or larvae with as little liquid as 
possible (maximum of 50 zebrafish) into Falcon tubes containing 5 mL of 4% PFA in PBS at 
room temperature. The samples were stored overnight at 4°C. 
 
2.2.2 Sudan black staining 
Sudan black staining was used to visualise leukocytes. For this fixed zebrafish embryos and 
larvae were utilised. The fixed samples were first washed twice with PBST (1 mL) before 
being stained with 60 µL Sudan black reagent (Sigma-Aldrich, Germany) for 20 minutes. After 
20 minutes, the stain was washed off thoroughly with 70% ethanol (1 mL) in three washes of 
1, 5 and 10 minutes. The samples were then washed twice with PBST (1 mL) and stored at 
4°C. Leukocytes were counted at the site of interest using a Leica MZF10 fluorescence stereo 
microscope (Leica, Germany).  
 
2.3 Statistical analysis 
All the graphs presented in this thesis show mean values and standard deviation error bars. 
 
2.3.1 Students T-Test 
When comparing only two variables a student’s T-test with Welch’s correction was 
performed with the significance level set at P<0.05. Microsoft Excel 2010 (Microsoft, UK) was 
used to perform the analysis.  
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2.3.2 ANOVA 
One-way ANOVA analysis was performed to determine significant differences between the 
means of three or more independent groups followed by a Holm-Bonferroni post hoc test to 
protect from family wise error (probability of getting at least one false positive result) with 
the significance level set at P<0.05 and the null hypothesis rejected when P<α/k. The 
equation used was: α(j) = α(T)/(k – j +1), where j = selected t-test, k = number of t-tests 
performed in total, α(T) = 0.05. GraphPad Prism 5.0 (GraphPad Software Incorporation, USA) 
and Microsoft Excel 2010 (Microsoft, UK) were used to perform the statistical analyses. 
 
2.3.3 Multivariate analysis 
All multivariate analysis including PCA, PLS and OPLS was performed using SIMCA (Umetrics 
AB, Umeå, Sweden). The significance level was set at P<0.05 for all modelling performed. For 
all models R2X and Q2 values were also calculated to determine the dispersion and stability 
of the data. A model with an R2X value >0.7 and a Q2 value >0.4 was deemed to be of good 
quality.  
 
2.4 Fish husbandry and embryological techniques 
2.4.1 Adult zebrafish maintenance 
All adult zebrafish were kept in group sizes of around 15 fish in a ZEBTEC™ zebrafish housing 
system (Tecniplast, Italy). The water quality, water hardness and conductivity were 
controlled daily and the pH of the water was kept at 7-7.5. The zebrafish were fed twice 
daily, once with live food (artemia) and once with dry food. The temperature in the fish 
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room was maintained at 28°C and the light and dark cycle was controlled automatically with 
14 hours of light and 10 hours of darkness.  
 
2.4.2 Zebrafish breeding and embryo collection 
The day before embryos were required pairs consisting of one adult male and one adult 
female zebrafish were placed in breeding cages. The breeding cages were equipped with 
spawning trays to collect the zebrafish embryos and a divider was placed in the breeding 
cage separating the male from the female. The divider was removed the next morning, 
zebrafish embryos were collected and then transferred to new Petri dishes containing E3 
embryo medium. Zebrafish embryos were kept at 28°C. 
 
2.4.3 Raising of zebrafish embryos 
Zebrafish embryos from all lines were bred in house with a constant temperature of 28°C 
and all procedures were performed in accordance with the Ethics Committee at Karlsruhe 
Institute of Technology (KIT), the UK Home Office Animals Scientific Procedures Act (1986) 
and the Hungarian Law for animal experimentation. Zebrafish embryos were raised in E3 
medium with the medium replaced daily. When zebrafish embryos were required without 
pigmentation, zebrafish embryos were first raised in E3 embryo medium for 24 hours before 
being transferred to 0.002% PTU solution. At the end of experiments, zebrafish embryos and 
larvae were humanely killed by an overdose of MS222 anaesthetic. For all experiments, no 
zebrafish larvae were used beyond 5 dpf except in the case of the locomotion studies. 
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2.4.4 Dechorionation 
When there were a small number of zebrafish embryos chorions were removed 
mechanically by using forceps. With larger numbers of zebrafish embryos the chorions were 
removed enzymatically using Pronase enzyme (Sigma-Aldrich, UK). For the enzymatic 
digestion of the chorions zebrafish embryos were first transferred to a new Petri dish with 
almost all of the liquid removed. A 1 in 10 dilution of the Pronase stock solution (10 mg/mL) 
was then performed in E3 embryo medium to give a final dilution of 1 mg/mL. This was then 
added to the Petri dish at a volume of 1 mL. The zebrafish embryos were then swirled for 
several minutes and constantly observed under the microscope to see when the first few 
started to emerge out of their chorions. When around a quarter of the zebrafish embryos 
were out of their chorions they were pipetted into a 500 mL beaker to which 500 mL of E3 
embryo medium was added. The zebrafish embryos were then washed three times in 500 
mL of E3 embryo medium. After washing, zebrafish embryos were transferred to new Petri 
dishes containing E3 embryo medium plus gentamycin. After dechorionation zebrafish 
embryos were found to be morphologically normal, i.e. the same as zebrafish embryos still in 
their chorions. 
 
For early stage zebrafish embryos which needed to be dechorionated before 1 dpf, 
dechorionation was performed almost immediately after fertilization. The zebrafish embryos 
were dechorionated with Pronase using the same procedure outlined above. However, after 
the final washing step the zebrafish embryos were transferred to agar-coated Petri dishes 
containing E3 embryo medium. 
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Chapter Three: DEVELOPMENT OF A ZEBRAFISH EMBRYO AND 
LARVAL ELECTROCARDIOGRAPHY TOOL FOR THE DETECTION OF 
CARDIOTOXICITY 
Foreword: 
All the work presented in this chapter was supervised by Professor Ferenc Müller and 
Professor Attila Sik. Optimisation of the ECG recording method was performed jointly with 
Eva Doro (Biotecont Ltd, Hungary). Eva Doro performed invasive ECG recordings and also 
contributed equally to the immobilization, developmental stage, temperature and electrode 
positioning data (data was pooled together with mine). All drug treatment experiments 
performed in regards to exclusion of motion artefact and QTc prolongation were performed 
solely by me, as well as the experiments addressing ECG signal stability and reproducibility. 
All of the data analysis and interpretation of results presented in this chapter was performed 
solely by me.    
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3.1 Introduction and Overview 
3.1.1 The zebrafish embryo as a model for evaluating cardiotoxicity 
Cardiotoxicity is one of the leading causes of drug attrition in the pharmaceutical industry 
with many marketed compounds having been withdrawn from the market and others 
aborted in late phases of the drug development programme due to risk of cardiotoxicity 
(Anyukhovsky, 2011).  
 
Cardiotoxicity can manifest itself in various forms and can have a number of different 
underlying causes. For example QT prolongation (delay in ventricular repolarisation) occurs 
due to the main potassium ion channel responsible for ventricular repolarisation being 
blocked by a drug (e.g. terfenadine). QT prolongation can lead to secondary cardiotoxic 
conditions (e.g. Torsades de Pointes), which can be fatal. QRS prolongation (slowing of 
ventricular depolarisation) can occur due to the sodium ion channel responsible for 
ventricular depolarisation becoming blocked by a drug (e.g. flecainide) (Harmer et al., 2011). 
Paclitaxel (anti-cancer drug) causes heart rhythm disturbances (arrhythmias) by either 
directly acting on the Purkinje fibres responsible for transmitting an electrical single in the 
heart or by inducing histamine release stimulating histamine receptors in the myocardium 
(Brana and Tabernero, 2010)(Schimmel et al., 2004). Doxorubicin is another anti-cancer 
agent associated with cardiotoxicity. Doxorubicin causes left ventricular dysfunction and 
heart failure by affecting calcium homeostasis in myocytes and inhibiting the activity of the 
ATPases in the sarcoplasmic reticulum (Brana and Tabernero, 2010)(Olson and Mushlin, 
1990). This leads to cardiomyocyte apoptosis and eventual left ventricular dysfunction, 
which can ultimately result in heart failure (Olson and Mushlin, 1990).  
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At the moment there is no gold standard in vivo model for evaluating cardiotoxicity, 
however the zebrafish represents a promising option. As mentioned in Chapter 1, zebrafish 
share many features with mammals in terms of genetics and physiology, which make them 
good models for drug screening (Zon and Peterson, 2005). In regards to cardiotoxicity 
testing, despite the zebrafish heart having only two chambers (one atrium and one 
ventricle), the electrical properties are similar to higher mammals (MacRae, 2013).  
 
3.1.2 Zebrafish heart development 
Unlike the human heart which has four chambers (two atria and two ventricles), the 
zebrafish heart only has one ventricle and one atrium. The heart is one of the first organs to 
develop during zebrafish embryogenesis (Figure 3.1) (Hu et al., 2000). In the zebrafish, heart 
assembly occurs from mesodermal precursors, which are specific for either the ventricle or 
atrium (Rottbauer et al., 2001). These come together at the 18-somite stage and then fuse at 
the 21-somite stage to form a structure known as a ‘cone’ (Rottbauer et al., 2001). Further 
fusion then leads to the formation of a tube at 24 hpf, which has two layers, an endocardium 
and a myocardium (Rottbauer et al., 2001). The heart tube then undergoes a process known 
as D-looping, where the atrium loops to the right hand side (Stainier et al., 1996). By 48 hpf 
the basic structure of the heart has formed with the two chambers (ventricle and atrium), 
valves and a boundary between the atrium and ventricle present (Stainier et al., 1996). 
Between 72 and 96 hpf, the ventricle continues to grow and thicken developing trabeculae; 
this aids the development of an immature fast conduction network in the ventricle (Chi et 
al., 2008). Additionally, during early embryonic development, the L-type voltage dependent 
calcium channel (C-LTCC) is required for the ventricle to contract (Rottbauer et al., 2001). 
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This is the main route by which calcium enters myocytes and therefore plays a predominant 
role in excitation-contraction coupling (Rottbauer et al., 2001).  
 
Figure 3.1 – Summary of zebrafish heart development. 
Source: Adapted from http://www.bioscience.org/2003/v8/d/1092/fig1.jpg    
 
3.1.3 Electrophysiology of the zebrafish heart 
3.1.3.1 Generation of electrical activity in the heart 
In humans, pacemaker cells a group of cells that control the heart rate are responsible for 
initiating electrical activity within the myocardium by generating action potentials 
(Nerbonne and Kass, 2005). Pacemaker cells are located in the sinoatrial node of the heart 
and the electrical activity is propagated through the atria into the atrioventricular (AV) node 
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followed by a short pause (Nerbonne and Kass, 2005). After the short pause the electrical 
signal travels through to the apex of the heart via Purkinje fibres (specialised fibres 
responsible for conduction of the electrical signal) into the ventricles (Nerbonne and Kass, 
2005). In each region of the heart there are different cell types, for example in the Purkinje 
fibres, cells specialised for fast conduction are present (Nerbonne and Kass, 2005). 
Differences in the expression levels of ion channels within these cell types are responsible 
for the different action potential waveforms observed.  
 
In zebrafish embryos, pacemaker cells have also been identified, which are confined to the 
sinoatrial junction and marked by expression of the islet-1 gene (Tessadori et al., 2012). 
However, zebrafish lack Purkinje fibres that are present in humans for fast conduction of the 
electrical signal to the ventricles. Despite lacking Purkinje fibres, zebrafish have been shown 
to possess a fast cardiac conduction system (Chi et al., 2008). This is present already at 96 
hpf and is characterized by the presence of the Connexin-40 (Cx40) gap junction protein (Chi 
et al., 2008). The Cx40 gap junction protein is also found in the His-Purkinje conduction 
system in humans and it is thought to be responsible for ensuring rapid conduction within 
Purkinje fibres (Chi et al., 2008). Conduction in a unidirectional manner across the 
myocardium is already observed in zebrafish embryos at around 24 hpf (Chi et al., 2008). 
Additionally, AV conduction delay is first observed between 36-48 hpf (Chi et al., 2008). The 
Cx40 gap junction protein is found to be present at low levels in the atrial and ventricular 
myocytes during this time period, but not in the AV myocardial cells (Chi et al., 2008). It is 
therefore postulated that the AV myocardial cells, which form a ring structure around the AV 
canal are responsible for AV delay (Chi et al., 2008). As the ventricle continues to grow and 
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thicken during zebrafish development a specialised ventricular conduction system 
responsible for transmitting the electrical signal from the apex to the base of the heart 
develops (Chi et al., 2008)(Sedmera et al., 2003). 
 
3.1.3.2 Ventricular myocyte action potential cycle 
In humans the cardiac ventricular myocyte action potential cycle involves four phases, 
namely phase 0 (depolarisation), phase 1 (early repolarisation), phase 2 (plateau), phase 3 
(repolarisation) and phase 4 (return to resting membrane potential), as shown in Figure 3.2. 
 
Figure 3.2 – Ventricular myocyte action potential. Key: 0 = depolarisation, 1 = early 
repolarisation, 2 = plateau, 3 = repolarisation, 4 = return to resting membrane potential, INa = 
rapid inward sodium current, IKto = transient outward potassium current, ICa = slow inward 
calcium current, IKs = slow delayed rectifier potassium current, IKr = delayed rectifier 
potassium current, IK1 = Inward rectifier current 
 
The voltage-gated sodium channel (Nav1.5) through which the current INa passes can open 
and close rapidly (Golan et al., 2011). This sodium channel is responsible for the rapid 
depolarisation during phase 0, where the membrane potential changes from -90 mV to +70 
millivolts (mV), as sodium ions rush in, making the inside of the membrane more positive 
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than the outside (Golan et al., 2011). The channel closes rapidly after 1-2 milliseconds (ms) 
to prevent further influx of sodium ions (Golan et al., 2011). The time it takes for the sodium 
channels to recover from their inactivation is known as the refractory period and is a 
mechanism that protects the heart by ensuring that another action potential is not fired 
until the first one is completed (Golan et al., 2011). The homotetrameric voltage-gated 
potassium channel (Kv4.2) through which the transient current Ito passes is responsible for 
early repolarisation in phase 1 by driving out potassium ions (Golan et al., 2011).  
 
The plateau phase (phase 2) is maintained by the voltage-gated calcium channel (Cav1.2), 
through which the current Ica passes (Golan et al., 2011). There are two types of calcium 
currents important during the plateau phase, namely the transient current ICaT that passes 
through T-type calcium channels and the long lasting current ICaL that passes through L-type 
calcium channels (activate at -30 mV and are susceptible to block by dihydropyridines) 
(Golan et al., 2011). Both currents are required for influx of calcium ions, which initiates 
contraction (sliding of thick myosin filaments of the sarcomere past the thin actin filaments) 
(Golan et al., 2011). During the plateau phase there is a high membrane resistance which 
helps to insulate the myocyte and therefore allows efficient propagation of the electrical 
signal (Golan et al., 2011). The voltage-gated slow potassium channels allow potassium to 
flow out of the cell prolonging the plateau phase. 
 
In phase 3, the voltage-gated potassium channel (Kv11.1) through which the current Ikr 
passes drives the main part of repolarisation (outward flow of potassium ions) (Golan et al., 
2011). The Kv11.1 potassium channel is also more commonly known as human ether-à-go-
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go-related-gene (hERG) channel. The hERG channel deactivates at -40 mV and is particularly 
sensitive to block by various classes of compounds (Golan et al., 2011). Additionally, the 
voltage-gated potassium channel Kv7.1 (KvLQT1) through which the current Iks passes which 
is active during low heart rates is also able to drive repolarisation and behaves by opening 
and closing very slowly.  
 
The final phase of the ventricular myocyte action potential cycle involves the inward rectifier 
heterotetrameric potassium channel (Kir2.X) (Golan et al., 2011). This channel through which 
the current Ik1 passes restores the membrane potential to the resting condition of -90 mV 
(phase 4) (Golan et al., 2011). This occurs by pumping sodium ions out of the cell and 
potassium ions back into the cell (Golan et al., 2011).  
 
When comparing the ventricular myocyte action potential to the atrial myocyte action 
potential slight differences are observed (Figure 3.3). Due to dissimilarities in ion channel 
expression, in atrial myocytes the plateau phase (phase 2) is narrower and the repolarization 
phase (phase 3) more gradual.  
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Figure 3.3 – Atrial myocyte action potential. Key: 0 = depolarisation, 1 = early repolarisation, 
2 = plateau, 3 = repolarisation, 4 = return to resting membrane potential, INa = rapid inward 
sodium current, IKto = transient outward potassium current, ICa = slow inward calcium current, 
IKs = slow delayed rectifier potassium current, IKr = delayed rectifier potassium current, IK1 = 
Inward rectifier current 
 
 
Zebrafish embryo atrial and ventricular myocytes are similar in morphology to those of adult 
zebrafish and humans. Additionally, many counterparts of the human cardiac ion channels 
are found in zebrafish, such as orthologues of Nav1.5 and hERG (Golan et al., 2011). As in the 
human and the adult zebrafish heart, the cardiac action potential upstroke (phase 0) is 
dependent on sodium channels (Alday et al., 2014). However, in zebrafish embryos and 
adults the T-type calcium channels can also contribute to phase 0, whereas in mammals T-
type calcium channels are only present early during development (Alday et al., 2014). In 
phase 2 of the zebrafish embryo myocyte action potential cycle L-type calcium channels are 
responsible for action potential generation, just as in humans (Alday et al., 2014). 
Additionally, phase 3 of the zebrafish embryo cardiac myocyte action potential cycle like in 
humans is highly dependent on Ikr (Alday et al., 2014). However, there is one major 
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difference between zebrafish embryos and humans in that zebrafish embryos lack the 
cardiac ion channels Kv7.1 and Kv4.3, which are required for the generation of early 
repolarisation in phase 1 of the cardiac myocyte action potential cycle in humans (Alday et 
al., 2014).  
 
3.1.3.3 Adult zebrafish electrocardiogram 
An ECG is a recording of the electrical processes involved in the initiation of each heartbeat 
representing the overall electrical activity of the heart (Golan et al., 2011). The ECG signals 
that can be obtained from human and adult zebrafish hearts have been shown to be highly 
similar to one another (Milan et al., 2006)(Chaudhari et al., 2013). The whole cardiac cycle in 
adult zebrafish is around 480 ms, in humans it is around 1000 ms and in mice it is much 
shorter around 100 ms (Artman et al., 2008)(Leong et al., 2010). In zebrafish larvae, the 
cardiac cycle is longer, it becomes shorter as the fish develops (Yu et al., 2010). Additionally, 
the heartbeat also shows a high similarity between humans and adult zebrafish. In humans 
the heartbeat is around 60-100 beats per minute (bpm) and in adult zebrafish it is 110-140 
bpm (Leong et al., 2010). In mice however the heartbeat is much faster, approximately 500-
600 bpm (Leong et al., 2010).  
 
An ECG signal is characterised by three main waves with the first wave (P wave) representing 
atrial depolarisation, the second wave (QRS wave) representing ventricular depolarisation 
and the third wave (T wave) representing ventricular repolarization. A typical human ECG 
waveform is shown in Figure 3.4. 
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Figure 3.4 – Components of a human ECG recording. Key: P = atrial depolarization, Q = first 
part of ventricular depolarisation, R = main part of ventricular depolarisation, S = last part of 
ventricular depolarisation, QRS = overall ventricular depolarisation, T = ventricular 
repolarization, PR interval = AV conduction time, PR segment = Flat isoelectric segment 
between the end of the P wave and the beginning of the Q wave, ST segment = Period from 
the end of the QRS complex to the beginning of the T wave, QT interval = time duration of 
ventricular depolarisation and repolarisation 
 
The P wave which represents the depolarisation of the atria lasts around 80-110 ms in 
humans. In zebrafish this is shorter, around 50-70 ms (Ahumada, 1987). After the P wave, 
there is a period known as the PR segment, where the components involved in carrying the 
electrical impulse are activated (Ahumada, 1987). In humans, the components involved in 
this process are the bundle branches, His bundles and Purkinje tissue. In zebrafish, the 
ventricular trabeculae serve as the functional equivalent forming a specialised ventricular 
conduction system responsible for transmitting the electrical signal from the apex to the 
base of the heart (Sedmera et al., 2003). The PR segment is followed by the PR interval, 
which is the period that is measured before the start of the P wave to the beginning of the 
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QRS complex (Ahumada, 1987). The PR interval in adult zebrafish has been reported to be 
around 30 ms (Artman et al., 2008) and 66 ms (Milan et al., 2006). This discrepancy in the 
reported values may be due to differences in the recording methods utilised. However, in 
general the PR interval is shorter than that seen in humans. This is because in zebrafish 
electrical transmission from the atrium to the ventricle occurs much faster, as there is less 
delay between the atrial depolarisation and ventricular depolarisation due to the 
atrioventricular (AV) node being less well defined (Artman et al., 2008). 
 
The RR interval represents the time duration between the peak of one QRS complex to the 
next (Ahumada, 1987). In zebrafish the RR interval is around 350-400 ms, which is 
comparable to that of humans (Artman et al., 2008). The second main wave seen on an ECG 
recording the QRS complex (tallest peak) represents ventricular depolarisation, usually 
lasting around 60-100 ms in humans (Ahumada, 1987). In zebrafish this is shorter (around 30 
ms) owing to the rapid propagation of the signal (Artman et al., 2008). The P wave and the 
QRS complex differ in amplitude, because the ventricle is thicker generating a much bigger 
deflection than the atrium.  
 
The last wave seen on the ECG the T wave represents ventricular repolarisation. This part of 
the cardiac myocyte action potential cycle enables myocytes to regain a negative charge 
ready for the next cycle to begin. In zebrafish and humans the T wave is easily observed, but 
in mice it is not so easily observed as depolarisation and repolarisation occur simultaneously 
(Leong et al., 2010). Occasionally, in humans the T wave may be followed by a U wave, which 
is the remaining part of ventricular repolarisation (Wagner, 2008).  
62 
 
The QT interval is a measure of the overall time taken for the ventricular cell action potential 
to occur (i.e. ventricular depolarisation and repolarisation). In zebrafish the QT interval is 
around 200-290 ms, comparable to that of humans which is slightly longer at around 300-
400 ms; in mice it is notably shorter at around 80 ms (Leong et al., 2010). The QTc interval is 
a measure of the QT interval independent from the heart rate and is commonly used as a 
marker for cardiac toxicity (Wagner, 2008). It can be calculated using Bazzet’s formula: 
QTc=QT/√RR (Wagner, 2008). Other formulas however also exist to correct QT for heart rate 
including the Hodges, Friderica and Framingham formulas (Benatar and Decraene, 2001). 
 
3.1.4 Zebrafish as a model for QT prolongation 
The characteristics of the zebrafish cardiac myocyte action potentials closely resemble those 
of humans. This is because orthologues of the cardiac ion channels found in humans exist in 
zebrafish, such as orthologues of hERG and Nav1.5 (Nguyen et al., 2008). In humans and 
zebrafish the main channel involved in ventricular repolarisation is hERG (zERG in zebrafish). 
Disruption to this ion channel causes a delay in ventricular repolarisation, leading to a 
prolongation of the QT interval (duration of ventricular depolarisation and repolarisation), 
which can predispose to arrhythmia (irregular heart rhythm) and Torsades de Pointes (TdP), 
which is a ventricular tachycardia characterised by twisting of the QRS complex around the 
isoelectric baseline (Chaudhari et al., 2013). This condition can lead to sudden cardiac 
deaths, accounting for 50-100 unexpected sudden cardiac deaths for every 100,000 of a 
population each year in Europe and North America (Niemeijer et al., 2014).  
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QT prolongation is idiosyncratic in nature and can be acquired (drug-induced) or genetic. 
Individuals who develop drug-induced QT prolongation generally have an underlying 
condition such as hepatic impairment, hypokalaemia or structural heart disease (e.g. 
cardiomyopathy) (Gupta et al., 2007). Additionally, individuals taking QT prolonging drugs or 
drugs that interfere with their metabolism, as well as individuals with genetic 
polymorphisms in drug-metabolizing enzymes are at increased risk of developing QT 
prolongation (Gupta et al., 2007). QT prolongation may also be hereditary as is seen in 
sufferers of long QT syndrome (LQTS), which has a prevalence of around 1 in 3000 
(Goldenberg et al., 2008). LQTS exists in many forms presenting with varying degrees of 
severity due to mutations in different genes (LQT1-13). The first five LQT genes (LQT1-5) are 
associated with a prolonged QT interval.  
 
The zebrafish zERG channel protein consists of 1186 amino acids and overall shows 60% 
sequence identity to human hERG (Hassel et al., 2008). Like in humans, the zERG channel 
consists of six transmembrane domains with domains S1-S4 involved in sensing the 
membrane potential and domains S5-S6 making up the potassium selective pore of the 
channel (Figure 3.5) (Hassel et al., 2008). In the S4, S5 and S6 regions amino acid identity is 
particularly high and can reach up to 100% (Hassel et al., 2008). Additionally, the zebrafish 
zERG channel also has cyclic adenosine monophosphate (cAMP) binding domains which are 
found in human hERG, as well as a highly conserved Per-Arnt-Sim (PAS) domain involved in 
deactivation kinetics (Scholz et al., 2009)(Langheinrich et al., 2003). Additionally, studies with 
a human specific hERG blocker MK-499 have shown that it is able to inhibit zERG currents in 
vitro (Langheinrich et al., 2003). The zebrafish zERG and the human hERG do show some 
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minor biophysical differences but overall their functions are highly conserved, indicating that 
zebrafish are a good model for investigating hERG associated disorders (Scholz et al., 2009).  
 
Figure 3.5 – Structure of the zebrafish zERG channel. Two zERG channel sub-units are shown 
with S1-S4 forming the voltage sensing domain and S5-S6 the pore domain. Key: PH = pore 
helix, PAS domain = Per-Arnt-Sim, cNBD domain = cyclic nucleotide binding domain  
 
Zebrafish mutants with defects in zERG have been shown to be particularly useful to model 
human hERG disorders. For example, mutations of zERG in the S3 and S5 transmembrane 
domains have shown that homozygotes are unable to generate spontaneous action 
potentials and develop arrhythmias (Arnaout et al., 2007). Additionally, a zebrafish model of 
LQTS presenting with a prolonged QT interval has been established using morpholino 
knockdown of kcnh2 (Arnaout et al., 2007). The zebrafish reggae mutant presents with a 
shortened QT interval due to a mutation in the S4 transmembrane domain, which is involved 
in voltage-sensing (Hassel et al., 2008). These phenotypes, particularly the short and long QT 
phenotypes mirror what happens in humans who suffer from genetic QT disorders. The 
zebrafish embryo therefore presents an invaluable model to study such conditions. 
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3.1.5 Zebrafish as a model for drug-induced QT prolongation 
QT prolongation is not only a genetic phenomenon but can also occur due to binding of 
particular drugs to the drug-binding region of the hERG channel in the S6 transmembrane 
domain (Langheinrich et al., 2003). The phenylalanine 656 and tyrosine 652 residues of this 
part of the hERG channel are important for hERG block, as shown in Figure 3.6 (Zareba, 
2007).  
 
Figure 3.6 – Structural model of the hERG channel pore component.  
Source: Figure adapted from (Aronov, 2005) 
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Between the zERG and hERG channel in the region where the QT-prolonging drugs bind 
there is a difference of only one amino acid (Langheinrich et al., 2003). Drugs that cause QT 
prolongation often differ in pharmacological class and function, so it is not so easy to predict 
which compounds will cause this effect. It has been shown that compounds with molecular 
weights >250 and computed logP (clogP) values >3.7 are likely to be potent hERG blockers, 
whereas compounds with clogP values <1 and molecular weights <250 are unlikely to be 
hERG blockers (Aronov, 2005). This is most likely to do with the large pore size of the hERG 
channel as well as the highly lipophilic nature of the pore lining (Aronov, 2005). Drug-
induced QT prolongation can be caused by blocking of the hERG channel either when it is 
active/inactive or open/closed (see Figure 3.7) (Hecker et al., 2008). 
 
Figure 3.7 – Schematic of hERG channel gating. A) At negative membrane potentials the 
activation gate is closed whilst the inactivation gate remains open, B) At positive membrane 
potentials (e.g. +20mV) during depolarisation the activation gate opens slowly and the 
inactivation gate closes much of the way so that some current can pass through. 
 
Drug-induced QT prolongation is responsible for a large number of drug failures in drug 
development and new tools to screen compounds for QT prolongation could potentially save 
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money and lives. Detection of QT prolongation during the drug development process is a 
regulatory requirement, as outlined in the ICH guidelines S7B (ICH Expert Working Group 
Topic Leaders, 2002). At the moment there is no gold standard model for detecting QT 
prolongation of drug candidates in the drug development process. Current in vivo methods 
are based on measurement of ECGs in beagle dogs using telemetric devices, as this can be 
performed without anaesthetisation (Mattera et al., 2012). However, this requires a large 
number of animals and huge amounts of compound, generates a lot of data, is expensive 
and time consuming and needs to be performed according to strict regulatory guidelines 
(Mattera et al., 2012). Currently, the gold standard in vitro method used is the hERG cell 
patch clamp assay, as it is fast and specific (Barros et al., 2008). However, this assay does 
have its limitations in that it does not take into account plasma protein binding or 
metabolism (Barros et al., 2008).  
 
The repolarisation of the myocardium is complex with several ion channels and various other 
components such as cytoskeletal elements and receptors playing an important role (Barros 
et al., 2008). This has put zebrafish at the helm as a suitable model due to its relative 
simplicity compared to other mammalian model systems and the ability to investigate 
repolarisation abnormalities in an in vivo scenario (Barros et al., 2008).  
 
Cardiotoxicity screens that have been developed using the zebrafish embryo/larva as a 
model organism include video recording methods which use changes in heartbeat as a 
readout (Yoshida et al., 2009)(Fink et al., 2009)(Chan et al., 2009), 3D imaging techniques 
(Lin et al., 2014), optical mapping techniques (Sabeh et al., n.d.), fluorescence-based 
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techniques (Wen et al., 2012)(Burns et al., 2005)(Letamendia et al., 2012) and voltage 
dynamics visualisation techniques (Tsutsui et al., 2010). Recently, a comparative study of 15 
compounds was performed using three different methods (Park et al., 2013). The first 
method involved an in vivo zebrafish embryo assay to record changes in heartbeat after 
compound exposure (Park et al., 2013). The other two methods involved the use of in vitro 
hERG fluorescence polarization and hERG patch clamp assays to evaluate the 15 compounds 
(Park et al., 2013). A predictive model was generated using the results obtained from all 
three methods (Park et al., 2013). When validating this model it was found to show very high 
predictivity for the zebrafish embryo in vivo assay (R2=0.948), i.e. the hERG fluorescence 
polarization and hERG patch clamp assays could be used to predict with very high accuracy 
the change in heart rate of the zebrafish embryos after compound exposure (Park et al., 
2013). 
 
Despite the many zebrafish embryo/larval cardiotoxicity assays that have been developed so 
far showing good predictivity and comparability to in vitro and other in vivo models, they all 
lack the dynamic and temporal resolution that is needed to analyse components of the 
cardiac cycle. ECG recordings are able to provide this valuable information. An ECG recording 
method has been developed to record adult zebrafish ECGs in vivo (Sun et al., 2009)(Milan et 
al., 2006)(Chaudhari et al., 2013), as well as in vitro (Tsai et al., 2011). More recently, multi-
array electrode systems (Yu et al., 2012) and implantable ECG devices (Zhao et al., 
2013)(Cobo et al., 2013) have also been developed for adult zebrafish.  
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ECG recording methods that can be used for cardiotoxicity testing have been fully 
established for adult zebrafish (Milan et al., 2006) and late stage larvae (Yu et al., 2010). 
However, ECG recording methods for early stage larval zebrafish are in their infancy and 
have not been fully characterised or optimised (Forouhar et al., 2004)(Dong et al., 2012) 
(Rottbauer et al., 2001). Therefore, a zebrafish embryo/larval ECG recording method that 
could be used for cardiotoxicity testing is lacking, as well as any direct evidence that QT 
prolongation occurs in early stage zebrafish larvae. 
 
3.1.6 Zebrafish as a model for arrhythmia and related cardiac disorders 
Arrhythmogenesis is complex and involves several components including ion channels, 
receptors, adaptor proteins and signalling cascades (Zhu et al., 2013). It is one of the most 
difficult conditions to treat, as the underlying cause can be multifactorial (Milan and 
MacRae, 2005).  
 
As with QT prolongation at the moment there is no gold standard for detecting the potential 
of compounds to cause arrhythmia. Many drugs can cause arrhythmias, such as anti-
arrhythmics themselves, anti-psychotics, antibiotics, anti-anginals, gastrointestinal 
stimulants, narcotics and bronchodilators (Barnes and Hollands, 2010). Arrhythmia is also 
thought to be associated with a genetic component (Milan and MacRae, 2005). Animal 
models that have been used so far for investigating arrhythmia development include dogs, 
rabbits and guinea pigs that have a chronic condition of AV block (impaired conduction 
between atrium and ventricle) (Milan and MacRae, 2005). However, these models are not 
ideal for investigating arrhythmias as they are firstly expensive to generate and maintain, 
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they cannot be genetically modified, they show poor reproducibility and they cannot be 
used for drug screening purposes as they are low throughput (Milan and MacRae, 
2005)(Hoffmann and Warner, 2006)(Carlsson et al., 1993)(Chézalviel-Guilbert et al., 1995). 
The zebrafish on the other hand might provide a solution to this problem, as a wide selection 
of genetic techniques are available to knockout genes of particular interest that may be 
related to arrhythmia development with the possibility of also creating stable transgenic 
lines (Milan and MacRae, 2005). Additionally, zebrafish and humans are very similar on an 
electrophysiological level and drug studies have already shown that zebrafish can develop 
various forms of arrhythmias with different degrees of severity (Milan and MacRae, 2005). 
 
The zebrafish embryo has also been shown to be a very good model for drug-induced AV 
block with zebrafish embryos exposed to known human QT prolonging drugs developing AV 
block due to zERG block (Langheinrich et al., 2003). AV block occurs due to a disruption in 
conduction of the electrical signal from the atria to the ventricles (Clarke et al., 1976).  
 
3.2 Aims 
Previously, it was shown that ECGs can be recorded from zebrafish larvae as young as 5 dpf 
and as old as 35 dpf using micropipette-based systems (Forouhar et al., 2004)(Yu et al., 
2010). Additionally, it was demonstrated that a known cardiotoxic drug in humans causing 
QRS prolongation had the same effect on 7 dpf zebrafish larvae (Yu et al., 2010). 
Furthermore, on adult zebrafish ECGs QT prolongation could be observed following exposure 
of adult zebrafish to known human QT prolonging drugs (Milan et al., 2006). When 2 and 3 
dpf zebrafish embryos/larvae were exposed to these same drugs, QT-related conditions such 
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as bradycardia and atrioventricular block were observed (Langheinrich et al., 2003)(Milan et 
al., 2003). The main aim of this work was therefore to develop a zebrafish embryo and larval 
ECG recording set-up that could be used for investigating cardiac dysfunction.  
 
As it had already been shown that it was possible to record ECGs from zebrafish larvae as 
young as 5 dpf, the first objective was to reproduce the published data using our own ECG 
recording set-up. The first experiment therefore involved taking five minute ECG recordings 
from zebrafish larvae and determining the stability, as well as reproducibility of the ECG 
signals. The second objective was to then optimise the ECG recording set-up. Various 
parameters were optimised. The first parameter optimised was the form of immobilization 
used, as it was important to find an immobilizing agent that would effectively immobilize the 
zebrafish without having a significant effect on the ECG signal. The second parameter 
optimised was the recording temperature, as it was important to determine the 
temperature range at which ECG recordings could be conducted without inducing significant 
effects on the ECG signal. For this the Q10 coefficient (the ratio of the rates of a reaction or 
process at T+10°C and T°C) was calculated (Hegarty, 1973). The third parameter optimised 
was the electrode position, as differences in electrode position were previously reported by 
Forouhar and colleagues to affect ECG signal morphology (Forouhar et al., 2004). The final 
parameter optimised was the zebrafish developmental stage used for recording purposes, as 
it was important to identify a developmental stage that was easy to position in the recording 
plate whilst at the same time producing ECG signals with prominent P, QRS and T waves.   
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Once the ECG recording set-up had been optimised, the next question addressed was 
whether it could be utilised as a screening tool to detect cardiotoxic effects of drugs. Drug-
induced QT prolongation was of particular interest, as it is a condition caused by blockade of 
the hERG channel, which is the main cardiac ion channel involved in ventricular 
repolarisation (Katchman et al., 2006).  
 
Three drugs (terfenadine, haloperidol and pimozide) known to induce QT prolongation in 
humans were selected and thus tested for their effects on 3 dpf zebrafish larval ECGs. 
Terfenadine which is an anti-histamine can block several cardiac ion channels including the 
hERG channel, whereas haloperidol and pimozide (both anti-psychotics) bind to the hERG 
channel more specifically than to other cardiac ion channels (Testai et al., 2010). In addition 
to this the anti-arrhythmic agent verapamil was tested, which is known to block hERG in 
vitro but not in vivo (Martin et al., 2004). Penicillin was also tested as a negative control as it 
is known not to block hERG or cause QT prolongation in humans and adult zebrafish (Milan 
et al., 2006).  
 
3.3 Methods 
3.3.1 Preparation of electrocardiogram apparatus 
The ECG set-up consisted of several main components including a differential amplifier (NPI 
electronics GmbH, Germany), mechanical micromanipulator (Nashirige, UK), Inchworm step 
motor (Lumen Dynamic Group, Canada), PowerLab 4/35 data acquisition unit (ADI 
Instruments, UK) and a stereomicroscope (Nikon, UK). Everything was housed inside a 
grounded faraday cage on an air table (Scientifica, UK) to minimise background noise. The 
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mechanical manipulator was used as an attachment site for the motor and also the 
connection box for the positive and reference electrodes.  
 
A borosilicate glass micropipette (World Precision Instruments, England) was pulled with a 
micropipette puller (Nashirige, UK) and the end of the tip was cut with a glass block to give a 
tip with a 2 µm diameter. This micropipette was then filled using MicroFil (World Precision 
Instruments, UK) with 3 M potassium acetate solution (Sigma-Aldrich, UK) and coloured with 
methylene blue solution (Sigma-Aldrich, UK). The micropipette was attached to the end of 
the motor and locked into place on the motor end via a screw. A chloridised silver wire 
(recording electrode) which carries the electrical signal to the amplifier was then inserted 
into the micropipette.  
 
Experiments were performed at room temperature (21°C) unless otherwise stated. The 
temperature was controlled using a temperature controller (Cryogenic control systems Inc., 
California, USA) to which a temperature sensor and a homemade heating element were 
connected. 
 
3.3.2 ECG recording method 
For all experiments, except the immobilization optimisation experiments, zebrafish 
embryos/larvae were anaesthetised in 0.3 mg/mL MS222 (Sigma-Aldrich, UK) for 10 minutes. 
Once anaesthetised, one zebrafish embryo/larva was then transferred to the ECG recording 
plate. The recording plate consisted of a Petri dish covered with a 2% layer of agarose into 
which grooves had been made using a plastic template. To the recording plate 10 mL of fresh 
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E3 embryo medium without MS222 was added. For ECG recording purposes the zebrafish 
embryo/larva was always positioned ventrally within a groove in the agarose layer.  
 
The tip of the filled pre-pulled borosilicate glass micropipette was positioned on the skin 
surface between the ventricle and atrium (no penetration) using the mechanical 
micromanipulators (Narishige, UK), the Inchworm step motor (Burleigh, UK) and a stereo 
microscope (Nikon, UK). A second reference electrode was then placed in the surrounding 
medium in the recording plate. The differential amplifier (NPI electronics, Germany) used for 
recordings was operated in DC mode with the high pass filter set at 0.1 hertz (Hz). The raw 
ECG signals were digitised using the PowerLab 4/35 data acquisition unit (ADInstruments, 
UK) and viewed using LabChart 7 Pro (ADInstruments, UK). When viewing the ECG signal, the 
digital filter was changed to 15 and the Inchworm step motor (Burleigh, UK) was used to 
move the micropipette tip forwards and backwards until a stable ECG signal was found 
(Figure 3.8).  
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Figure 3.8 – Screenshot of an ECG recording from a 3 dpf zebrafish (digital filter 15). ECG 
recordings were taken for 5 minutes immediately after a consistent ECG signal was found 
that displayed stable P, QRS and T waves.  
 
3.3.3 ECG temperature experiments 
To determine the effect of temperature on ECG recordings, recordings were taken at 
different temperatures (20, 22, 24 and 28°C). A homemade heating element connected to a 
temperature controller (Cryogenic control systems Inc., USA) was used to increase the 
temperature in the recording plate containing 5 mL of E3 embryo medium. This was done by 
firstly embedding the heating pad of the device in 2% agarose inside a Petri dish. A plastic 
template was then used to create grooves on the upper surface of the agarose layer; this 
could then later be used to position the zebrafish larvae during ECG recordings. The 
temperature was monitored and controlled using a sensor that was placed inside the 
recording plate. Once the temperature inside the plate had reached the required level, a 
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zebrafish larva at 3 dpf was transferred to the recording plate and was left to acclimatize for 
30 minutes. The zebrafish larva was then transferred for 10 minutes to a 0.3 mg/mL MS222 
anaesthetic solution before being transferred back to the recording plate and being 
positioned within a groove. An ECG recording was then taken for five minutes.  
 
3.3.4 Invasive ECG recordings 
For invasive ECG recordings the exact same set-up as for non-invasive ECG recordings was 
used except that the speed of the step motor was tripled and the distance moved was 
increased from 5 to 500 µm. Through these changes, the positive electrode could be pushed 
with enough force directly into the heart by penetrating the skin. For the invasive ECG 
experiments, initially a non-invasive recording was performed for five minutes first before 
performing an invasive recording for five minutes.  
 
3.3.5 ECG drug treatments 
The compounds used to exclude motion artefact included cromakalim (Tocris Bioscience, 
UK) which is a KATP channel opener (Ripoll et al., 1990) along with (-)-blebbistatin (Sigma-
Aldrich, UK) & 2,3-butanedione monoxime (BDM) (Sigma-Aldrich, UK) which are excitation-
contraction uncouplers (Brines et al., 2012). The compounds used for immobilization of 
zebrafish embryos/larvae included MS222 (Sigma-Aldrich, UK) which is an anaesthetic that 
blocks the conductance of sodium and potassium in excitable cells (Rombough, 2007) and 
(+/-) tubocurarine chloride pentahydrate (Sigma-Aldrich, UK) which is a skeletal muscle 
relaxing alkaloid (Colquhoun et al., 1979). For the QT prolongation investigation experiments 
verapamil hydrochloride (Tocris Bioscience, UK) which is an anti-arrhythmic (Somogyi et al., 
77 
 
1981), haloperidol (Sigma-Aldrich, UK) which is a butyrophenone anti-psychotic (Gerace et 
al., 2012), terfenadine (Sigma-Aldrich, UK) which a histamine H1 receptor antagonist (Testai 
et al., 2010), pimozide (Sigma-Aldrich, UK) which is a diphenylbutylpiperidine anti-psychotic 
(Pa et al., 1968) and penicillin G sodium salt (Sigma-Aldrich, UK) which is an antibiotic (Milan 
et al., 2006) were tested.  
 
All drug stocks were made using DMSO except MS222 stock which was made with distilled 
water and verapamil hydrochloride and (+/-) tubocurarine chloride pentahydrate stocks 
which were both made with E3 embryo medium. All final dilutions made from the initial 
stock solutions were made up using E3 embryo medium.  
 
The recording plate used for drug treatment experiments consisted of a mini Petri dish 
(Fisher Scientific UK Ltd, UK) covered with a layer of unscented paraffin wax (Sigma-Aldrich, 
UK) into which grooves had been made manually. The recording plate was filled with 3 mL of 
E3 embryo medium. ECG recordings were taken for five minutes before addition of drug. 
Drug was then added directly to the recording plate (1 mL) to produce the desired drug 
concentration by undergoing a 1 in 4 dilution. After drug addition, a 15 minute segment 
where QT prolongation was first apparent by visual observation was selected for analysis. 
Recording lengths varied depending on the concentration of drug used, e.g. for terfenadine 
treatments at 0.1, 0.3 and 1 µM recordings were taken for up to 1 hour or more, and for 
terfenadine treatments at 50 µM recordings were taken for 40 minutes or less. 
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3.3.6 Agarose-embedded ECG recordings 
To obtain ECG recordings from agarose-embedded 3 dpf zebrafish larvae, firstly the 
zebrafish larvae were individually pipetted into mini-Petri dishes (Fisher Scientific UK Ltd, 
UK). They were then covered with a 1% solution of molten low melting point agarose 
(PEQLAB Biotechnologie, Germany) and positioned ventrally within the agarose with the 
agarose allowed to set for a few minutes before 3 mL of E3 embryo medium was added. 
Forceps were used to remove the excess agarose from the top portion of the zebrafish 
larvae exposing the head and the heart. An ECG recording was then taken for five minutes. 
 
3.3.7 ECG data analysis 
Analysis of the digitised ECG signal was carried out using LabChart Pro 7 (ADInstruments, 
UK). After a selection of an ECG recording had been highlighted for analysis the ECG settings 
function on the LabChart Pro 7 (ADInstruments, UK) programme was used. Using the ECG 
settings function (shown in Figure 3.9) values were automatically calculated for different 
ECG parameters based on the species tested. If these values did not match up with the ECG 
recording the correct values could be manually entered. As no set values exist for the 
recording of fish ECGs on LabChart Pro 7 (ADInstruments, UK), values had to be entered 
manually each time for each ECG recording analysed. On the ECG settings function, the 
following were selected: 1) bazett, 2) human, 3) block averaging and 4) rodent T wave. 
Values were then entered manually for the following parameters: QRS interval width, 
distance between R waves, pre-P baseline, PR interval, RT interval and ST height. These 
values were obtained from the ECG recording itself and entered into the appropriate fields 
in the ECG settings window.  
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Figure 3.9 – Screenshot of the ECG settings window in LabChart Pro7. 
 
After entering the correct values for the different ECG parameters, the ‘analyse’ function 
was selected on the ECG settings window. On the ECG analysis toolbar, ‘average view’ was 
selected and a plot was produced showing the average waveform (black) over the selected 
recording period. Several green waveforms surrounding the average waveform were also 
generated with each green waveform representing a single cardiac cycle (Figure 3.10).  
 
Figure 3.10 – Screenshot of single waveforms (green) and an averaged waveform (black) 
generated from an analysed ECG recording segment. 
80 
 
Several ECG landmarks (start of P wave, P wave peak, end of P wave, start of QRS, max QRS, 
end of QRS, T wave peak and T wave end) were then assigned automatically on the plot. 
Then by selecting the ‘tableview’ function from the ECG analysis toolbar, a table detailing 
the time durations of the different ECG parameters, such as the QT interval, RR interval, etc. 
was generated (Figure 3.11). 
 
Figure 3.11 – Screenshot of the ‘tableview’ showing ECG parameters generated from the 
average waveform. 
 
From the table generated the interval durations for the ECG parameters RR, QRS, QT and 
QTc were selected for further analysis. These parameters are explained in Table 3.1 below.  
 
Table 3.1 – ECG parameters measured and their meanings. 
ECG parameter Meaning 
RR interval Duration of ventricular cardiac cycle 
PR interval 
Time interval for the onset of atrial depolarisation to the onset of 
ventricular depolarisation 
QRS interval Duration of ventricular depolarisation 
QT interval Duration of ventricular depolarisation and repolarisation 
QTc interval QT interval corrected for heart rate 
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Using these ECG parameter values comparisons could then be made between different ECG 
recordings or different segments of the same ECG recording. Additionally, for drug 
treatments the percentage change in the QTc interval duration before and after drug 
treatment was determined for each tested zebrafish larva. Data obtained from several 
zebrafish larvae exposed to the same recording conditions were then pooled and averaged 
and used for graphical representation and statistical analysis.  
 
For the temperature experiments, the temperature coefficient Q10 (Reyes et al., 2008) was 
additionally calculated to quantify the effect of temperature on ECG recordings using the 
following equation: Q10 = (R2-R1)
(10/T2-T1) where R1 = heart rate at temperature T1, R2 = heart 
rate at temperature T2. 
 
3.4 Results 
3.4.1 Stability and reproducibility of zebrafish embryo and larval ECG signals 
As a glass electrode-based set-up had been previously described for recording ECG signals 
from zebrafish larvae (Forouhar et al., 2004), the objective of the first experiment was to 
reproduce this published data by recording ECG signals from 3 dpf zebrafish larvae using our 
own ECG set-up. The experiment was performed by first anaesthetising 3 dpf zebrafish 
larvae in 0.3 mg/mL of MS222 anaesthetic for 10 minutes before transferring one zebrafish 
larva into the recording plate (2% agarose covered plate with grooves) containing 10 mL of 
E3 embryo medium. Each larva was positioned ventrally within the grooves and the positive 
electrode was positioned on the surface of the heart at the atrium and ventricle boundary. A 
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reference electrode was also placed in the recording plate away from the zebrafish larva. 
Once everything was in place an ECG signal could be recorded (Figure 3.12). 
 
Figure 3.12 – ECG set-up. For ECG recording purposes all the equipment was housed in a 
Faraday cage to minimise background noise. A stereomicroscope, external light and forceps 
were used to position anaesthetised zebrafish embryos/larvae ventrally inside grooves of a 
2% agarose-covered Petri dish. A micromanipulator and motor were used to position the 
positive electrode on the skin surface at the atrium and ventricle boundary. A reference 
electrode was also placed in the recording plate along with a temperature sensor to monitor 
the temperature during recordings. The raw ECG signals were digitised and viewed using 
LabChart 7 Pro (ADInstruments, UK). 
 
Once all the equipment was in place, the LabChart Pro7 software was used to detect the ECG 
signal. A representative raw ECG trace from a 3 dpf zebrafish larva is shown in Figure 3.13A. 
In order to make the signal clearer low-pass filtering was introduced to eliminate 
background noise (Figure 3.13B). Using the analysis function on the LabChart Pro7 software 
a section of the filtered ECG recording was analysed and a mean ECG waveform was 
generated (black line) (Figure 3.13C). The recorded ECG signal was found to be stable (no 
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change in waveform), as all individual waveforms (grey lines) from the recording period were 
found to be close to the mean (Figure 3.13C). Additionally, the ECG signals recorded were 
found to have the three distinctive features that make up a typical ECG, including a small P 
wave representing atrial depolarisation, a large QRS complex representing ventricular 
depolarisation and a moderate T wave representing ventricular repolarisation (Figure 
3.13D). 
 
 
Figure 3.13 – ECG signal filtering and processing. A) Raw 3 dpf zebrafish ECG signal (two 
minute segment) before filtering viewed using LabChart 7 Pro, B) Low-pass digitally filtered 
(digital filter = 15) 3 dpf zebrafish ECG signal (two minute segment) viewed using LabChart 7 
Pro, C) Analysed 1 minute segment of a 3 dpf zebrafish ECG recording viewed using LabChart 
7 Pro (grey lines = single waveforms, black line = mean), D) Schematic of 3 dpf zebrafish ECG 
waveform.  
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Once the ECG recording set-up was in place the reproducibility of the set-up could be 
determined. In order to address this issue; surface ECG recordings were taken using the 
same method described above for 30 zebrafish larvae aged 3 dpf. Mean values were 
calculated for the RR, QT and QTc time interval durations over a five minute recording period 
using these 30 zebrafish larvae. All of the results were then collated and averaged (Figure 
3.14A). The standard deviation (SD) values for RR (0.035), QT (0.028) and QTc (0.032) 
interval durations were found to be small, thus showing that reproducible ECG signals could 
be obtained from different 3 dpf zebrafish larvae using this set-up. Additionally, when 
looking specifically at the QTc interval it was found that with increasing numbers of zebrafish 
larvae the SD values were found to remain relatively stable in the 0.03 range (Figure 3.14B). 
For example, the SD value for both 15 and 30 zebrafish larvae was found to be 0.032. There 
was found to be no significant difference between the QTc interval duration values for 
differing numbers of zebrafish larvae (P>0.05), hence this confirmed that the ECG set-up had 
relatively good reproducibility even when using a small number of zebrafish larvae.  
Figure 3.14 – ECG signal reproducibility. A) Mean time duration values for RR, QT and QTc 
intervals (n=30 zebrafish larvae aged 3 dpf), B) Mean QTc interval durations for increasing 
numbers of 3 dpf zebrafish larvae (P>0.05).  
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3.4.2 Investigation into methods to exclude motion artefact from zebrafish embryo and 
larval ECG recordings 
The initial experiments performed showed that reproducible recordings could be obtained 
from zebrafish larvae; however the next question that needed to be addressed was whether 
motion artefact was responsible for the ECG signals observed. Motion artefact has been 
extensively documented to contaminate surface ECG recordings (Tong et al., 2001)(Redfern 
et al., 1993)(Tong et al., 2002). It can occur due to mechanical movements, such as beating 
of the heart or in the case of mammals additionally due to respiratory motion (Wang et al., 
1995)(Tournebize et al., 2006). A number of approaches have been used to counteract this 
problem including using analogue/digital filters and various mathematical techniques, such 
as temporal/spatial averaging and independent component analysis which can remove 
motion artefact from ECG recordings during or after processing (He et al., 2006). However, 
electro-mechanical uncouplers are commonly used to exclude motion artefact before an 
ECG recording is taken by preventing the mechanical movement of the heart without 
perturbing the electrical signal (Brines et al., 2012).  
 
To exclude possible motion artefact due to mechanical movement of the heart in zebrafish 
larvae two different approaches were used. The first approach was to use a drug, namely 
cromakalim in order to separate the electrical activity of the heart from the mechanical 
movement. Cromakalim hyperpolarises potassium channels resulting in relaxation of the 
cardiac muscle of the heart (Fujii et al., 1990). Seven different concentrations of cromakalim 
were tested (10, 25, 50, 100, 200, 300 and 400 µM). The reason for using such a wide 
concentration range was because, it was not known at which concentration this drug would 
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be active in zebrafish larvae. The experiment was performed by anaesthetising zebrafish 
larvae in 0.3 mg/mL of MS222 anaesthetic for 10 minutes before transferring one zebrafish 
larva individually to the recording plate.  
 
The recording plate consisted of a mini Petri dish containing an unscented paraffin wax layer 
with grooves. After positioning the zebrafish larva in the recording plate a surface ECG 
recording before drug addition for 5 minutes and then after drug addition for 15 minutes 
was taken. In addition to this heart contractility was also monitored over the recording 
period. The percentage change in the mean RR, QT and QTc interval durations was then 
calculated for each concentration of cromakalim tested (Figure 3.15, n=5 zebrafish larvae at 
3 dpf per drug concentration). It was found that cromakalim at all of the tested 
concentrations was found to have no significant effect on the RR interval (P>0.05), QT 
interval (P>0.05) or QTc interval (P>0.05). Additionally, the contractility of the heart 
remained unchanged, suggesting that the drug either was not taken up or the 
concentrations tested were too low.  
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Figure 3.15 – Effect of cromakalim drug treatment on ECG interval durations. Mean 
percentage change in RR, QT and QTc interval durations after treatment of zebrafish larvae 
with different concentrations of cromakalim (n=5 zebrafish larvae at 3 dpf per drug 
concentration, P>0.05 for RR, QT and QTc). 
 
As cromakalim was found to have no effect two other drugs were then tested, which 
included the excitation-contraction uncouplers 2,3-butanedione-monoxime (BDM) and 
blebbistatin. BDM is a routinely used agent in the field of cardiac electrophysiology and 
blebbistatin is a synthetic peptide that is a relatively newer agent (Brines et al., 2012).  
 
Zebrafish larvae were first anaesthetised in 0.3 mg/mL of MS222 anaesthetic for 10 minutes 
before transferring one zebrafish larva individually to the recording plate and then taking a 
surface ECG recording before drug addition for 5 minutes and then after drug addition for 30 
minutes (n=10 zebrafish larvae at 3 dpf per drug concentration). BDM was only tested at 15 
mM, whereas blebbistatin was tested at two concentrations; namely 10 and 15 µM. These 
concentrations were chosen based on those reported in the literature for excised 2 dpf 
zebrafish embryo hearts (Jou et al., 2010). With both agents there was found to be a 
complete abolishment of contraction of the zebrafish larval heart. The mean QTc interval 
durations with both agents were found to be slightly prolonged, however this was found not 
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to be significant (Figure 3.16A,B, n=10 zebrafish larvae at 3 dpf per drug concentration, 
P>0.05). The RR and QT intervals (not shown) were also prolonged but again these changes 
were found not to be significant (P>0.05). The waveform amplitudes were found to be 
reduced after treatment with these two drugs. Additionally, both drugs were also found to 
severely affect the survival of the zebrafish larvae with ECG recordings only obtainable up to 
10 minutes in the case of BDM and up to 30 minutes in the case of blebbistatin at 10 and 15 
µM. After this time blood accumulation in the heart and necrosis of the extremities (head 
and tail) was observed.  
 
Figure 3.16 - Exclusion of motion artefact through the use of electro-mechanical 
uncouplers. A) Mean QTc interval durations before and after 15 mM BDM treatment of 3 dpf 
zebrafish larvae (n=10 zebrafish larvae at 3 dpf per drug concentration, P>0.05), B) Mean 
QTc interval durations before and after treatment of 3 dpf zebrafish larvae with 10 & 15 µM 
blebbistatin (n=10 zebrafish larvae at 3 dpf per drug concentration, P>0.05).  
 
To overcome the problems observed with the drug treatments (i.e. non-responsiveness and 
toxicity) a second approach was taken to exclude motion artefact. This involved altering the 
recording method by puncturing the zebrafish heart and taking an invasive ECG recording.  
 
The invasive ECG recording was performed using the exact same set-up and operating 
parameters utilised for measuring surface ECGs. The only difference was that the speed of 
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the step motor was tripled and the distance by which it moved which was increased from 5 
to 500 µM. Through these changes, the positive electrode could be pushed with enough 
force directly into the heart by penetrating the skin. The results obtained from this 
experiment showed that there were minimal differences between taking an invasive and a 
non-invasive ECG recording (Figure 3.17, n=5 zebrafish larvae at 3 dpf, P>0.05). Taken 
together these results suggest that the surface ECG recording technique currently being 
utilized enables true electrical recordings of the heart to be obtained. 
 
Figure 3.17 – Exclusion of motion artefact by performing an invasive ECG recording. 
Changes in ECG parameters for non-invasive and invasive larval zebrafish ECG recordings 
(n=5 zebrafish larvae at 3 dpf per method, P>0.05 for RR, QT and QTc). 
 
3.4.3 Investigation into methods to immobilize zebrafish embryos and larvae during ECG 
recordings 
For ECG recording purposes zebrafish embryos and larvae had to immobilized, so that 
motion artefact from physical movement (e.g. movement of fins) did not interfere with the 
ECG signals obtained. To address this issue various immobilization methods were explored 
including the use of low melting point agarose. When using low melting point agarose non-
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anaesthetised zebrafish larvae aged 3 dpf were first individually pipetted into mini-Petri 
dishes and then covered with a 1% solution of molten low melting point agarose. The 
zebrafish larvae were positioned ventrally within the agarose and the agarose was then 
allowed to set for a few minutes before 3 mL of E3 embryo medium was added to the plates. 
Forceps were used to remove the excess agarose from the top portion of the zebrafish 
larvae exposing the head and the heart (Figure 3.18A). Surface ECG recordings were then 
taken for five minutes (n=10 zebrafish larvae).  
 
Additionally, ECG recordings were also taken from 3 dpf zebrafish larvae which had been 
anaesthetised with 0.3 mg/mL of MS222 for 10 minutes before being immobilized in the low 
melting point agarose (n=10 zebrafish larvae). ECG interval durations were determined for 
the two different methods used and then compared (Figure 3.18B). The RR interval was 
found to differ significantly between unanaesthetised and anaesthetised zebrafish larvae 
(Figure 3.18B, n=10 zebrafish larvae at 3 dpf per condition, P<0.05), whereas the QT and QTc 
interval durations were found to show no significant differences (Figure 3.18B, n=10 
zebrafish larvae at 3 dpf per condition, P>0.05).  
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Figure 3.18 – Agarose embedding as a form of immobilization. A) Schematic of 3 dpf 
zebrafish larva embedded in low melting point agarose with heart exposed, B) Differences in 
ECG parameters between non-anaesthetised and 0.3 mg/mL MS222 anaesthetised 3 dpf 
zebrafish larvae (n=10 zebrafish larvae at 3 dpf per condition, P<0.05 for RR, P>0.05 for QT 
and QTc). 
 
As it was time consuming and difficult to position zebrafish larvae in low melting point 
agarose, the agarose plate method that was initially used for ECG recording purposes was 
optimised. However, when using the agarose plate method the zebrafish larvae had to be 
immobilized in some way with a paralysing or anaesthetic agent in order to position them 
within the agarose grooves and keep them still throughout the recording. The anaesthetic 
agent MS222 was used for this purpose and was tested at several different concentrations 
(0.1, 0.3, 0.5 and 1 mg/mL). When using MS222 zebrafish larvae were first anaesthetised for 
10 minutes before being individually transferred to the recording plate. ECG recordings were 
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then taken for 15 minutes. A paralysing agent tubocurarine (Buss et al., 2003) was also 
tested as an alternative sedating agent at two concentrations (100 and 400 µM). With 
tubocurarine zebrafish larvae had to be continuously exposed to the agent, hence it was 
added directly to the recording plate and ECG recordings were then taken for 15 minutes. 
Both agents were found to produce comparable recordings with little difference observed in 
the calculated ECG parameters (Figure 3.19A, B).  
Figure 3.19 – Forms of immobilization. A) Effect of different concentrations of MS222 on 
mean ECG interval durations (n=10 zebrafish larvae at 3 dpf per drug concentration, P<0.05 
for RR, P>0.05 for QT and QTc), B) Effect of different concentrations of tubocurarine on mean 
ECG interval durations (n=10 zebrafish larvae at 3 dpf per drug concentration, P>0.05 for RR, 
QT and QTc). 
 
For MS222 at the highest tested concentration of 1 mg/mL (n=10 zebrafish larvae at 3 dpf 
per drug concentration) there was found to be a significant increase in the RR interval 
(P<0.05). The QT interval (P>0.05) and the QTc interval (P>0.05) on the other hand were 
found to show no significant differences. When analysing the results obtained for 
tubocurarine it was found that the RR interval (P>0.05), QT interval (P>0.05) and QTc interval 
(P>0.05) all showed no significant differences. However, as tubocurarine has been 
documented to undergo drug-drug interactions, specifically with anti-arrhythmics (Harrah et 
al., 1970), it was decided not to use it for ECG recording purposes. Therefore, MS222 at 0.3 
93 
 
mg/mL was subsequently used for ECG recordings as at this concentration it was found to 
have no significant effect on the QTc interval duration or any of the other ECG intervals. 
 
3.4.4 Identification and characterisation of variables of zebrafish embryo and larval ECG 
recordings 
To optimise the ECG recording set-up various factors were addressed that could influence 
either detection of the ECG signal or heart function itself. One such factor included the 
ambient temperature at which ECG recordings were taken. As zebrafish are ectothermic 
animals (organisms where ambient temperature influences body temperature) at lower 
temperatures the electrical activity of the cardiac myocytes is reduced resulting in a 
decreased QRS amplitude and heart rate (ƒH) (Seth et al., 2013)(Maricondi-Massari et al., 
1998). At higher temperatures the opposite effect is observed where there is an increase in 
fH and the electrical activity of the cardiac myocytes (Maricondi-Massari et al., 1998).  
 
As zebrafish develop normally at 28oC but can also develop at a slower rate at 18oC, four 
temperatures (20, 22, 24 and 28°C) within this range were subsequently chosen in order to 
investigate the effects of temperature on ECG recordings. A homemade heating element 
connected to a temperature controller was used to increase the temperature in the 
recording plate containing 5 mL of E3 embryo medium. This was done by firstly embedding 
the heating pad of the device in 2% agarose inside a Petri dish. A plastic template was then 
used to create grooves on the upper surface of the agarose layer; this could then later be 
used to position the zebrafish larvae during ECG recordings. The temperature was monitored 
and controlled using a sensor that was placed inside the recording plate. Once the 
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temperature inside the plate had reached the required level, a zebrafish larva at 3 dpf was 
transferred to the recording plate and was left to acclimatize for 30 minutes. The zebrafish 
larva was then transferred for 10 minutes to 0.3 mg/mL MS222 anaesthetic solution before 
being transferred back to the recording plate and being positioned within a groove. An ECG 
recording was then taken for five minutes. This process was repeated several times with ECG 
recordings taken at each temperature using 10 different 3 dpf zebrafish larvae each time.  
 
After calculating the mean RR, QT and QTc interval durations it could be seen that at higher 
temperatures the mean RR, QT and QTc interval durations were reduced whereas the 
opposite effect occurred at lower temperatures (Figure 3.20A). The changes observed in the 
RR (P<0.05), QT (P<0.05) and QTc (P<0.05) interval durations by an increase or decrease in 
temperature were found to be significant. Additionally, the results also demonstrated that 
heart function was sensitive to temperature and this was further confirmed by calculating 
Q10 coefficients which were found to be 2.7 over the 10°C range (Figure 3.20B). 
 
Figure 3.20 – Optimisation of recording temperature. A) Effect of different recording 
temperatures on mean ECG interval durations (n=10 zebrafish larvae at 3 dpf, P<0.05 for RR, 
QT and QTc), B) Change in calculated Q10 coefficients over a 10°C temperature range. 
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The next variable that was addressed was the developmental stage of the zebrafish used for 
obtaining ECG recordings. At 2 dpf zebrafish have a fully functional ventricle and atrium, 
however the ventricle continues to mature and thicken during development even after the 
heart has formed (Glickman and Yelon, 2002)(Rottbauer et al., 2001). This could therefore 
impact on the ECG signal that is recorded by causing a possible increase in the amplitude of 
the T wave and a narrowing of the QRS complex (Yu et al., 2010). To determine whether the 
zebrafish developmental stage had an influence on the morphology of the ECG signal an 
experiment was performed where ECG recordings were taken from 2, 3, 4 and 5 dpf 
zebrafish and compared. Eight zebrafish from each developmental stage were tested and 
ECG recordings were taken for five minutes.  
 
It was found that reproducible ECG recordings could be obtained from all stages tested 
including at 2 dpf where P, QRS and T waves were clearly visible on the ECG recordings 
(Figure 3.21A). Between 2 dpf zebrafish embryos and 3, 4 and 5 dpf zebrafish larvae there 
was found to be a significant difference in QT interval durations (Figure 3.21B, n=8 zebrafish 
per developmental stage, P<0.05). Additionally, there was found to be a significant 
difference in QTc intervals between 2 and 5 dpf zebrafish (P<0.05). The mean RR interval 
durations on the other hand did not differ significantly among any of the age groups 
(P>0.05). For subsequent drug treatment experiments 3 dpf zebrafish larvae were used due 
to ease of manipulation in terms of positioning in the recording plate as with later stages 
(e.g. 5 dpf) it was more difficult to position the zebrafish properly due to inflated swim 
bladders.  
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Figure 3.21 – Optimisation of recording stage. A) Analysed ECG trace from a 2 dpf zebrafish 
embryo for a one minute recording segment (grey lines = single waveforms, black line = 
mean), D) Effect of recording age on mean ECG interval durations (n=8 zebrafish per 
developmental stage, P>0.05).  
 
Another variable addressed was the electrode position on the heart. In adult zebrafish ECG 
studies it was noted that differences in electrode position were possibly responsible for the 
variation in T wave amplitude and morphology (Milan et al., 2006)(Sun et al., 2009). In the 
experiments described in this chapter, ECG Recordings were performed by placing the 
electrode on the boundary between the atrium and ventricle (Figure 3.22A), the same 
position used by Forouhar and colleagues, as this position is thought not to disturb the 
function of cardiac ion channels (Forouhar et al., 2004). To find out whether the electrode 
position could influence ECG signals, ECG recordings were taken at eight different positions 
along the heart axis (Figure 3.22B). The mean RR, QT and QTc interval durations were then 
determined for each position (Figure 3.22C). The results obtained showed no significant 
differences in the mean RR (P>0.05), QT (P>0.05) or QTc (P>0.05) interval durations at each 
of the tested positions. 
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Figure 3.22 – Optimisation of electrode position on zebrafish heart. A) Picture of a 3 dpf 
zebrafish larva with the electrode tip positioned between the atrium and ventricle, B) 
Schematic of a 3 dpf zebrafish larva with different recording positions along the heart axis 
marked, C) Mean ECG interval durations obtained at different electrode positions on the 
heart in 3 dpf zebrafish larvae (n=10 zebrafish larvae per position). Key: 1=sinus venosus, 
2=between atrium and sinus venosus, 3=base of atrium, 4=apex of atrium, 5=between atrium 
and ventricle, 6=base of ventricle, 7=apex of ventricle and 8=bulbus arteriosus. 
 
Furthermore, the distance of the electrode from the surface of the heart was also 
investigated in order to see if this affected the ECG recordings. There was found to be no 
statistically significant change in the QTc interval after movement of the electrode 
longitudinally by 5 and 10 µm towards the surface of the heart (P>0.05). The ECG waveform 
however was found to be influenced with a decrease in the ECG signal amplitude observed 
(Figure 3.23A,B, n=3 zebrafish larvae at 5 dpf). Taken together, these findings concluded that 
electrode positioning was not important when performing ECG recordings.  
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Figure 3.23 – Effect of electrode distance from the zebrafish heart on ECG signal 
morphology. A) Mean QTc interval durations obtained from 5 dpf zebrafish larvae at an 
atrium/ventricle boundary starting position and after movement of the electrode 
longitudinally by 5 and 10 µm (n=3 zebrafish larvae at 5 dpf), B) 5 dpf zebrafish larval ECG 
trace (two seconds) after movement of electrode 5 µm longitudinally from initial starting 
position, C) 5 dpf zebrafish larval ECG trace (two seconds) after movement of electrode 
longitudinally by 10 µm from initial starting position.  
 
3.4.5 Zebrafish larval ECG recording set-up as a tool for detecting drug-induced 
cardiotoxicity 
Once the ECG recording set-up had been optimised, the next question addressed was 
whether this set-up could be utilised as a screening tool to detect cardiotoxic effects of 
drugs. As mentioned previously drug-induced QT prolongation which is a condition caused 
by blockade of the hERG channel (the main cardiac ion channel involved in ventricular 
repolarisation) that can predispose to life threatening conditions such as TdP was of 
particular interest to study in 3 dpf zebrafish larvae (Katchman et al., 2006). Three drugs 
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(terfenadine, haloperidol and pimozide) known to induce QT prolongation in humans were 
selected and thus tested for their effects on 3 dpf zebrafish larval ECG recordings. In addition 
to this a drug not known in humans to cause QT prolongation (verapamil) (Redfern et al., 
2003), as well as a drug not shown in either adult zebrafish or humans to cause QT 
prolongation (penicillin) were tested (Milan et al., 2006). Drug treatments were performed 
by first anaesthetising the zebrafish larvae at 3 dpf in 0.3 mg/mL of MS222 anaesthetic for 
10 minutes before transferring them to a recording plate with a wax surface. Wax was used 
instead of agarose, as with agarose there was the possibility that drug would diffuse into it. 
Once the zebrafish larva was transferred to the recording plate 3 mL of E3 embryo medium 
was added to the plate. An ECG recording was then taken for five minutes. After five 
minutes, 1 mL of drug solution was added to the recording plate as carefully as possible, so 
as not to move the zebrafish larva. Another ECG recording was then taken for a minimum of 
15 minutes; however the recording time varied depending on the concentration of drug 
tested. For example with terfenadine at the lower concentrations of 0.1 and 0.3 µM ECG 
recordings were taken for more than an hour.  
 
From the ECG recordings the percentage change in the QTc interval after drug treatment 
compared to before treatment was determined for each drug at each of the tested 
concentrations. Terfenadine was found to increase the QTc interval in a dose-dependent 
manner, which was found to be significant for all tested concentrations (Figure 3.24A, n=8 
zebrafish larvae at 3 dpf per concentration, P<0.05). The QTc prolongation observed with 
terfenadine was characterised by widening of the T wave (Figure 3.24B), similar to what has 
been observed in adult zebrafish ECG recordings following exposure to this drug (Milan et 
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al., 2006). Additionally, the heart rate was also found to significantly decrease in a dose-
dependent manner (Figure 3.24C, n=8 zebrafish larvae at 3 dpf per concentration, P<0.05). 
 
 
Figure 3.24 – QTc prolongation in zebrafish larvae after treatment with terfenadine. A) 
Mean QTc interval percentage change after treatment of 3 dpf zebrafish larvae with different 
concentrations of terfenadine (n=8 zebrafish larvae at 3 dpf per concentration, P<0.05), B) 
Schematic of T wave widening after treatment of a 3 dpf zebrafish larvae with 50 µM 
terfenadine (1 = before, 2 = after 10 minutes, 3 = after 20 minutes), C) Mean heart rate after 
treatment of 3 dpf zebrafish larvae with different concentrations of terfenadine (n=8 
zebrafish larvae at 3 dpf per concentration, P<0.05). 
 
A similar effect to terfenadine was also seen with the other two QT prolonging drugs, 
namely haloperidol and pimozide, which were both found to cause a significant increase in 
the QTc interval duration and a significant decrease in the heart rate (Figure 3.25, n=8 
zebrafish larvae at 3 dpf per concentration, P<0.05). However, in contrast to terfenadine 
both pimozide and haloperidol were found not to show concentration-dependence in their 
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QTc prolonging effects. This could be due to greater specificity of haloperidol and pimozide 
to bind to the zERG channel, therefore leading to a maximal response at lower 
concentrations compared to terfenadine (Testai et al., 2010).   
 
Figure 3.25 – QTc prolongation in zebrafish larvae after treatment with haloperidol and 
pimozide. A) Mean QTc interval percentage change after treatment of 3 dpf zebrafish larvae 
with different concentrations of haloperidol (n=8 zebrafish larvae at 3 dpf per drug 
concentration, P<0.05), B) Mean QTc interval percentage change after treatment of 3 dpf 
zebrafish larvae with different concentrations of pimozide (n=8 zebrafish larvae at 3 dpf per 
drug concentration, P<0.05), C) Mean heart rate after treatment of 3 dpf zebrafish larvae 
with different concentrations of haloperidol (n=8 zebrafish larvae at 3 dpf per concentration, 
P<0.05), D) Mean heart rate after treatment of 3 dpf zebrafish larvae with different 
concentrations of pimozide (n=8 zebrafish larvae at 3 dpf per concentration, P<0.05). 
 
 
Penicillin which was used as a negative control as it is a known non-QT prolonging drug in 
humans and adult zebrafish (Milan et al., 2006) was found to have no significant effect on 
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the QTc interval duration or heart rate in 3 dpf zebrafish larvae (Figure 3.26A,D, n=8 
zebrafish larvae at 3 dpf per drug concentration, P>0.05). Surprisingly, the anti-arrhythmic 
agent verapamil which is a known hERG blocker in vitro (Martin et al., 2004) but not in vivo 
in humans at therapeutic concentrations (Fossa et al., 2002) was found to cause QTc 
prolongation in 3 dpf zebrafish larvae but only at the higher concentrations tested (Figure 
3.26B, n=8 zebrafish larvae at 3 dpf per drug concentration, P<0.05 for 100, 200, 300, 400 
and 1000 µM, P>0.05 for 10 and 25 µM). With verapamil at 1 mM widening of the T wave 
and an increase in its amplitude were clearly evident (Figure 3.26C). However, with 
verapamil no effect on the heart rate was observed (Figure 3.26E, n=8 zebrafish larvae at 3 
dpf per concentration, P>0.05). 
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Figure 3.26 – QTc interval changes in zebrafish larvae after exposure to drugs not known to 
prolong the QT interval in vivo. A) Mean QTc interval percentage changes after treatment of 
3 dpf zebrafish larvae with different concentrations of penicillin (n=8 zebrafish larvae at 3 dpf 
per drug concentration, P>0.05), B) Mean QTc interval percentage changes after treatment 
of 3 dpf zebrafish larvae with different concentrations of verapamil (n=8 zebrafish larvae at 3 
dpf per drug concentration, P<0.05), C) 3 dpf zebrafish larval ECG traces (one second 
segments) before and after one hour of treatment with 1 mM verapamil, D) Mean heart rate 
after treatment of 3 dpf zebrafish larvae with different concentrations of penicillin (n=8 
zebrafish larvae at 3 dpf per concentration, P>0.05), D) Mean heart rate after treatment of 3 
dpf zebrafish larvae with different concentrations of verapamil (n=8 zebrafish larvae at 3 dpf 
per concentration, P>0.05). 
 
With the exception of verapamil the results obtained for the rest of the tested drugs were 
found to be comparable to those documented in adult zebrafish (Milan et al., 2006), humans 
(Haverkamp et al., 2000)(Fossa et al., 2002)(Källén et al., 2005) and the commonly used in 
vivo mammalian models, such as the conscious adult dog, guinea pig and rabbit (Haverkamp 
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et al., 2000). These results confirmed that the set-up was robust enough to detect 
compounds that had QT prolonging effects.  
 
Apart from QT prolongation, other cardiotoxic conditions such as arrhythmias can also be 
useful readouts on ECG recordings, particularly when they are difficult to detect and 
characterise via other means. From the drug treatment ECG recordings various secondary 
cardiotoxic conditions were observed. These were found to be dose and time dependent.  
For example, with terfenadine the development of arrhythmias was observed as a secondary 
effect of QT prolongation at the two highest concentrations tested (25 and 50 µM). The 
arrhythmias were characterised by premature ventricular contractions (PVC) and ectopic 
beats and occurred in 50% of cases, generally 20 minutes after initial drug treatment (Figure 
3.27). The arrhythmias observed were not quantified in terms of severity, only the number 
of drug-treated zebrafish embryos displaying such an effect was recorded. Arrhythmia is a 
well-known effect of terfenadine, which has also been found to occur in adult zebrafish 
(Chaudhari et al., 2013), humans (Salata et al., 1995) and other animal models (Webster et 
al., 2001)(Usui et al., 1998)(Pinney et al., 1995). With haloperidol and pimozide a similar type 
of arrhythmia was also observed, but it was less frequent (25%) and also less pronounced 
than that observed with terfenadine. Haloperidol and pimozide have also been reported to 
cause arrhythmia in humans (O’Brien et al., 1999)(Hondeghem et al., 2003) and other animal 
models (Dhein et al., 2008)(Hondeghem et al., 2003). 
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Figure 3.27 – Arrhythmia development in zebrafish larvae after exposure to terfenadine. 
ECG trace (16 seconds) showing arrhythmia development in a 3 dpf zebrafish larva after 40 
minutes of exposure to 50 µM terfenadine. Key: PVC = premature ventricular contractions 
 
Another cardiotoxic condition that was observed with terfenadine, haloperidol and pimozide 
was AV block, which was characterised by widened ECG waveforms and prolonged cardiac 
cycles (Figure 3.28). This condition was found to occur in all of the zebrafish larvae treated 
with these three drugs, which agrees with what has been documented in the literature 
(Langheinrich et al., 2003). The AV block was found to occur immediately after the initial QT 
prolongation. With terfenadine AV block was only observed after treatment at 10, 30 and 50 
µM, whereas with pimozide and haloperidol it was observed at all concentrations tested. 
The AV block observed after 50 µM pimozide treatment presented with a widened QRS 
interval (Figure 3.28) (Zeltser et al., 2004). The AV block was found to worsen with time 
ultimately leading to complete cardiac arrest.  
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Figure 3.28 – AV block in zebrafish larvae after exposure to the QT prolonging drug 
pimozide. ECG trace (six seconds) showing possible AV block in a 3 dpf zebrafish larva after 
25 minutes of exposure to 50 µM pimozide. 
 
With verapamil an AV block was also observed, characterised by severe PR prolongation and 
a normal QRS interval (Figure 3.29) (Zeltser et al., 2004). This effect of verapamil has been 
reported in humans as well (Epstein and Rosing, 1981). The AV block in zebrafish larvae was 
only found to occur after a relatively long exposure period (over one hour) following 
treatment at the highest tested concentration (1 mM) and was not observed at any of the 
lower concentrations tested due to toxicokinetics. 
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Figure 3.29 – AV block in zebrafish larvae treated with verapamil. ECG trace displaying 
possible AV block in a 3 dpf zebrafish larva after one hour and 20 minutes of exposure to 1 
mM verapamil.  
 
3.5 Discussion 
3.5.1 Optimisation of a zebrafish embryo and larval ECG recording set-up 
An ECG recording set-up capable of producing reliable and reproducible ECG recordings from 
zebrafish embryos and larvae aged between 2 and 5 dpf using a similar technique to that 
previously developed for 5 dpf zebrafish larvae was optimised and refined (Forouhar et al., 
2004). Compared to previous documented zebrafish ECG studies where only P and R waves 
were recorded (Forouhar et al., 2004)(Yu et al., 2010)(Dong et al., 2012) our ECG recording 
set-up was able to detect all the components of an ECG waveform including P, QRS and T 
waves. This opened up the way for measuring QT intervals and thus determining the effect 
of QT prolonging drugs on 3 dpf zebrafish larvae. Additionally, the ECGs obtained using our 
ECG set-up were also found to be much more similar to human and adult zebrafish ECGs 
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(Figure 3.30), highlighting potentially that our set-up was much more sensitive compared to 
previously-developed larval zebrafish ECG set-ups. 
 
Figure 3.30 – Comparison of ECG signals between human adults, adult zebrafish and 
zebrafish embryos. A) Basic outline of an adult human ECG (taken from Li et al., 2008), B) 
Basic outline of an adult zebrafish ECG (taken from Li et al., 2008), C) Basic outline of a 
zebrafish embryo ECG. 
 
To optimise our zebrafish embryo and larval ECG recording set-up, various factors were 
addressed such as motion artefact, immobilization method, electrode positioning, recording 
temperature and developmental stage of the zebrafish embryo used.  
 
By performing invasive ECG recordings we were able to show that our surface ECG recording 
set-up was capable of recording ECG signals that represented the true electrical activity of 
the zebrafish embryo and larval heart. Using drugs such as cromakalim, blebbistatin and 
BDM could not confirm this finding due to technical issues that were experienced. The 
ineffectiveness of cromakalim may have been due to reduced penetration into the zebrafish 
or due to tested drug concentrations being too low. BDM and blebbistatin on the other hand 
affected the ECG waveform morphology, as well as causing zebrafish mortality. BDM is well 
known to have electrophysiological side effects, which have been documented in several 
species and also in explanted zebrafish embryo hearts (Jou et al., 2010)(Lou et al., 2012). 
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Blebbistatin on the other hand has not been documented to produce any notable 
electrophysiological side effects such as those seen with BDM or cytochalasin D, even in 
explanted zebrafish embryo hearts (Lou et al., 2012). The reason for the observed side 
effects with blebbistatin may have been due to toxic decomposition products being 
produced after exposure of blebbistatin to light during ECG recordings, as blebbistatin has 
been documented to be sensitive to light (Kolega, 2004).  
 
For immobilization of zebrafish embryos and larvae MS222 was chosen, as tubocurarine was 
found to be effective only when the zebrafish were continuously exposed, limiting its use, as 
it could potentially interact with other drugs in solution whilst performing drug treatments. 
Tubocurarine has been documented to undergo drug-drug interactions, specifically with 
anti-arrhythmics (Harrah et al., 1970). However, compared to MS222 tubocurarine did not 
affect the heart rate. MS222 at very high concentrations induced bradycardia, as it impairs 
ion transport in excitable cells by blocking the conductance of potassium and sodium ions 
(Rombough, 2007). Despite the unwanted side effects at higher concentrations of MS222, at 
a concentration of 0.3 mg/mL no significant side effects were observed, which agrees with 
what has been documented in the literature (Denvir et al., 2008). Additionally, treatment of 
zebrafish larvae with QT prolonging drugs in the absence of any anaesthesia produced the 
same effects on ECG recordings (data not shown); providing further support that MS222 
does not significantly influence the QTc interval at 0.3 mg/mL. Based on this, MS222 at 0.3 
mg/mL was used as the immobilization agent of choice for all ECG recordings. 
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ECG recordings were found to be heavily influenced by the recording temperature. A 
temperature between 21°C and 22°C was found to be optimal for taking ECG recordings. At 
lower temperatures the ECG waveform was found to be prolonged whereas at higher 
temperatures the opposite was found to occur.  
 
The calculated Q10 values over the 10°C range were found to be 2.7, reflecting the 
temperature effects (Barrionuevo and Burggren, 1999). These values closely resemble those 
documented for trout larvae with a Q10 of around 2.4 over a 5-15°C temperature range 
(Mirkovic and Rombough, 1998).  
 
The increase in RR, QRS, QT and QTc interval durations seen in zebrafish larvae with a 
decrease in temperature was found to be similar to that seen in other teleosts including the 
Nile tilapia (Oreochromis niloticus) as well as in humans with therapeutic hypothermia 
(Maricondi-Massari et al., 1998)(Amin et al., 2008). At lower temperatures biochemical 
processes  are slowed leading to slower heart activity (Gillis and Tibbits, 2002)(Schwerte and 
Fritsche, 2003). At higher temperatures the opposite occurs with the ECG waves becoming 
narrower and the QTc interval durations shortening due to increased heart activity (Khan et 
al., 2010). As zebrafish embryos obtain oxygen through dermal diffusion, the effect of 
temperature on oxygen levels in the water only becomes important at around 7-14 dpf 
(Jacob et al., 2002)(Rombough, 2002). 
 
ECG recordings could be obtained from zebrafish embryos as young as 2 dpf, which has 
previously never been done. Overall, zebrafish embryo and larval ECG recordings were found 
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to be similar at all stages of development tested, which included 2, 3, 4 and 5 dpf. The heart 
of the zebrafish embryo is an evolutionary antecedent of the mammalian four chambered 
heart (Simões-Costa et al., 2005). On an anatomical level, despite the obvious difference in 
heart structure between zebrafish and humans, even at an early embryonic stage the 
zebrafish has an immature conduction system (Arrenberg et al., 2010)(Tessadori et al., 
2012). The primary pacemaking site is situated in the dorsal right quadrant of the sinoatrial 
ring and is characterised by islet-1 expression (Arrenberg et al., 2010)(Tessadori et al., 2012). 
Furthermore, during development a fast ventricular conduction system develops alongside 
ventricular trabeculation (Kirchmaier et al., 2012). The ventricular trabeculation and 
thickening is highly dependent on the presence of a cardiac specific L-type calcium channel 
(Rottbauer et al., 2001). At 5 dpf the ventricle has thickened substantially due to a gradual 
increase in the number of ventricular cardiomyocytes, so that it is in its mature adult 
configuration (Taneda et al., 2010)(Huang et al., 2013). Therefore, at 5 dpf it is much easier 
to detect T waves. 
 
3.5.2 Comparison of our ECG recording set-up to other zebrafish ECG recording set-ups 
The ECG recording set-up we developed was found to be comparable to other zebrafish ECG 
recording set-ups but also showed some differences. For example, the ECG recording set-up 
developed by Yu and colleagues for recording larval zebrafish ECGs above 7 dpf differed 
somewhat in that a suction electrode and a micropipette with a bigger tip were used, which 
might have had an influence on the quality of recordings obtained (Yu et al., 2010). 
Additionally, the recording time used was very short (one minute) and the R waves were 
found to be very wide, which could have been due to incorrect annotation of the waveform 
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as possibly the recording was inverted (Yu et al., 2010). This may have also been the case for 
the recordings obtained by Forouhar and colleagues where the ECG recordings from 5 dpf 
zebrafish larvae showed very wide R waves as well (Forouhar et al., 2004).  
 
The ECG recording set-up used by Dong and colleagues on the other hand differed in that an 
invasive approach was used with micropipettes of an unknown tip length but these 
recordings on 3 dpf zebrafish larvae showed more similarity to our and adult zebrafish ECG 
recordings than the previous studies mentioned (Dong et al., 2012). The annotation of R 
waves on these ECG recordings may also have been incorrect, as the values quoted for 
various ECG parameters such as the QRS interval (0.305 seconds) and QT interval (0.786 
seconds) were almost two times higher in comparison to our calculated values.  
 
ECG recordings performed by Rottbauer and colleagues also on 3 dpf zebrafish larvae 
showed the greatest resemblance to our recordings with clear P, QRS and possibly T waves 
evident (Rottbauer et al., 2001). The ECG recording methodology used was not described in 
detail but based on the description provided it seemed to be similar to our recording 
method; hence confirming that it is possible to obtain high quality ECG signals from 3 dpf 
zebrafish larvae.  
 
3.5.3 A larval zebrafish model for QT prolongation 
In this chapter the three known human QT prolonging drugs tested (terfenadine, haloperidol 
and pimozide) along with the anti-arrhythmic (verapamil) were found to cause QTc 
prolongation in 3 dpf zebrafish larvae, similar to that seen in adult zebrafish and also humans 
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(Milan et al., 2006). QT prolongation is something that has previously never been 
demonstrated before in zebrafish larvae. Terfenadine QTc prolongation in zebrafish larvae 
was found to be dose-dependent and broadly sigmoidal, which is similar to what is seen in 
dogs treated with terfenadine (Salata et al., 1995). Haloperidol and pimozide on the other 
hand did not show any dose-dependency in their QT prolonging effects.  
 
Structurally all compounds inducing QT prolongation were found to be different, however it 
has been shown that compounds with molecular weights >250 and clogP values >3.7 are 
likely to be potent hERG blockers (Aronov, 2005). This is most probably to do with the large 
pore size of the hERG channel as well as the highly lipophilic nature of the pore lining 
(Aronov, 2005). All three compounds tested, namely terfenadine, haloperidol and pimozide 
meet these criteria (DrugBank, 2013a)(DrugBank, 2013b)(DrugBank, 2013d). Interestingly, 
verapamil also meets the above criteria (DrugBank, 2013e).  
 
Verapamil is a calcium channel blocker that specifically binds to the alpha 1c subunit of the 
L-type calcium channel, which prevents it from opening and thereby decreases the influx of 
calcium ions  (Rottbauer et al., 2001). In the larval zebrafish ECG studies verapamil was 
found to reduce myocardial contractility, inducing mild bradycardia and most surprisingly QT 
prolongation. This is contrary to what has been reported in mammalian models and humans 
at therapeutic concentrations (Hondeghem et al., 2003)(Cheng et al., 2006). This result 
however is consistent with data obtained in in vitro hERG cell assays (e.g. human embryonic 
kidney cells) (Martin et al., 2004) and Xenopus laevis oocytes (Duan et al., 2007). 
Additionally, in humans in overdose conditions verapamil has been shown to cause QT 
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prolongation (Fossa et al., 2002). It is possible that the observed QTc prolongation in 
zebrafish embryos with verapamil is due to greater sensitivity of zERG to block compared to 
hERG (Langheinrich et al., 2003).  
 
Penicillin was used as a negative control in the ECG drug treatment studies as it is known not 
to prolong the QT interval in humans or adult zebrafish (Milan et al., 2006). In 3 dpf larval 
zebrafish it was also found to have no effect on the QTc interval duration at any of the 
tested concentrations.  
 
3.5.4 A larval zebrafish model for atrioventricular block and arrhythmia 
With verapamil, terfenadine, haloperidol and pimozide AV block was observed as a 
secondary cardiotoxic condition after prolonged drug exposure, which could be related to 
the uptake of these drugs and the time course of internal concentrations. With verapamil 
the AV block was characterised by prolongation of the PR interval, resembling changes seen 
in humans and mammals following verapamil exposure at concentrations above the 
therapeutic limit (Enyeart et al., 1983)(Thomas et al., 1996). AV block has also been 
previously reported in zebrafish larvae exposed to verapamil (Berghmans et al., 
2008)(Rottbauer et al., 2001). 
 
With terfenadine at 30 and 50 µM and with all concentrations of haloperidol and pimozide 
the AV block observed was similar to that seen in humans with this condition and induced by 
terfenadine in adult zebrafish (Clarke et al., 1976)(Milan and MacRae, 2005).  
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It is known that when hERG is inhibited in mammals and zERG is inhibited in zebrafish AV 
block is observed (Haverkamp et al., 2000)(Langheinrich et al., 2003). At the moment there is 
no evidence indicating that blocking other cardiac ion channels produces the same effect 
(Letamendia et al., 2012). In humans the occurrence of AV block is rare; occurring mostly in 
neonates and newborns due to the effects of cardiotoxic drugs or due to a genetic condition 
(Langheinrich et al., 2003). In neonates and newborns AV block is found to occur alongside 
QT prolongation (Langheinrich et al., 2003), which is also the case in 3 dpf zebrafish larvae. 
Therefore, this suggests that the results obtained for the ECG drug treatment studies in 3 dpf 
zebrafish may be more relevant to human neonates and newborns than to human adults. 
Additionally, zERG has been shown to be more sensitive to developing block than hERG 
(Langheinrich et al., 2003). It has been postulated that the reason behind this is that the 
zebrafish ventricle depends more heavily on the IKr current for repolarisation than the atrium 
(Langheinrich et al., 2003).  
 
Another secondary cardiotoxic effect observed primarily with terfenadine was the 
development of a ventricular arrhythmia. The ventricular arrhythmia was characterised by 
premature ventricular contractions and ectopic beats, similar to what is seen in humans 
(Guilleminault et al., 1983). In humans terfenadine is found to induce ventricular 
arrhythmias at plasma concentrations between 30-300 nM, concentrations at which hERG 
can be blocked in vitro (Taglialatela et al., 1998). In canine and rabbit models arrhythmia 
development (particularly TdP) has been found to be difficult to reproduce (Carlsson et al., 
1993)(Chézalviel-Guilbert et al., 1995)(Hoffmann and Warner, 2006). Current in vitro 
methods are based predominantly on measuring the effects on the Ikr current either directly 
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or indirectly using cell-based systems without considering the effect of proteins found 
downstream or considering possible effects of drug-drug interactions (Milan and MacRae, 
2005). Thus, the zebrafish embryo presents a promising alternative model to study this 
condition in an in vivo scenario. This is backed up by the recent findings that adult zebrafish 
also develop arrhythmia as well as TdP after terfenadine treatment (Milan and MacRae, 
2005). 
 
3.5.5 The zebrafish larva as a preclinical model for cardiotoxicity 
At the moment for investigating QT prolongation and associated cardiac disorders there is 
no gold standard animal model. The current animal models (e.g. beagle dogs and rabbits) 
show a lot of variability and have low reproducibility (Langheinrich et al., 2003). A number of 
readouts for cardiotoxicity are obtainable using zebrafish embryos and larvae which do not 
require any specialized equipment, such as bradycardia, AV block, atrial fibrillation and 
arrhythmias which can all be observed using a simple stereomicroscope (Langheinrich et al., 
2003). However, the detail that can be obtained by taking in vivo ECG recordings is far 
greater than that which can be obtained just through simple microscopic observations, 
optical mapping (Peal et al., 2011), high throughput transgenic screens (Letamendia et al., 
2012) or photocardiography (Yoshida et al., 2009) alone. ECG recordings are able to detect in 
real time various cardiac dysfunctions including QT prolongation, QRS prolongation, PR 
prolongation, AV block, bradycardia, arrhythmia and atrial fibrillation, along with possibly 
many other conditions that still need to be uncovered. Apart from compound screening the 
ECG recording set-up could also be applied to studying cardiac-specific mutations and their 
associated manifestations.  
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3.5.6 Current limitations of the zebrafish embryo and larval ECG recording set-up and 
future perspectives 
The current ECG set-up presents an exciting tool for future studies. The next step would be 
to develop the ECG recording set-up further by increasing the throughput. Preliminary work 
in this area has already shown that multi-electrode recordings can be taken from the same 
fish simultaneously. ECG measurements along with the other techniques mentioned before 
could comprise a battery of tests to identify drugs that present with cardiotoxicity during 
drug development. However, the main limitation that still needs to be addressed not just for 
this ECG screening tool but for all types of zebrafish compound screening are drug uptake 
and metabolism.  
 
With this current ECG set-up drug uptake and internal drug concentrations cannot be 
quantified in the zebrafish larvae. However, such a step could be introduced as an additional 
test accompanying the ECG measurements. For example, one approach could be to calculate 
the body burden of the drug inside the zebrafish larva by using liquid chromatography-mass 
spectrometry (LC-MS) technology, which could be done immediately after taking zebrafish 
larval ECG recordings (Diekmann and Hill, 2013)(McGrath, 2012). Hence, using such an 
approach the exact internal concentrations of the parent drug or metabolite could be 
determined. This would also help to uncover species-specific differences. For example, it was 
recently shown that terfenadine metabolism in zebrafish is different to that in humans with 
azacyclone and terfenadine alcohol the main metabolites in zebrafish and fexofenadine the 
main metabolite in humans (Diekmann and Hill, 2013).  
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The exposure times that were applied in this study were relatively short. This may have led 
to some drugs failing to approach equilibrium in order to induce an effect. A way around this 
would be to perform a time-course analysis (i.e. using different exposure times), as it would 
indicate whether equilibrium has been reached. However, using such an approach on a 
whole embryo basis may not be representative of what is occurring at the target organ (the 
heart). Therefore, results obtained in this way would need to be interpreted with care. 
 
For the QT prolongation studies only one negative control was tested. Therefore, for future 
studies it would be important to test further negative controls to ensure that the baseline 
responses of zebrafish larvae to negative drugs can be compared against those causing QT 
prolongation. Additionally, in the ECG drug treatment studies performed it was assumed 
that any electrophysiological effects observed were due to a direct action on cardiac ion 
channels. However, QT prolongation does not solely occur via blockade of cardiac ion 
channels but also by non-ion channel mechanisms, such as through disturbances to pumps, 
exchangers, calcium storage/release mechanisms, caveolin-3 (membrane protein) and 
ankyrin B (adapter protein found in brain and muscles) (Milan and MacRae, 2005). 
Therefore, these effects must also be taken into consideration when interpreting drug-
induced QT prolongation results especially for compounds not known or expected to affect 
cardiac ion channels, such as hERG. 
 
One further limitation of the work performed in this chapter was that the analysis of ECG 
waveforms had to be done manually in our case as it was not possible to do this 
automatically using the existing LabChart 7 Pro software. Therefore, this issue would need to 
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be addressed for future studies and also when up-scaling this technology in order to reduce 
the variability introduced by human error. 
 
3.6 Conclusion 
The zebrafish larva presents a promising model for investigating drug-induced cardiotoxicity, 
particularly QT prolongation which has not been previously demonstrated in early stage 
zebrafish larvae. Further studies using other classes of cardiotoxic drugs, such as QRS 
prolonging agents would need to be performed in order to validate this set-up as a screening 
tool and to show that it has applications beyond screening for QT prolongation. Testing of 
further controls would also help to determine the specificity and sensitivity of the set-up. 
Additionally, the characterisation of cardiac specific mutants using the ECG recording set-up 
would be a further step to show its versatility. Finally, development of the set-up into high 
throughput with automated analysis and additional studies on drug uptake and metabolism 
would help to promote this system as an in vivo pre-clinical screening tool for evaluating 
cardiotoxic potential of candidate drugs during drug development, an area in which a gold 
standard is still lacking. 
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Chapter Four: CHARACTERISATION OF THE BIOLOGICAL ACTIVITY OF 
NOVEL AZETIDINE AND Ƴ-LACTAM COMPOUNDS USING THE 
ZEBRAFISH EMBRYO 
Foreword: 
The work presented in this chapter was a joint collaboration with the chemistry department 
at the University of Birmingham. For the azetidines all biological work including analysis and 
interpretation of results was performed solely by me under the supervision of Professor 
Ferenc Müller. All chemical work for the azetidines was performed solely by Dr. Antonio 
Feula. In the case of the Ƴ-lactams, the compounds were provided by Dr. John S. Fossey and 
Mariwan H. Salih from their ongoing research. The general morphology and toxicity 
assessments for the Ƴ-lactams were performed equally between me and Mariwan H. Salih. 
All fluorescence microscopy and stainings were performed by me with some contribution 
from Mariwan H. Salih. All data analysis and interpretation of results was performed by me. 
The work was supervised jointly by Professor Ferenc Müller and Dr. John S. Fossey. 
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4.1 Introduction and Overview 
4.1.1 Zebrafish as a model for testing of novel small molecules 
The assessment of the biological activity of small molecules has been mainly based on using 
targeted in vitro assays such as cell-based or purified protein assays (MacRae and Peterson, 
2003). Such assays can be done quickly in high throughput formats. However, they are not as 
informative as whole organism assays, where the interaction of a small molecule with 
different cell types, tissues and proteins can be followed and the effects on the whole 
organism observed (MacRae and Peterson, 2003). Additionally, in vitro assays are restricted 
due to their selectivity. For example, in the case of protein-based assays the screens that are 
performed are biased towards a small selection of molecules, i.e. those that will inhibit a 
particular protein (MacRae and Peterson, 2003).  
 
In the case of whole organism screening, small molecules may elicit a range of different 
observable phenotypes via previously unknown pathways or mechanisms (MacRae and 
Peterson, 2003). Additionally, using a whole organism to probe for biological activity of small 
molecules can also give an indication of toxicity. For example, a compound that may be toxic 
to an individual cell may not be toxic in a whole organism due to various factors including 
metabolism and plasma protein binding. This is also true the other way round. Toxicity is 
particularly important when assessing the biological activity of novel compounds. It is 
important to identify the dose ranges where a small molecule is effective/potent but has low 
toxicity. This is commonly done by calculating EC50 (concentration of a compound producing 
a response in 50% of the tested population) and LC50 (concentration of a compound causing 
mortality in 50% of the tested population) values. Additionally, LOEC (lowest observed effect 
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concentration) and NOEC (no observed effect concentration) values can also be calculated as 
additional toxicity endpoints.  
 
Zebrafish embryos are particularly useful for assessing the biological activity of novel 
compounds as the disruption of any one of the many genes that are found in zebrafish may 
lead to the development of an observable phenotype (MacRae and Peterson, 2003). These 
include developmental, physiological and behavioural phenotypes (MacRae and Peterson, 
2003). Therefore, many large scale chemical screens are being performed using zebrafish 
embryos in order to determine the effects of small molecules, as these can be carried out in 
large numbers with small quantities of compound in a very short period of time (MacRae 
and Peterson, 2003)(Langheinrich et al., 2003)(Spring et al., 2002). In addition to this, the 
acute toxicity of small molecules can be easily recorded using zebrafish embryos, thereby 
enabling the relationship between efficacy and acute toxicity of a compound to be explored. 
 
4.1.2 The zebrafish larva as a model for hepatotoxicity 
Toxicity can manifest itself in various forms, including organ-specific toxicities such as 
hepatotoxicity. Hepatotoxicity accounts for most of the drug withdrawals both during the 
drug development process and also post-marketing showing the lowest correlation in animal 
testing to humans (Olson et al., 2000). Drug-induced liver injury (DILI) is often manifested as 
an idiosyncratic response occurring in 1 in 10,000 patients treated with certain drugs and 
accounting for around 10% of drug-induced liver failure cases (Jaeschke, 2007).  
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Many of the conditions that can occur as a result of liver damage, infection or drug toxicity 
often present with similar pathological features, hence making it sometimes difficult to 
define the underlying cause (Shin and Fishman, 2002). However, acute liver failure is 
predominantly attributed to DILI (Ostapowicz and Lee, 2000).  
 
Although, there a number of in vitro assays which perform very well in detecting 
hepatotoxicity (e.g. liver microsomes, primary hepatocyte cell cultures, hepatocyte/kupffer 
cell co-cultures, bioreactors and immortalised hepatoma cell lines), many candidate drugs 
are only found to be hepatotoxic when they are tested in strongly regulated models like 
macaque monkeys or in humans in clinical trials (Soldatow et al., 2013). Therefore, there is a 
big demand to find a suitable model to detect hepatotoxicity early on in drug development. 
 
The zebrafish larva represents a good model for investigating drug-induced hepatotoxicity, 
as it has a separate liver and pancreas and not a hepatopancreas like other teleosts (Fischer 
and Dietrich, 2000). Additionally, the zebrafish larva has orthologues of human CYP enzymes, 
therefore having the capability to replicate CYP-mediated hepatotoxicity seen in humans 
(Goldstone et al., 2010). 
 
Recent zebrafish assays that have been developed to assess hepatotoxicity include: 1) a 
brightfield microscopy method where changes in liver size and extent of necrosis are 
quantified through semi-automated analysis (He et al., 2013) and 2) a fluorescence-based 
microscopy method where a transgenic zebrafish line with a fluorescently labelled liver is 
used to determine changes in liver size after drug exposure (Zhang et al., 2014). Additionally, 
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gene expression, histology and liver-specific stainings have also been used to assess 
hepatotoxicity in zebrafish embryos and larvae (Driessen et al., 2013)(Driessen et al., 
2014)(Lam et al., 2013). Stainings that have been used include Oil Red O (ORO) staining 
which can be used to identify hepatic steatosis (accumulation of fat in the liver) (Braunbeck 
et al., 1990) (Amali et al., 2006). Such assays in zebrafish specific for liver toxicity should 
advance lead compounds and reduce costs for pharmaceutical companies.  
 
4.1.3 Zebrafish liver development 
The zebrafish liver is formed in two phases, namely phase 1 (budding) and phase 2 (growth). 
In the first phase, there are three sub-phases. In the first sub-phase endodermal cells located 
caudal to the pharyngeal region aggregate to form a rod by 24 hpf (Tao and Peng, 2009). At 
28 hpf the part of the rod underneath the first somite starts thickening and this continues to 
thicken during the second sub-phase until it reaches a certain size and bends to the left 
forming the liver primordium (Horne-Badovinac et al., 2003). At 34 hpf in sub-phase three, a 
trough develops between the liver primordium and the adjacent lying oesophagus (Tao and 
Peng, 2009). This trough continues to grow and the hepatic duct is formed connecting the 
liver to the intestine (Field et al., 2003). In phase 2 (growth phase), rapid on-going cell 
proliferation causes changes in liver shape, size and position, as well as differentiation of 
hepatoblasts into specific liver cell types (Tao and Peng, 2009). By 96 hpf the liver is fully 
formed consisting of two liver lobes, which are positioned just above the yolk (Field et al., 
2003). By 5 dpf the liver is situated posterior to the pericardium and anterior to the gut. Two 
important genes involved in liver development include prox1 (required for the migration of 
the hepatoblasts and the outgrowth of the liver bud) and hhex (required for controlling liver 
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progenitor initiation and development) (Tao and Peng, 2009). The whole liver development 
process is outlined in Figure 4.1. 
 
Figure 4.1 – Overview of zebrafish liver development. Genes important in liver development 
are coloured purple. Images are shown as ventral views with anterior at the top. Key: gb = 
gall bladder, cd = cystic duct, es = esophagus, p = pancreas, pd = pancreatic duct, in = 
intestine, hd = hepatic duct, lv = liver 
Source: Figure adapted from (Tao and Peng, 2009) 
 
4.1.4 Zebrafish liver structure 
The liver is the main organ involved in: 1) metabolism/detoxification of various endogenous 
and exogenous substances, 2) creation of vital blood protein/clotting factors, 3) synthesis of 
enzymes required for digestion, 4) detoxification of ammonia through the urea cycle and 5) 
production of bile that is secreted by the gall bladder (Tao and Peng, 2009).  
 
In 4 dpf zebrafish the hepatocytes of the liver are hexagonal in shape but are arranged in 
tubules and not in plates like in mammals (Strmac and Braunbeck, 1999). The hepatocytes 
have a nucleolus with some heterochromatin, the mitochondria are arranged around the 
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nucleus and cisternae of rough endoplasmic reticulum (RER) form sheaths around these 
structures (Strmac and Braunbeck, 1999). Smooth endoplasmic reticulum (SER) and golgi 
fields are concentrated in the peribiliary area with peroxisomes dispersed in the cytoplasm 
(Strmac and Braunbeck, 1999). The hepatic arteries, bile ducts and portal veins show a 
random distribution in zebrafish, whereas in humans they are organised in portal tracts 
(Vliegenthart et al., 2014).   
 
4.2 Aims 
In this chapter novel compounds were probed for biological activity using the zebrafish 
embryo. This was done in order to gain an insight into how structural differences between 
the compounds produced different biological effects. The compounds that were tested in 
this chapter included a selection of azetidines and Ƴ-lactams, which represent novel 
compounds previously not tested in zebrafish embryos. These compounds have potential 
applications in agricultural or pharmaceutical industries, as insecticides or treatments for 
alcohol use disorders. The rate-limiting step in the synthesis of these compounds is 
producing enough starting material to make a 1, 3, 5-trisubstituted pyrrolidin-2-one 
(Katritzky et al., 2000). This rate-limiting step has been overcome by the John Fossey group 
using a novel synthesis method, which involves using a homoallylamine (1) as a starting 
material to form azetidines (2) and Ƴ-lactams (3) (see Figure 4.2) (Feula et al., 2010).  
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Figure 4.2 – Scheme of azetidine and Ƴ-Lactam synthesis.  
Source: Adapted from data provided by Mariwan H. Salih  
 
From the azetidines synthesized six were selected for biological activity testing including 
racemic cis-2a, 2b, 2c, 2d, 2e and 2f representing a chemically diverse set of azetidines with 
aromatic, heteroaromatic, benzyclic and aliphatic moieties in their structures (Table 4.1).  
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Table 4.1 – Chemical structures of tested azetidines. Key: Bn = Benzene  
Source: Chemical structures provided by Dr. Antonio Feula 
 
 
The Ƴ-lactam compounds created on the other hand were not individual isomers like the 
azetidines but instead mixtures of the two diastereoisomers and associated enantiomers in 
varying ratios (Table 4.2). 
 
 
 
Compound Chemical structure LogP 
2a 
 
3.61 
2b 
 
2.84 
2c 
 
-1.6 
2d 
 
2.55 
2e 
 
5.3 
2f 
 
0.66 
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Table 4.2 – Chemical structures and diastereoisomer ratios for tested Ƴ-lactams. 
Source: Chemical structures and data provided by Mariwan H. Salih 
Compound Diastereoisomer ratio 
(DR) 
Chemical structure LogP 
3a 58:42 
 
2.81 
3b 56:44 
 
2.48 
3c 24:76 
 
4.53 
3d 60:40 
 
3.52 
3e 61:39 
 
2.73 
3f 54:46 
 
1.98 
3g 36:64 
 
2.45 
3h 45:55 
 
1.05 
3i 67:33 
 
3.67 
 
The chemical structures of both sets of compounds implied that they could have potential 
insecticidal or therapeutic properties. Hence, the aim as mentioned before was to assess 
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these compounds for biological activity (acute toxicity and development of morphological 
effects) using the zebrafish embryo as a model. Biological activity was evaluated by 
performing general toxicity assessments where zebrafish embryo mortality after exposure to 
these drugs was recorded. Additionally, morphological assessments were performed to 
characterise the biological effects of these compounds. Interesting phenotypes that 
developed were then selected for further analysis in order to determine whether the 
development of a particular phenotype was due to certain features of the compound 
chemical structure. For the Ƴ-lactams a much broader dose range was tested, as the closely 
related β-lactams were shown to elicit effects in zebrafish embryos only at relatively high 
doses (Oliveira et al., 2013). A selection of Ƴ-lactams which showed particularly interesting 
phenotypes (e.g. liver toxicity) was also selected for further testing. The responses observed 
with the Ƴ-lactams in zebrafish embryos were compared against those documented with the 
β-lactams in zebrafish embryos to see if there were any similarities. Azetidines on the other 
hand are analogues of nicotine; hence the effects of the selected azetidines on zebrafish 
embryo development, as well as any neurotoxic effects were compared to effects reported 
with nicotine. 
 
Finally, the responses observed with the azetidines and Ƴ-lactams were also compared with 
one another in order to see if any phenotypes were similar between them and in instances 
where this was the case whether this was due to structural similarities. 
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4.3 Methods 
4.3.1 Toxicity and morphology testing of novel Ƴ-lactams  
Nine diverse compounds from the Ƴ-lactam family were tested for toxicity in zebrafish 
embryos. Zebrafish embryos were tested in 96 well plates with one zebrafish embryo placed 
in each well. One row was allocated to each tested concentration, in total six concentrations 
were tested per drug. One row per plate was also assigned to the solvent control (0.1% 
DMSO) and one row per plate to the E3 embryo medium control. Treatments were initiated 
at the 75% epiboly stage and zebrafish embryos were treated with compound over five days 
without compound renewal. Compound stock solutions were prepared using DMSO and 
subsequent dilutions were prepared using E3 embryo medium. Oxygen levels were not 
measured. 
 
In the first part of the toxicity testing zebrafish embryos were exposed to each compound at 
six different concentrations (0.01, 0.1, 1, 10, 100 and 1000 µM). For compound 3c however, 
the range was adjusted to 0.001, 0.01, 0.1, 1, 10 and 100 µM due to solubility problems at 
1000 µM. In this first phase mortality was recorded daily over a five day exposure period. 
Using the mortality data, the percentage cumulative mortality over the five day exposure 
period was calculated. The logarithm of the tested concentrations was then plotted against 
percentage mortality to produce concentration mortality plots. From these plots LC50 values 
were calculated using GraphPad Prism 5.0 (GraphPad Software Incorporation, USA) by 
determining the concentration at which 50% mortality was observed (see Figure 4.3). 
Additionally, NOEC and LOEC values were also determined (see Supplementary Table 8.1 for 
model parameters in Appendix). 
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Figure 4.3 – Example of a log concentration mortality plot for Ƴ-lactam 3a. The LC50 value 
represents the concentration at which 50% mortality is observed.  
 
For the second phase a narrower concentration range was used to score a wide variety of 
morphological effects with 20 features scored for severity, as shown in Table 4.3.  
 
 
 
 
 
 
 
 
 
133 
 
Table 4.3 – Morphology features scored and their associated abbreviations. 
Feature Abbreviation 
Reduced circulation CR 
Reduced movement MO 
Hatching HA 
Reduced heart rate HR 
Developmental delay DD 
Deformation DF 
Notochord NO 
Trunk curvature TC 
Protruding mouth PM 
Pectoral fin PF 
Somites SO 
Jaw malformations JM 
Yolk edema YE 
Yolk size YS 
Heart edema HE 
Liver necrosis LN 
Brain hemorrhage BH 
Hydrocephalus HYD 
Reduced pigmentation PI 
Mortality MORT 
 
In this chapter and also in chapter 5, a scoring system was used to assign severity scores to 
the features observed where 0 = normal, 1 = within normal range, 2 = mild, 3 = moderate, 4 
= severe and 5 = very severe. Using such a quantitative morphometric approach eliminated 
the possibility of bias, which may have occurred if a personal scoring system had been used. 
Using the morphology data, the percentage of zebrafish embryos presenting with 
morphological effects over the five day exposure period was determined. The logarithm of 
the tested concentrations was then plotted against the percentage of zebrafish embryos 
presenting with morphological effects to produce concentration effect plots. From these 
plots EC50 values were calculated using GraphPad Prism 5.0 (GraphPad Software 
Incorporation, USA) by determining the concentration at which 50% of zebrafish embryos 
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presented with morphological effects. Additionally, NOEC and LOEC values were also 
determined (see Supplementary Table 8.2 for model parameters in Appendix). 
 
By dividing the LC50 by the EC50 teratogenic index values were calculated in order to 
determine the potency of the compounds with a ratio >2 indicating specific effects and 
therefore teratogenicity. Additionally, excess toxicity in the form of toxic ratio (TR) was also 
determined for each of the compounds using the experimentally derived LC50 values and 
predicted LC50 values. Predicted LC50 values were obtained using the following equation: 
log(1/LC50) = 0.871logP – 4.87 (n=50, r=0.998, s=0.237) (Könemann, 1981) 
 
The toxic ratio was calculated from these predicted and experimentally derived LC50 values 
using the following equation: 
logTR = log(1/LC50 experimental) – log(1/LC50 predicted) (Zhang et al., 2013) 
 
The threshold for the logTR was set at 1. Compounds with a logTR value <1 were considered 
to show baseline toxicity, whereas compounds with a logTR value >1 were considered to 
show excess toxicity.  
 
4.3.2 Fluorescence imaging of vasculature/red blood cells in Ƴ-lactam-treated embryos 
In order to determine the effects of the Ƴ-lactam 3a on blood vessel stability, red blood cell 
circulation and red blood cell clotting the double transgenic zebrafish line Tg(gata-
1:DsRed);Tg(fli-1:EGFP) was used. Zebrafish embryos from this line were treated with the Ƴ-
lactam 3a at the 75% epiboly stage and then observed at 72 and 96 hpf using the GFP and 
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DsRed filter of a Nikon SMZ1500 stereomicroscope with an epi-fluorescence illuminator 
(Nikon, UK).  
 
4.3.3 Toxicity and morphology testing of novel azetidines  
To assess the toxicity and morphological effects induced by a selection of azetidines in 
zebrafish embryos, 10 zebrafish embryos at the 75% epiboly stage were transferred to each 
well of a 24 well plate. Zebrafish embryos were then exposed continuously to the six 
selected azetidines (2a-2f) in a total volume of 1.5 mL with three wells assigned to each 
compound/control (0.1% DMSO and E3 embryo medium) over a five day period. All zebrafish 
embryos were observed daily and a selection of morphological defects were recorded. These 
included tail curvature (TC), abnormal jaw formation (JM), delayed development (DD), 
hypopigmentation (PI), slowed heart rate (HR), tail necrosis (TN), heart edema (HE), brain 
edema (BE) and reduced circulation/blood clots (CR). Additionally, the number of mortalities 
was also recorded daily over the five day exposure period. Mortality was defined based on 
the OECD guidelines TG 236 for the fish embryo toxicity (FET) test as coagulation, lack of 
heartbeat after 48 hpf and lack of detachment of the tail bud from the yolk sac (OECD, 
2013). One well per treatment group was used for imaging zebrafish embryos daily over the 
five day period. All dilutions were prepared fresh on the day using E3 embryo medium. All 
plates were kept at 28°C and covered in kitchen foil to prevent possible photodegradation of 
the compounds. Treatments with the azetidines at concentrations of 10 and 25 µM were 
started at the 75% epiboly stage, whereas treatments with a 30 µM concentration were 
started at the prim-5 stage to determine whether the azetidines also produced similar 
effects when treated at late stages. Stages were determined using the staging series outlined 
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by Kimmel and colleagues (Kimmel et al., 1995). The experiment was carried out in triplicate 
and the results were then averaged. 
 
4.3.4 Fluorescence imaging of vasculature/red blood cells in azetidine-treated embryos 
In order to determine the effects of azetidine 2a on blood vessel stability, the transgenic 
zebrafish line Tg(fli-1:EGFP) was employed. To assess red blood cell circulation and clotting 
the double transgenic zebrafish line Tg(gata-1:DsRed);Tg(fli-1:EGFP) was used. Zebrafish 
embryos from these lines were treated with compound 2a at the 75% epiboly stage and then 
observed at 72 and 96 hpf using the GFP and DsRed filter of a Nikon SMZ1500 
stereomicroscope with an epi-fluorescence illuminator (Nikon, UK). 
 
4.3.5 Oil Red O staining 
Oil Red O (ORO) staining was performed in order to stain lipids. For ORO staining fixed 
zebrafish embryos and larvae were utilised. Before staining with ORO solution (Sigma-
Aldrich, Germany) fixed samples were infiltrated with propylene glycol (Sigma Aldrich, UK) in 
a graded series (25%, 50%, 75% and 100%). Samples were then stained with 0.5% ORO 
solution in 100% propylene glycol overnight at room temperature. The following day the 
samples were washed with decreasing concentrations of propylene glycol (100%, 75%, 50% 
and 25%) before being washed twice with PBS. After the final wash, the samples were first 
transferred to 25% glycerol for five minutes before finally being transferred to 80% glycerol 
for final storage and imaging. Samples were imaged on a Nikon SMZ800 stereomicroscope 
(Nikon, UK).  
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4.3.6 Acridine orange staining 
Acridine orange staining was used to visualise dead cells. Firstly, a 1000X stock solution (5 
mg/mL) of acridine orange was made using distilled water and stored at 4°C. From this initial 
stock solution, a 1 in 1000 dilution was performed using E3 medium to create a final working 
dilution of 5 µg/mL. Drug-treated and untreated zebrafish larvae at 3 dpf were then exposed 
to 3 mL of 5 µg/mL of acridine orange for 30 minutes in the dark. The zebrafish larvae were 
then rinsed with 20 mL of E3 embryo medium to wash off the stain. The zebrafish larvae 
were immediately imaged using the GFP filter on a SMZ1500 Zoom stereomicroscope with 
an epi-fluorescence illuminator (Nikon, UK) and the number of dead cells was quantified. 
Dead cells were identified as those brightly fluorescing. 
 
4.3.7 Sudan black staining 
Sudan black staining was performed to stain leukocytes. Zebrafish larvae were firstly fixed in 
PFA and then stained with 60 µL Sudan black reagent before a final washing step was 
performed in a graded series of ethanol to remove excess stain. The stained zebrafish larvae 
were then stored in PBS and the number of leukocytes located in and around the liver were 
counted using a stereo microscope. The experiment was repeated three times and final 
results were averaged. 
 
4.3.8 Brightfield liver image analysis 
Zebrafish embryos that had been treated with 1000 and 2000 µM Ƴ-lactam 3h at the 75% 
epiboly stage were evaluated for changes in liver size at 5 dpf compared to untreated 
controls. Raw brightfield images of livers were processed using ImageJ version 4.2 
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(http://rsbweb.nih.gov/ij/) to obtain values for the liver area. These values were then 
averaged for each treatment group and used for final comparisons. In total 12 zebrafish 
larvae from three independent experiments were tested. 
 
4.3.9 Motility assays  
Motility assays with the six selected azetidines (2a-2f) were performed to determine the 
effects of these compounds on the neurobehavioral responses of 6 dpf zebrafish larvae. All 
experiments were carried out in the laboratory of Biotecont Ltd. in accordance with 
Hungarian law for animal experimentation.  
 
Azetidines were administered at a concentration of 20 µM to 6 dpf zebrafish larvae and the 
distances moved by the larvae were recorded for 30 minutes. The assays were carried out in 
a four well plate (Thermo Fisher Scientific, Germany) with two wells allocated per compound 
and two wells allocated per control (1% DMSO) with the total volume in each well totalling 
20 mL. To each well 10 zebrafish larvae were added, which were allowed to acclimatize in 
the recording plate for 30 minutes before the plate was inserted into the FLIPR Tetra 
locomotion measurement system (Richter Gedeon Nyrt., Hungary). This locomotion 
measurement system was able to take pictures of every well every second whilst shining 
blue light repeatedly at 999 ms. The images taken were processed using custom-made 
software (KomiPL) provided by to Pictron Ltd. (Budapest, Hungary). The software 
automatically identified individual zebrafish larvae and then used changes in pixel intensity 
over the whole time frame as a measure of how much each zebrafish larva had moved 
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during that time period (shown in Figure 4.4) with greater pixel changes indicating greater 
movement.  
Figure 4.4 – Screenshot from KomiPL software showing tracking of individual zebrafish 
larvae by the software (highlighted in white). Values found at the top of each well indicate 
number of zebrafish larvae successfully tracked and the number of pixels detected. 
 
The corrected pixel changes obtained every minute over the 30 minute time period were 
then used for further data analysis. The corrected pixel changes were used because they 
corrected the pixel intensity for the number of zebrafish larvae correctly identified by the 
software. The corrected pixel changes were then averaged for the three independent 
repeats and plotted against time. The results for the azetidine-treated zebrafish larvae were 
then compared against their respective 1% DMSO controls.  
 
 
 
Larva identified by 
the software 
Number of larvae 
identified by the 
software 
Pixels Corrected pixels 
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4.4 Results 
4.4.1 Ƴ-Lactam dose-range finding study 
The Ƴ-lactams were evaluated for biological activity by determining their effects on zebrafish 
embryo development. The Ƴ-lactams represent a class of compounds particularly important 
in the field of synthetic organic chemistry. Several biologically active natural products 
contain a Ƴ-lactam core including the cotinine alkaloid and the anti-fungal agent (-)-
pramanicin (Dübon et al., 2009)(Schwartz et al., 1994).  
 
A two phase study was performed with the Ƴ-lactams. Phase 1 was used to determine the 
toxicity of the compounds using a logarithmic concentration series (0.01, 0.1, 1, 10, 100 and 
1000 µM) by recording mortality daily over five days (see section 4.3.1 for further details). 
For compound 3c due to solubility problems at 1000 µM, the concentration range was 
adjusted (0.001, 0.01, 0.1, 1, 10 and 100 µM).  
 
The results for phase 1 (Figure 4.5) showed that over the 120 hour exposure period all 
compounds except compound 3h caused 100% mortality at the highest tested 
concentration. Compound 3c was found to be the most toxic compound causing high 
mortality even at concentrations as low as 10 µM.  
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Figure 4.5 – Heat map showing the mean cumulative percentage mortality of zebrafish 
embryos treated with Ƴ-lactams at different concentrations over time. In total 36 zebrafish 
embryos were tested per concentration/control (SD range +/- 0-11.12%). Key: T1-T5 = 24, 48, 
72, 96 and 120 hpf, C1-C6 = 0.01, 0.1, 1, 10, 100 and 1000 µM (except 3c where C1-C6 = 0.01, 
0.1, 1, 10, 100 and 1000 µM). Colour key: light pink = 0%, red = 100% 
 
Using these results log concentration mortality curves were plotted and from these toxicity 
endpoints such as LC50, NOEC and LOEC values were calculated (Table 4.4). Compound 3c 
was found to have the lowest calculated LC50, LOEC and NOEC values and compound 3h the 
highest.  
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Table 4.4 – Calculated toxicological endpoints for tested Ƴ-lactams. 
 
4.4.2 Evaluation of the morphological effects induced by Ƴ-lactams 
For the second phase of the study, a narrower concentration range was used to score a large 
number of morphological features for severity every day over a five day period (see Table 
4.3 for full list of features). This was done in order to see how the Ƴ-lactams affected 
zebrafish embryo development and if there was any dose-dependency in the phenotypes 
produced. For the scoring of morphological effects the concentration at which 100% 
mortality was observed in the first study was used as the highest tested concentration in this 
study. For the remaining concentrations a geometric range was used. The concentration 
range (C1-C6) used for compounds 3a, 3b, 3d, 3e, 3f, 3g and 3i was 31.25, 62.5, 125, 250, 
500 and 1000 µM. For compound 3c a concentration range of 3.125, 6.25, 12.5, 25, 50 and 
100 µM was used. For compound 3h a concentration range of 62.5, 125, 250, 500, 1000 and 
2000 µM was used, as 100% mortality was not observed at 1000 µM. For the scoring of 
morphological features a scoring system was used to assign severity where 0 = normal, 1 = 
within normal range, 2 = mild, 3 = moderate, 4 = severe and 5 = very severe. Following 
treatment of zebrafish embryos with a selection of Ƴ-lactams a number of phenotypes were 
observed as can be seen in Figure 4.6. 
Compound LOEC (µM) NOEC (µM) LC50 (µM) LogP 
3a 100 10 27.98 2.81 
3b 100 10 55.08 2.48 
3c 10 1 8.07 4.53 
3d 1000 100 140.28 3.52 
3e 1000 100 142.28 2.73 
3f 100 10 17.99 1.98 
3g 100 10 11.86 2.45 
3h 2000 1000 1584.89 1.05 
3i 1000 100 484.17 3.67 
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Figure 4.6 – Selection of phenotypes observed following treatment of zebrafish embryos 
with Ƴ-lactams. A) Delayed development and hypopigmentation after 48 hours of treatment 
with 1000 µM compound 3b, B) Brain hemorrhage, delayed development and heart edema 
after 72 hours of treatment with compound 3g, C) Severe developmental arrest after 24 
hours of exposure with 1000 µM compound 3d, D) Liver necrosis after 120 hours of treatment 
with 10 µM compound 3f. All images are lateral views. 
 
It was found that with a few of the compounds, specific phenotypes developed at certain 
concentrations. For example with compound 3a there was a dose-dependency in the 
development of brain hemorrhage (62.5-500 µM). With compound 3f on the other hand 
liver toxicity was found to occur at specific doses (31.25 and 10 µM). Additionally, with 
144 
 
compound 3h only at the highest and second highest tested concentrations (2000 and 1000 
µM) liver toxicity was observed.  
 
Using the morphology data log concentration response curves were plotted and EC50 values 
were calculated (Table 4.5). EC50 values were found to be highest for compound 3d and 
lowest for compound 3c. In addition to this the ratio between LC50 and EC50 values was 
calculated in order to obtain a value for the teratogenic index (Table 4.5). The Ƴ-lactams 3a, 
3b, 3f and 3g were found to have LC50/EC50 ratio values <2, suggesting that the phenotypes 
observed with these compounds were secondary effects of generic primary effects. The 
remaining Ƴ-lactams were found to have LC50/EC50 ratio values >2, especially Ƴ-lactam 3h 
which was found to have a ratio value of around 25 suggesting that this compound was 
provoking specific effects at sub-lethal concentrations. Additionally, compound 3c was also 
found to be highly teratogenic.  
 
Table 4.5 - EC50 and teratogenic index values for the nine tested Ƴ-lactams. Teratogenic 
index values >2 indicate specific effects. 
Compound EC50 (µM) Teratogenic index (LC50/EC50) 
3a 15.07 1.86 
3b 31.33 1.76 
3c 3.13 2.58 
3d 65.01 2.16 
3e 17.58 8.09 
3f 17.99 1.00 
3g 31.33 0.38 
3h 62.66 25.29 
3i 57.94 8.36 
 
As a next step, a PCA model was generated to determine if there was any relationship 
between physiochemical descriptors of the Ƴ-lactams (logP, MW, HBA, HBD and HB) and the 
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biological responses (LOEC, NOEC, EC50, LC50 and morphological feature scores). The PCA 
model that was generated was found to be of good quality (R2X=0.687, Q2=0.433, four 
significant components). From the PCA scores plot (Figure 4.7A) it could be seen that the 
scores (observations) for Ƴ-lactam 3h at different concentrations were separated away from 
the rest of the scores. When looking at the loading plot (Figure 4.7B) which shows the 
variables it could be seen that this compound showed the least mortality, as well as the least 
severity in terms of morphological responses, which explains why it is placed so far apart 
from the rest of the scores on the scores plot. The further a score is on the scores plot from 
other scores the more different it is. 
 
The scores for the remainder of the Ƴ-lactams at the highest tested concentration were 
found to be clustered close together in the top right quadrant of the PCA plot (circled) based 
on their high mortality rates and severity scores for the morphological features reduced 
heart rate (HR), reduced circulation (CR) and reduced movement (MO), which are indicators 
of lethality. These features were found to have the most influence on the location of the 
scores. A high logP value was found to have some influence on the development of certain 
morphological features, such as yolk edema, heart edema, jaw malformations, notochord 
abnormalities and yolk size. 
 
 
146 
 
Figure 4.7 - A two-component PCA model of zebrafish embryo biological responses (observations) against morphological features, 
toxicity endpoints and physiochemical descriptors (variables) following treatment with Ƴ-lactams over a 120 hour exposure period. 
Only the morphological features scored at 5 dpf were used to create the model. A) Scores plot, B) Loading plot. Biological features = HR 
(slowed heart rate), HE (heart edema), CR (reduced circulation), JM (jaw malformations), TC (tail curvature), DD (delayed development), 
BE (brain edema), BH (brain hemorrhage) and PI (hypopigmentation), MO (reduced movement), HA (hatching), DF (deformation), NO 
(abnormal notochord), PM (abnormal protruding mouth), PF (abnormal pectoral fin), SO (abnormal somites), YE (yolk edema), YS 
(increased yolk size), LN (liver necrosis) and MORT (mortality). Toxicological endpoints = EC50, LC50, LOEC and NOEC. Chemical descriptors 
= logP, MW, HB, HBA and HBD. The loading vector (p) and the scores vector (t) are displayed as vectors p and t. The numbers beside p and 
t indicate the PCA component (1 or 2). The observations for tested Ƴ-lactams are denoted by coloured circles with different concentrations 
labelled. Coloured circles also denote the location of the variables within the loading plot with differences in colour indicating whether the 
variables are biological (green) or chemical (blue).The further scores or variables are from one another the more different they are.
147 
 
To confirm that effects observed with certain Ƴ-lactams (e.g. 3h) were specific and not a 
result of baseline toxicity logP values were plotted against log(1/EC50) values (Figure 4.8). 
From this graph no strong correlation could be seen between increased logP values and 
decreased log(1/EC50) values. 
 
Figure 4.8 – LogP values plotted against log(1/EC50) values for tested Ƴ-lactams. Line of 
best fit and correlation coefficient (r2) are also shown on graph. 
 
Another approach was then taken to determine whether the biological responses observed 
with the Ƴ-lactams were a result of specific activity or baseline toxicity. Toxic ratio (TR) 
values were calculated for each of the Ƴ-lactams using predicted and experimental LC50 
values (see Table 4.6). It could be seen that for the Ƴ-lactams 3g and 3h the logTR values 
were >1 suggesting that the toxicity observed was due to a specific mechanism of action 
rather than baseline toxicity. However, with the remaining Ƴ-lactams the logTR values were 
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found to be <1 suggesting that the toxicity observed was due to baseline toxicity. This was 
most evident for Ƴ-lactam 3c.  
 
Table 4.6 – Toxic ratio (TR) values for toxicity observed with Ƴ-lactams. LogTR>1 = specific 
toxicity, logTR<1 = baseline toxicity. 
Ƴ-lactam LogP 
log(1/LC50) predicted 
(mmol/L) 
log(1/LC50) 
experimental (mmol/L) 
logTR (toxic 
ratio) 
3a 2.81 -2.43 -1.45 0.98 
3b 2.48 -2.71 -1.74 0.97 
3c 4.53 -0.93 -0.91 0.02 
3d 3.52 -1.81 -2.15 -0.34 
3e 2.73 -2.49 -2.15 0.34 
3f 1.98 -3.15 -1.26 1.89 
3g 2.45 -2.74 -1.07 1.66 
3h 1.05 -3.96 -3.20 0.76 
3i 3.67 -1.68 -2.69 -1.01 
  
4.4.3 Specific characterisation of Ƴ-lactams 3a, 3f and 3h 
After the biological activity of the Ƴ-lactams had been determined, compounds 3a, 3f and 3h 
were selected for further testing, as with these three compounds specific phenotypes were 
observed. With Ƴ-lactam 3a and in some cases with Ƴ-lactam 3g brain hemorrhage and 
hydrocephalus was observed. With compounds 3f and 3h liver toxicity was observed.  
 
Brain hemorrhage and hydrocephalus are particularly interesting, as they present life-
threatening conditions that are not very well understood (Aronowski and Hall, 2005)(Huang 
et al., 2002). Brain hemorrhage phenotypes have been observed in other zebrafish embryo 
studies as a result of targeted block of a specific gene involved in maintaining blood vessel 
stability in the brain (Liu et al., 2007)(Buchner et al., 2007)(Zou et al., 2011). It was therefore 
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of interest to investigate whether the brain hemorrhage phenotype observed with 3a 
occurred by the same or different mechanism. Liver toxicity on the other hand represents a 
condition that can have many underlying causes. It was therefore of interest to find out the 
causes of the liver toxicity observed with 3f and 3h. 
 
4.4.3.1 Specific characterisation of Ƴ-lactam 3a 
The brain hemorrhage phenotype observed with Ƴ-lactam 3a was further investigated to see 
which part of the brain it was targeted to and what could be the underlying cause without 
going into molecular detail. It was found that brain hemorrhage development with 3a was 
specifically confined to the brain ventricle (Figure 4.9A). Additionally, hydrocephalus 
(accumulation of cerebrospinal fluid) was found to accompany the brain hemorrhage 
induced by 3a (Figure 4.9A). No such conditions were observed in untreated controls (Figure 
4.9B). All the zebrafish embryos that were treated with 100 µM 3a from the 75% epiboly 
stage were found to develop ventricular brain hemorrhage (VBH) by 3 dpf (Figure 4.9C, n=30 
zebrafish larvae at 3 dpf per compound treatment/control, P<0.05). However in some cases, 
the hemorrhage also spread to other parts of the brain including the midbrain, which was 
found to occur in about 50% of cases and also the forebrain in around 25% of cases (Figure 
4.9D). Hemorrhage formation in the brain ventricle and in the mid-brain was found to be 
significant, whereas this was not the case for the forebrain (n=30 zebrafish larvae per 
compound treatment/control at 3 dpf, P<0.05 for brain ventricle and mid-brain, P>0.05 for 
forebrain). Compound 3g was also found to induce hemorrhage formation but only in 25% of 
cases and the localization of the hemorrhage was not as consistent as with compound 3a.
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Figure 4.9 – Ventricular brain hemorrhage (VBH) formation in zebrafish larvae after treatment with Ƴ-lactam 3a. A) Untreated 
zebrafish larva at 3 dpf (lateral view (left) and dorsal view (right)), B) 100 µM compound 3a-treated zebrafish larva at 3 dpf (lateral view 
(left) and dorsal view (right)), C) Percentage of zebrafish larvae at 3 dpf presenting with ventricular brain hemorrhage (VBH) (n=30 
zebrafish at 3 dpf per compound treatment/control, P<0.05) and D) Percentage of zebrafish larvae presenting with hemorrhage in 
different areas of the brain (n=30 zebrafish at 3 dpf per compound treatment/control, P<0.05 for brain ventricle and midbrain, P>0.05 for 
forebrain).  Key: VBH = ventricular brain hemorrhage, FB = forebrain, MB = midbrain, HB = hindbrain 
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To further explore the brain hemorrhage phenotype observed with 3a a transgenic zebrafish 
line Tg(gata-1:DsRed);Tg(fli-1:EGFP) was employed to visualise red blood cells and blood 
vessels (Figure 4.10). It could be clearly seen that an accumulation of red blood cells 
occurred in the brain ventricle of the 100 µM 3a-treated zebrafish larvae, which was not 
present in the controls (Figure 4.10A,B). Additionally, it was observed that bleeding was 
predominantly restricted to the basement membrane underlying the brain ventricle (Figure 
4.10C,D). The brain hemorrhage was also seen to be confined only to the brain ventricle with 
the surrounding vasculature undamaged (Figure 4.10E,F). At 4 dpf the brain angiogenesis in 
the 100 µM 3a-treated zebrafish larvae was found to be reduced compared to controls and 
signs of cell death in this region were also apparent (Figure 4.10G,H). Additionally, the 
number of zebrafish larvae treated with 100 µM 3a displaying blood cell pooling in the brain 
and reduced overall circulation was found to be significant (Figure 4.10I,J, n=30 zebrafish 
larvae at 3 dpf per treatment/control, P<0.05).  
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Figure 4.10 – Red blood cell localization and blood vessel architecture of 100 µM 3a-treated zebrafish embryos visualised using 
Tg(gata-1:DsRed);Tg(fli-1:EGFP). Images (A-F) are shown as Brightfield, GFP and DsRed overlays. A) Lateral overlay of an untreated and 
B) a 100 µM 3a-treated zebrafish at 3 dpf, C) Lateral overlay of an untreated and D) a 100 µM 3a-treated zebrafish at 3 dpf zoomed in, E) 
Dorsal overlay of an untreated and F) a 100 µM 3a-treated zebrafish at 3 dpf, G) Black and white image showing GFP expression in an 
untreated and H) a 100 µM 3a-treated zebrafish at 4 dpf, I) Percentage of zebrafish with blood pooling in the brain (n=30 zebrafish at 3 
dpf per compound treatment/control, P<0.05), J) Percentage of zebrafish with reduced blood circulation (n=30 zebrafish at 3 dpf per 
compound treatment/control, P<0.05). Key: VBH = ventricular brain hemorrhage, FB = forebrain, MB = midbrain, HB = hindbrain 
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Based on the previous experiment where cell death in the brains of 100 µM 3a-treated 4 dpf 
zebrafish larvae was seen, acridine orange staining was performed (see section 4.3.6) to 
determine whether this cell death was mediated by apoptosis. It was found that in the 100 
µM 3a-treated zebrafish larvae compared to the controls there was extensive apoptotic cell 
death visible in the hindbrain and also around the midbrain part of the brain ventricle 
characterized by brightly fluorescing cells (Figure 4.11). The number of apoptotic cells in this 
region was found to be significant (Figure 4.11, n=12 zebrafish larvae at 4 dpf per compound 
treatment/control, P<0.05). Additionally, this region was also found to coincide with the 
region where hemorrhage was observed. This finding agrees with the literature where 
neural cell death due to apoptosis in the brain ventricles of premature human infants born 
with intraventricular hemorrhage (IVH) is observed (Dummula et al., 2011). 
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Figure 4.11 – Acridine orange staining of dead cells in zebrafish larvae presenting with 
ventricular brain hemorrhage. A) Acridine orange staining of an untreated zebrafish larva at 
4 dpf viewed under the GFP channel (dorsal view), B) Acridine orange staining of a 100 µM 
compound 3a-treated zebrafish larva at 4 dpf viewed under the GFP channel (dorsal view), C) 
Drawing of dead cell localization in an untreated zebrafish larva at 4 dpf (dorsal view), D) 
Drawing of dead cell localization in a 100 µM compound 3a-treated zebrafish larva at 4 dpf 
(dorsal view), E) Average number of dead cells counted in the brains of untreated (control) 
and 100 µM 3a-treated zebrafish larvae (n=12 zebrafish larvae at 4 dpf per compound 
treatment/control, P<0.05). Key: FB = forebrain, MB = midbrain, HB = hindbrain  
 
4.4.3.2 Specific characterisation of Ƴ-lactams 3f and 3h 
The next aim was to characterize Ƴ-lactams 3f and 3h further, as with both of these 
compounds liver toxicity was observed in the initial morphology studies. Liver toxicity is 
difficult to detect and has led to a number of drug withdrawals from the market. Between 
1994 and 2006, 14 out of 38 drugs approved by the US Food and Drug Administration (FDA) 
had to be removed due to safety concerns regarding potential liver toxicity (Dykens and Will, 
2007). 
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With compound 3f liver necrosis was observed only at a concentration of 10 µM after 120 
hours of exposure (Figure 4.12A,B). This phenotype was also found to occur specifically in 
the absence of any other morphological effects. After performing ORO staining to stain lipids 
(see section 4.3.5), it was found that the zebrafish larvae with liver necrosis had abnormal 
lipid accumulation in the liver indicative of steatosis (Figure 4.12C,D). Steatosis, also known 
as fatty liver can occur due to impairment of triglyceride excretion and synthesis (Leclercq et 
al., 1998). To determine whether the steatosis observed was also accompanied by 
inflammation, untreated zebrafish larvae and those presenting with liver necrosis were fixed 
and stained with Sudan black reagent (see section 4.3.7). This was done in order to see 
whether leukocytes were localized in and around the liver region as this would be indicative 
of hepatitis (inflammation of the liver). However, it was found that both the untreated 
zebrafish larvae and those with liver necrosis did not to have any leukocyte localization in 
and around the liver (Figure 4.12E,F). This therefore suggested that the liver necrosis and 
steatosis observed with 3f was independent of an inflammatory response. In addition, liver 
size was also assessed and was found to be unchanged in both treated and untreated 
zebrafish larvae (data not shown).  
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Figure 4.12 – Liver necrosis and steatosis in zebrafish larvae treated with 10 µM Ƴ-lactam 
3f. A) Untreated zebrafish larva at 5 dpf, B) 10 µM 3f-treated zebrafish larva at 5 dpf, C) 
Untreated zebrafish larva at 5 dpf stained with Oil red O, D) 10 µM 3f-treated zebrafish larva 
at 5 dpf stained with Oil red O, E) Untreated zebrafish larva at 5 dpf stained with Sudan 
black, F) 10 µM 3f-treated zebrafish larva at 5 dpf stained with Sudan black. 
 
The Ƴ-lactam 3h was then also characterized in a similar way to 3f to see whether it caused 
liver necrosis by the same mechanism. Exposure to compound 3f resulted in an enlarged 
necrotic liver (Figure 4.13A,B). This was accompanied by steatosis characterized by large 
lipid droplets in and around the liver, as shown by ORO staining (Figure 4.13C,D). 
Additionally, after performing Sudan black staining it was apparent that an inflammatory 
response was also involved with leukocytes found to infiltrate the liver (Figure 4.13E,F).  
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Figure 4.13 – Liver necrosis and steatohepatitis in zebrafish larvae treated with Ƴ-lactam 
3h at 2000 µM. A) Untreated zebrafish larva at 5 dpf, B) 2000 µM 3h-treated zebrafish larva 
at 5 dpf, C) Untreated zebrafish larva at 5 dpf stained with Oil red O, D) 2000 µM 3h-treated 
zebrafish larva at 5 dpf stained with Oil red O, E) Untreated zebrafish larva at 5 dpf stained 
with Sudan black, F) 2000 µM 3h-treated zebrafish larva at 5 dpf stained with Sudan black. 
 
Additionally, with compound 3h the extent of liver necrosis and steatosis was found to be 
concentration dependent, occurring at two concentrations, namely 1000 and 2000 µM 
(Figure 4.14).  
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Figure 4.14 – Partial liver necrosis and steatohepatitis in zebrafish larvae treated with Ƴ-
lactam 3h at 1000 µM. A) Untreated zebrafish larva at 5 dpf, B) 1000 µM 3h-treated 
zebrafish larva at 5 dpf, C) Untreated zebrafish larva at 5 dpf stained with Oil red O, D) 1000 
µM 3h-treated zebrafish larva at 5 dpf stained with Oil red O, E) Untreated zebrafish larva at 
5 dpf stained with Sudan black, F) 1000 µM 3h-treated zebrafish larva at 5 dpf stained with 
Sudan black. 
 
The leukocyte number as well as the percentage increase in liver size was determined for 
both concentrations of Ƴ-lactam 3h (Figure 4.15). With both concentrations of Ƴ-lactam 3h a 
significant increase in the leukocyte number localized around the liver was observed (Figure 
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4.15A, n=12 zebrafish larvae at 5 dpf per compound treatment/control, P<0.05). 
Additionally, the average liver size was found to be significantly increased after treatment 
with Ƴ-lactam 3h at 2000 µM but not at 1000 µM (Figure 4.15B, n=12 zebrafish larvae at 5 
dpf per compound treatment/control, P<0.05 for 2000 µM 3h, P>0.05 for 1000 µM 3h). 
 
Figure 4.15 – Increase in circulating leukocytes in and around the liver and increase in liver 
size after treatment of zebrafish larvae with Ƴ-lactam 3h. A) Average leukocyte number in 
livers of control, 1000 µM and 2000 µM compound 3h-treated zebrafish (n=12 zebrafish 
larvae at 5 dpf per compound treatment/control, P<0.05 for 1000 and 2000 µM 3h), B) 
Average percentage increase in liver size relative to control for 1000 and 2000 µM compound 
3h-treated zebrafish (n=12 zebrafish larvae at 5 dpf per compound treatment/control, P<0.05 
for 2000 µM). 
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4.4.4 Morphology analysis of azetidine-treated zebrafish embryos 
The initial aim was to explore the biological activity of six selected azetidines by observing 
how they affected zebrafish embryo development. Due to time constraints three different 
treatment regimens were utilised (treatments with each azetidine at a concentration of 10 
and 25 µM commencing at the 75% epiboly stage up until 120 hpf and treatments with each 
azetidine at 30 µM beginning at 24 hpf up until 120 hpf). The latter treatment regimen was 
employed in order to see whether the selected azetidines also affected later stages of 
zebrafish embryo development once the major cellular processes had been completed.  
 
The percentage of zebrafish embryos presenting with particular morphological effects were 
quantified and averaged from three separate repeats over a five day exposure period for all 
three treatment regimens (Figure 4.16, n=30 zebrafish larvae at 5 dpf per compound/control 
[0.1% DMSO and E3 embryo medium]). Morphological features recorded included tail 
curvature (TC), abnormal jaw formation (JM), delayed development (DD), hypopigmentation 
(PI), slowed heart rate (HR), tail necrosis (TN), heart edema (HE), brain edema (BE) and 
reduced blood circulation (CR). 
 
All tested azetidines at 10 µM except azetidine 2f showed significant differences in the 
morphological effects they produced compared to the controls (P>0.05 for 2f, P<0.05 for the 
rest). At 25 µM, all tested azetidines showed significant differences compared to the 
controls (P>0.05 for all). When zebrafish embryos were treated at 24 hpf at a concentration 
of 30 µM, azetidines 2b, 2d and 2f were found to show no significant differences in the 
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morphological effects they produced compared to the controls (P>0.05). However, 
azetidines 2a, 2c and 2e were found to show significant differences (P<0.05). 
 
Figure 4.16 – Heat map showing morphological effects observed in zebrafish larvae after 
exposure to the six selected azetidines. Top) Mean percentage of zebrafish larvae presenting 
with morphological defects after 120 hours of 10 µM azetidine treatment initiated at the 75% 
epiboly stage (n=30 zebrafish larvae at 5 dpf per compound/control, SD range +/- 0-31.75%, 
P>0.05 for 2f, P<0.05 for rest), Middle) Mean percentage of zebrafish larvae presenting with 
morphological defects after 120 hours of 25 µM azetidine treatment initiated at the 75% 
epiboly stage (n=30 zebrafish larvae at 5 dpf per compound/control, SD range +/- 0-46.19%, 
P<0.05 for all), Bottom) Mean percentage of zebrafish larvae presenting with morphological 
defects after 96 hours of 30 µM azetidine treatment initiated at the prim-5 stage (n=30 
zebrafish larvae at 5 dpf per compound/control, SD range +/- 0-30.41, P>0.05 for 2b, 2d, 2f, 
P<0.05 for rest). Key: TC = tail curvature, JM = abnormal jaw formation, DD = delayed 
development, PI = hypopigmentation, HR = slowed heart rate, TN = tail necrosis, HE = heart 
edema, BE = brain edema and CR = reduced circulation. Colour key: light yellow = 0%, red = 
100% 
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Compound 2a at all tested concentrations and exposure times was found to be the most 
biologically active producing various morphological effects in zebrafish embryos including 
hypopigmentation, delayed development, reduced circulation, reduced heart rate, trunk 
curvature, pericardial edema, scoliosis, hydrocephalus and abnormal somite development 
(U-shaped somites). Some of these effects including abnormal somite development, delayed 
development, scoliosis and pericardial edema have also been observed in zebrafish embryos 
after nicotine treatment (Welsh et al., 2009). 
 
Compound 2c (containing an ortho-bromophenyl substituent) was found to be the next most 
active compound producing a variety of morphological effects including reduced heart rate, 
slowed circulation, pericardial edema and trunk curvature. Compound 2e (containing a furan 
group) was also found to cause similar effects such as pericardial edema, reduced heart rate, 
slowed circulation and delayed development. The remaining azetidines 2b, 2d and 2f were 
found to have little or no effect on zebrafish embryo development.  
  
Mortality of zebrafish embryos after exposure to the six selected azetidines was also 
recorded over the 120 hour exposure period. Mortality was defined as coagulation of the 
zebrafish embryo, lack of somite development, non-detachment of the tail and after 48 
hours lack of a heartbeat based on the OECD guidelines (OECD, 2013).  
 
It was found that azetidine 2a caused the highest mean cumulative percentage mortality in 
all of the different treatment regimens and this was found to be significantly different from 
the controls (0.1% DMSO and E3 embryo medium) (Figure 4.17, n=30 zebrafish embryos, 
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P<0.05). Mortality with azetidine 2a was found to occur relatively early (100% mortality by 
72 hpf) when the zebrafish embryos were treated at 25 µM. Azetidine 2c was also found to 
cause a significantly high number of mortalities leading to 100% mortality at 120 hpf when 
zebrafish embryos were treated with a 30 µM concentration (n=30 zebrafish embryos, 
P<0.05). The mortality rates observed for the other tested azetidines were found to be 
comparable to the controls with little mortality observed (n=30 zebrafish embryos, P>0.05). 
Based on these results it was evident that azetidine 2a caused the most number of 
mortalities followed by azetidine 2c. The remaining azetidines were found to cause little or 
no mortality.  
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Figure 4.17 – Heat map showing the mean mortality rate of zebrafish embryos after treatment with the six selected azetidines over 
time. Time is indicated on the top of each heat map in hours (24, 48, 72, 96 and 120). Left) Mean cumulative percentage mortality of 
zebrafish embryos treated at the 75% epiboly stage with azetidines at a concentration of 10 µM (n=30 zebrafish embryos per 
compound/control, SD range +/- 0-11.35%, P<0.05 for 2a and 2c, P>0.05 for rest), Middle) Mean cumulative percentage mortality of 
zebrafish embryos treated at the 75% epiboly stage with azetidines at a concentration of 25 µM (n=30 zebrafish embryos per 
compound/control, SD range +/- 0-10.41%, P<0.05 for 2a and 2c, P>0.05 for rest), Right) Mean cumulative percentage mortality of 
zebrafish embryos treated at the prim-5 stage with azetidines at a concentration of 30 µM (n=30 zebrafish embryos per 
compound/control, SD range +/- 0-10%, P<0.05 for 2a and 2c, P>0.05 for rest). Colour key: light yellow = 0%, red = 100% 
 
 
 
 
 
 
 
 
165 
 
Using the biological data (mean percentage of zebrafish larvae at 5 dpf presenting with a 
particular morphological defect after treatment at 25 µM) and a few chemical descriptors, 
such as logP (lipophilicity of a compound), MW (molecular weight), HB (sum of hydrogen 
bond donors and acceptors), HBA (number of hydrogen bond acceptors) and HBD (number 
of hydrogen bond donors) a PCA model (R2X=0.992, Q2=0.619, two significant components) 
was created (Figure 4.18).  
 
Using the PCA model the relationship between the physiochemical properties of the 
compounds and their biological activities could be investigated to a certain extent. From the 
PCA model it was observed that azetidine 2a was separated from the rest of the group as it 
showed the most biological activity producing various morphological effects. Compared to 
the other azetidines azetidine 2a also had the least number of hydrogen bond donors, as 
well as a relatively high logP with a low molecular weight, suggesting that it may have been 
able to penetrate into the zebrafish embryo better than the other compounds. The 
remaining azetidines were found to cluster relatively close together as they produced no or 
little morphological effects in comparison to azetidine 2a. 
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Figure 4.18 – A combined biplot two-component PCA model of zebrafish embryo biological 
responses (observations) against morphology features and physiochemical descriptors 
(variables) following treatment with a selection of azetidines over a 120 hour exposure 
period. Biological features = TN (tail necrosis), HR (slowed heart rate), HE (heart edema), CR 
(reduced circulation), JM (jaw malformations), TC (tail curvature), DD (delayed development), 
BE (brain edema) and PI (hypopigmentation). Results presented after treatment at 25 µM. 
Chemical descriptors = logP (lipophilicity), MW (molecular weight), HB (sum of hydrogen 
bond donors and acceptors), HBA (number of hydrogen bond acceptors) and HBD (number of 
hydrogen bond donors). The loading vector (p) and the scores vector (t) are displayed 
correlation scaled as vector p(corr) and t (corr). The numbers beside p(corr) and t(corr) 
indicate the PCA component (1 or 2). All points are distributed within the correlation circle of 
radius and thus everything is contained within the model. The observations (scores) for 
tested azetidines are denoted by brown squares. The different coloured circles denote the 
location of the variables within the loading plot.  
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4.4.5 Neurobehavioural effects of azetidines 
As the biological activity of the tested azetidines had been evaluated by determining their 
effects on zebrafish embryo development the next step was to see how these compounds 
affected zebrafish behavioural responses as a second readout for biological activity. Due to 
the structural similarities of the tested azetidines to nicotine it was of interest to see 
whether they would potentially also induce neurobehavioural effects similar to those 
observed with nicotine (Petzold et al., 2009). 
 
To investigate this, a locomotor activity assay was employed where the swimming behaviour 
of zebrafish larvae was investigated. In brief, zebrafish larvae at 6 dpf were acclimatized for 
30 minutes in the recording plate consisting of 4 wells (Thermo Fisher Scientific, Germany) 
with each well containing 20 mL of E3 embryo medium and 10 larvae each. The medium in 
two of the wells was then replaced with a selected azetidine at a concentration of 20 µM, 
whereas the medium in the other two wells was replaced with control solution (1% DMSO). 
The locomotor activity was then assessed by inserting the recording plate into the FLIPR 
Tetra locomotion measurement system (Richter Gedeon Nyrt., Hungary). This locomotion 
measurement system was able to take pictures of every well every second whilst shining 
blue light repeatedly at 999 ms. The images taken were processed using custom-made 
software (KomiPL) provided by to Pictron Ltd. (Budapest, Hungary). The software 
automatically identified individual zebrafish larvae and then used changes in pixel intensity 
over the whole time frame as a measure of how much each zebrafish larva had moved 
during that time period with greater pixel changes indicating greater movement. For each 
azetidine the experiment was performed three times at a concentration of 20 µM. 
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The corrected pixel changes over the recording period were used as a readout to determine 
the extent of movement of the zebrafish larvae, as these values were corrected for the 
number of zebrafish larvae that had been correctly identified by the software (see Figure 
4.19). It was found that azetidines 2a, 2c and 2e all significantly decreased the locomotor 
activity of zebrafish larvae compared to controls (n=60 zebrafish larvae at 6 dpf per 
compound/control, P<0.05 for 2a, 2c and 2e). This was also in line with what has been 
reported with high nicotine concentrations (Thomas et al., 2009a). Azetidines 2b, 2d and 2f 
however were found to have no significant effect on larval zebrafish locomotor activity 
producing comparable results to the controls (n=60 zebrafish larvae at 6 dpf per 
compound/control, P>0.05 for 2b, 2d and 2f).  
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Figure 4.19 – Effects of six selected azetidines on 6 dpf zebrafish larval locomotor activity.   
A) 2a and 1% DMSO control (P<0.05), B) 2b and 1% DMSO control (P>0.05), C) 2c and 1% 
DMSO control (P<0.05), D) 2d and 1% DMSO control (P>0.05), E) 2e and 1% DMSO control 
(P<0.05), F) 2f and 1% DMSO control (P>0.05). Corrected pixel changes represent mean 
locomotor activity of azetidine-treated (20 µM) and untreated 6 dpf zebrafish larvae over a 
30 minute recording period with averages for each five minute segment shown (n=60 
zebrafish larvae at 6 dpf per azetidine/control).  
 
4.4.6 Specific characterization of azetidine 2a 
As azetidine 2a was found to cause various biological effects in the initial studies it was 
investigated further. Treatment of zebrafish embryos with azetidine 2a as mentioned 
previously produced a variety of morphological effects including reduced blood circulation, 
hypopigmentation, tail curvature, brain edema/hydrocephalus, cardiac edema, enlarged yolk 
sac and abnormal somite development (see Figure 4.20).  
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Figure 4.20 – Morphological effects observed after treatment of zebrafish embryos with 
azetidine 2a. A) Brightfield image (lateral view) of a control (untreated) zebrafish embryo at 
2 dpf, B) Brightfield image (lateral view) of a 25 µM 2a-treated zebrafish embryo at 2 dpf. 
 
Reduced blood circulation was the main effect observed after azetidine 2a treatment 
contributing to the development of a wide variety of secondary phenotypes including blood 
clotting. Using a transgenic zebrafish line Tg(fli-1:EGFP) the vasculature was studied in 
further detail to identify any blood vessel damage in azetidine 2a-treated zebrafish embryos 
(Figure 4.21). It was found that after treatment of 75% epiboly stage zebrafish embryos for 
36 hours with 50 µM azetidine 2a the vasculature in the tips of the tails was not fully formed 
with tail necrosis evident (Figure 4.21A,B,C,D). This was significantly different to what was 
seen in controls (Figure 4.21E, n=40 zebrafish embryos at 36 hpf per drug/control, P<0.05). 
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Figure 4.21 – Specific characterization of azetidine 2a vasculature effects using the Tg(fli-1:EGFP) transgenic zebrafish line. A) 
Brightfield image (lateral view) of a control (untreated) zebrafish embryo at 36 hpf, B) Brightfield image (lateral view) of a 50 µM 2a-
treated zebrafish embryo at 36 hpf, C) Fluorescence GFP image (lateral view) displaying the vasculature of a control (untreated) zebrafish 
embryo at 36 hpf, D) Fluorescence GFP image (lateral view) displaying the vasculature of a 50 µM 2a-treated zebrafish embryo at 36 hpf, 
E) Mean percentage of zebrafish embryos displaying tail necrosis at 36 hpf after treatment with 50 µM of azetidine 2a compared to 
untreated controls (n=40 zebrafish embryos at 36 hpf per drug/control, P<0.05). 
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Using a double transgenic line Tg(fli-1:EGFP)(gata-1:DsRed), red blood cells were then 
assessed for clotting and perturbed circulation. It was found that after initial treatment of 
zebrafish embryos from this transgenic line at the 75% epiboly stage with 50 µM azetidine 
2a until 36 hpf the blood circulation was severely reduced compared to controls with blood 
clots evident in the tail (Figure 4.22A,B,C,D). The occurrence of blood clots was also found to 
be significant compared to the untreated controls (Figure 4.22E, n=40 zebrafish embryos at 
36 hpf per drug/control, P<0.05).  
 
A brain hemorrhage phenotype was observed in 10% of zebrafish embryos at 2 dpf after 
treatment with 25 µM azetidine 2a at the 75% epiboly stage. This phenotype was 
particularly interesting, as it was specific to azetidine 2a. By performing ORO staining to stain 
lipids it was found that the hemorrhage was specifically confined to the brain ventricle, 
causing ventricular brain hemorrhage (VBH) (Figure 4.23). Out of the 40 zebrafish embryos 
treated with azetidine 2a only four showed this phenotype with none of the controls 
displaying such a phenotype (n=40 zebrafish embryos at 2 dpf per drug/control, P<0.05).  
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Figure 4.22 – Specific characterization of azetidine 2a blood circulation effects using the Tg(fli-1:EGFP)(gata-1:DsRed) transgenic 
zebrafish line. A) Brightfield image (lateral view) of a control (untreated) zebrafish embryo at 36 hpf, B) Brightfield image (lateral view) of 
a 50 µM 2a-treated zebrafish embryo at 36 hpf, C) Fluorescence DsRed image (lateral view) displaying the red blood cells of a control 
(untreated) zebrafish embryo at 36 hpf, D) Fluorescence DsRED image (lateral view) displaying the red blood cells of a 50 µM 2a-treated 
zebrafish embryo at 36 hpf, E) Mean percentage of zebrafish embryos presenting with blood clots at 36 hpf after treatment with 50 µM 
azetidine 2a compared to untreated controls (n=40 zebrafish embryos at 36 hpf per drug/control, P<0.05).  
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Figure 4.23 – Ventricular brain hemorrhage (VBH) phenotype observed with azetidine 2a. Oil Red O staining images of: A) Untreated 2 
dpf control zebrafish embryo (lateral view), B) Azetidine 2a-treated zebrafish embryo at 2 dpf (lateral view), C) Untreated 2 dpf control 
zebrafish embryo (dorsal view), D) Azetidine 2a-treated zebrafish embryo at 2 dpf (dorsal view), E) Mean percentage of embryos 
presenting with ventricular brain hemorrhage (n=40 zebrafish embryos at 2 dpf, P<0.05). Key: VBH = ventricular brain hemorrhage, FB = 
forebrain, MB = midbrain, HB = hindbrain 
175 
 
 
4.5 Discussion 
4.5.1 Toxicity and morphological effects of Ƴ-lactams on zebrafish embryos 
A diverse set of Ƴ-lactams were evaluated for biological activity in the zebrafish embryo 
using a two phase approach. The results from phase 1 (dose-range finding) showed that 
compound 3c was the most toxic and compound 3h was the least toxic of the nine Ƴ-lactams 
tested. Toxicity observed with Ƴ-lactam 3c was most probably due to its methoxy groups, 
which have been extensively documented in the literature to cause high toxicity due to 
radical formation (Smith et al., 2002).  
 
All nine compounds were found to produce morphological effects with effects most 
pronounced for 3a, 3f, 3g and 3h. Treatment of zebrafish embryos with all nine compounds 
was also repeated using dechorionated embryos (data not shown) where the observations 
were found to be the same, suggesting that the chorion was not acting as a barrier to drug 
uptake.  
 
4.5.2 Possible mechanisms for hemorrhage formation with Ƴ-lactam 3a 
The Ƴ-lactam 3a was chosen for further investigation following the initial toxicity studies, as 
it caused hemorrhage formation in the brain ventricle from 3 dpf onwards, which was not 
evident in controls (Figure 4.24A,B). Hemorrhage formation was also found to occur with 
compound 3g, but at a lower frequency and with less specificity compared to compound 3a, 
so it was not considered for further investigation (Figure 4.24C).  
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Figure 4.24 – Depiction of hemorrhage localization in the brain ventricles of 3 dpf zebrafish 
larvae. Annotated drawings of 4 dpf zebrafish larvae brain ventricles: A) Untreated control, 
B) 100 µM compound 3a-treated, C) 100 µM compound 3g-treated. Key: FB = forebrain, MB = 
midbrain, HB = hindbrain 
 
The development of ventricular brain hemorrhage and hydrocephalus after exposure to Ƴ-
lactam 3a was possibly caused by knockdown of the βPix gene. The βPix gene is highly 
expressed in the neuroepithelial lining of the brain ventricle in zebrafish embryos and has 
two splice variants βPixA and βPixB (Liu et al., 2007). Knockdown of both splice variants 
results in hydrocephalus and hemorrhage, whereas knockdown of splice variant B only leads 
to hemorrhage formation and knockdown of splice variant A only leads to hydrocephalus 
formation (Liu et al., 2007). As both hydrocephalus and hemorrhage formation was apparent 
after Ƴ-lactam 3a treatment it is possible that this compound affects both splice variants of 
the βPix gene. Additionally, zebrafish mutants with a βPix gene knockdown have a less 
complex vascular pattern in the brain compared to their wild-type siblings (Liu et al., 2007), a 
feature also observed with Ƴ-lactam 3a. These similarities in features suggest that disruption 
of the βPix-Pak pathway most likely is responsible for the development of ventricular brain 
hemorrhage observed with Ƴ-lactam 3a. However, synergistic effects with other genes 
(pak2a, ccm1 and rap1) cannot be ruled out, as all of these produce a hemorrhage 
phenotype in zebrafish (Gore et al., 2008). Hence, analysis on a genetic level would be the 
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next step to identify which genes have an altered expression pattern in zebrafish embryos 
presenting with brain hemorrhage after treatment with Ƴ-lactam 3a and whether 
knockdown of the βPix gene is the main cause.  
 
In terms of clinical relevance, in human pre-term and low birth weight babies 
intraventricular hemorrhage (IVH) and hydrocephalus can lead to morbidity (cognitive 
impairment) and mortality (Kazan et al., 2005). The specific intraventricular 
hemorrhage/hydrocephalus induced by compound 3a could be utilized as a drug-induced 
zebrafish disease model for intraventricular hemorrhage/hydrocephalus where drugs could 
be screened to identify those that can reverse this condition.  
 
4.5.3 Liver toxicity with Ƴ-lactams 3f and 3h 
The Ƴ-lactam 3f was selected for further investigation due to the development of a specific 
liver necrosis and steatosis phenotype in the absence of any other morphological 
abnormalities. The liver necrosis observed with Ƴ-lactam 3f was most likely due to the action 
of the furan side group, which is known to induce liver toxicity and carcinogenicity (Cordelli 
et al., 2010). For example, female mice fed furans develop elevated liver enzyme levels and 
liver necrosis (Fransson-Steen et al., 1997). It has been recently found that the highly 
reactive oxidation product of furans cis-2-butene-1,4-dial (BDA) is produced predominantly 
by CYP2E1 oxidation in human microsomes (Gates et al., 2012). This metabolite has been 
shown to be conjugated to glutathione in rat hepatocytes to form 2-(S-
glutathionyl)succinaldehyde which can then form pyrrole cross-links with lysine, glutamine, 
ornithine, putrescine and spermidine (Peterson et al., 2011). These polyamines are thought 
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to be the main culprits of furan toxicity as they will bind to negatively charged molecules like 
DNA, RNA or proteins to form adducts (Minois et al., 2011). Hence, protein adduct formation 
with liver proteins could explain the liver necrosis observed after treatment with Ƴ-lactam 
3f. Steatosis which was also observed could be explained by impaired synthesis and 
elimination of triglycerides by the liver. 
 
With compound 3h the liver necrosis phenotype was only found to develop late during 
zebrafish development and at relatively high tested concentrations 2000 and 1000 µM 
suggesting that compound 3h was not able to penetrate very well into the zebrafish embryo, 
most probably due to its very low logP value.  
 
At 2000 µM liver necrosis was accompanied by delayed development, trunk curvature, lipid 
droplet formation, severe pericardial edema, reduced heart rate and reduced circulation. 
Additionally, the hatching gland was still present at 5 dpf and the liver was found to be 
enlarged compared to controls. At 1000 µM the zebrafish was morphologically normal with 
partial liver necrosis. However, in both cases liver necrosis was accompanied by steatosis 
and inflammatory infiltration.  
 
Compound 3h has a nitroxy group which is known to be liver toxic and possibly carcinogenic 
in humans (Rickert et al., 1983). For example, male Sprague-Dawley CD rats treated with 
nitrobenzene develop enlarged hepatocytes with big nucleoli and inflammation (Tyl et al., 
1987). This phenotype seems to show similarities to the phenotype observed with Ƴ-lactam 
3h. Liver toxicity of nitrobenzene is attributed to its metabolism. Nitrobenzene metabolism 
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can produce a large variety of metabolites, including phenolic metabolites by CYP1A2 
oxidation, e.g. p-aminophenol, p-nitrophenol, m-nitrophenol and p-hydroxyacetanilide 
(Rickert et al., 1983). These metabolites mainly undergo sulphation before they are excreted 
from the body (Rickert et al., 1983). Nitrobenzene can also form free radicals (Rickert et al., 
1983). The nitroanion is the first free radical formed, which can react with oxygen to form 
the superoxide radical (Jw, 1999). These superoxide radicals can in turn interact with nitric 
oxide to form peroxynitrite as well as hydrogen peroxide (Knight et al., 2003). Peroxynitrite 
and hydrogen peroxide can cause lipid peroxidation by reacting with unsaturated lipids to 
form lipid radicals and also lipid peroxyl radicals (Knight et al., 2003). This ultimately can lead 
to necrosis of liver cells, as well as other cell types (Knight et al., 2003). The formation of lipid 
droplets could be attributed to the disruption of regulatory networks involved in regulating 
intracellular lipid storage and also possibly due to decreased fatty acid metabolism (Zitting et 
al., 1982).  
 
Another effect documented with compound 3h was the presence of an inflammatory 
infiltrate in and around the liver. In humans it has been shown that toxic hepatitis can occur 
following nitrobenzene exposure (Kaplowitz, 2004). This is likely due to one of the 
nitrobenzene metabolites forming adducts with cellular proteins (Kaplowitz, 2004). In turn, 
these macromolecules could act as haptens resulting in an autoimmune reaction (Kaplowitz, 
2004). Thus, the above described mechanisms are likely to be responsible for the liver 
toxicity observed with compound 3h, because zebrafish have the capacity to metabolize 
aromatic amines through a CYP1A family orthologue, therefore being able to potentially 
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form the same metabolites found in rodents and humans after nitrobenzene exposure 
(Scornaienchi et al., 2010). 
 
4.5.4 Toxicity and morphological effects of azetidines on zebrafish embryos 
A small selection of structurally diverse azetidines was assessed for biological activity using 
the zebrafish embryo as a model. The azetidine 2a which possesses a piperidine (secondary 
amine) fragment was found to be the most biologically active, producing a vast array of 
phenotypes including hypopigmentation, delayed development, reduced blood circulation, 
scoliosis and U-shaped somites. It was also found to be the most toxic. Azetidine 2a is 
structurally similar to azetidine 2b. Azetidine 2b however was found to be relatively non-
toxic in the zebrafish embryo assays suggesting that the piperidine fragment of 2a was 
important in conferring toxicity. Additionally, azetidines 2c and 2e which are structurally 
similar to one another were both found to induce similar biological responses, although 
azetidine 2c was found to be the more active. Azetidines 2d and 2f also structurally similar to 
one another produced little biological effects. These results showed that slight differences in 
chemical structure greatly influenced the biological activity of these compounds.  
 
By using multivariate analysis it was found that the biologically active azetidine 2a had a very 
high logP value with reduced hydrogen bond donor sites, thus making it very cell permeable. 
This may have contributed to its potency and high toxicity. Azetidine 2c on the other hand 
was found to have a very low logP value and this might explain why it was only found to 
have an effect on zebrafish embryos late during development, as it may have not penetrated 
into zebrafish embryos at earlier stages. The remaining azetidines (2b, 2d, 2e and 2f) were 
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found to have lower toxicity and produced fewer morphological effects despite having 
comparable logP values to azetidine 2a. Thus, logP may have not been the only factor 
contributing to biological activity. For azetidine 2a it is possible that release of the piperidine 
fragment by metabolism may have been responsible for its effects as well as conversion into 
an ionised form.  
 
4.5.5 Azetidine locomotor effects and similarities to nicotine 
The six selected azetidines were also investigated for their effects on the nervous system by 
performing locomotor activity assays. Reduced locomotor activity was observed after 
treatment of 6 dpf zebrafish larvae with azetidines 2a, 2c and 2e. This reduction in 
locomotor activity was found to be similar to that observed with high nicotine 
concentrations in zebrafish (Thomas et al., 2009a).  
 
Nicotine at low concentrations acts as a stimulant causing an increase in locomotor activity 
as binding of nicotine to nACh receptors stimulates the release of acetylcholine, whereas at 
high concentrations nicotine acts as a depressant by reducing this activity leading to 
desensitization of nACh receptors so that they are no longer responsive (Petzold et al., 
2009)(Silvette et al., 1962). It has been demonstrated that zebrafish larvae (above 4 dpf) can 
be sensitized to nicotine, as re-exposure to nicotine following prior exposure increases the 
locomotor activity much more than that of zebrafish larvae exposed to nicotine for the first 
time (Petzold et al., 2009). This effect on locomotor activity is also seen in rats exposed to 
nicotine (Cohen et al., 1991). Additionally, over-excitation of muscle cells and mechanical 
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forces also contribute to reduced locomotor activity, effects which are commonly observed 
with acetylcholinesterase inhibitors (Behra et al., 2002). 
 
4.5.6 Similarities between azetidine and nicotine phenotypes 
Nicotine represents the structurally most similar compound to the tested azetidines. 
Nicotine is a naturally occurring alkaloid and in its pure form is extremely toxic to humans 
and mammals (mouse oral LD50 = 24 mg/kg) (Ujváry, 1999)(Yamamoto and Casida, 1999). 
Nicotine has been previously tested in zebrafish embryos and has been documented to be a 
potent teratogen inducing a number of morphological effects (Welsh et al., 2009). These 
include reduced notochord length, jaw malformations, reduced somite number, apoptotic 
death of brain cells and muscle paralysis (Parker and Connaughton, 2007)(Klee et al., 
2011)(Thomas et al., 2009b). The morphological effects observed with a few of the tested 
azetidines were found to resemble those reported with nicotine. For example, treatment of 
zebrafish embryos with azetidines 2a, 2c and 2e led to the development of curved tails, 
reduced heart rate, slowed circulation and cardiac edema.  
 
4.5.7 Similarities between azetidine 2a and nicotine phenotypes 
Azetidine 2a was found to show the greatest resemblance to nicotine in terms of its 
chemical structure and the morphological effects it produced in zebrafish embryos. Nicotine 
like azetidine 2a has no hydrogen bond donors but two hydrogen bond acceptors, which 
may be an important factor in azetidine 2a toxicity. In regards to lipophilicity, azetidine 2a 
however has a higher logP value than nicotine (DrugBank, 2013c). Despite nicotine having a 
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low logP value it has been shown to be readily absorbed at neutral pH when it is in its 
unionized state (Hukkanen et al., 2005). 
 
The morphological effects observed with azetidine 2a which were found to be similar to 
nicotine included the formation of U-shaped somites, muscular bends, reduced notochord 
length and jaw malformations (summarised in Table 4.7) (Parker and Connaughton, 2007). 
U-shaped somites are a characteristic feature of nicotine toxicity in zebrafish embryos. This 
phenotype occurs due to disruption of the hedgehog signalling pathway which is important 
for ensuring the correct development of slow muscles (Woods and Talbot, 2005). The 
associated muscular bends develop early in zebrafish embryos due to incorrect growth of 
motor neurons leading to disorganization of the slow muscle fibres (Welsh et al., 2009). As 
zebrafish embryos treated with azetidine 2a were unable to hatch out of their chorions, the 
weakened muscular development can be partially attributed to this. However, inhibition of 
the chorionase enzyme or osmotic disturbances may have also contributed to the 
development of this particular phenotype, hence further investigation would be required to 
identify the exact cause (He et al., 2012). The slow movement of muscles could also be 
related to over-excitation of muscles (Parker and Connaughton, 2007).  
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Table 4.7 - Comparison of the effects observed after nicotine and azetidine 2a treatment of 
zebrafish embryos. 
Source: Data on nicotine treatments in zebrafish embryos obtained from (Klee et al., 2011) 
and (Welsh et al., 2009). 
Morphology features Nicotine Azetidine 2a 
Delayed development √ √ 
Jaw malformations √ √ 
Curved tail √ √ 
U-shaped somites √ √ 
Bradycardia √ √ 
Reduced circulation √ √ 
Pericardial edema √ √ 
Reduced locomotion √ √ 
Short stature √ √ 
Hypopigmentation X √ 
Brain hemorrhage X √ 
 
Azetidine 2a was found to lead to the development of hydrocephalus and also ventricular 
brain hemorrhage, an effect which has not been documented with nicotine. It is likely that 
this phenotype developed due to vascular stability in the brain being compromised through 
vessel or membrane rupture. It has been documented that effects on the βPix Pak2a 
signalling pathway in zebrafish embryos can result in the formation of ventricular brain 
hemorrhage (Liu et al., 2007).  
 
An additional effect observed with azetidine 2a and not with nicotine included 
hypopigmentation. The hypopigmentation phenotype observed with azetidine 2a was found 
to be similar to that observed with anti-thyroid agents such as thiamazole (Elsalini and Rohr, 
2003), which indicate that azetidine 2a possibly affects thyroid signalling. It has been 
reported that pigmentation effects in zebrafish embryos may be linked to reduced levels of 
cyclic adenosine monophosphate (cAMP) and disruptions to the function of microtubules, 
which are both important in ensuring the dispersion and aggregation of the pigment melanin 
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(Logan et al., 2006). At later stages of zebrafish embryonic development disturbances to the 
function of xanthophores can also contribute to the development of a hypopigmentation 
phenotype (Odenthal et al., 1996). Recently, it was discovered that the zebrafish 
melanosomes (organelles involved in melanin production) are sensitive to light and at 3 dpf 
start to aggregate via stimulation from the eyes (Nguyen et al., 2013). This optical 
stimulation may have been perturbed in azetidine 2a-treated zebrafish embryos and 
therefore contributed to abnormal dispersion of melanin.  
 
Many of the features observed with azetidine 2a such as hypopigmentation, delayed 
development, craniofacial abnormalities and pericardial edema are also observed after 
treatment of zebrafish embryos with piperidines, e.g. 2-methylpiperidine (Schulte and Nagel, 
n.d.). Therefore, it seems more likely that the piperidine fragment is responsible for the 
morphological effects observed with azetidine 2a. Additionally, ionisation of azetidine 2a 
may also contribute to its toxicity. 
 
4.5.8 Similarities in responses between Ƴ-lactams and azetidines 
When comparing the biological responses observed with the Ƴ-lactams to those observed 
with the azetidines it was interesting to note that the azetidine 2a and the Ƴ-lactam 3a 
produced similar phenotypes. These included hydrocephalus, brain hemorrhage and a 
cardiac phenotype (AV block). The main difference between them was that azetidine 2a also 
caused hypopigmentation, which was not seen with 3a. However, the brain hemorrhage 
phenotype observed was found to be very similar between both 2a and 3a, suggesting that 
azetidine 2a also affects brain vasculature stability in the same way as Ƴ-lactam 3a, so it 
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would be interesting to carry out further work on both compounds to see whether they 
indeed have a similar mode of action. Both of these compounds were also found to have low 
molecular weights compared to the other compounds in their respective groups as well as 
logP values above 2 which may have contributed to their high potency.   
 
Two other compounds with structural similarities are the azetidine 2c and the Ƴ-lactam 3i, 
which both contain bromine in their chemical structures. Both compounds were found to be 
biologically active and produced similar morphological effects such as trunk curvature, 
pericardial edema, yolk edema, slowed circulation and a reduced heart rate. Such effects 
have also been reported in zebrafish embryos treated with brominated phenols and indoles 
(Kammann et al., 2006). The toxicity of these brominated compounds in zebrafish embryos is 
likely to be attributed to the metabolism of the bromobenzene constituent. In humans 
bromobenzene is metabolized by CYP2B to a reactive bromobenzene 3,4-epoxide but also 
forms a stable 2,3-epoxide (Ioannides, 1996)(Lau and Zannoni, 1981). The reactive 3,4-
epoxide can bind to protein thiol groups resulting in protein adducts and the 2,3-epoxide can 
form covalent bonds with haemoglobin (Koen et al., 2000)(Lau and Zannoni, 1981).  
 
The azetidine 2e and the Ƴ-lactam 3f were also found to be structurally similar with both 
compounds containing a furan group. Additionally, morphological effects including 
pericardial edema, slowed circulation and reduced heart rate were observed with both of 
these compounds. However, liver necrosis that was observed with the Ƴ-lactam 3f was not 
observed with azetidine 2e, which could be due to the structural differences between them 
or the concentrations tested for azetidine 2e being too low to induce a similar effect. 
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4.5.9 Limitations of current study and future work 
In the current study, azetidines were tested using three treatment regimens at three 
different concentrations and one azetidine was selected for further investigation. If more 
time had been available, the mortality and morphology studies could have been improved by 
testing a wider range of concentrations, so as to make sure that all six azetidines were tested 
at a concentration at which they would be active. As more time was available when 
investigating the Ƴ-lactams, a two phase study was performed where initially a dose-range 
finding and then a morphology study was performed. This approach would have also been 
useful when testing the azetidines. Additionally, for the azetidines it would be useful in the 
future to perform assays specifically targeting the mode of action which nicotine employs. 
This could be done by performing receptor binding studies for example.  
 
For azetidine 2a and the Ƴ-lactam 3a cellular or molecular studies should be performed in 
the future in order to understand their exact modes of action and to determine the exact 
causes behind the hydrocephalus/brain hemorrhage phenotypes. Similarly, identifying the 
exact causes behind liver necrosis observed with Ƴ-lactams 3f and 3h would also be 
particularly useful. Performing bioanalysis or metabolomic studies may be one way this 
could be done, as information on the metabolites formed could help to identify the 
metabolic pathways leading to toxicity. 
 
Further characterisation of these compounds in terms of their physiochemical properties 
would also be useful in order to link the observed biological effects to their chemical 
structures. Particularly, the acid dissociation constant (pKa) would be useful in 
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understanding the kinetics of the compounds and whether they are more cell permeable in 
an ionised or unionised state at physiological pH. Furthermore, the stability of the 
compounds would need to be investigated as well as exposure concentration profiles. 
 
Another limitation of the studies performed in this chapter was that a limited amount of 
compound was available for testing. Also, the compounds that were tested were mixtures of 
isomers in the case of the Ƴ-lactams and so it is not known whether all the isomers or one 
isomer of each compound represent the active component/s responsible for the observed 
effects. Therefore, currently all of the isomers of each of the Ƴ-lactam compounds are being 
isolated and will be tested for biological activity in zebrafish embryos in the near future. It 
would be particularly interesting to find out the results for compound 3a as it could be that 
only a single isomer of this compound can induce brain hemorrhage formation. 
 
4.6 Conclusions 
Despite the small range of compounds tested, a variety of biological effects were observed 
with slight changes in chemical structure having a profound impact on activity. Additionally, 
the morphology analysis performed enabled clustering of compounds providing a first 
indication as to which compounds share a similar mode of action. The studies performed 
also gave an indication of what structural properties may be desired when synthesising 
compounds in the future. The compounds tested in this chapter which were designed based 
on Lipinski’s rule of five for drug-likeness evoked a large variety of biological effects and 
through further work particularly on compound 2a and 3a possible therapeutic benefits 
could be unveiled or disease models established. Additionally, the liver toxicity observed 
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with compound 3f and compound 3h showed that the zebrafish larva presents a good model 
for investigating hepatotoxicity, particularly drug-induced hepatitis for which no gold 
standard animal model exists at the moment. 
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Chapter Five: DEVELOPMENT OF A DRUG TOXICITY PREDICTION 
TOOL USING THE ZEBRAFISH EMBRYO 
 
FOREWORD 
The results presented in this chapter were obtained through collaboration with Professor 
Torbjörn Lundstedt, Associate Professor Katrin Lundstedt-Enkel and Professor Johan Trygg 
from AcurePharma AB, Uppsala University and AcureOmics AB, respectively who provided 
the data for the physiochemical descriptors. All biological work was carried out by me under 
the supervision of Professor Ferenc Müller. Training in multivariate analysis was provided by 
Associate Professor Katrin Lundstedt-Enkel. All subsequent multivariate analysis was 
performed by me. Associate Professor Katrin Lundstedt-Enkel, Professor Torbjörn Lundstedt 
and Professor Johan Trygg aided in the interpretation of multivariate models. Additional 
interpretation of results in terms of biological context was performed solely by me.   
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5.1 Introduction and Overview 
5.1.1 Zebrafish embryo as a model for toxicological studies 
The zebrafish embryo as mentioned in the previous chapters has numerous advantages over 
conventional mammalian animal models for drug testing and toxicology studies. The rapid 
development of zebrafish embryos and the large numbers that can be tested mean that 
many experiments can be performed in a short period of time (Langheinrich, 2003). 
Experiments that are performed with rodents on the other hand involve much smaller 
numbers and are also more time consuming with rodent development relatively slow in 
comparison (Langheinrich, 2003). However, rodents do have an advantage in that they are 
genetically more similar to humans than zebrafish embryos are. It is also possible to utilise 
the same dosage route intended for human use when performing tests in rodents, which can 
provide useful information on the ADME properties of a compound. 
 
For drug screening purposes the zebrafish embryo has several advantageous features 
including the ability to absorb chemicals dermally or orally 3 dpf onwards, the ability to 
survive in minimal quantities of liquid and tolerance to DMSO concentrations of up to 1.5%, 
which is useful when using drugs not particularly soluble in water (Goldsmith, 2004). For 
rodents the quantities of chemicals required for dosing are much larger and exposure times 
are also longer (Hill et al., 2005). As zebrafish embryos are small in size, they can be tested in 
96 well or even 384 well plates which are amenable to automation, thus automated high 
throughput assays can be performed by utilising zebrafish embryo sorting robots, liquid 
handling robots and automated imaging microscopes (d’ Alençon et al., 2010).  
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Additionally, as the zebrafish embryo is optically transparent throughout development it is 
possible to study the effects of drugs on various morphology features including the heart 
using a simple stereomicroscope (Burns et al., 2005). Thus, scoring these features for 
severity after drug exposure can be used as endpoints in addition to classical toxicology 
endpoints such as LC50 (concentration that kills 50% of the population), EC50 (concentration 
that produces an effect in 50% of the population), NOEC (no observed effect concentration) 
and LOEC (lowest observed effect concentration) values (Hermsen et al., 2011)(Panzica-Kelly 
et al., 2010).  
 
Currently, in vivo toxicology studies involve using rodents, which as mentioned previously is 
expensive, requires large amounts of compound and takes a relatively long time to perform. 
The zebrafish embryo could present a cheaper and quicker alternative. It has already been 
demonstrated that the zebrafish embryo shares many similarities with humans in terms of 
toxic responses and that it is possible to perform large scale toxicity screens (Padilla et al., 
2012)(Weigt et al., 2011)(Goldsmith, 2004)(Hill et al., 2005)(Ali et al., 2011). Hence, the 
zebrafish embryo offers the opportunity to test compounds first cheaply and inexpensively 
in an in vivo setting, whilst at the same time achieving a similar throughput to in vitro assays. 
 
5.1.2 Using biological data to create predictive models 
As mentioned in Chapter 1, in drug development large compound libraries need to be 
screened to identify potential candidate drugs. These candidate drugs then undergo further 
testing in in vitro and in vivo models. However, in order to save resources and time, 
predictive models can be utilised either in the initial drug candidate selection process or 
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after candidate drugs have been selected. For example, predictive models can be created to 
predict the ADME properties of compounds, as well as their biological activity, potency, 
accumulation and toxicity (Hansch et al., 1995)(Yoshida and Topliss, 2000)(Nendza, 1998). 
This enables those compounds with unfavourable properties to be removed before further 
testing is done.  
 
Predictive models are based on structure activity relationships (SARs), where the aim is to 
identify substituents in the chemical structure of a compound that could potentially cause 
toxicity or unfavourable ADME properties. These substituents are referred to as structural 
alerts and will be flagged up when a compound containing such a structural alert is 
introduced into the model. More recently, quantitative structure activity relationship (QSAR) 
models are being increasingly explored. QSAR models are used to relate the physiochemical 
properties of a compound to its biological activity (Lessigiarska et al., 2006) (Hansch et al., 
1995). QSAR models not only provide information on toxicity but can also give some 
indication on the mechanism of toxicity of a compound (Lessigiarska et al., 2006). QSAR 
models generated today heavily rely on using multivariate analysis techniques such as 
principal component analysis (PCA), partial least squares (PLS) and orthogonal partial least 
squares (OPLS) (see Chapter 1 for further details).  
 
5.1.3 Problems encountered with predictive models and how these can be overcome  
QSAR modelling is particularly useful for predicting toxicity and ADME of new drugs 
undergoing development. However, many QSAR models that are generated are based on 
experimental datasets obtained from different sources, where experiments are performed 
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under different conditions and with different drugs, therefore making them not directly 
comparable to one another (Sköld et al., 2006). This can therefore affect the quality of the 
models generated.  
 
To overcome such problems a study was performed by Sköld and colleagues (Sköld et al., 
2006). The aim of the study  was to start the experimental characterisation of a reference 
‘benchmark’ group of compounds that were drug-like, low-cost, commercially available, 
physiochemically diverse and amenable to analytical measurements (Sköld et al., 2006). In 
this study, firstly all the available information on 691 pharmaceuticals marketed in Sweden 
at the time was collated (Sköld et al., 2006). A filtering step was then introduced to remove 
those compounds which were not commercially available and had unusual administration 
routes leaving only 284 pharmaceuticals (Sköld et al., 2006). Multivariate analysis in the form 
of PCA was then performed on these 284 compounds using 28 chemical descriptors (Sköld et 
al., 2006). From this PCA model 24 drugs were selected which showed the greatest chemical 
and spatial diversity, i.e. drugs which were most distantly spaced from one another on the 
PCA scores plot. These 24 drugs designated reference drugs were then characterised and 
experimentally-derived values for lipophilicity, solubility and permeability were determined 
and combined with the existing physiochemical data (Table 5.1) (Sköld et al., 2006). By using 
this approach, a high quality benchmark dataset for a group of reference drugs that cover 
the whole chemical spectrum and which are readily available has been developed ready to 
be used by other groups for further characterisation.  
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Table 5.1 - Chemical descriptors with explanation of terms. 
Source: Adapted from (Sköld et al., 2006) 
Chemical descriptor Explanation 
MW molecular weight 
V  molecular volume 
S  molecular surface area 
O ovality 
ELUMO  energy of lowest unoccupied molecular orbital  
EHOMO energy of highest occupied molecular orbital 
H  hardness 
DM dipole moment 
NPSA  nonpolar surface area 
PSA polar surface area 
PSA/NPSA ratio of polar to non-polar surface area 
logP log P values taken from http://www.drugbank.ca/  
logPCr 
log P calculated according to the method developed by Ghose 
and Crippen 
logPMor 
log P calculated according to the method developed by 
Moriguchi et al. 
logPACD log P calculated with ACD/Labs 
logDACD_6.5 log D at pH 6.5 calculated with ACD/Labs 
logDACD_7.4  log D at pH 7.4 calculated with ACD/Labs 
QH  highest partial charge on a hydrogen atom 
HBD number of hydrogen-bond donors 
ΣQH (SQH) 
sum of the partial charge of all hydrogen atoms attached to an 
O, N, or S atom,  
CWPSAHBD  
sum of absolute charge-weighted surface area of all hydrogen 
atoms attached to an O, N, or S atom 
QMN absolute value of lowest partial charge of a non-hydrogen atom 
HBA number of hydrogen-bond acceptors 
ΣQMN (SQMN) 
sum of absolute partial charge of all negatively charged O, N, S, 
and F atoms 
CWPSAHBA 
sum of absolute charge-weighted surface area of all negatively 
charged N, O, S, F, Cl, Br, and I atoms 
HB 
sum of HBD and HBA, PSA = molecular surface area of all N, O, S, 
and attached H atoms 
PSANO  molecular surface area of all N, O, and attached H atoms  
PSArel PSA/S × 100, PSA/NPSA 
PSAcw  
sum of (absolute) charge-weighted surface area of all N, O, 
halogen, and attached H atoms 
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5.2 Aims 
The aim of this study was to use the reference drug set derived by Sköld and colleagues to 
determine the association between the physiochemical properties of these drugs and their 
biological effects in zebrafish embryos. In this study toxicity was used as a measure of 
biological effects. Therefore, various indicators of toxicity were determined such as LC50, 
EC50, LOEC and NOEC values, which could then be used as biological outputs. Additional 
biological outputs measured included morphological effects that developed during zebrafish 
embryo development, which were assigned severity scores.  
 
The ideal situation would be that predictions for the biological effects of new compounds 
could be made based solely on chemical descriptors. However, in practice this would be 
difficult to do and may only be possible for specific groups of compounds. Therefore, using 
the biological outputs determined for the reference drug set the aim in this chapter was to 
create a QSAR model that could be used as a predictive tool in order to identify similarities 
between compounds and relate them to their physiochemical properties. This could support 
read-across in mammalian toxicology for compounds that share significant similarities in the 
zebrafish model. Hence, the overall objective was to create a QSAR model which had the 
potential to be implemented in pre-clinical testing regimes to predict the toxicity of 
compounds undergoing development. 
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5.3 Methods 
In this chapter the reference drug set derived by Sköld and colleagues was biologically 
characterised in zebrafish embryos (Sköld et al., 2006). However, two of the 24 reference 
drugs namely carisoprodol and tinidazole were not tested due to problems in shipping and 
poor availability. Hence, six additional drugs were selected from the initial PCA model that 
had been developed by Sköld and colleagues to maintain the spatial and chemical diversity 
of the drug set tested (Sköld et al., 2006). In total 28 reference drugs with varied therapeutic 
indications (Table 5.2) and diverse chemical structures (Figure 5.1) were tested in this 
chapter and also in Chapter 6. 
  
Table 5.2 - 28 reference drug set. 
Reference drugs derived from the study performed by Sköld and colleagues. They are 
representative of marketed drugs in terms of their chemical structures and functions. 
Terfenadine is no longer marketed due to QT prolonging effects (Woosley RL et al., 1993). 
Compound Function Compound Function 
flupenthixol 
dihydrochloride anti-psychotic 
metoclopramide 
hydrochloride anti-emetic 
fenofibrate anti- cholesterol tetracycline antibiotic 
sulindac anti-inflammatory thiamazole anti-thyroid 
glipizide anti-diabetic erythromycin antibiotic 
hydrochlorothiazide anti-hypertensive carbamazepine anti-epileptic 
amantadine 
hydrochloride anti-Parkinson's folic acid required  in diet 
amiloride hydrochloride anti-hypertensive levodopa anti-Parkinson's 
bendroflumethiazide anti-hypertensive terfenadine anti-histamine 
d-penicillamine anti-rheumatic metformin anti-diabetic 
chlorprothixene 
hydrochloride anti-psychotic enalapril anti-hypertensive 
chlorzoxazone muscle relaxant liothyronine anti-thyroid 
levothyroxine anti-thyroid tioguanine anti-cancer 
meclizine 
dihydrochloride anti-emetic malathion OP insecticide 
prednisone immunosuppressant captopril anti-hypertensive 
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Figure 5.1 – Chemical structures of the 28 reference drugs. A) 6-thioguanine, B) Amantadine, C) Amiloride, D) Bendroflumethiazide, E) 
Captopril, F) Carbamazepine, G) Chlorprothixene, H) Chlorzoxazone, I) Enalapril,  J) Erythromycin, K) Fenofibrate, L) Flupenthixol, M) 
Folate, N) Glipizide, O) Hydrochlorothiazide, P) Levodopa, Q) Levothyroxine, R) Malathion, S) Meclizine, T) Mercaptovaline, U) Metformin, 
V) Metoclopramide, W) Prednisone, X) Sulindac, Y) Terfenadine, Z) Tetracycline, AA) Thiamazole, AB) Liothyronine. 
Source: www.chemspider.com  
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5.3.1 Toxicity and morphology assessment of 28 reference drugs in zebrafish embryos 
The biological characterisation of the 28 reference drugs was done by determining the 
toxicity of these drugs in the zebrafish embryo. Beneficial or therapeutic effects of these 
drugs were not investigated in this chapter, but were investigated in Chapter 6.  
 
Toxicity was investigated using two studies. In the first study (dose-range finding) zebrafish 
embryos were treated with six different concentrations (0.1, 1, 10, 100, 1000 and 10000 µM) 
of each drug along with two controls (0.1% DMSO and E3 embryo medium). Treatments 
were performed in 96 well plates with one zebrafish embryo placed in each well containing 
150 µL of liquid. Treatments were initiated at the 75% epiboly stage and in total for each 
concentration 36 zebrafish embryos were tested (12 zebrafish embryos per repeat). 
Zebrafish embryos were observed using a Leica MZF10 fluorescence stereo microscope 
(Leica, Germany). Mortality was recorded every 24 hours over the 120 hour exposure period. 
Mortality was defined as coagulation of the zebrafish embryo, lack of somite development, 
non-detachment of the tail and after 48 hpf lack of a heartbeat based on the OECD 
guidelines outlined for the FET test (OECD, 2013). The mortality data was then used to plot 
logarithmic concentration-mortality curves from which toxicity endpoints such as LC50, LOEC 
and NOEC values were calculated using GraphPad Prism 5.0 (GraphPad Software 
Incorporation, USA).  
 
In the second part of the study, visible morphological effects induced in zebrafish embryos 
by the 28 reference drugs were recorded and scored for severity. Morphological features 
were scored for every 24 hours over the 120 hour exposure period. The features scored 
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included reduced circulation (Circ), reduced movement (Movement), hatching (Hatch), 
reduced heart rate (Hrate), developmental delay (DelDev), deformation (Deformed), 
notochord (Notoch), tail curvature (TailCurv), protruding mouth (Pmouth), pectoral fin (Pfin), 
somites (Somites), jaw malformation (JawMal), yolk edema (Yedem), yolk size (Ysize), heart 
edema (Hedem), liver necrosis (LiverNec), brain hemorrhage (BrainHem), brain edema 
(Bedem) and overall health (Health). For the scoring of morphological features a scoring 
system was used to assign severity where 0 = normal, 1 = within normal range, 2 = mild, 3 = 
moderate, 4 = severe and 5 = very severe. EC50 was used as an additional toxicity indicator 
and was calculated for each drug from log concentration-response curves using GraphPad 
Prism 5.0 (GraphPad Software Incorporation, USA).  
 
By dividing the LC50 by the EC50 teratogenic index values were calculated in order to 
determine the potency of the compounds with a ratio >2 indicating specific effects and 
therefore teratogenicity. Additionally, excess toxicity in the form of toxic ratio (TR) was also 
determined for each of the compounds using the experimentally derived LC50 values and 
predicted LC50 values. Predicted LC50 values were obtained using the following equation: 
log(1/LC50) = 0.871logP – 4.87 (n=50, r=0.998, s=0.237) (Könemann, 1981) 
 
The toxic ratio was calculated from these predicted and experimentally derived LC50 values 
using the following equation: 
logTR = log(1/LC50 experimental) – log(1/LC50 predicted) (Zhang et al., 2013) 
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The threshold for the logTR was set at 1. Compounds with a logTR value <1 were considered 
to show baseline toxicity, whereas compounds with a logTR value >1 were considered to 
show excess toxicity due to a specific mechanism of action. 
 
To determine whether the chorion acted as a barrier preventing certain drugs from 
producing an effect in zebrafish embryos, a test was performed using a selection of 10 drugs 
(metformin, riboflavin, erythromycin, glipizide, 6-thioguanine, d-penicillamine, folate, 
prednisone, levodopa and hydrochlorothiazide) that did not show a response in either the 
dose-range finding study or the morphological effect study. These drugs were evaluated for 
toxicity and morphological effects in 75% epiboly stage zebrafish embryos that had been 
dechorionated. The drug concentrations used were the same as those used in the study for 
zebrafish embryos in their chorions. As before, morphological defects and mortality were 
recorded daily over a five day exposure period. Results were then averaged and compared. 
 
5.4 Results 
5.4.1 Zebrafish embryo mortality induced by 28 reference drugs 
In the first study, the aim was to determine the toxicity of the 28 reference drugs in 
zebrafish embryos. This was done by recording zebrafish embryo mortality after exposure to 
each reference drug every 24 hours over a 120 hour exposure period. A logarithmic 
concentration series was used (0.1, 1, 10, 100, 1000 and 10000 µM) to ensure that all drugs 
were tested at concentrations at which they would induce an effect, as well as to uncover 
any relationships between concentration and mortality. An E3 embryo medium control and a 
solvent control (0.1% DMSO) were also included in the experiments.  
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To find out whether there was any difference between the E3 embryo medium and 0.1% 
DMSO controls orthogonal partial lest squares discriminant analysis (OPLS-DA) modelling 
was performed (data not shown). Using this modelling no significant difference was found 
between the two groups (R2Y=0.007, Q2=0.006). Therefore, for subsequent analysis the E3 
embryo medium and 0.1% DMSO controls were considered as one control group.  
 
To determine which drugs were highly toxic and teratogenic a PCA model of the zebrafish 
embryo mean cumulative percentage mortality for each drug over the 120 hour exposure 
period at each tested concentration was created (Figure 5.2). In the PCA model the tested 
concentrations were denoted by C1-C6 (0.1, 1, 10, 100, 1000 and 10000 µM) and the 
exposure times by T1-T5 (24, 48, 72, 96 and 120 hours).  
 
The PCA model generated was found to be of good quality (R2X=0.899, Q2=0.533, two 
significant components) and from the scores plot (Figure 5.2A) it could be seen that 
bendroflumethiazide, terfenadine and chlorprothixene (coloured red) were outside of the 
model, i.e. not located within the white circle. These three compounds could not be 
explained by the model due to their values being erroneous or very different. Upon further 
inspection and by looking at the loading plot (Figure 5.2B) it was found that these three 
drugs were extremely toxic and teratogenic causing high mortality at almost all tested 
concentrations, which was not the case with any of the other drugs tested. In contrast, 
erythromycin, d-penicillamine and folate (coloured green) showed little toxicity similar to 
the controls (coloured blue) over the whole exposure period. Additionally, a cluster of drugs 
including carbamazepine, malathion and amantadine located in the bottom left quadrant of 
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the scores plot were found to cause high mortality only at the highest tested concentration. 
From this initial PCA model already differences could be seen between the drugs based on 
their propensity to cause mortality with drugs associated close to the controls showing little 
or no mortality and drugs located towards the right hand side of the scores plot 
demonstrating high mortality.  
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Figure 5.2 – A two-component PCA model of zebrafish embryo mortality (observations) 
against concentrations and exposure times (variables) following treatment with 28 
reference drugs over a 120 hour exposure period. A) Scores plot showing biological 
responses, B) Loading plot showing variables. The loading vector (p) and the scores vector (t) 
are displayed as vectors p and t. The numbers beside p and t indicate the PCA component (1 
or 2). On the scores plot, the observations for the 28 reference drugs are denoted by coloured 
circles (green = drugs contained within the model, blue = controls [E3 and 0.1% DMSO] and 
red = outliers [show high toxicity]). On the loading plot the different concentration/exposure 
time combinations are denoted by coloured circles. Key: C1-6 = concentrations tested (0.1, 1, 
10, 100, 1000 and 10000 µM), T1-5 = exposure period (24, 48, 72, 96 and 120 hours). 
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From the data LC50, NOEC and LOEC values were calculated (Table 5.3). Chlorprothixene 
was found to have the lowest LC50 and one of the highest logP values. For nine reference 
drugs (6-thioguanine, d-penicillamine, erythromycin, folate, glipizide, hydrochlorothiazide, 
levodopa, metformin and prednisone) LC50 values could not be calculated. 
 
Table 5.3 – Toxicological endpoints (LC50, NOEC and LOEC) calculated for each of the 28 
reference drugs during phase 1 after 120 hours of exposure. The physiochemical descriptors 
logP and pKa are also shown for each of the compounds. 
Compound LC50 (µM) NOEC (µM) LOEC (µM) LogP pKa 
6-thioguanine N/A 10000 N/A -0.1 10.5 
Amantadine 290 100 1000 2.5 10.7 
Amiloride 7430 1000 10000 -0.3 8.7 
Bendroflumethiazide 18 10 100 1.9 8.5 
Captopril 2113 1000 10000 0.3 4.0 
Carbamazepine 304 100 1000 2.5 16.0 
Chlorprothixene 4 1 10 5.2 9.8 
Chlorzoxazone 186 100 1000 1.6 9.4 
D-penicillamine N/A 10000 N/A -1.8 -1.8 
Enalapril 7142 1000 10000 0.1 3.0 
Erythromycin N/A 10000 N/A 3.1 8.9 
Fenofibrate 7027 1000 10000 5.3 -4.9 
Flupenthixol 32 10 100 4.5 15.6 
Folate N/A 10000 N/A -2.5 3.4 
Glipizide N/A 10000 N/A 1.9 5.9 
Hydrochlorothiazide N/A 10000 N/A -0.1 7.9 
Levodopa N/A 10000 N/A -2.4 2.3 
Liothyronine 43 1 10 2.9 0.3 
L-thyroxine 7 1 10 4.0 0.3 
Malathion 129 100 1000 2.4 -6.8 
Meclizine 228 100 1000 5.8 8.1 
Metformin N/A 10000 N/A -0.5 12.4 
Metoclopramide 184 100 1000 2.6 9.3 
Prednisone N/A 10000 N/A 1.5 12.6 
Sulindac 185 100 1000 3.4 4.7 
Terfenadine 9 1 10 7.1 13.2 
Tetracycline 5605 1000 10000 -1.3 3.3 
Thiamazole 4515 1000 10000 -0.3 10.4 
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5.4.2 Morphological effects of 28 reference drugs on zebrafish embryos during 
development 
The next aim was to investigate the toxicity and teratogenicity induced by the 28 reference 
drugs further by recording and scoring morphological phenotypes that developed during 
zebrafish embryo development. To address this aim a study was performed with a geometric 
concentration series consisting of six concentrations along with two controls (E3 embryo 
medium and solvent control). A narrower geometric concentration series was used so that 
the development of phenotypes could be investigated. The concentrations tested in this 
study were based on those where an effect was observed in the first study (Table 5.4). 
 
For the second study mortality along with the number of zebrafish embryos presenting with 
morphological effects was recorded every 24 hours over the whole 120 hour exposure 
period. Log-concentration response curves were then plotted and from this EC50 values for 
each of the 28 reference drugs over the 120 hour exposure period were calculated, as well 
as NOEC and LOEC values named NOEC2 and LOEC2, so as not to confuse them with NOEC 
and LOEC values calculated in the first study (Table 5.5). Morphological features were also 
scored for severity daily over the 120 hour exposure period (see section 5.3.1 for further 
details). In addition to this the teratogenic index (LC50/EC50) was calculated for each of the 
drugs (Table 5.5). It was found that a large number of drugs (amantadine, captopril, 
carbamazepine, chlorprothixene, chlorzoxazone, enalapril, liothyronine, l-thyroxine, 
meclizine, sulindac, terfenadine, tetracycline and thiamazole) were teratogenic with 
teratogenic index values >2. However, for a small number of drugs a teratogenic index value 
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could not be calculated, as for these drugs LC50 values could not be determined due to low 
or no toxicity. 
 
Table 5.4 – Concentration ranges of 28 reference drugs used in study 2. 
Compound Concentration (µM) 
6-thioguanine 1000-32000 
Amantadine 400-12800 
Amiloride 400-12800 
Bendroflumethiazide 5-160 
Captopril 400-12800 
Carbamazepine 400-12800 
Chlorprothixene 0.5-16 
Chlorzoxazone 40-1280 
D-penicillamine 1000-32000 
Enalapril 31.25-1000 
Erythromycin 31.25-1000 
Fenofibrate 1000-32000 
Flupenthixol 4-128 
Folate 500-16000 
Glipizide 6.25-200 
Hydrochlorothiazide 31.25-1000 
Levodopa 15.625-500 
Liothyronine 400-12800 
L-thyroxine 0.5-16 
Malathion 50-1600 
Meclizine 35-1120 
Metformin 1000-32000 
Metoclopramide 400-12800 
Prednisone 25-800 
Sulindac 300-9600 
Terfenadine 1.25-40 
Tetracycline 400-12800 
Thiamazole 400-12800 
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Table 5.5 – Toxicological endpoints (EC50, NOEC2 and LOEC2) and teratogenic index values 
calculated for each of the 28 reference drugs from study 2. Teratogenic index values >2 
indicate specific effects. 
 
Compound EC50 (µM)  NOEC2 (µM) LOEC2 (µM) 
Teratogenic index 
(LC50/EC50) 
6-thioguanine 19952.62 2000.00 4000.00 N/A 
Amantadine 48.19 N/A N/A 6.02 
Amiloride 3784.43 3200.00 6400.00 1.96 
Bendroflumethiazide 29.24 10.00 20.00 0.62 
Captopril 807.24 400.00 800.00 2.62 
Carbamazepine 88.72 40.00 80.00 3.43 
Chlorprothixene 0.68 0.50 1.00 5.88 
Chlorzoxazone 83.75 80.00 160.00 2.22 
D-penicillamine 16368.17 16000.00 32000.00 N/A 
Enalapril 644.17 625.00 1250.00 11.09 
Erythromycin 2588.21 2500.00 5000.00 N/A 
Fenofibrate 3564.51 2000.00 4000.00 1.97 
Flupenthixol 17.82 16.00 32.00 1.80 
Folate 18492.69 16000.00 32000.00 N/A 
Glipizide 105.44 100.00 200.00 N/A 
Hydrochlorothiazide 5420.01 5000.00 10000.00 N/A 
Levodopa 997.70 500.00 1000.00 N/A 
Liothyronine 1.21 N/A N/A 35.54 
L-thyroxine 0.11 N/A N/A 63.64 
Malathion 81.10 80.00 160.00 1.59 
Meclizine 35.08 35.00 70.00 6.50 
Metformin 9120.11 1000.00 2000.00 N/A 
Metoclopramide 855.07 800.00 1600.00 0.22 
Prednisone 414.95 400.00 800.00 N/A 
Sulindac 54.58 0.00 0.00 3.39 
Terfenadine 1.25 1.25 2.50 7.20 
Tetracycline 80.35 80.00 160.00 69.76 
Thiamazole 400.87 400.00 800.00 11.26 
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To confirm that effects observed with a sub-set of 28 reference drugs were specific and not a 
result of baseline toxicity the logP values of the 28 reference drugs were plotted against 
their respective log(1/EC50) values (Figure 5.3). From this graph a weak correlation was 
observed between high logP values and high log(1/EC50) values. 
 
Figure 5.3 – LogP values plotted against log(1/EC50) values for the 28 reference drugs. Line 
of best fit and correlation coefficient (r2) are also shown on graph. 
 
Another approach was then taken to determine whether the biological responses observed 
with the 28 reference drugs were a result of specific activity or baseline toxicity. Toxic ratio 
(TR) values were calculated for each of the 28 reference drugs using predicted and 
experimental LC50 values (see Table 5.6). It could be seen that for a sub-set of the 28 
reference drugs (amiloride, bendroflumethiazide, captopril, chlorzoxazone, tetracycline and 
thiamazole) the logTR values were >1 suggesting that the toxicity observed was due to a 
specific mechanism of action rather than baseline toxicity. However, with the remaining 
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drugs the logTR values were found to be <1 suggesting that the toxicity observed was due to 
baseline toxicity and therefore caused by narcosis (membrane interaction).  
 
Table 5.6 – Toxic ratio (TR) values for toxicity observed with 28 reference drugs. LogTR>1 = 
specific toxicity, logTR<1 = baseline toxicity. 
Drug LogP 
log(1/LC50p) 
(mmol/L) 
log(1/LC50e) 
(mmol/L) 
logTR (toxic 
ratio) 
6-thioguanine -0.1 -4.96 N/A N/A 
Amantadine 2.5 -2.70 -2.46 0.23 
Amiloride -0.3 -5.13 -3.87 1.26 
Bendroflumethiazide 1.9 -3.22 -1.26 1.96 
Captopril 0.3 -4.61 -3.32 1.28 
Carbamazepine 2.5 -2.70 -2.48 0.21 
Chlorprothixene 5.2 -0.35 -0.60 -0.26 
Chlorzoxazone 1.6 -3.48 -2.27 1.21 
D-penicillamine -1.8 -6.44 N/A N/A 
Enalapril 0.1 -4.78 -3.85 0.93 
Erythromycin 3.1 -2.17 N/A N/A 
Fenofibrate 5.3 -0.26 -3.85 -3.59 
Flupenthixol 4.5 -0.96 -1.51 -0.55 
Folate -2.5 -7.05 N/A N/A 
Glipizide 1.9 -3.22 N/A N/A 
Hydrochlorothiazide -0.1 -4.96 N/A N/A 
Levodopa -2.4 -6.96 N/A N/A 
Liothyronine 2.9 -2.35 -1.63 0.71 
L-thyroxine 4 -1.39 -0.85 0.54 
Malathion 2.4 -2.78 -2.11 0.67 
Meclizine 5.8 0.18 -2.36 -2.53 
Metformin -0.5 -5.31 N/A N/A 
Metoclopramide 2.6 -2.61 -2.26 0.34 
Prednisone 1.5 -3.57 N/A N/A 
Sulindac 3.4 -1.91 -2.27 -0.36 
Terfenadine 7.1 1.31 -0.95 -2.26 
Tetracycline -1.3 -6.00 -3.75 2.25 
Thiamazole -0.3 -5.13 -3.65 1.48 
 
A variety of phenotypes were found to develop in zebrafish embryos after exposure to the 
28 reference drugs. Some of these phenotypes were found to be common between many 
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drugs such as cardiac effects, including pericardial edema, reduced heart rate and reduced 
circulation. These common phenotypes were found to occur close to lethality and therefore 
represent secondary unspecific events. Other phenotypes were found to be more specific, 
e.g. brain edema/hydrocephalus observed with thiamazole. The specific phenotypes 
observed were found to be generalised between particular classes of drugs with reduced 
pigmentation for example observed with those drugs affecting the thyroid gland (l-thyroxine, 
liothyronine and thiamazole) (Table 5.7). This would make sense based on the function of 
these compounds, as compounds with similar pharmacological actions and shared biological 
pathways would be expected to produce similar toxic effects.  
 
Table 5.7 – Specific phenotypes associated with drug classes from the 28 reference drug 
set. 
Compound class Phenotype 
Anti-histamines (meclizine,  
terfenadine) 
Cardiac toxicity (reduced HR, pericardial edema, 
AV block) 
Anti-thyroid (l-thyroxine, liothyronine, 
thiamazole) 
Reduced pigmentation, brain 
edema/hydrocephalus (thiamazole at highest 
tested concentration only) 
Antibiotics (erythromycin, tetracycline) Little/no toxicity 
Anti-lipemics (fenofibrate) Little/no toxicity 
Anti-convulsants (carbamazepine) Craniofacial abnormalities (jaw malformations) 
Anti-diabetics (glipizide, metformin) Little/no toxicity 
Muscle relaxants (chlorzoxazone) Reduced movement and developmental arrest 
Diuretics (captopril, enalapril) Enlarged yolk 
Dietary supplement (folate) Little/no toxicity 
Anti-psychotics (flupenthixol, 
chlorprothixene) Craniofacial abnormalities (jaw malformations) 
Insecticides (malathion) Reduced pigmentation 
Anti-rheumatics (D-penicillamine) Little/no toxicity 
Anti-neoplastic (6-thioguanine) Little/no toxicity 
Anti-Parkinson’s (amantadine) Craniofacial abnormalities (jaw malformations) 
Anti-hypertensives 
(bendroflumethiazide) Developmental arrest 
Anti-inflammatory (sulindac) Black yolk 
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In order to distinguish those drugs producing severe morphological effects and toxicity from 
those drugs producing no or little effects a PCA model was generated. The model was 
created using the severity scores for the morphological features at only one time point and 
concentration, namely after 120 hours of exposure and at the highest tested concentration 
(C6T5) along with mortality (Dead) and the toxicity endpoints (LC50, EC50, LOEC1, NOEC1, 
LOEC2, NOEC2) that had been previously calculated. This model was found to be of good 
quality (R2X=0.716, Q2=0.48, three significant components) showing a clear separation 
between the highly toxic drugs and those causing little toxicity (Figure 5.4). On the scores 
plot (Figure 5.4A) drugs showing no or little toxicity were found to be clustered on the left 
hand side (circled), whereas toxic drugs were found to be clustered on the right hand side 
(circled). Additionally, from the scores plot it was evident that folic acid (circled and coloured 
in red) was outside of the model, i.e. outside of the white circle. This was because it caused 
the least mortality and the least morphological effects compared to the other drugs tested. 
 
When looking at the loading plot (Figure 5.4B) it could be seen that the drugs situated in the 
top left quadrant of the scores plot were those that had high LC50, LOEC1 and NOEC1 values 
and were most similar in these variables. In contrast, the drugs situated in the top right 
quadrant of the scores plot were those drugs that produced various morphological effects, 
such as jaw malformations, tail curvature, abnormal somite development, etc. These drugs 
were found to be the same selection of drugs that caused high mortality in the first study 
(e.g. chlorprothixene). Additionally, features indicative of mortality, i.e. no movement 
(Movement), no heart rate (Hrate) and no circulation (Circ) were found to cluster close 
together on the loading plot. 
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Figure 5.4 – A three-component PCA model of zebrafish embryo responses (observations) 
against variables (toxicity endpoints and morphological features) following treatment with 
28 reference drugs over a 120 hour exposure period. A) Scores plot showing biological 
responses, B) Loading plot showing variables. The loading vector (p) and the scores vector (t) 
are displayed as vectors p and t. The numbers beside p and t indicate the PCA component (1 
or 2). On the scores plot, the observations for the 28 reference drugs are denoted by coloured 
circles (green = drugs contained within the model and red = outliers). On the loading plot the 
variables (toxicity endpoints and morphology features) are denoted by green circles. Toxicity 
endpoints = LC50, EC50, NOEC1, LOEC1, NOEC2 and LOEC2. Morphological features = 
reduced circulation (Circ), reduced movement (Movement), hatching (Hatch), reduced heart 
rate (Hrate), developmental delay (DelDev), deformation (Deformed), notochord (Notoch), 
tail curvature (TailCurv), protruding mouth (Pmouth), pectoral fin (Pfin), somites (Somites), 
jaw malformation (JawMal), yolk edema (Yedem), yolk size (Ysize), heart edema (Hedem), 
liver necrosis (LiverNec), brain hemorrhage (BrainHem), brain edema (Bedem), mortality 
(Dead) and overall health (Health). 
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5.4.3 Development of a QSAR model based on zebrafish embryo toxicity endpoints and 
morphological features 
To determine whether there was any relationship between the physiochemical properties of 
the 28 reference drugs and the induction of biological effects in zebrafish embryos a QSAR 
model was generated. To generate the model the principal components from the initial PCA 
model of the 28 reference drugs (refer back to Figure 5.4) were used as the Y variables on a 
hierarchical OPLS regression. In a standard PLS the Y vector can be anywhere relative to X. In 
OPLS modelling however the Y vector is placed in alignment with the first component in the 
X matrix enabling separation of the correlated and uncorrelated variables. A hierarchical 
OPLS regression enables a clear distinction to be made between the non-correlating 
variables on the Y axis and the correlating variables on the X axis.  
 
The hierarchical OPLS model generated was found to be of very good quality (R2X=0.729, 
Q2=0.975, three significant components). From the scores plot (Figure 5.5A) a clear 
distinction could be made between the drugs showing little or no toxicity located in the top 
right quadrant (circled) to those which increased in toxicity starting from the bottom right 
quadrant working up towards the top left quadrant (circled). Additionally, on the scores plot 
folic acid (circled red) was found to be outside of the model. This was because it caused no 
mortality and produced little or no morphological effects even at the highest tested 
concentration.  
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From the loading plot (Figure 5.5B) it was evident that many physiochemical descriptors 
were clustered close together with the morphological features. One of these physiochemical 
descriptors included logP (determinant of lipophilicty and drug cell permeability). High logP 
values were found to be associated with increased toxicity (i.e. decreased LC50, EC50, NOEC 
and LOEC values) and increased severity scores for the morphological features heart rate, 
movement and circulation (all indicators of death). The same relationship was also seen with 
logDACD_6.5 and logDACD_7.4 values, which describe the lipophilicty for both the ionised and 
unionised form of a drug. A low polar surface area (PSA) was also found to be an important 
determinant for toxicity. A high EHOMO also contributed to increased toxicity and was found 
to have a very big influence on the model. Additionally, low ELUMO and low hardness (H) 
values were also found to be associated with increased toxicity. 
 
Overall from the model it could be seen that several chemical features of the drugs were 
associated with the development of morphology phenotypes and also mortality. Particularly, 
logP which is an indicator of hydrophobicity and EHOMO which is an indicator of the 
electron releasing ability of a drug were found to be important toxicity determinants.   
 
However, the QSAR model generated also needs to be interpreted with caution, as it may be 
biased due to scores for the phenotypes at one concentration only being used to generate 
the model. 
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Figure 5.5 – Three-component hierarchical OPLS model of physiochemical descriptors and 
biological endpoints (variables) against biological responses (observations). A) Scores plot, 
B) Loading plot. On the scores plot the scores vector is displayed as t with the number next to 
it indicating the OPLS component (1 or 2). The scores of PCA components 1 and 2 are labelled 
on the X and Y axis, respectively. The scores for each drug are labelled and enclosed within 
green circles with a clear separation seen between those that are toxic and non-toxic. On the 
loading plot the X and Y loadings are represented by p and q, respectively. The biological 
variables and chemical descriptors (X) are enclosed in green circles. The PCA components (Y) 
are enclosed in blue circles. The loadings of PCA components 1 and 2 are labelled on the X 
and Y axis, respectively. 
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From the variable importance plot (VIP) plot shown in Figure 5.6 which shows the most 
important variables contributing to mortality it can also be seen that logP is the most 
important physiochemical descriptor for mortality, closely followed by a high EHOMO value.    
 
Figure 5.6 – VIP plot showing the most important physiochemical properties contributing 
to zebrafish embryo mortality after exposure to the 28 reference drugs. The VIP scores 
which are a measure of the importance of each variable in modelling X and Y are displayed 
on the Y axis with the name of each individual variable displayed along the x axis. The error 
bars indicate standard deviation. 
 
The next objective of the study was to validate the QSAR model generated by making 
predictions for the biological outputs of similar structured compounds. In order to validate 
the QSAR model, biological data for a validation drug set (diclofenac, doxorubicin, ibuprofen, 
glutamate, hydroxyurea and riboflavin) was acquired in the same way as for the 28 reference 
drug set. These six validation drugs were selected due to their functional and physiochemical 
diversity (Figure 5.7).  
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Figure 5.7 – Chemical structures of six validation drugs. A) Diclofenac, B) Doxorubicin, C) 
Ibuprofen, D) L-glutamate, E) Hydroxyurea, F) Riboflavin. 
Source: www.chemspider.com  
 
For the six validation drugs firstly a dose-range finding study was performed with log-
concentration mortality curves plotted for each drug based on the mortalities observed over 
a 120 hour exposure period. From the log-concentration mortality curves LC50, NOEC1 and 
LOEC1 values were calculated (Table 5.8). In the second study, zebrafish embryos were 
treated with the six validation drugs over a 120 hour exposure period and mortality was 
recorded daily (Table 5.8). The concentration ranges used for the drugs in the second study 
are shown in Table 5.8. Morphological features were also scored for severity (see section 
5.3.1 for further details). From this EC50 values were also calculated (Table 5.8). In addition 
to this the teratogenic index was calculated for the six validation drugs (Table 5.9). It was 
found that ibuprofen, diclofenac and doxorubicin were particularly teratogenic to zebrafish 
embryos presenting with teratogenic index values >2. Furthermore, the calculated logTR 
(toxic ratio) values showed that ibuprofen and glutamate most probably operated via a 
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specific mechanism of action and not via narcosis (membrane interaction) which is the case 
for the other four drugs (Table 5.9).  
 
Table 5.8 – Calculated toxicological endpoints for validation drug set and concentration 
ranges used for phase 2 study.  
All values listed are in µM. 
Compound EC50  LC50 NOEC1 LOEC1 NOEC2 LOEC2 Phase 2  
Diclofenac 1.21 5.53 1.00 10.00 N/A N/A 2.5-80 
Doxorubicin 93.97 173.56 100.00 1000.00 50.00 100.00 25-800 
Glutamate 272.27 259.53 100.00 1000.00 125.00 250.00 62.5-2000 
Hydroxyurea 12705.70 N/A 10000.00 N/A 6250.00 12500.00 
3125-
100000 
Ibuprofen 9.98 27.85 10.00 100.00 5.00 10.00 5-160 
Riboflavin 798.00 N/A N/A N/A N/A N/A 50-1600 
 
Table 5.9 – Teratogenic index values, logTR (toxic ratio) values and physiochemical 
descriptors (logP and pKa) for validation drug set. Teratogenic index values >2 indicate 
specific effects. LogTR>1 = specific toxicity, logTR<1 = baseline toxicity. 
Compound LogP pKa 
Teratogenic 
index 
(LC50/EC50) 
log(1/LC50p) 
(mmol/L) 
log(1/LC50e) 
(mmol/L) 
logTR 
(toxic 
ratio) 
Diclofenac 4.51 4.15 4.57 -0.95 -0.74 0.20 
Doxorubicin 3.97 4.91 1.85 -1.42 -2.24 -0.82 
Glutamate -1.80 10.14 0.95 -6.44 -2.41 4.02 
Hydroxyurea -1.46 10.20 N/A -6.14 N/A N/A 
Ibuprofen 1.27 9.53 2.79 -3.77 -1.44 2.32 
Riboflavin -3.69 2.23 N/A -8.08 N/A N/A 
 
To assess the predictivity of the QSAR model the mean severity scores of a selection of 
morphological features for diclofenac at the highest tested concentration and the longest 
exposure time (C6T5) were predicted and compared to the observed values (Figure 5.8A). It 
was found that the predictions made were almost identical to the observed values. When 
using the model to predict the mean cumulative mortality for the six validation drugs at the 
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highest tested concentration and the longest exposure time (C6T5) (Figure 5.8B) the 
mortalities predicted for diclofenac, doxorubicin, glutamic acid and riboflavin were close to 
the observed values with the exception of hydroxyurea where mortality was under-
predicted by 33%.  
 
In general the QSAR model generated shows good predictivity, despite a small number of 
drugs having been used to generate it. Further drugs would need to be introduced into the 
model to further optimise it. Based on the current results the model seems to be good for 
predicting the biological responses for highly toxic compounds; however a larger drug set 
would need to be validated in order to test the limits of the model sufficiently.  Additionally, 
the high predictive capacity could be biased by many of the compounds acting as narcotics in 
zebrafish embryos. 
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Figure 5.8 – Predictivity of the hierarchical OPLS regression model. A) Observed and 
predicted zebrafish embryo mean severity scores for a selection of morphology features 
following diclofenac treatment at one time point and concentration (C6T5), B) Observed and 
predicted values for the zebrafish embryo mean cumulative mortality following treatment 
with the six validation drugs at one time point and concentration (C6T5). 
 
5.4.4 Effect of dechorionation on the morphological responses of the 28 reference drugs 
In some studies it has been reported that the chorion of the zebrafish embryo could act as a 
barrier to drug penetration (Henn and Braunbeck, 2011)(Mandrell et al., 2012)(Ali et al., 
2011)(King Heiden et al., 2007)(Truong et al., 2011). Therefore, a study was performed to 
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determine whether penetration of drugs into the zebrafish embryo chorion affected their 
ability to produce a morphological response. Particularly, for the drugs that were found to 
be non-responsive in the initial studies this was an issue that needed to be addressed. A 
selection of 10 drugs taken from the 28 reference and validation drug set (metformin, 6-
thioguanine, d-penicillamine, folate, prednisone, levodopa, hydrochlorothiazide, glipizide, 
riboflavin and erythromycin) were re-examined for mortality and the generation of 
morphological responses by using dechorionated zebrafish embryos. The zebrafish embryos 
were dechorionated immediately after fertilisation (see Chapter 2 for further details) and 
then treated at the 75% epiboly stage using the drug concentrations outlined in Table 5.4 
and Table 5.8. Morphological responses and mortality were recorded daily over the 120 
hour exposure period. 
  
OPLS-DA modelling was performed to determine whether removal of the chorion had an 
effect on the toxicity of these drugs. By assigning a class to each treatment method, i.e. still 
in chorion (class 1) and dechorionated (class 2); the two groups could be discriminated. 
Using this modelling (Figure 5.9, R2X=0.0622, Q2=-1.94) it was found that there was no 
significant difference between the two treatment methods (n=36 zebrafish larvae at 5 dpf 
per drug concentration/control, P>0.05). When looking at the scores plot (Figure 5.9A) it 
could be seen that the dechorionated drug treatments (blue circles) and the drug treatments 
with zebrafish in their chorions (green circles) produced similar morphological responses and 
mortalities, clearly identifiable by overlapping of the scores for each drug using both 
treatment methods.  
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Figure 5.9 – A two-component OPLS-DA model of biological responses (observations) 
against morphological features and mortality (variables) following drug treatment of 
zebrafish embryos with or without chorion. A) Scores plot, B) Loading plot. On the scores 
plot the scores vectors are displayed as t and to with the number next to them indicating the 
OPLS-DA component (1 or 2). The scores of the OPLS-DA classes 1 and 2 are labelled on the X 
and Y axis, respectively. The scores for the responses observed for each drug after treatment 
with embryos in their chorions are labelled and enclosed within green circles. The scores for 
the responses observed for each drug after treatment of dechorionated embryos are labelled 
and enclosed within blue circles and marked with a small letter d in front of the drug name. 
The numbers on the axes represent the scores for each class. On the loading plot the X and Y 
loadings are represented by p and q and po and so, respectively for each class. The 
morphological features are displayed as X variables and are enclosed in green circles. The 
two treatment methods (classes 1 and 2) are displayed as Y variables and enclosed in blue 
circles. Key: Morphological features labelled with concentration (c1-c6) and exposure time. 
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5.4.5 Comparison of the toxicity of the 28 reference drug set between zebrafish embryos 
and rodents 
In order to evaluate the applicability of the zebrafish embryo as a toxicological model the 
logLC50 values calculated for the 28 reference and six validation drugs from the zebrafish 
embryo toxicity studies were compared to existing logLD50 values for rodents from the 
literature. This has also been done in other studies (Ali et al., 2011). Ideally, a better 
comparison would have been mammalian embryo data; however this is scarce and not 
readily available.  
 
By performing a simple regression analysis between zebrafish embryo logLC50 and rat 
logLD50 values there was found to be a weak correlation (R2=0.12) (Figure 5.10A). The same 
was seen when comparing zebrafish embryo logLC50 and mice logLD50 values (R2=0.08) 
(Figure 5.10B). Despite the weak correlation, the logLC50/LD50 values for some drugs were 
similar between all three species, such as in the case of sulindac and doxorubicin. A few 
drugs on the other hand showed big differences between the three species. For example, l-
thyroxine was found to be extremely toxic in zebrafish embryos compared to rodents. 
Additionally, amiloride was found to be less toxic in zebrafish than in rodents. It could also 
be seen that the more lipophilic drugs were the ones that were more toxic in zebrafish 
embryos than in rodents. Based on this data it seems that toxicity endpoints such as LC50 
may not be the best parameter when comparing toxicity between different species. 
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Figure 5.10 – Correlation between zebrafish logLC50 and rodent logLD50 values for 28 
reference drugs and six validation drugs. A) Correlation between zebrafish logLC50 and rat 
logLD50 values (R2=0.12), B) Correlation between zebrafish logLC50 and mouse logLD50 
values (R2=0.08). 
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5.5 Discussion 
5.5.1 Relationship between toxicity and physiochemical descriptors 
The 28 reference drugs were evaluated for toxicity in zebrafish embryos by performing dose-
range finding and morphology studies using a similar approach to other zebrafish embryo 
toxicity studies (Scholz et al., 2013)(Panzica-Kelly et al., 2010)(Hermsen et al., 2011)(Ali et al., 
2011). Out of the 28 compounds tested nine were found to show little or no toxicity. The 
remaining 19 compounds were all found to cause significant levels of mortality with five 
particularly toxic. These included flupenthixol, chlorprothixene, l-thyroxine, terfenadine and 
bendroflumethiazide which were found to cause high mortality at several concentrations. 
Additionally, by calculating toxicity endpoints such as LC50, EC50, NOEC and LOEC values, as 
well as scoring morphological features for severity and determining teratogenic index and 
toxic ratio values it was found that chlorprothixene showed the most toxicity out of the 28 
reference drugs tested.  
 
From the QSAR model generated of the toxicity endpoints and morphological feature scores 
against the physiochemical properties of the drugs it was found that logP was an important 
physiochemical descriptor. A high logP value was found to correlate with increased toxicity 
and the development of severe morphological defects. This relationship has also been 
reported in other zebrafish studies (Padilla et al., 2012)(Berghmans et al., 2008)(Weimin et 
al., 2001)(Chen et al., 2012), as well as in other organisms (Wayne Schultz et al., 
1991)(Newsome et al., 1991)(Landis et al., 1993). As logP gives an indication of how well a 
drug can penetrate through the cell membrane, a drug with a higher logP value will be able 
to get into cells more easily to induce an effect than a drug which has a low logP value. The 
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logP value for a chemical can be calculated directly from its chemical structure therefore 
making it a useful indicator in predicting drug uptake and drug toxicity in zebrafish embryos 
(Petersen and Kristensen, 1998). Additionally, logP is inversely correlated to the number of 
hydrogen bond acceptors (HBA) and hydrogen bond donors (HBD) (Kamlet et al., 1987). A 
high logP value is also associated with increased cell membrane permeability across the 
blood brain barrier, which might explain the high toxicity observed with chlorprothixene, 
terfenadine and flupenthixol. 
 
High logDACD_6.5 and logDACD_7.4 values were also found to be associated with toxicity and 
increased severity of morphological features. This is because logDACD_6.5 and logDACD_7.4 
values indicate the lipophilicity of a drug at a given pH compensated for ionisation, whereas 
logP only indicates the lipophilicty of a drug in its neutral state. 
 
A low polar surface area (PSA) was also found to be an important determinant for toxicity in 
conjunction with high logP, logDACD_6.5 and logDACD_7.4 values. This is because compounds 
with a low polar surface area can cross biological membranes more easily and thus distribute 
to various tissues, which can result in off target effects and therefore cause toxicity (Hughes 
et al., 2008).  
 
Molecular weight was not found to have a very big influence on toxicity, as even large 
molecular weight compounds like l-thyroxine were highly toxic. In the case of erythromycin 
however molecular weight was found to be important. Despite erythromycin having a fairly 
high logP, it also has a very high molecular weight thus affecting its ability to penetrate into 
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cells. It has been documented that erythromycin has to be injected into the zebrafish 
embryo in order for it to have an effect (Milan et al., 2003). This probably explains why 
erythromycin produced little or no effects in the zebrafish embryo studies. 
 
A high EHOMO value was also associated with increased toxicity and was found to have a 
very big influence on the QSAR model that was generated. As EHOMO gives an indication of 
the electron-releasing capabilities of a drug, a drug with a higher EHOMO value would be 
able to release electrons more easily. These released electrons could ionise the drug making 
it more reactive, so that it has the potential to interact with cells and tissues causing 
damage. Additionally, low ELUMO and low hardness (H) values were also found to be 
associated with increased toxicity, as the electronic structure of the molecules in drugs with 
low ELUMO and hardness values can be changed more easily thus increasing their reactivity 
(Cronin, 2004).  
 
A small molecular volume (V), molecular surface area (S) and ovality (O) were also associated 
with increased toxicity, as these properties enable greater drug uptake together with a high 
logP value and a low PSA value (Cronin, 2004). All of these parameters intercorrelate with 
logP as they increase the hydrophobic character of drugs thereby increasing their toxic 
potential. 
 
Overall from the QSAR model generated it could be seen that a high logP value (high 
hydrophobicity) was the main driving force behind increased toxicity. For the majority of 
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drugs toxicity was caused by baseline toxicity, i.e. narcosis (membrane interaction) and only 
in a very few cases a specific mechanism of toxicity was involved.  
 
5.5.2 Novelty of QSAR model based on zebrafish embryo developmental toxicity 
QSAR models are an important part of toxicity testing today. Particularly, in the 
pharmaceutical industry when selecting candidate drugs to take forward in the drug 
development process testing each individual compound for toxicity is not feasible. 
Therefore, QSAR models are created that can predict the toxicity of compounds based on 
structural alerts such as the presence of functional groups associated with toxicity.  
 
In the past many different approaches were used when generating QSAR models for 
predicting toxicity of compounds (Wayne Schultz et al., 1991)(Newsome et al., 1991)(Landis 
et al., 1993)(Weimin et al., 2001)(Chen et al., 2012). Originally, QSAR models were 
developed to predict toxicity of compounds from the same chemical class, however this was 
found to impair model quality, as compounds even from the same chemical class may have 
different toxicity mechanisms (Ren, 2002). QSAR models in use today are more targeted and 
predict the toxicity of compounds with a similar mechanism of action to increase the 
predictive power of the model (Ren, 2002)(Hansch et al., 1995). This in itself has drawbacks 
as the mechanism of action of the untested compounds needs to be known before a QSAR 
model can be made, which is not always possible. Additionally, when performing QSAR 
modelling it is assumed that a compound’s properties can be defined based on its structure, 
its charge density and molecular composition implying that similar structured compounds 
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have similar activity based on these properties, which may not always be the case and needs 
to be taken into consideration (Nendza, 1998).  
 
QSAR models that are generated based on in vitro results do not provide adequate enough 
information on their own on the hazard potential of a compound in an in vivo scenario 
(Elmore et al., 2014). This is mainly because, it is difficult to extrapolate effects seen in vitro 
such as non-specific cytotoxicity to an in vivo scenario (Elmore et al., 2014).  
 
QSAR models have been previously created using biological data derived from zebrafish 
assays (Chen et al., 2012)(Ding et al., 2011)(Weimin et al., 2001)(Aldeco et al., 2011). 
However, these models have been restricted to particular biological endpoints and particular 
classes of compounds, such as triazoles or chloroanilines (Ding et al., 2011)(Weimin et al., 
2001). Therefore, so far no QSAR model has been generated to cover compounds from 
different chemical classes with different mechanisms of action. 
 
In this study a QSAR model was created using drugs from various chemical classes with 
different functions in order to cover the whole chemical space of pharmaceuticals. By 
including biological data derived from zebrafish embryo assays into the model the quality 
and also the predictive power of the model was increased. Using this approach, the aim was 
to generate a model where the general toxicity could be determined for any pharmaceutical 
regardless of its pharmacological class or chemical structure. This has not been done before 
and presents the real novelty of the QSAR model that was generated. In time, further 
zebrafish embryo assays could be performed using this 28 reference drug set to collect 
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further biological data that could be incorporated into the model, so as to increase its quality 
and also predictivity.   
 
5.5.3 Influence of the zebrafish embryo chorion on drug penetration 
In the zebrafish embryo toxicity and morphology studies performed it was found that ten 
compounds including erythromycin, hydrochlorothiazide, d-penicillamine, glipizide, 
levodopa, metformin, 6-thioguanine, prednisone, folate and riboflavin produced no or little 
toxicity. 
 
In order to address the question whether the chorion presented a barrier to diffusion of 
these drugs into the zebrafish embryo preventing the generation of any morphological 
effects these drugs were re-examined for biological effects by dechorionating the zebrafish 
embryos before treatment. It was found there was no difference in the results obtained with 
or without the chorion. This shows that the non-responsiveness of these ten drugs was not 
due to the chorion acting as a barrier to drug diffusion.  
 
The chorion represents an under-studied aspect of zebrafish embryo physiology. However, 
slowly more and more research is being done on it. A few zebrafish embryo studies have 
shown that with some types of compounds (particularly those with large molecular weights) 
the chorion can present a barrier to the diffusion of a drug into the zebrafish embryo (Henn 
and Braunbeck, 2011)(Kim et al., 2004)(Hagedorn et al., 1998). Particularly, in one of these 
studies it was shown that a high molecular weight cationic polymer Luviquat HM 522 only 
caused toxicity in dechorionated zebrafish embryos and not in zebrafish embryos with a 
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chorion (Henn and Braunbeck, 2011). However, in some cases a compound may not be able 
to diffuse into the zebrafish embryo even when it is dechorionated. This is seen with 
erythromycin which has to be injected directly into the zebrafish embryo in order for it to 
have an effect (Milan et al., 2003). These reported findings highlight that a bioanalysis test 
would be useful to determine whether compound uptake does occur in zebrafish embryos 
with or without a chorion.  
 
As manual dechorionation or enzyme-mediated dechorionation using pronase is often time 
consuming and has low survival rates (Henn and Braunbeck, 2011), implementing 
dechorionation into large scale zebrafish drug screens has remained relatively unexplored. 
However, the latest advances in technology have meant that even automated zebrafish 
chorion removal is now possible, so that in the future dechorionation could be implemented 
into zebrafish embryo drug screens (Mandrell et al., 2012).   
 
5.5.4 Comparability of zebrafish embryo toxicity data to rodent toxicity data 
When comparing calculated logLC50 values to published rodent logLD50 values for the 28 
reference drugs the correlation was found to be weak. Possibly if a larger number of drugs 
had been tested the correlation may have been stronger, as demonstrated in the study by 
Ali and colleagues where 60 drugs were tested (Ali et al., 2011). However, a difference in 
exposure routes between zebrafish embryos and mammals is probably the main reason for 
the weak correlation. Zebrafish embryos undergo constant water-borne drug exposure and 
receive drugs mainly by dermal diffusion, whereas rodents are exposed to drug as a single 
dose orally. This means in zebrafish embryos the liver is by-passed and the drug directly 
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enters the systemic circulation. This could lead to differences in internal drug concentrations 
between the two species. Therefore, determining the plasma drug concentrations at the 
LC50 may be more representative, as has been shown when in vitro LC50 values are 
compared to plasma concentrations at the LC50 (LC50plasma) (Ekwall et al., 1998) (Sjöström 
et al., 2008).  
 
Additional reasons for the weak correlation between zebrafish logLC50 and rodent logLD50 
values could be due to differences in metabolism, particularly species specific sensitivity with 
zebrafish embryos more sensitive to certain types of drugs compared to rodents and vice 
versa (Ali et al., 2011). 
 
Despite the weak correlation, some drugs did show similar toxicities between the three 
species, such as in the case of sulindac and doxorubicin. However, a few drugs showed big 
differences between species. These included for example, l-thyroxine which was found to be 
extremely toxic in zebrafish embryos compared to rodents and amiloride which was found to 
be less toxic in zebrafish embryos than in rodents. Particularly, compounds containing a 
carboxylic acid (COOH) functional group with the exception of folate and fenofibrate were 
found to be more toxic to zebrafish embryos than rodents. Amines, particularly 
chlorprothixene were found to be extremely toxic to zebrafish embryos compared to 
rodents. Overall, it could be seen that the more lipophilic drugs were the ones that were 
more toxic in zebrafish embryos than in rodents, presumably due to their ability to 
penetrate into the zebrafish embryo more efficiently to cause an effect. 
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5.5.5 Limitations of study and future perspectives  
Despite the QSAR model generated using zebrafish embryo toxicity endpoints and 
morphology severity scores showing good predictivity for a validation drug set, the study 
used to create the model could have been improved. Particularly, the study design could 
have been improved by including a bioanalysis step. This could have involved performing a 
time course analysis to determine whether an equilibrium concentration has been reached. 
There is not enough known at the moment about the metabolism of different drugs in 
zebrafish embryos, hence bioanalysis could help in determining whether there are species-
specific differences in metabolism and whether there are significant differences in the 
metabolism of certain drugs between zebrafish and humans. Additionally, the model could 
be improved in the future by characterising more drugs and by incorporating more biological 
data from other zebrafish embryo assays into the model. Including additional 
physiochemical descriptors such as rotatable bonds and metabolic stability may also improve 
the predictivity of the model in the future (Abraham et al., 2002). Additionally, as the QSAR 
model was generated using the severity scores only at one time point and concentration it 
may be biased. Therefore, the model could be improved in the future by including EC50 
values for the severity scores. 
  
The logLC50 values that were determined from the zebrafish embryo studies were found to 
show a weak correlation with published logLD50 values for rodents. As mentioned 
previously, the main reason for the weak correlation was probably the difference in 
exposure route between zebrafish embryos and rodents. Other reasons include differences 
in metabolism, exposure time, developmental stage and study design. 
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It also has to be said that the zebrafish embryo may not present the best model for 
predicting toxicity for all types of drugs and that a combination of different species may be 
needed to determine the toxicity of specific drug types. For example, to test the safety and 
efficacy of antibiotics rodents do not present a good model due to differences in intestinal 
flora which can result in outcomes not representative of the human situation (Billstein, 
1994). Therefore, larger mammals (e.g. primates) are normally used for testing antibiotics. 
This supports the idea that the QSAR model generated using zebrafish embryo data should 
serve as a complementary model to existing techniques already in place. It can be envisaged 
that the QSAR model is implemented early on in drug development to exclude those 
compounds showing very high toxicity, as those are also likely to show toxicity in rodents 
and higher mammals. For compound classes where it is known that the zebrafish shows 
species-specific differences to mammals the results from the QSAR model would need to be 
evaluated with caution and preferably double-checked in vivo in an appropriate animal 
model where a species-specific difference is known not to occur.  
 
5.6 Conclusion 
A QSAR model which was developed by characterising a reference drug set in zebrafish 
embryos could be used as a predictive tool to predict the toxicity of similar structured 
compounds in zebrafish embryos. Additionally, due to the many similarities between 
zebrafish and humans particularly in terms of toxic responses, this model could also be used 
to predict human toxicity. 
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Despite the model showing limitations with further refinement it has the potential in the 
future to be implemented into pre-clinical testing routines for hazard risk assessment where 
it could save money, time, reduce the number of animals tested and in the long-term 
potentially also save lives by excluding those drugs with toxicity potential early on in the 
drug development process. 
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Chapter Six: CHARACTERISATION OF THE ANTI-INFLAMMATORY 
RESPONSES OF A 28 REFERENCE DRUG SET IN ZEBRAFISH LARVAE 
 
Foreword: 
All the work presented in this chapter was performed by me with supervision from Dr. 
Clemens Grabher and Dr. Urban Liebel. Christine Wittmann provided initial support with 
carrying out ChIn assays and Dr. Luke Pase provided initial support with carrying out HyPer 
assays. All analysis was performed solely by me. The automated image analysis tool was 
developed by Dr. Urban Liebel and Dr. Markus Reischl. 
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6.1 Introduction and Overview 
6.1.1 Zebrafish immune system 
The zebrafish presents a good model for investigating the immune system and its responses, 
particularly as the innate and adaptive immune system are conserved between mammals 
and teleosts (Meeker and Trede, 2008). In adult zebrafish the kidney is the functional 
equivalent of the human bone marrow generating all the components of a functioning 
immune system (Meeker and Trede, 2008)(Lieschke et al., 2001).  
 
6.1.2 Zebrafish innate immune system 
The innate immune system which is the first line of defence against infection or mechanical 
damage mainly comprises leukocytes (white blood cells) which consist of macrophages and 
neutrophils (Meeker and Trede, 2008)(Lieschke et al., 2001). At around 15 hpf embryonic 
macrophages are present which originate from the rostral blood compartment and travel to 
the yolk expressing the marker pu.1; at later stages the marker lysozyme C is expressed 
(Meeker and Trede, 2008)(Hall et al., 2007). Once the circulatory system has formed, 
macrophages spread to several tissues phagocytising cell debris and clearing bacteria from 
the circulation (Herbomel et al., 2001). Neutrophils are produced at around 48 hpf and 
originate from the intermediate cell mass (ICM) (Hall et al., 2007). Neutrophils which are 
from the heterophil lineage have a multi-lobed nucleus and express a neutrophil specific 
protein myeloperoxidase (zMPO) (Meeker and Trede, 2008). In fully developed adult 
zebrafish there are two main granulocyte lineages; the heterophil lineage and the eosinophil 
lineage (Lieschke et al., 2001). Eosinophils (involved in combating parasites) have a non-
segmented nucleus and have only been identified in adult zebrafish (Lieschke et al., 2001).  
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6.1.3 Zebrafish adaptive immune system 
In zebrafish the adaptive immune system which is the second line of defence against 
infection or mechanical damage develops late after around 4-6 weeks (Meeker and Trede, 
2008). The adaptive immune system is comprised of T cells, B cells and natural killer (NK) 
cells. T cells which are involved in mediating the immune response and directly getting rid of 
infected cells undergo differentiation in the thymus before migrating to various tissues, such 
as the skin (Meeker and Trede, 2008). T cell receptors, MHC class I, II and III proteins have all 
been identified in zebrafish and the T cell receptors have been shown to undergo V(D)J 
recombination like in mammals (Meeker and Trede, 2008). In zebrafish B cells are initially 
produced in the pancreas and later produced in the kidney (Meeker and Trede, 2008). B cells 
produce antibodies against various antigens (Meeker and Trede, 2008). Zebrafish B cells are 
able to undergo V(D)J rearrangements like in mammals and can produce the mammalian 
antibody subtypes IgD and IgM (Meeker and Trede, 2008). In zebrafish the complement 
system and homologs of toll-like receptors have also been identified (Meeker and Trede, 
2008). The NK cells which also form part of the innate immune response eliminate diseased 
cells (Goldsmith and Jobin, 2012). 
 
6.1.4 Zebrafish as a model for studying inflammation 
Inflammation is a natural mechanism that ensues following damage to tissue by either a 
physical wound or infection. Inflammation is characterised by infiltration of immune cells 
such as macrophages and granulocytes by chemotaxis to the wound site following release of 
pro-inflammatory mediators. These pro-inflammatory mediators include hydrogen peroxide, 
chemokines and cytokines (d’ Alençon et al., 2010)(Nomiyama et al., 2008)(Lieschke, 2001). 
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The inflammatory processes are well conserved between zebrafish and humans (Meeker and 
Trede, 2008). For example, orthologues of the human chemokine CXCL12 and the human 
cytokine interleukin 1β are present in zebrafish (d’ Alençon et al., 2010)(Nomiyama et al., 
2008)(Lieschke, 2001).  
 
To study the inflammatory process in zebrafish, wounding of the tail-fin can be carried out 
which attracts inflammatory cells to the wound site (Meeker and Trede, 2008). Macrophages 
which are located in perivascular locations will travel to the wound site due to chemotaxis 
and phagocytise cell debris (Meeker and Trede, 2008). Neutrophils will undergo morphology 
changes as they migrate to the wound site by producing a pseudopod (Mathias et al., 2006). 
After arriving at the wound some neutrophils will move around the wound site, whereas 
others will stop and take on a globular structure (Mathias et al., 2006). During resolution of 
inflammation, the leukocytes will migrate back to the vasculature; this differs from humans 
where normally neutrophils are apoptosed following resolution (Meeker and Trede, 2008).  
 
Using fluorescently labelled macrophages and neutrophils; migration of immune cells can be 
visualised in real time in zebrafish (Meeker and Trede, 2008). Inflammation can be induced 
in zebrafish larvae through chemical treatment (e.g. copper sulphate) or mechanical damage 
(e.g. tail-fin wounding) (Mathias et al., 2006). The zebrafish therefore enables inflammation 
to be studied down to cellular resolution offering many advantages over other animal 
models where tissues are not transparent hampering the possibility of imaging immune cells 
and in vitro assays where only individual components of the immune response can be 
studied at one time. 
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6.1.5 Chemically induced inflammation (ChIn) assay 
By inducing inflammation in zebrafish larvae therapeutic drug screens can be performed to 
detect anti-inflammatory compounds. Particularly, the zebrafish tail-fin wounding assay has 
been extensively used for this purpose (Mathias et al., 2006)(Ellett et al., 2011)(Loynes et al., 
2010)(Mathias et al., 2009). Despite the many advantages of the tail-fin wounding assay it 
does have its drawbacks in that it is low throughput, takes a lot of time and requires some 
technical ability to perform consistently (Renshaw and Ingham, 2010). With this in mind a 
chemically induced inflammation (ChIn) screening assay was generated using zebrafish 
larvae (d’ Alençon et al., 2010). In this assay, hair cells which are located in neuromasts and 
form the lateral line of the zebrafish are damaged to induce an inflammatory response (d’ 
Alençon et al., 2010)(Williams and Holder, 2000)(Ghysen and Dambly-Chaudière, 2004). A 
double transgenic zebrafish line Tg(cldnB:GFP);Tg(lysC:DsRed2) where the neuromasts 
fluoresce green under GFP and the leukocytes fluoresce red under DsRed is utilised in the 
ChIn assay (Williams and Holder, 2000)(d’ Alençon et al., 2010)(Hall et al., 2007). For the 
ChIn assay zebrafish larvae at 3 dpf are used, as they have established a primitive lateral line 
at this stage of development (d’ Alençon et al., 2010).  
 
To induce hair cell damage in the Chin assay copper sulphate is used, which induces 
oxidative stress and causes leukocytes to migrate to neuromasts (Olivari et al., 2008)(Yoong 
et al., 2007). Once arrived there, the leukocytes will remain there for several hours (d’ 
Alençon et al., 2010). After around 6 hours following the removal of copper leukocytes start 
to migrate away from the neuromasts (d’ Alençon et al., 2010).  
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In brief, the ChIn assay involves using 3 dpf zebrafish larvae from the transgenic line 
Tg(cldnB:GFP);Tg(lysC:DsRed2) where the neuromasts and leukocytes are fluorescently 
labelled (see section 6.3.3 for full method). The zebrafish larvae are incubated with 
compound for one hour before subsequent incubation in copper sulphate for one hour (d’ 
Alençon et al., 2010). Copper is then washed off and the zebrafish larvae are anaesthetised 
before being individually positioned laterally in wells of a 384 well plate for subsequent 
automated fluorescence imaging. Images are analysed automatically enabling the 
quantification of leukocytes within neuromasts. Compounds with anti-inflammatory 
properties will reduce the number of leukocytes occupying the neuromasts. Hence, the ChIn 
assay can be used to perform large scale screens for the detection of anti-inflammatory 
compounds.  
 
6.1.6 Role of hydrogen peroxide in inflammation 
Hydrogen peroxide belongs to the reactive oxygen species (ROS) group and is generated as a 
side product of metabolism or deliberately produced by cells (e.g. neutrophils) to initiate a 
respiratory burst to kill bacteria (Wittmann et al., 2012). Recently using zebrafish, hydrogen 
peroxide was found to play a vital role in the recruitment of inflammatory cells to a site of 
injury by forming a gradient, which attracts immune cells to the site of injury (Niethammer 
et al., 2009). The gradient is formed by the activity of a specific class of the nicotinamide 
dinucleotide monophosphate (NADPH) oxidases known as dual oxidase (Duox), which is able 
to generate hydrogen peroxide directly (Wittmann et al., 2012). In zebrafish neutrophils a 
kinase from the Src family known as Lyn was discovered and was found to have a role in 
guiding neutrophils to wound sites by detecting the levels of hydrogen peroxide (Yoo et al., 
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2011)(Wittmann et al., 2012). Additionally, it was found that when the Duox enzyme was 
inhibited and no hydrogen peroxide was generated by epithelial cells Lyn could not perform 
its function preventing the migration of neutrophils to wound sites (Yoo et al., 2011). These 
studies showed that hydrogen peroxide plays an important role in initiating inflammation by 
guiding neutrophils to sites of damage.  
 
6.1.7 In vivo visualisation of leukocytes and hydrogen peroxide levels following acute 
inflammation in zebrafish larvae 
As mentioned above hydrogen peroxide performs an important function in initiating 
inflammation. The zebrafish transgenic line Tg(lyz.HyPer) which has the hydrogen peroxide 
sensor fluorophore HyPer can be used to monitor hydrogen peroxide levels in vivo (Belousov 
et al., 2006). HyPer has two excitation maxima at 420 and 500 nm with high hydrogen 
peroxide levels emitting more light when excited at 500 nm compared to 420 nm (Pase et 
al., 2012). The ratio between these two can be calculated to determine differences in 
hydrogen peroxide levels over time (Pase et al., 2012). Using this approach, the HyPer assay 
can be used to screen for anti-oxidants. 
 
In brief, the zebrafish HyPer assay is performed by inducing inflammation in 3 dpf 
Tg(lyz.HyPer) zebrafish larvae by cutting the caudal fins (see section 6.3.4 for full method). 
Following cutting of the caudal fins, the zebrafish larvae are anaesthetised and immobilised 
in low melting point agarose and imaged using an automated fluorescence microscope. 
Ratiometric analysis (determination of the ratio between two fluorescence intensities) is 
then performed to quantify changes in the levels of hydrogen peroxide over time. 
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6.2 Aims 
Anti-inflammatories represent a large market worldwide due to their many disease 
indications, as a large number of diseases have an inflammatory component (Masferrer and 
Needleman, 2000). There is continually ongoing research to identify novel compounds with 
anti-inflammatory properties (Ehrman et al., 2010). However, there has also been growing 
interest to identify existing marketed compounds which have been marketed for other 
indications to see if they have possible anti-inflammatory effects not previously documented 
(Nath et al., 2009).  
 
Based on this the main aim of this work was to determine the potential anti-inflammatory 
activity of the 28 reference drug set characterised in Chapter 5 firstly using a manual assay 
and secondly a high throughput automated fluorescence-based assay (d’ Alençon et al., 
2010).  
 
6.3 Methods 
The anti-inflammatory activity of the 28 reference drugs was firstly characterised by 
performing a manual tail-fin wounding assay followed by an automated high throughput 
chemically induced inflammation (ChIn) assay. Positive hits from these assays were then 
verified by performing SYTOX® blue staining. Additionally, these hits were also tested for 
anti-oxidant activity using the HyPer assay.  
 
 
a) 
b) 
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6.3.1 Sudan black staining 
Sudan black staining was used to visualise leukocytes. To perform Sudan black staining 
zebrafish larvae at 3 dpf were firstly exposed to drug for one hour before being 
anaesthetised in 0.02% MS222. The caudal fin tips were then cut and the zebrafish larvae 
were allowed to recover in E3 embryo medium for three hours. After the recovery period 
the zebrafish larvae were fixed in 4% PFA in PBS (1 mL) for two hours at room temperature. 
The zebrafish larvae were then washed twice with PBST (1 mL) and stained with 60 µL Sudan 
black reagent (Sigma-Aldrich, Germany) for 20 minutes. After 20 minutes, the stain was 
washed off thoroughly with 70% ethanol (1 mL) in three washes of 1, 5 and 10 minutes. The 
zebrafish larvae were then washed twice with PBST (1 mL). To remove pigment and aid 
counting of cells, the stained zebrafish larvae were treated with 1% hydrogen peroxide and 
1% potassium hydroxide solution for 15 minutes at room temperature. After this time the 
solution was replaced with PBST and the samples were stored at 4°C until required for use. 
To quantify the number of neutrophils at the wound site, the end of the notochord until the 
site of the tail cut was used as the region for counting (see Figure 6.1).  
 
Figure 6.1 – Depiction of the area used for counting the number of leukocytes after cutting 
the tail fins of 3 dpf zebrafish larvae. Neutrophils are represented by black dots and dashed 
lines mark area of cut. Tail is shown from left to right with the tail tip on the right. 
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Leukocytes were counted at the wound site using a Leica MZF10 fluorescence stereo 
microscope (Leica, Germany). The experiment was repeated three times for each 
concentration and final results were averaged. 
 
6.3.2 SYTOX® blue staining 
SYTOX® blue staining was performed to detect copper chelation that could occur due to 
interaction of copper with certain drugs resulting in the formation of a copper-drug complex. 
To test for copper chelation, 15 zebrafish larvae at 3 dpf were tested per drug/control.  
 
All 28 drugs were prepared at a concentration of 10 µM along with a control solution (1% 
DMSO). The zebrafish larvae were first cleaned and then separated into wells of a six well 
plate with 60 zebrafish larvae placed in each well. SYTOX® blue stain (Sigma-Aldrich, 
Germany) at a concentration of 5 µM was prepared using E3 embryo medium from an initial 
stock solution of 5 mM. The stain was then added to each well at a volume of 5 mL and then 
left to incubate for two hours at 28°C. After incubation, the stain was washed off three times 
with E3 embryo medium and the zebrafish embryos were transferred in groups of 15 to one 
well of a 24 well plate. To each well a different drug at a concentration of 10 µM was added 
at a volume of 1 mL. To one of the wells a control solution of 1% DMSO was added and to 
the other E3 embryo medium was added. The plate was then left to incubate for one hour at 
28°C. After incubating for one hour, 1 mL of 20 µM copper sulphate (Merck Millipore, 
Germany) solution was added to each well except to one of the 1% DMSO control wells to 
give a final concentration of 10 µM of copper in each well. The whole plate was then left to 
incubate for one hour at 28°C. After this time the zebrafish larvae in each individual well 
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were observed using the CFP filter on a Leica MZF10 fluorescence stereo microscope (Leica, 
Germany) with set exposure parameters (brightness=26%, pseudo-colours=511 nanometres 
(nm), gain=X1 and exposure time=1000 milliseconds (ms)). 
 
The same procedure outlined above was then repeated for three drugs (sulindac, 
chlorzoxazone and tetracycline) at a concentration of 100 µM. In each case the experiment 
was repeated three times and the fluorescence intensity was noted. 
 
6.3.3 Chemically induced inflammation (ChIn) assay 
The chemically induced inflammation (ChIn) assay was performed in order to determine the 
anti-inflammatory potential of the 28 reference drugs. Zebrafish larvae at 3 dpf from the 
transgenic line Tg(cldnB:GFP)(lyz:DsRed2)nz50 were separated into batches of 16 zebrafish 
larvae and distributed into a six well plate. To the wells E3 + 1% DMSO (4 mL) was added. 
Drugs were made up to a concentration of 30 µM from their initial stock solutions using E3 
embryo medium. Drugs were then added at 2 mL to each of the wells giving a final dilution 
of 10 µM in each well. To four of the wells only 2 mL of 1% DMSO was added. These wells 
served as the controls. The plates were then incubated at 28°C for one hour. After one hour, 
copper sulphate stock solution (20 mM) was diluted in E3 embryo medium to make 20 mL of 
a 70 µM dilution. To each well except to two of the 1% DMSO control wells 1 mL of the 70 
µM copper sulphate stock solution was added to give a final copper sulphate concentration 
of 10 µM in each well. The plates were then incubated for another hour at 28°C.  
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After incubation for one hour, all the wells were washed with E3 embryo medium and 
replaced with a solution consisting of E3 embryo medium, 1% DMSO and 0.02% MS222. A 
multipette® plus multi-pipette (Eppendorf, Germany) was then used to fill each well of a 384 
well plate (Greiner Bio-One GmbH, Germany) with 20 µL of the above solution. The zebrafish 
larvae were then transferred individually in a volume of 80 µL to a well in the 384 well plate. 
One drug was allocated one column on the 384 well plate. Two columns were assigned to 
the 1% DMSO controls (columns 1 and 24) and two to the positive copper controls (columns 
2 and 23). After transferring all the zebrafish larvae to the 384 well plate, each individual 
zebrafish larva was positioned laterally in the well within an hour of removal of copper 
sulphate to make sure the inflammatory response did not diminish before imaging was 
performed.  
 
Imaging of each well was performed using a Scan˄R screening microscope (Olympus 
Biosystems, Germany) with images taken under brightfield (25 ms), cyanine 3 (300 ms) and 
GFP (350 ms) every hour over six hours with a 4X objective (ULAPO). Images were acquired 
in four dimension z-slices with a distance of 50 µm. The detection of the zebrafish larvae in 
the wells was automated using an autofocus algorithm. After image collection, the images 
were processed using LabView Vision (National Instruments, Germany) with scripts written 
in ImageJ version 4.2 (http://rsbweb.nih.gov/ij/) by Markus Reischl (KIT, Germany). This 
enabled sorting of brightfield and fluorescence images of each well into red-green-blue 
(RGB) overlay images as extended focus projections. Using these sorted images the number 
of leukocytes (coloured red) occupying the neuromasts (coloured green) was automatically 
quantified (Figure 6.2). This was used as a measure of the inflammatory response.  
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Figure 6.2 – Fluorescence analysis of leukocyte localization within neuromasts using the 
Tg(cldnB:GFP)(lyz:DsRed2)nz50 transgenic zebrafish line. Lateral overlays (brightfield, GFP, 
DsRed) of: A) 3 dpf zebrafish larva treated with 1% DMSO only (negative control) and B) 3 dpf 
zebrafish larva treated with copper (positive control). 
 
Additionally, using MATLAB 7.11 R2010b (MathWorks, Germany) plots of the inflammatory 
response over time (Figure 6.3) were automatically generated from the sorted data. 
Figure 6.3 – Plot of inflammatory response over time for 1% DMSO control zebrafish larvae 
at 3 dpf. Red line = percentage increase in inflammatory response after treatment of 
zebrafish larvae with copper, blue line = percentage increase in inflammatory response after 
treatment of zebrafish larvae with 1% DMSO. 
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Tabulated values were also generated which were used to solve the equation e(a0 + a1x) with 
a0 representing the initial inflammatory response, a1 the resolution of inflammation (slope 
of the curve) and x the time point. By substituting x for 0, the initial inflammatory response 
(%) = ea0 X 100 could be calculated by inserting the value for a0 into the equation.  
 
The threshold for the initial anti-inflammatory response was set at ≤50%. Drugs with initial 
anti-inflammatory responses above this threshold were considered not to present with 
significant anti-inflammatory activity.  
 
6.3.4 HyPer zebrafish assay (In vivo quantification of hydrogen peroxide levels) 
To quantify the levels of hydrogen peroxide produced during an acute inflammatory 
response in 3 dpf zebrafish larvae, a Tg(lyz.HyPer) transgenic zebrafish line containing the 
hydrogen peroxide sensor fluorophore HyPer was utilised. Zebrafish larvae obtained from 
this line were first sorted so as to ensure that only those zebrafish larvae showing expression 
throughout the whole body were chosen for experimentation. After sorting, two zebrafish 
larvae were incubated in 4 mL of either 1% DMSO or drug solution at a specified 
concentration for one hour before adding 200 µL of 0.4% MS222 to give a final 
concentration of 0.02% MS222 in each well. The caudal fins were then cut and the zebrafish 
larvae were then transferred to a PELCO® clear well glass bottom dish (PLANO GmbH, 
Germany) with 500 µL of liquid. The zebrafish larvae were then sucked up in a Pasteur 
pipette together with molten 1.5% low melting point agarose (PEQLAB, Erlangen, Germany). 
The two zebrafish larvae were then arranged laterally with the tail tips positioned opposite 
one another. The Scan˄R screening microscope (Olympus Biosystems, Munich, Germany) 
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was then used to take brightfield images (25 ms) and fluorescence images with the FITC-
Hyper channel (150 ms) using the excitation filter FF01-425-/30-25 for HyPer low and the 
FF01-482/35-25 excitation filter for HyPer high every minute over 60 minutes.  
 
ImageJ version 4.2 (http://rsbweb.nih.gov/ij/) was then used to perform a ratiometric 
analysis on the captured images by calculating ratios for HyPer low/HyPer high. This was 
done by firstly opening the image sequence for a specific dataset in non-numerical order. 
The channels were then split into brightfield, HyPer low and HyPer high and saved separately 
as TIFF files. For each channel an area in the background was then selected (area without tail 
in view) and subtracted using a scaling factor of one. Both the HyPer low and HyPer high 
channels were then converted to 32 bit images and thresholding was performed using the 
default settings on ImageJ and a NaN background. Using this function, only the tails 
themselves were outlined excluding background artefacts and saturated pixels. The image 
calculator function was then used to divide the HyPer high by the HyPer low channel. The 
resulting stack was then thresholded as before and the brightness and contrast were set to 
values in the range of 0.6 and 2.2, respectively. The lookup table function was then used to 
produce a 16 colour stack where different colours indicated different pixel intensities.  
 
In most cases before ratiometric analysis could be performed tail movement had to be 
corrected for as the tail tip needed to be fixed in the same place to perform accurate 
analysis. To correct for tail movement, each tail was analysed individually by first drawing a 
box around the tail tip and then duplicating this part of the stack. The duplicated stack was 
then multiplied by 1000 before being converted to a 16 bit stack in order to retain the pixel 
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values. The rigid body function on the stackreg plug-in was then used to correct for tail 
movement. Once this was done, the stack was converted back to 32 bit and divided by 1000.  
 
For the ratiometric analysis a small box was drawn around the tail tip at the site of the cut. 
Using the T-functions plug-in an intensity time monitor plot was generated to show the 
changes in pixel intensity values over the 60 minute time period. The pixel values obtained 
from this plot were averaged for each drug treatment. For each drug in total eight zebrafish 
larvae were tested. An outline of the whole image analysis process is shown in Figure 6.4.  
 
Figure 6.4 – Outline of image analysis process for hydrogen peroxide ratiometric analysis. 
 
For the HyPer assay only malathion (10 µM), meclizine (100 µM), chlorzoxazone (100 µM) 
and d-penicillamine (100 µM) were tested out of the 28 reference drug set. 
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6.4 Results 
6.4.1 Tail-fin wounding 
To determine the anti-inflammatory activity of the 28 reference drugs, initially a tail-fin 
wounding assay was carried out in order to get a broad overview of the possible anti-
inflammatory responses of these drugs.  
 
Manual tail-fin wounding for all 28 reference drugs was initially carried out at a 
concentration of 10 µM for each drug. This involved treatment of 3 dpf zebrafish larvae with 
each drug at a concentration of 10 µM followed by cutting of caudal tail fins, fixation and 
staining with Sudan black, as outlined in section 6.3.1. The experiment was repeated three 
times and the average leukocyte count for each treatment/control group was calculated 
(Figure 6.5). It was observed that malathion, metformin, terfenadine, meclizine and 
thiamazole all significantly decreased the mean number of leukocytes compared to the cut 
control (Figure 6.5, n=45 zebrafish larvae at 3 dpf per drug/control, P<0.05). The uncut 
control showed staining of leukocytes mainly in the caudal vein as expected (Herbomel et 
al., 1999). Both of the positive controls in this assay sulindac and prednisone (known anti-
inflammatory agents) on the other hand had no significant effects on reducing leukocyte 
number at the wound site (Figure 6.5, n=45 zebrafish larvae at 3 dpf per drug/control, 
P>0.05). This may have been due to the concentration of drug used being too low to induce 
an effect or due to ineffective penetration of the drugs into the zebrafish larvae.  
a) 
b) 
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Figure 6.5 – Anti-inflammatory responses of 28 reference drugs at 10 µM after tail-fin wounding of zebrafish larvae. Treatments were 
initiated at 3 dpf (n=45 zebrafish larvae at 3 dpf per drug/control, P<0.05 for meclizine, metformin, terfenadine, thiamazole and 
malathion, P>0.05 for rest). Key: red = positive controls, green = drugs that significantly reduce the leukocyte count at the wound site, 
black = untreated cut and uncut controls 
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Manual tail-fin wounding was also performed at a higher concentration of 100 µM (Figure 
6.6). Terfenadine, chlorprothixene, flupenthixol and malathion could not be evaluated at the 
higher concentration as they caused toxicity (heart edema, cellular necrosis and hypoxia), so 
they were therefore not included in the results.  
 
It was found that thiamazole, chlorzoxazone, meclizine and metformin at 100 µM all 
significantly reduced leukocyte number at the wound site compared to the cut control 
(Figure 6.6, n=45 zebrafish larvae at 3 dpf per drug/control, P<0.05). The staining in the 
uncut control was as expected (mainly in the caudal vein). Additionally, one of the positive 
controls (sulindac) was also found to significantly reduce the leukocyte number at the 
wound site (Figure 6.6, n=45 zebrafish larvae at 3 dpf per drug/control, P<0.05), whilst the 
other (prednisone) was found to have no effect (Figure 6.6, n=45 zebrafish larvae at 3 dpf 
per drug/control, P>0.05).   
 
 
 
 
 
 
 
 
256 
 
 
 
Figure 6.6 – Anti-inflammatory responses of 28 reference drugs at 100 µM after tail-fin wounding of zebrafish larvae. Treatments were 
initiated at 3 dpf (n=45 zebrafish larvae at 3 dpf per drug/control, P<0.05 for d-penicillamine, meclizine, chlorzoxazone and metformin, 
P>0.05 for rest). Key: red = positive controls, green = drugs that significantly reduce the leukocyte count at the wound site, black = 
untreated cut and uncut controls 
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6.4.2 Automated chemically induced inflammation assay (ChIn) 
The next aim was to determine the anti-inflammatory activity of the 28 reference drugs via 
the automated ChIn assay. In brief, this was done by treating 3 dpf zebrafish larvae from the 
Tg(cldnB:GFP)(lyz:DsRed2)nz50 transgenic line with drug for one hour, followed by 
treatment with copper sulphate for one hour to induce inflammation before subsequent 
imaging of the inflammatory response using an automated fluorescence microscope. Using 
the processed images the initial inflammatory response was calculated with a cut-off point 
for significant anti-inflammatory activity set at ≤50%. 
 
As in the manual tail-fin wounding assay, all 28 reference drugs were initially tested at a 
concentration of 10 µM (Figure 6.7). It was observed that malathion, 6-thioguanine and 
thiamazole all caused a significant reduction in the inflammatory response under the cut-off 
point of 50% (Figure 6.7, n=48 zebrafish larvae at 3 dpf per drug/control, P<0.05 for 
malathion and thiamazole, P<0.005 for 6-thioguanine). One of the positive controls sulindac 
was also found to significantly reduce the inflammatory response below the cut-off point 
(Figure 6.7, n=48 zebrafish larvae at 3 dpf per drug/control, P<0.05). The other positive 
control prednisone however had no effect (Figure 6.7, n=48 zebrafish larvae at 3 dpf per 
drug/control, P>0.05). Terfenadine caused serious malformations (cardiac edema, reduced 
circulation, reduced heart rate and tail necrosis) of zebrafish larvae at 10 µM in the presence 
of copper sulphate, therefore its anti-inflammatory activity could not be evaluated using the 
ChIn assay. 
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Figure 6.7 – Anti-inflammatory responses of the 28 reference drugs at 10 µM using the zebrafish ChIn assay. Treatment was initiated at 
3 dpf (n=48 zebrafish larvae at 3 dpf per drug/control, P<0.05 for thiamazole, malathion and sulindac, P<0.005 for 6-thioguanine). Key: 
red = positive controls, green = drugs significantly reducing the inflammatory response, black = DMSO and copper controls  
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Similarly, at 100 µM all 28 reference drugs except terfenadine, chlorprothixene, flupenthixol 
and malathion were evaluated for anti-inflammatory activity using the ChIn assay (Figure 
6.8). These drugs were excluded as they caused toxicity (cellular necrosis). It was found that 
levodopa, 6-thioguanine, d-penicillamine, thiamazole, chlorzoxazone, meclizine and 
tetracycline all significantly reduced the inflammatory response below the cut-off point of 
50% (Figure 6.8, n=48 zebrafish larvae at 3 dpf per drug/control, P<0.0005 for levodopa, 
chlorzoxazone, 6-thioguanine, d-penicillamine, meclizine and tetracycline, P<0.005 for 
thiamazole). The positive control sulindac was also found to significantly reduce the 
inflammatory response below the cut-off point of 50% (Figure 6.8, n=48 zebrafish larvae at 3 
dpf per drug/control, P<0.0005), whereas the other positive control prednisone again had no 
effect (Figure 6.8, n=48 zebrafish larvae at 3 dpf per drug/control, P>0.05).  
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Figure 6.8 - Anti-inflammatory responses of the 28 reference drugs after treatment at 100 µM evaluated using the zebrafish ChIn 
assay. Treatments were initiated at 3 dpf (n=48 zebrafish larvae at 3 dpf per drug/control, P<0.0005 for levodopa, 6-thioguanine, 
sulindac, d-penicillamine, meclizine, chlorzoxazone and tetracycline, P<0.005 for thiamazole). Key: red = positive controls, green = drugs 
significantly reducing the inflammatory response, black = DMSO and copper controls 
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6.4.3 SYTOX® blue staining 
To confirm the results obtained in the automated ChIn assay SYTOX® blue staining was 
performed. The SYTOX® blue nuclear stain which fluorescently labels neuromasts was used 
to exclude false positives that may have been generated after performing the ChIn assay. 
False positives may have arisen through the interaction of a drug with copper generating a 
drug/copper complex, thereby preventing an inflammatory response from being generated 
and thus exhibiting a negative control phenotype with reduced localization of leukocytes in 
neuromasts.  
 
Initially, all 28 reference drugs were tested for copper chelation ability at a concentration of 
10 µM using the SYTOX® blue stain (Table 6.1, n=15 zebrafish larvae at 3 dpf per 
drug/control). In brief, SYTOX® blue staining was performed by staining zebrafish larvae at 3 
dpf for two hours with 5 µM SYTOX® blue, followed by washing off the stain, treating with 
drug solution for one hour before final incubation with copper sulphate for one hour. The 
neuromasts of the zebrafish larvae were then visualised using a fluorescence microscope 
and the extent of fluorescence was noted for each drug treatment group. Based on this each 
drug was classified as a strong copper chelator, a weak copper chelator or no copper 
chelator. It was found that thiamazole, 6-thioguanine and d-penicillamine were strong 
copper chelators (strong neuromast fluorescence still present), whereas levodopa, enalapril 
and captopril were weak copper chelators (weak neuromast fluorescence still present) 
(Table 6.1, n=15 zebrafish larvae at 3 dpf per drug/control).  
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Table 6.1 – SYTOX® blue staining results for 28 reference drugs at 10 µM.  
Compound  Copper chelation 
Thiamazole √√ 
6-thioguanine √√ 
D-penicillamine √√ 
Levodopa √ 
Enalapril √ 
Captopril √ 
Tetracycline X 
Erythromycin X 
Bendroflumethiazide X 
Hydrochlorothiazide X 
Metformin X 
Glipizide X 
Fenofibrate X 
Prednisone X 
Sulindac X 
Liothyronine X 
L-thyroxine X 
Amantadine X 
Carbamazepine X 
Amiloride X 
Malathion X 
Chlorzoxazone X 
Folate X 
Flupenthixol X 
Chlorprothixene X 
Metoclopramide X 
Terfenadine X 
Key: X = no response, √ = weak response, √√ = strong response 
 
Tetracycline, sulindac and chlorzoxazone were also tested for copper chelation ability at 100 
µM. It was found that tetracycline was an intermediate copper chelator at 100 µM contrary 
to what was seen at 10 µM. However, both sulindac and chlorzoxazone showed no copper 
chelation ability even at 100 µM. 
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After having performed the SYTOX® blue staining it was determined that out of the nine 
drugs showing a positive response in the ChIn assay (6-thioguanine, levodopa, thiamazole, 
tetracycline, sulindac, d-penicillamine, meclizine, malathion and chlorzoxazone) only four 
were true positives and did not interact with copper (malathion, sulindac, meclizine and 
chlorzoxazone). After having filtered out the false positives; the next step was to see 
whether there was a relationship between the drug concentration and the extent of 
inhibition of inflammation for these four drugs. Hence, malathion, sulindac, meclizine and 
chlorzoxazone were tested for anti-inflammatory activity using the ChIn assay at 50 µM. it 
was also of interest to determine whether there was a relationship between the drug 
concentration and the extent of copper chelation, so therefore thiamazole and tetracycline 
were also tested at 50 µM using the ChIn assay.  
 
The results from the ChIn assay showed that both malathion and sulindac at 50 µM had anti-
inflammatory index values below the cut-off point of 50% (Figure 6.9A, n=48 zebrafish larvae 
at 3 dpf per drug, P<0.05 for malathion, P<0.005 for sulindac). Chlorzoxazone and meclizine 
on the other hand were both found to have anti-inflammatory index values above the 50% 
cut-off point (Figure 6.9A, n=48 zebrafish larvae at 3 dpf per drug, P<0.05). Thiamazole at 50 
µM was found to show strong copper chelation (anti-inflammatory index value ≤50%), 
whereas tetracycline at 50 µM was found to show weak copper chelation (anti-inflammatory 
index value >50%). When combining this data with the previous ChIn data at 10 µM and 100 
µM for these drugs, it could be seen that even when using only three concentrations all six 
drugs showed some concentration-dependency (Figure 6.9B).  
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Figure 6.9 – Anti-inflammatory activity and extent of copper chelation observed with a 
selection of the 28 reference drugs evaluated using the zebrafish ChIn assay at 50 µM. A) 
Responses observed with malathion, chlorzoxazone, tetracycline, sulindac, meclizine and 
thiamazole at 50 µM in the ChIn assay (n=48 zebrafish larvae at 3 dpf per drug/control, 
P<0.05 for malathion, chlorzoxazone, tetracycline, meclizine, thiamazole and P<0.005 for 
sulindac). Key: red = positive controls, green = drugs significantly reducing the inflammatory 
response, black = DMSO and copper controls. B) Overview of the responses observed in the 
ChIn assay for malathion, chlorzoxazone, tetracycline, sulindac, meclizine and thiamazole at 
10, 50 and 100 µM (n=48 zebrafish larvae at 3 dpf per drug concentration/control, P<0.05 for 
10 µM thiamazole, malathion and sulindac, P<0.005 for 10 µM 6-thioguanine, P<0.0005 for 
100 µM levodopa, 6-thioguanine, sulindac, d-penicillamine, meclizine, chlorzoxazone and 
tetracycline, P<0.005 for 100 µM thiamazole, P<0.05 for 50 µM malathion, chlorzoxazone, 
tetracycline, meclizine, thiamazole and P<0.005 for 50 µM sulindac). Key: red = positive 
control, green = tetracycline, light blue = malathion, purple = chlorzoxazone, orange = 
meclizine, dark blue = thiamazole, black = DMSO and copper controls 
 
 
Based on the results obtained from all three assays (manual tail-fin wounding assay, ChIn 
assay and SYTOX® blue staining) it was found that sulindac, chlorzoxazone, meclizine and 
malathion all showed positive responses in the tail-fin wounding and ChIn assays and 
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showed no response in the SYTOX® blue staining assay (Table 6.2). Thiamazole was found to 
be a copper chelator which was confirmed by SYTOX® blue staining despite showing an 
effect in the tail-fin wounding assay. This is because, thiamazole is known to have inherent 
anti-inflammatory activity, as well as being able to chelate copper (Alturfan et al., 
2007)(Lagorce et al., 1997). Drugs which were only found to show a response in the ChIn 
assay (levodopa, tetracycline, 6-thioguanine, d-penicillamine) were all found to be copper 
chelators, which was confirmed by SYTOX® blue staining (Table 6.2). Metformin only 
displayed a response in the tail-fin wounding assay and had no effect in the ChIn assay or the 
SYTOX® blue staining. It is unclear why metformin did not show a response in the ChIn assay, 
despite metformin being documented to have anti-inflammatory properties (Isoda et al., 
2006)(Logie et al., 2012). It is possible that the concentrations tested may have been too 
low.  
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Table 6.2 – Overview of the responses of the 28 reference drugs in the zebrafish tail-fin 
wounding assay, ChIn assay and SYTOX® blue staining. 
Drugs 
Assay 
Tail-fin wounding ChIn SYTOX® blue 
Malathion decrease decrease no effect 
Liothyronine no effect no effect no effect 
Amiloride no effect no effect no effect 
Glipizide no effect no effect no effect 
Terfenadine toxicity toxicity no effect 
Fenofibrate no effect no effect no effect 
Meclizine decrease decrease no effect 
L-thyroxine no effect no effect no effect 
D-penicillamine no effect decrease interacts with copper 
Carbamazepine no effect no effect no effect 
Tetracycline no effect decrease interacts with copper 
Prednisone no effect no effect no effect 
Folate no effect no effect no effect 
Chlorzoxazone decrease decrease no effect 
Enalapril no effect slight decrease interacts with copper 
Metformin decrease no effect no effect 
Bendroflumethiazide no effect no effect no effect 
Flupenthixol no effect no effect no effect 
Thiamazole decrease decrease interacts with copper 
Sulindac decrease decrease no effect 
Metoclopramide no effect no effect no effect 
Chlorprothixene no effect toxicity no effect 
6-thioguanine no effect decrease interacts with copper 
Hydrochlorothiazide no effect no effect no effect 
Amantadine no effect no effect no effect 
Levodopa no effect decrease interacts with copper 
Captopril no effect slight decrease Interacts with copper 
Erythromycin no effect no effect no effect 
Key: green = reduce inflammation in tail-fin wounding and ChIn assays + no copper chelation, black = cause 
toxicity, purple = reduce inflammation in ChIn assay + chelate copper, blue = reduce inflammation in tail-fin 
wounding and ChIn assays + chelate copper, brown = reduce inflammation in tail-fin wounding assay but no 
effect in ChIn assay + no copper chelation 
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6.4.4 Evaluation of the anti-oxidant properties of a selection of the 28 reference drugs 
As malathion, chlorzoxazone and meclizine were found to show anti-inflammatory activity 
despite not being documented in the literature to have such effects they were also 
investigated for possible anti-oxidant activity. This was done by carrying out a HyPer assay to 
quantify the levels of hydrogen peroxide produced during an acute inflammatory response in 
zebrafish larvae treated with these drugs. In brief, Tg(lyz.HyPer) zebrafish larvae at 3 dpf 
were firstly treated with drug for one hour, followed by cutting of caudal fin tips before 
performing automated fluorescence imaging using the Scan˄R screening microscope. Images 
were taken every minute over 60 minutes with ImageJ used to perform a ratiometric 
analysis of the images by calculating ratios for HyPer low/HyPer high. The results obtained 
from the HyPer assay showed that 10 µM malathion reduced the levels of hydrogen 
peroxide significantly during acute inflammation compared to the 1% DMSO control (Figure 
6.10, n=8 zebrafish larvae at 3 dpf per drug/control, P<0.05). Meclizine and chlorzoxazone at 
100 µM on the other hand showed no significant differences when compared to the 1% 
DMSO control (Figure 6.10, n=8 zebrafish larvae at 3 dpf per drug/control, P>0.05). 
Additionally, d-penicillamine was also tested in this assay as it is a known anti-oxidant and 
therefore served as a positive control. D-penicillamine at 100 µM was found to significantly 
reduce the levels of hydrogen peroxide and this reduction was found to be much greater 
than that achieved by malathion (Figure 6.10, n=8 zebrafish larvae at 3 dpf per drug/control, 
P<0.0001). 
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Figure 6.10 – Change in HyPer ratio after treatment of 3 dpf zebrafish larvae with a 
selection of the 28 reference drugs following initial acute inflammation by cutting of tail-
fins. Zebrafish larvae at 3 dpf were treated with 1% DMSO, 10 µM malathion, 100 µM 
chlorzoxazone, 100 µM meclizine and 100 µM d-penicillamine (n=8 zebrafish larvae at 3 dpf 
per drug/control, P<0.05 for 10 µM malathion, P<0.0001 for 100 µM d-penicillamine, P>0.05 
for rest)  
 
6.5 Discussion 
6.5.1 Anti-inflammatory responses of 28 reference drugs  
Out of the 28 reference drugs tested for anti-inflammatory activity in zebrafish larvae it was 
found that only sulindac, chlorzoxazone, meclizine and malathion represented true hits. 
Thiamazole was found to be a copper chelator in the SYTOX® blue staining but still showed a 
strong anti-inflammatory response in the tail-fin wounding assay. Levodopa, tetracycline, 6-
thioguanine and d-penicillamine were all found to be false positives in the ChIn assay and 
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were confirmed as copper chelators following SYTOX® blue staining. Metformin was found 
to show an anti-inflammatory response in the tail-fin wounding assay but not in the ChIn 
assay. Terfenadine showed a response only in the tail-fin wounding assay at the lower 
concentration of 10 µM but could not be evaluated at the higher concentration of 100 µM 
due to toxicity. Additionally, due to toxicity terfenadine could not be evaluated for anti-
inflammatory activity in the ChIn assay.  
 
Malathion, not previously documented to have anti-inflammatory effects was found to show 
strong anti-inflammatory effects in zebrafish larvae. Malathion which is an 
acetylcholinesterase inhibitor is known to induce oxidative stress, which has been 
demonstrated in rats where it was found to reduce the activity of superoxide dismutase, 
catalase and glutathione S-transferase (Selmi et al., 2013)(Ruckmani et al., 2011). However, 
malathion has also been shown at sub-chronic and sub-lethal doses to reduce the neutrophil 
counts in rats (Bhatia et al., 1996). Hence, it could be that malathion also reduces the 
leukocyte count in zebrafish larvae. This would make sense with the above argument, as 
both the tail-fin wounding assay and ChIn assay are based solely on quantifying leukocyte 
number and no other inflammation parameter. Therefore, if malathion does reduce the 
leukocyte count it would be identified as a positive hit in both assays. Further studies 
however would be required to verify this. 
 
The second generation anti-histamine terfenadine was found to display anti-inflammatory 
effects in zebrafish larvae at 10 µM in the tail-fin wounding assay. Terfenadine has been 
documented in vitro to down-regulate the generation of superoxide radicals by neutrophils 
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(Hayashi and Hashimoto, 1999) and suppress neutrophil chemotactic responses (Eda et al., 
1994). Recently, it has been discovered that inhibition of zERG which is predominantly 
expressed in the zebrafish heart but is also expressed in leukocytes leads to reduced 
leukocyte migration (Brown et al., 2007). It is thought that zERG plays an important role in 
leukocyte adhesion (Brown et al., 2007). This could therefore explain the reduced leukocyte 
number observed in the zebrafish tail-fin wounding assay, as terfenadine is a known zERG 
inhibitor. Further detailed investigation of this drug would be needed though to verify this as 
a mechanism for its anti-inflammatory action. 
 
Meclizine which reduced inflammation in both the zebrafish tail-fin wounding and ChIn assay 
is a first generation anti-histamine reported to protect against oxidative damage and 
reactive oxygen species by inhibiting mitochondrial respiration (Gohil et al., 2011). Although 
zERG block has not been reported so far with meclizine it is possible that like terfenadine 
meclizine causes reduced leukocyte migration due to zERG block (Simons, 2004). Further 
studies would be needed to verify this. 
 
Metformin was found to be positive in the tail-fin wounding assay but not in the ChIn assay. 
Metformin has been shown to inhibit NF-ΚB and TNF-α IL-6 production in endothelial cells in 
the vasculature (Isoda et al., 2006). It is unclear why metformin showed a response in the 
tail-fin wounding assay and not the Chin assay. This would require further investigation. 
 
Thiamazole was found to reduce inflammation both in the ChIn and the tail-fin wounding 
assays. It was also found to strongly chelate copper. Thiamazole is a powerful chelator of the 
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cuprate ion being able to inhibit many copper-dependent enzymes, such as tyrosinases 
(Hanlon and Shuman, 1975). Thiamazole has been documented to have anti-inflammatory 
properties independent of its copper chelating effects including the ability to inhibit 
prostaglandin H synthase, reduce the levels of prostaglandin E2 and scavenge superoxide 
radicals (Lagorce et al., 1997)(Komosinska-Vassev et al., 2000).   
 
Chlorzoxazone which is a muscle relaxant and analgesic also displayed anti-inflammatory 
effects in zebrafish larvae (Abdel-Azeem et al., 2009). Chlorzoxazone specifically inhibits SK2 
channels, which are a sub-type of calcium activated potassium channels mainly expressed in 
neurons of the brain (Sah, 1996)(Cao et al., 2001). The effect of chlorzoxazone on SK 
channels is responsible for its muscle relaxant properties; however it could be that this is 
also related to its anti-inflammatory effects. Further studies would be needed to verify this. 
 
Sulindac the positive control for both the zebrafish tail-fin wounding and ChIn assays was 
found to show strong anti-inflammatory activity, agreeing with reported effects (d’ Alençon 
et al., 2010). Sulindac is an NSAID that blocks the cyclooxygenase (COX) enzymes COX-1 and 
COX-2, preventing the synthesis of prostaglandins (Figure 6.11) (Cryer and Feldman, 1998). 
The anti-inflammatory effects of sulindac are mediated by its metabolite sulindac sulphide, 
which has poor selectivity for COX-2 and is therefore associated with gastrointestinal toxicity 
due to inhibition of COX-1 (Cryer and Feldman, 1998).  
 
Prednisone the other positive control for the zebrafish tail-fin wounding and ChIn assays was 
found to show no anti-inflammatory activity. Prednisone is a glucocorticoid that attenuates 
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an inflammatory response by decreasing vascular permeability and reducing prostaglandin 
synthesis (Figure 6.11) (Coutinho and Chapman, 2011). Prednisone can also alter cellular 
inflammatory responses through glucocorticoid receptor (GR) antagonism or suppression of 
genes involved in initiating inflammation (Coutinho and Chapman, 2011). The reason for 
prednisone showing no anti-inflammatory activity in zebrafish larvae could be due to weak 
penetration. 
 
Figure 6.11 – Arachidonic acid pathway. Free arachidonic acid is made from phospholipids 
via the action of the phospholipase A2. Arachidonic acid can then form leukotrienes via 5-
lipoxygenase or it can be converted to prostaglandins via the action of cyclo-oxygenases. 
Both leukotrienes and prostaglandins have an important function as inflammatory 
mediators. Non-steroidal anti-inflammatory drugs (NSAIDs) block the synthesis of 
prostaglandin G2. Glucocorticoids (e.g. prednisone) can increase the synthesis of the 
lipocortin (annexin-1) protein resulting in the inhibition of Phospholipase A2, thereby 
reducing levels of free arachidonic acid.  
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Levodopa, d-penicillamine, 6-thioguanine, captopril, enalapril and tetracycline were all 
found to be false positives in the ChIn assay due to their ability to chelate copper. 
Particularly, d-penicillamine is a well-known copper chelator and its copper chelating ability 
is exploited therapeutically in the treatment of Wilson’s disease, a genetic disease where 
excess copper builds up in tissues (Delangle and Mintz, 2012).  
 
6.5.2 Current limitations and future perspectives of the zebrafish anti-inflammatory screen 
In total out of the 28 reference drugs tested, the anti-inflammatory activity of 20 drugs was 
found to be the same between zebrafish larvae and humans/rodents showing good 
agreement (Table 6.3). Many of the drugs displaying anti-inflammatory activity in 
humans/rodents but not in zebrafish larvae are those drugs that only produce an anti-
inflammatory response in certain conditions, e.g. in cases of microbial infection and disease. 
This highlights a limitation of the zebrafish larval anti-inflammatory screening set-up in that 
such conditions are not incorporated into the set-up and that only leukocyte migration is 
being recorded and no other endpoints of inflammation. Another limitation is that some 
drugs (e.g. prednisone) may not be able to penetrate into the zebrafish larva due to the 
short exposure time or unfavourable physiochemical properties therefore producing a 
negative result. As mentioned in previous chapters, a bioanalysis step would be useful to 
check that these drugs are indeed taken up into zebrafish larvae and whether equilibrium 
concentrations are reached. Using longer exposure times or creating a time series of 
different concentrations could help to determine whether the concentrations used are 
sufficient. However, for high throughput screening purposes using more than two different 
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concentrations and several exposure times would not be feasible, so a compromise would 
need to be reached. 
 
Table 6.3 – Comparison between documented anti-inflammatory effects of 28 reference 
drugs reported in humans/rodents to those observed in zebrafish larvae. 
Drugs 
Reported anti-inflammatory effects in 
humans/rodents 
Anti-inflammatory effects 
in zebrafish larvae 
Malathion X √ 
Liothyronine X X 
Amiloride √ X 
Glipizide X X 
Terfenadine √ √ 
Fenofibrate √ X 
Meclizine √ √ 
L-thyroxine X X 
D-penicillamine X X 
Carbamazepine X X 
Tetracycline √ X 
Prednisone √ X 
Folate √ X 
Chlorzoxazone X √ 
Enalapril X X 
Metformin √ √ 
Bendroflumethiazide X X 
Flupenthixol X X 
Thiamazole √ √ 
Sulindac √ √ 
Metoclopramide X X 
Chlorprothixene X X 
6-thioguanine X X 
Hydrochlorothiazide X X 
Amantadine X X 
Levodopa X X 
Captopril X X 
Erythromycin √ X 
Key: red = no effect observed, green = effect observed 
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To determine the specificity of the anti-inflammatory responses observed concentration 
ranges at or close to lethality would need to be tested for both the toxic and non-toxic 
drugs. However, when doing this it would need to be taken into consideration that a specific 
mode of action leading to high toxicity may overlap with an unspecific anti-inflammatory 
effect. This could occur for example with a drug which causes hepatitis at a specific 
concentration. As hepatitis is associated with inflammatory cells migrating to the liver, a 
positive response may be observed in the ChIn assay as less inflammatory cells will be 
observed occupying neuromasts.  
 
Future studies could be improved by testing more positive controls including anti-
inflammatory drugs from different classes, increasing the exposure time, as well as adjusting 
the concentration ranges used for each compound as not all compounds will be active at the 
same concentrations. Furthermore, it would be useful to include follow up studies for hits to 
determine their exact mechanism of anti-inflammatory action if it is not already known. This 
could involve performing studies on zebrafish embryo mutants with defective zCOX.  
 
Taken together these results demonstrate that the zebrafish larval anti-inflammatory set-up 
consisting of a manual tail-fin wounding assay, ChIn assay and SYTOX® blue staining has the 
potential to be implemented into pre-clinical drug testing routines and could aid in the 
identification of new anti-inflammatories. It can be envisaged that the ChIn assay could be 
combined together with other high throughput zebrafish screens to generate a multi-assay 
pipeline where both therapeutic and toxic properties of drugs could be investigated.  
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6.5.3 Anti-oxidant properties of selected reference drugs 
A HyPer assay was performed in zebrafish larvae in order to determine whether the positive 
hits obtained from the zebrafish larval anti-inflammatory screening set-up also displayed 
anti-oxidant activity. The results obtained showed that malathion and the positive control d-
penicillamine displayed anti-oxidant activity, whereas meclizine and chlorzoxazone did not. 
 
Malathion was found to display marked anti-oxidant activity, despite being known to be a 
causative agent of oxidative stress (Ruckmani et al., 2011). However, in one study it was 
reported that when rats were exposed to sub-chronic sub-lethal doses of malathion there 
was an increase in the activity of super oxide dismutase and catalase in the blood and liver 
(Akhgari et al., 2003). This raises the possibility that in zebrafish larvae exposed to low levels 
of malathion there could be an over-stimulation of the anti-oxidant defence system in the 
absence of any overt toxic effects. Therefore, once tail-fin wounding is performed hydrogen 
peroxide is converted much more rapidly to water and oxygen. An alternative mechanism 
for malathion’s anti-oxidant effects could be inhibition of NOXes or Duox. NOXes are the 
major source for generating hydrogen peroxide (see Figure 6.12) (Niethammer et al., 2009). 
There are five different types of NOXes in zebrafish, which all generate superoxide radicals 
which can be converted to hydrogen peroxide by superoxide dismutase (Niethammer et al., 
2009). Zebrafish possess one isoform of Duox which can generate hydrogen peroxide directly 
(see Figure 6.12) (Niethammer et al., 2009). Whether or not the inhibition of NOXes or Duox 
is responsible for the anti-oxidant effects of malathion would require further investigation 
on a molecular level. 
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D-penicillamine is a known anti-oxidant and as expected displayed strong anti-oxidant 
effects in the HyPer assay. The anti-oxidant effects of d-penicillamine are due to its metal 
chelating abilities, as it can chelate pro-oxidant heavy metals like copper, thus reducing free 
radical generation (Soroka et al., 1992). D-penicillamine acts by directly scavenging hydrogen 
peroxide reducing it to water and in turn becoming oxidised itself in the process (Ledson et 
al., 1992). Additionally, the thiol moiety of d-penicillamine can also interact with aldehydes 
to form thiazolidines (Phelps et al., 1996).  
 
Figure 6.12 – Free radical generation and anti-oxidant defence mechanisms. Inflammation 
due to manual wounding or drug exposure can lead to superoxide radical generation. The 
oxygen radical can form hydrogen peroxide by the actions of the superoxide dismutase 
enzyme. The hydrogen peroxide can then either be converted to harmless waste products 
(water and oxygen) by the actions of glutathione peroxidase and catalase or it can undergo a 
reaction with Fe2+ ions (Fenton’s reaction) to form hydroxyl radicals and Fe3+ ions. These 
hydroxyl radicals are unstable and can lead to oxidative damage of DNA, proteins and lipids.   
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6.5.4 Current limitations and future perspectives of the zebrafish HyPer screen 
The HyPer assay highlights the usefulness of the zebrafish larva in identifying compounds 
with anti-oxidant effects. The study carried out however could be improved in the future by 
testing a larger number of drugs, including several positive controls and also by 
incorporating follow up studies, such as Duox/NOX inhibition studies to fully understand the 
anti-oxidant mechanisms. As mentioned previously, for the zebrafish larval anti-
inflammatory set-up bioanalysis studies would also be useful to confirm drug uptake in 
zebrafish larvae. For this assay to be potentially implemented into pre-clinical testing 
routines the throughput would also need to be increased by automating the image analysis 
and increasing the numbers of zebrafish larvae that can be tested at one time.  
 
6.6 Conclusion 
A high throughput automated imaging assay for the evaluation of the anti-inflammatory 
effects of the 28 reference drugs in zebrafish larvae was found to produce interesting and 
surprising results. Through the completion of confirmatory tests in conjunction with the 
automated assay three compounds previously not reported as being anti-inflammatory 
agents (malathion, meclizine and chlorzoxazone) were uncovered as having anti-
inflammatory properties. Furthermore, malathion was also uncovered as a potential anti-
oxidant agent. As mentioned previously, further studies would need to be performed to 
confirm these initial findings and to determine the modes of action of these compounds in 
attenuating parts of the inflammatory response. Overall, the studies performed in this 
chapter show that the zebrafish larva presents a suitable model for therapeutic drug 
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screening and that particularly in the field of immunology it could advance the discovery of 
new anti-inflammatory and anti-oxidant compounds. 
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Chapter Seven: GENERAL DISCUSSION AND PERSPECTIVES 
7.1 Overview 
In this thesis, firstly a zebrafish embryo and larval ECG screening tool was developed to 
specifically address drug-induced cardiotoxicity, which represents one of the major reasons 
why drugs fail during development. Secondly, the biological activity of a novel group of 
compounds was assessed using the zebrafish embryo in order to determine whether 
differences in chemical structure influenced biological activity. Thirdly, a reference drug set 
was biologically characterised using the zebrafish embryo in order to create a predictive 
model which could be used to predict the toxicity of similar structured compounds. Finally, a 
reference drug set was assayed for anti-inflammatory activity using a high throughput 
zebrafish larval assay to determine potential anti-inflammatory effects of these drugs and to 
assess the suitability of the zebrafish larva as a model for therapeutic drug screens. 
 
7.2 The implementation of the zebrafish embryo as a pre-clinical model in 
drug development 
Currently, there is increased pressure on pharmaceutical companies to develop drugs that 
are effective, commercially valuable and safe (Roberts et al., 2014). In order to meet these 
requirements, drugs that present with toxicity or low efficacy need to be eliminated early on 
in the drug development process. Potential drug candidates are first identified through in 
vitro tests before safety and efficacy studies are performed in vitro and in vivo. In vivo testing 
is primarily conducted in rodents but depending on the drug indication and probable 
metabolic pathway of the drug, larger mammals such as dogs or primates may be needed. In 
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vivo testing also involves using a large number of animals, which is expensive and time-
consuming. The zebrafish embryo however may present a quicker, more effective and 
inexpensive in vivo model for drug screening. Therefore, the main aim of this thesis was to 
evaluate the utility of the zebrafish embryo in pre-clinical drug testing regimes. Particularly, 
the idea of introducing the zebrafish embryo as the first step in candidate drug selection, as 
well as an intermediary step in pre-clinical testing, i.e. after initial in vitro drug candidate 
selection and before the commencement of in vivo testing was investigated.  
 
To address this main aim, a reference set of 28 chemically diverse marketed compounds was 
biologically characterised using the zebrafish embryo in order to create a predictive model 
that could be used to predict the toxicity of similar structured compounds (see Chapter 5). A 
two tier toxicology screen was performed with an initial dose-range finding study followed 
by a morphological effect screen. Out of the 28 compounds tested, 9 were found to have 
minimal or no effects on zebrafish embryos, whereas the remaining 19 were found to 
produce pronounced morphological effects.  
 
When comparing the zebrafish embryo logLC50 values to the logLD50 values of the adult rat 
and mouse the correlation between them was found to be weak. Some compounds were 
found to be more toxic or less toxic in zebrafish embryos than in rodents and vice versa, 
which has also been documented in other studies (Ali et al., 2014)(Ali et al., 2011). As 
discussed in Chapter 5, these differences may have been due to several reasons, but the 
main reason was probably the difference in exposure routes. Additionally, toxicity endpoints 
such as LC50/LD50 may not be the best endpoints to compare toxicity between different 
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species, as this endpoint only gives an indication of lethality without providing any further 
information on mechanisms. Also, the rodent foetus and human foetus may be more 
suitable comparisons for comparing zebrafish embryo toxicity. However, the problem 
persists that data on rodent foetus toxicity and human foetus toxicity is scarce, which means 
it is difficult to compare these to zebrafish embryo toxicity. Despite the drawbacks 
mentioned the QSAR model that was generated from the zebrafish embryo data showed 
good overall predictivity of toxicity. From the model it could be clearly seen that there was a 
strong association between increased toxicity (low LC50 values and high morphological 
feature severity scores) and a high logP value which describes the lipophilicity of a 
compound. This relationship has also been documented in other zebrafish studies (Weimin 
et al., 2001)(Chen et al., 2012) as well as in other organisms (Wayne Schultz et al., 
1991)(Newsome et al., 1991)(Landis et al., 1993). For the majority of the drugs tested 
baseline toxicity (narcosis) was found to be the main mechanism of toxicity and only with a 
few drugs specific mechanisms of toxicity were observed. 
 
The zebrafish studies used to create the model however could have been improved by 
determining additional toxicity endpoints or morphology scores. Furthermore, incorporating 
biological data from other zebrafish embryo assays into the model could increase its 
versatility, meaning that it could be used for other indications and not only toxicity 
determination in the future. 
 
Overall, it can be envisioned that this prediction tool could be implemented after initial in 
vitro screens during drug development to predict toxicity of candidate drugs. This could 
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prevent drugs reaching the market which present with ADRs and significant toxicity, thus 
saving time, money and the number of animals tested, as well as preventing human fatalities 
and morbidity due to drug-induced toxicities. However, the model also has the potential to 
be applied in environmental toxicology for predicting fish aquatic toxicity for example to 
pharmaceuticals, agrochemicals and synergistic compound mixtures released into the 
environment.  
 
7.3 Using the zebrafish embryo as a model to detect cardiotoxicity 
As mentioned previously, drug toxicities remain a real problem of drug attrition, particularly 
in the case of cardiotoxicity which together with hepatotoxicity accounts for the most 
number of drug withdrawals during the drug development process (Roberts et al., 2014). 
Currently, there are no gold standard in vivo or in vitro models to screen for cardiotoxicity. 
Therefore, in Chapter 3 of this thesis I aimed to develop a cardiotoxicity screening tool using 
the zebrafish embryo as a model organism. The aim was to develop an assay which had the 
potential to be implemented in pre-clinical testing routines as a screening tool. The 
cardiotoxicity screening tool that was developed was a zebrafish embryo and larval 
electrocardiogram (ECG) measurement set-up. ECG measurements were performed on 
zebrafish larvae treated with known QT prolonging drugs in humans in order to determine 
whether QT prolongation could be recapitulated using zebrafish larvae.  
 
QT prolongation is a major cause of drug failure during drug development and can also have 
serious implications on patient health if it is not detected during pre-clinical testing (Yap and 
Camm, 2000). Currently, there is no gold standard animal model for detecting drug-induced 
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cardiotoxicity. Interestingly, all tested drugs known to cause QT prolongation in humans 
were found to induce QT prolongation in zebrafish larvae, which has not been documented 
before. These findings were extremely exciting, as zebrafish embryos are not regulated until 
5 dpf and have the capacity to be tested in high numbers and at a reasonable throughput 
meaning that the zebrafish larva could potentially become a gold standard model for 
cardiotoxicity testing. Additionally, secondary conditions of cardiotoxicity, such as 
arrhythmia and AV block were also detectable and clearly observable using the ECG set-up, 
thus demonstrating the versatility of the ECG set-up in detecting many forms of 
cardiotoxicity.  
 
To our surprise, verapamil which is not known to induce QT prolongation in humans except 
in rare cases of overdose was also found to cause QT prolongation in zebrafish larvae. The 
increased sensitivity of zERG to block compared to hERG may have been responsible for this 
effect (Langheinrich et al., 2003). This shows that for some drugs results may need to be 
interpreted with caution, as effects may be over-exaggerated in the zebrafish larva.  
 
The measurement of zebrafish embryo/larval ECGs presents an exciting tool for detecting 
drug-induced cardiotoxicity, particularly QT prolongation. However, testing of further drugs 
known to be cardiotoxic in humans (e.g. QRS prolonging agents), as well as further 
development of the set-up to increase throughput would be required before it can be 
implemented into routine testing during drug development. It would also be of interest to 
see whether zebrafish mutants which present with short QT syndrome (e.g. zebrafish reggae 
mutants) (Hassel et al., 2008) can be rescued after treatment with QT prolonging drugs. This 
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would further validate the set-up and presents an additional area that could be explored. 
The main limitations of this set-up such as no automated analysis software, low throughput 
and uncertainty regarding drug uptake would need to be addressed in the future. 
Particularly, drug uptake presents an important factor, as for pre-clinical testing it would be 
important to know the exact dose that is inducing QT prolongation in the zebrafish larvae. To 
address this, bioanalysis may need to be incorporated as an additional step or alternatively 
drugs could be injected directly in the blood stream and toxicokinetic models developed 
which would be feasible but would make the process much more time consuming. However, 
in either case, a step would be needed to determine the internal concentrations of 
compounds. 
 
If the above limitations are addressed, it is possible for the zebrafish embryo and larval ECG 
screening tool to be successfully implemented into routine pre-clinical testing in the future 
where it could potentially reduce drug failures by identifying those compounds causing 
cardiotoxicity early on in the drug development process. Additionally, the ECG screening tool 
could also be used to identify new therapies for diseases caused by electrophysiological 
abnormalities in the heart including those where a genetic component is involved, thus 
presenting an opportunity to perform chemical genetic screens.  
 
7.4 The zebrafish larva as a model for therapeutic drug screening 
In Chapter 6, the anti-inflammatory properties of the 28 reference drugs were explored in 
zebrafish larvae using an automated chemically induced inflammation assay (ChIn). Using 
the ChIn assay and associated confirmatory tests four drugs were found to show true anti-
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inflammatory activity. Of these four drugs only one was a known anti-inflammatory, namely 
sulindac. Meclizine, chlorzoxazone and malathion represented drugs not previously 
documented to have anti-inflammatory properties. Furthermore, malathion was also found 
to show anti-oxidant activity. These findings potentially uncovered novel uses for drugs that 
were marketed for other indications. Further work, particularly on a cellular or molecular 
level may help to unravel how these compounds initiate their anti-inflammatory effects. 
Experiments could be performed to look at effects on calcium signalling, as calcium signalling 
is important for orchestrating an inflammatory response (Razzell et al., 2013). Additionally, 
experiments could be performed to determine changes in the expression of anti-
inflammatory genes after drug exposure. For malathion, studies could be performed on 
Duox to determine whether this oxidase is inhibited by malathion and whether this is 
responsible for the observed anti-oxidant effects. 
 
Overall, in this chapter the utility of the zebrafish larva for therapeutic drug screening and its 
possible implementation in initial drug candidate selection processes was demonstrated. The 
zebrafish larva provides additional advantages over current in vitro methods for drug 
candidate selection and it can be envisaged that further validation of the zebrafish ChIn 
assay in particular may lead to its routine implementation into drug candidate selection 
processes in the near future.   
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7.5 The zebrafish embryo as a screening tool to assess the biological activity 
of novel compounds 
In Chapter 4, novel compounds previously not explored for biological activity were tested in 
zebrafish embryos. After treatment of zebrafish embryos with these compounds a variety of 
morphological effects were observed. Particularly, azetidine 2a and Ƴ-lactams 3a, 3h and 3f 
presented with interesting phenotypes. Azetidine 2a and Ƴ-lactam 3a presented with a 
specific type of hemorrhage, namely ventricular brain hemorrhage. Both compounds were 
found to show structural similarities which could possibly explain the likenesses seen in the 
effects they produced. It would be interesting in the future to test the separate isomers of Ƴ-
lactam 3a to see whether one or both of them can recapitulate the ventricular brain 
hemorrhage phenotype. Additionally, studies on a molecular level to determine the 
mechanism responsible for ventricular brain hemorrhage formation would be invaluable. 
Such studies could focus on the βPix gene, as knockdown of both splice variants of this gene 
in zebrafish embryos has been shown to produce the same brain hemorrhage phenotype 
(Liu et al., 2007).  
 
With compounds 3f and 3h it was postulated that their hepatotoxic effects were mediated 
by their side groups, as the furan and nitroxy groups have been extensively documented in 
the literature to cause liver toxicity in humans and other animals (Cordelli et al., 2010)(Tyl et 
al., 1987). To verify that this is really the case bioanalysis studies would need to be 
performed to determine which reactive intermediates are produced and if these are the 
same as those produced in humans and other animals. It would also be interesting to test 
these two compounds for potential anti-inflammatory activity in the future, as many drugs 
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known to cause hepatotoxicity are also anti-inflammatories (O’Brien, 1992), such as in the 
case of the NSAIDs.  
 
The results obtained from testing these novel azetidines and Ƴ-lactams showed that small 
changes in chemical structure produced diverse biological effects. It was seen that certain 
functional groups were associated with increased toxicity whereas others were not. These 
results could aid in the synthesis of new compounds which have more favourable properties. 
Eventually, using such a feedback loop between chemical synthesis and biological activity 
assessment may lead to the discovery of novel compounds that could be used for disease 
modelling or as therapeutics.  
 
7.6 Overall conclusion 
With the vast number of technologies and techniques available, such as automated zebrafish 
embryo sorting robots, automated imaging devices, liquid handling devices and various 
genetic techniques there is the possibility of performing the initial candidate drug selection 
process and pre-clinical testing fast and efficiently using only the zebrafish embryo. It can be 
envisaged that a high throughput automated screen such as the zebrafish ChIn assay 
described in this thesis could be used as the first step in such a pipeline where a compound 
library is screened for candidate drugs which attenuate a particular phenotype, in this case 
inflammation. Alternatively, targeted screens could also be performed by screening 
compound libraries against molecular targets, such as specific genes that induce a disease 
phenotype. After the initial drug candidate selection has been performed a QSAR model like 
the one described in this thesis could then be introduced to filter out those drugs predicted 
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to have a high toxicity in humans. After this filtering step the remaining candidate drugs 
could then be tested for general toxicity in high throughput zebrafish embryo assays where 
mortality and morphological effects are automatically quantified. Following on from this a 
bioanalysis step could be introduced in order to determine the ADME properties of the 
compounds, as well as potential metabolites formed. The candidate drugs remaining after 
this step could then be assessed for specific organ toxicities using specialized zebrafish 
embryo screening tools. These could include the ECG screening tool described in this thesis, 
which could be used to determine cardiotoxicity. Other tools that could be used include 
fluorescence-based screening tools where organs of interest (e.g. liver) are fluorescently 
labelled and changes in size or shape after compound exposure are used as endpoints. Using 
such a rigorous approach the candidate drugs that remain could be optimised and then 
tested in mammalian models before going into human clinical trials. Implementing such a 
method routinely in drug development could save time, resources and money, as well as 
reduce the number of animals that are tested. 
  
Although, many questions still remain regarding drug uptake and metabolism in zebrafish 
embryos, particularly pharmacokinetics and internal drug concentrations, these are slowly 
being addressed. All in all, the zebrafish embryo presents a versatile vertebrate model that 
can be used to assess the toxicity and therapeutic effects of compounds in vivo. 
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Chapter Eight: APPENDIX 
 
Supplementary Table 8.1 - Modelling parameters used to create log concentration 
mortality plots for selection of Ƴ-lactams. 
Ƴ-lactam compounds 
Modelling parameters 
logLC50 HillSlope F Bottom Top Span 
3a 1.45 1.07 = 50.01 -0.01 100.00 100.00 
3b 1.74 2.08 = 50.00 -0.01 100.20 100.20 
3c 0.91 11.20 = 50.00 0.00 100.00 100.00 
3d ~ 2.15 ~ 5.55 = 50.00 0.69 100.00 99.31 
3e 2.15 ~ 5.56 = 50.00 0.71 100.00 99.98 
3f 1.26 3.97 = 50.00 5.56 100.10 94.50 
3g 1.07 10.78 = 50.00 0.00 100.00 100.00 
3h 3.20 10.61 = 50.00 0.00 13.89 13.89 
3i 2.69 9.88 = 50.00 0.07 100.00 100.00 
 
Supplementary Table 8.2 - Modelling parameters used to create log concentration 
response plots for selection of Ƴ-lactams. 
Ƴ-lactam compounds 
Modelling parameters 
logEC50 HillSlope F Bottom Top Span 
3a 1.18 3.71 = 50.00 1.85 100.00 98.19 
3b 1.50 31.77 = 50.00 -11.99 100.00 112.00 
3c 0.50 33.47 = 50.00 -59.78 100.00 159.80 
3d 1.81 34.88 = 50.00 16.67 100.00 83.33 
3e ~ 1.25 ~ 5.36 = 50.00 0.93 100.00 99.08 
3f 1.26 3.97 = 50.00 5.56 100.10 94.50 
3g 1.50 37.03 = 50.00 -59.48 100.00 159.50 
3h 1.80 34.82 = 50.00 4.20 100.00 95.80 
3i 1.76 18.14 = 50.00 16.67 100.00 83.33 
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